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TOBACCO CONTROL-WHAT IS IMPORTANT FOR
ONCOLOGISTS TO KNOW
C. Dresler Tobacco Prevention and Cessation Program, Arkansas Depart-
ment of Health, Little Rock/USA
The known relationship between tobacco and lung cancer goes back to the
1950s. Despite this knowledge, lung cancer remains the leading cause of
cancer deaths in developed countries, and is becoming so in developing
economies. This increase in lung cancer death rates can be related to
economic development – due to the fact that tobacco industries have
increased their marketing in these developing economies. We know the
causative agent for a significant majority of lung cancers and we know the
vector – the tobacco transnational oligopolies. Fortunately there has been
tremendous growth in the strength and impact of the tobacco control
movement globally. Europe, in many ways, has been a leader in promulgat-
ing effective policies. It is fascinating to look at the cross-disciplinary
concepts between the generally more advocacy based tobacco control move-
ment and the basic and clinical science of the treatment of lung cancer.
Although there is often little cross-talk, the science between the two is
converging. Examples would include the studies performed to ascertain the
effective chemotherapeutic agent and/or dose depending on whether the lung
cancer patient smokes tobacco or not; or, the constituents either in or created
by combustion and inhaled in the cigarette and how they impact the
initiation, histology or growth of a lung cancer; or the genetic determinants
that lead to nicotine addiction and/or susceptibility to lung cancer. It is
critical that the disparate research fields are aware of developments in each
other’s area of expertise. For example, as the various countries implement
regulations that limit or eliminate certain constituents, such as nitrosamines,
there will be changes in the epidemiology of the growing proportion of
adenocarcinomas, and the related biomarkers associated with adenocarcino-
mas. Similarly, knowledge of such changes may impact the treatment, and
the studies performed to determine appropriate treatment for the potentially
shifting proportions of histologic types of lung cancer. Thus, practitioners
and researchers will need to be cognizant of the continual changes occurring
in the tobacco control environment. It is an exciting time to observe the
growth of knowledge and impacts in both tobacco control and lung cancer
treatment.
Disclosure: The author has declared no conflicts of interest.
2IN
FUTURE DIRECTIONS IN THE TREATMENT OF NSCLC
P.A. Bunn, Jr. Medicine-Oncology, University of Colorado Cancer Center,
Aurora/USA
The most striking advances in NSCLC have been the recognition that tumors
with activating mutations in the EGFR gene are likely to be addicted to this
signal pathway, are likely to respond to EGFR TKIs and are likely to develop
resistance to EGFR TKIs through secondary resistance mutations that inhibit
TKI binding to the receptor and the recognition that EML4/ALK fusion
genes predict response to ALK TKIs. Mutations in known oncogenes are
present in at least 50% of NSCLC tumors.
What are the challenges and limitation to this molecular approach? 1) A
significant minority of patients will have intrinsic resistance and will not
respond, 2) all responding patients will develop acquired resistance. 3)
mutations in genes such as KRAS for which there are no known therapies,
new agents need to be developed. 4) we need to develop a way to deliver
tumor suppressor genes. 5) we need to distinguish between “driving” muta-
tions and “passenger” mutations. 6) we need to be able to develop validate
and receive regulatory approval of mutation and other biomarker tests. 7) we
need predictive biomarkers for patients with wildtype tumors. We must
recognize that EGFR TKI such as erlotinib can improve DFS and OS even
in EGFR wt tumors.
There has been limited study of EGFR TKIs in patients with Stage I-III
NSCLC. These agents have the potential to improve the cure rate in the early
stage patients. Oncogenes can be activated by fusion with other genes as well
as by mutation in NSCLC. The EML4/ALK fusion gene is present in about
4% of lung adenocarcinomas essentially limited to never smokers. Patients
whose tumors harbor these fused genes have high ALK expression and had
high response rates to the ALK TKI term PF1066 in a phase I trial of this
agent. These results have led to a phase II/III randomized trial in these
patients. Many of these oncogenic transformations lead to activation of
downstream signal proteins such as MAPK, AKT, mTOR and others. Use of
therapies directed at these downstream targets used alone and in combination
will occur in the next several years. Thus, screening of NSCLC tumor for
multiple mutations is likely to be a common occurrence in the future.
There are a host of other targets that are under investigation and the list of
these is too long for this presentation but is available in other publications.
Prominent among these targets are PARP inhibitors; inhibitors of other
growth factor pathways (eg. FGF, IGF-1); inducers of apoptosis such as DR4
and DR5 agonists; Bcl-2 inhibitors and IAP inhibitors; vaccines; SMAC
mimetics; vascular disruption agents, angiogenesis inhibitors; mitotic check
point inhibitors; and others. The potential for these new therapies to improve
the outcome in NSCLC patients is large and the hope is that predictive
biomarkers will develop along with each of these classes of agents.
Disclosure: The author has declared no conflicts of interest.
MEET THE EXPERT
3IN
THE EMERGING ROLE OF IMMUNOTHERAPY IN LUNG
CANCER
J. Vansteenkiste Respiratory Oncology Unit, University Hospital Gasthuis-
berg, Leuven/BELGIUM
For patients with resectable NSCLC, resection is the standard approach, resulting
in a 5-year survival of about 40%, with a further absolute increase of 5-10% with
adjuvant chemotherapy (IALT, NEJM 2004). Patients with unresectable stage III
NSCLC are treated with chemotherapy and radiotherapy, with 5-year survival
rates of about 20% with a concurrent approach (Fournel, JCO 2005). So, despite
complete resection or radical dose of radiotherapy, many patients still die of their
cancer, because NSCLC cells remaining after a radical approach cause tumour
relapse. In these patients, the aim of immunotherapy is to eliminate as much as
possible the cancer cells remaining after radical treatment, in order to delay
relapse, or even avoid relapse and increase cure rate. For that purpose, a well
defined tumour target and a strong adjuvans to boost immune response are
mandatory as – after all – the tumour initially developed in a failing immune
environment. We will mainly discuss approaches in this setting which are in
phase III testing. In the postoperative setting, effective adjuvant strategies with
better tolerability than cisplatin-based chemotherapy are needed. The MAGE-A3
antigen might be a good target: it is expressed on tumours only (35 to 50% for
NSCLC, depending on the stage), not on normal tissues. The MAGE-A3
immunotherapy consists of a recombinant protein combined with a potent GSK
proprietary immunological adjuvant. Pilot studies demonstrated humoral and
cellular responses, and clinical responses in metastatic melanoma (Kruit, Int J
Cancer 2005). In the proof-of-concept double-blind randomised phase II study,
patients with completely resected MAGE-A3 positive NSCLC who received
MAGE-A3 immunotherapy had a hazard ratio (HR) of 0.76 for disease-free
survival and 0.81 for overall survival, figures similar to the benefit with adjuvant
chemotherapy (Vansteenkiste, JTO 2008). Immunotherapy with liposomal
BLP25 (Stimuvax®) is a promising adjuvant approach after chemoradiotherapy
in stage III NSCLC. In a phase II randomised study, the subgroup of patients
with stage IIIB had a HR of 0.52 for overall survival (Butts, JCO 2005). In both
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studies, the immunotherapy was well tolerated with very little grade III/IV
toxicity. Both strategies are in phase III testing.
Disclosure: J. Vansteenkiste: Advisory function for GSK Bio
4IN
RESTAGING TECHNIQUES
P.E. Van Schil, M. De Waele, J.M. Hendriks, P. Lauwers Department of
Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem/
BELGIUM
Downstaging after induction therapy is an important prognostic factor in
locally advanced stage III non-small cell lung cancer with N2 or N3
involvement. Patients with persisting mediastinal involvement will not ben-
efit from surgical resection. For this reason, accurate restaging is of utmost
importance and a histological proof of downstaging should be obtained
before considering surgical resection. The different restaging techniques are
summarized in table 1. They all have distinct advantages and disadvantages.
The non-invasive modalities computed tomography (CT) and magnetic
resonance imaging are not accurate enough to predict response. Integrated
CT-PET (positron emission tomographic) scanning performs better but as
well false-positive as false-negative cases occur and the precise technical
modalities remain to be determined. Minimally invasive techniques as
transbronchial needle aspiration (TBNA), endobronchial ultrasound (EBUS)
and endoscopic ultrasound (EUS) with fine-needle aspiration (FNA) are
promising but only provide a cytological diagnosis and the false-negative
rate remains high. Repeat mediastinoscopy is an invasive staging technique
which is less accurate than an initial procedure and technically more difficult.
However, it provides a histological proof of mediastinal downstaging,
determines prognosis and guides further therapy. VATS has not been
extensively investigated for restaging at the present time. As minimally
invasive staging techniques are gradually improving, especially in patients
with enlarged mediastinal lymph nodes, there is currently a tendency to use
these techniques for initial staging. Mediastinoscopy is reserved for restaging
providing a thorough superior mediastinal evaluation at that time. Patients
with mediastinal downstaging are considered for subsequent surgical resec-
tion, especially when a complete resection can be obtained by lobectomy
with systematic nodal dissection.
Disclosure: All authors have declared no conflicts of interest.
5IN
THE MANAGEMENT OF PLEURAL EFFUSION
G. Rocco Department of Thoracic Surgery and Oncology, National Cancer
Institute, Naples/ITALY
The management of suspicious pleural effusions in a patient with a history of
cancer is aimed at establishing the diagnosis, evacuating the pleural collec-
tion, and, obliterating the pleural space in order to avoid recurrences. The
crucial issue is the presence of a trapped lung, either by cancer or by long
standing fibrinous exudates. Failure to re-expand the lung is the single most
adverse predictor against the success of pleurodesis. Despite due to breast
and lung cancer in the majority of patients, in almost 11% of the cases the
origin of the effusion is unknown. The overall efficacy of pleurodesis is
about 66% but the likelihood of success is higher with thoracoscopic
instillation of talc (failure rate 0 to 7%) than with chest tube ( 11 to 24%
failure rate). The available pleurodetic agents are grouped into categories
including mineral agents (talc), antibiotic (doxycycline,quinacrine), antisep-
tic (iodopovidone, silver nitrate), anticancer drug (bleomycin, mitoxantrone,
cisplatin), bacterial product or component (corynebacterium parvum, staph-
ylococcus aureus superantigen, OK432), and, cytokine (interferon alpha-2 ß).
A success rate of 95-100% has been reported for talc, quinacrine, silver
nitrate, staphylococcus aureus, interferon alpha. Talc is to be favoured as a
single agent for pleurodesis instilled through VATS rather than as slurry,
especially for pleural effusion resulting from breast or lung cancer. Slurry
should be reserved to fragile, cachectic patients. Talc is the least expensive
agent but it is reported to cause respiratory failure and empyema. Maximum
benefit from talc is obtained in women with re-expandable lung, acceptable
performance status (60% according to Karnofsky), and, in patients with a
BMI greater than 25. Management of trapped lung is one of the most
challenging issues the clinician is faced with. Domiciliary care with self
managed chest drains (Pleurx) have proved to be beneficial for symptom
relief albeit the percentage of completely controlled effusions vas reported to
be around 60%. An implantable access system to the pleural has also been
described to facilitate home care. However, several reviews have demon-
strated a high level of compliance with the chronically indwelling tube by
patients with malignant, recurring pleural effusions.
Disclosure: The author has declared no conflicts of interest.
6IN
NOVEL TARGETED THERAPIES FOR SPECIFIC
SUBGROUPS OF NSCLC WITH SPECIFIC GENE
MUTATIONS
D. Costa Hematology Oncology, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston/USA
Non-small-cell lung cancers (NSCLCs) are heterogeneous cancers. A major
paradigm shift in understanding and treating this disease has occurred in the
last years as new oncogenes have been identified and subsequently targeted
in patients. In 2004, the identification of epidermal growth factor receptor
(EGFR) somatic mutations provided the first glimpse of a clinically-relevant
NSCLC oncogene. Over 70% of NSCLCs with EGFR mutations (exon 19
deletions or the exon 21 L858R) attain responses to EGFR TKIs (gefitinib
and erlotinib), with improved response rate (RR), progression-free survival
(PFS) and in some reports overall survival (OS) when compared to EGFR
wild-type (WT) cases. Randomized phase III trials of gefitinib versus
chemotherapy in stage IV NSCLC have consistently demonstrated better RR
and PFS for EGFR mutated patients treated with gefitinib. IPASS reported a
RR of 71.2% for gefitinib and 47.3% for carboplatin-paclitaxel (p0.001),
with PFS HR of 0.48 (p0.001) favoring gefitinib; and WJTOG3405
reported a RR of 62.1% for gefitinib and 32.2% for cisplatin-docetaxel
Table. Techniques for Mediastinal Restaging
Noninvasive
Computed tomography (CT)
Magnetic resonance imaging (MRI)
Positron emission tomography (PET)
Integrated CT-PET
Minimally invasive
Transthoracic fine-needle aspiration (FNA) biopsy
Transbronchial needle aspiration (TBNA)
Endobronchial ultrasound (EBUS) with FNA
Endoscopic ultrasound (EUS) with FNA
Invasive
Redo, second or repeat mediastinoscopy (reMS)
Video-assisted thoracic surgery (VATS)
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(p0.001), with PFS HR of 0.489 (p0.001) favoring gefitinib. Novel
irreversible EGFR TKIs (BIBW2992, XL647, PF00299804) show similar
activity in EGFR mutated patients. A translocation involving the anaplastic
lymphoma kinase (ALK) gene with echinoderm microtubule-associated
protein-like 4 (EML4) is the most recent oncogene found in NSCLC. Rarer
ALK fusion partners (TGF-ALK and KIF5B-ALK) also exist. PF-02341066,
a novel ALK TKI, has shown impressive activity against ALK translocated
NSCLC in an expanded cohort of a phase I trial (NCT00585195). Over 60
patients have been treated and the RR exceeds 60%. Due to short follow-up
the median PFS has not been reached, however many patients have been on
study drug for over 6-10 months. A registration phase III trial of PF-
02341066 versus second line chemotherapy (pemetrexed/docetaxel) is un-
derway (NCT00932893). KRAS, EGFR mutations and ALK translocations
are usually mutually exclusive and few KRAS mutated, EGFR WT or ALK
translocated NSCLC respond to EGFR TKIs. The promising results of EGFR
and ALK TKIs in molecular subgroups of NSCLC herald a new age of drug
and clinical trial development for patients with NSCLC.
Disclosure: The author has declared no conflicts of interest.
7IN
CHEMOTHERAPY FOR THE ELDERLY
E. Quoix Pneumology Service, Nouvel Hopital Civil, Strasbourg/FRANCE
Incidence of advanced Non-Small Cell Lung Cancer in the elderly is
increasing with a median age at diagnosis around 65 years, a third of the pts
being more than 70 years old. After a nihilistic period during which elderly
were under represented in clinical trials, more interest for these pts has
emerged during the previous decade with publication of clinical trials
devoted to them and expert meetings leading to some treatment recommen-
dations. The Elvis trial, a phase III study, published in 1999, compared in 161
pts aged 70 and more best supportive care to vinorelbine alone. There was a
significant benefit of survival with a relative risk of 0.65 (95% CI O.45; 0.93)
in the vinorelbine arm. In a randomized study comparing in japanese pts
vinorelbine to docetaxel there was a significant advantage for docetaxel
concerning response rate (22.2% vs 9%) and progression-free survival (5.5
vs 3.1 months) and a non significant trend for longer survival (10.3 vs 6.4
months). The next step was to compare single agents with a doublet. The
Miles trial performed in 698 pts compared vinorelbine or gemcitabine alone
to a doublet (vinorelbine  gemcitabine) with no improvement in survival.
Another study was in favor of the doublet but included only 120 patients.In
a phase III trial comparing in elderly or poor PS pts weekly docetaxel to
combined docetaxel and gemcitabine, there was a modest improvement in
time to progression with no impact on overall survival (5.55 months versus
5.1 months). The role of platin salts is still debated. It has been investigated
mostly through trials not devoted to elderly and thus there is obviously a
selection bias. In those trials, toxicity was more important in elderly but the
outcomes were generally speaking similar. The only published trial compar-
ing a platin salt doublet (carboplatin  paclitaxel versus paclitaxel alone)
devoted to poor performance status pts concluded in a significant benefit of
the doublet in young and older pts. The results of the IFCT phase III study
comparing in pts aged 70 to 89 years vinorelbine or gemcitabine alone to
carboplatin and paclitaxel are awaited for this year. Bevacizumab in addition
to chemotherapy seems to be of no interest in elderly. In conclusion, specific
trials for elderly need to be implemented to improve the outcome at the
expense of lower toxicity.
Disclosure: E. Quoix: Travel grants for congresses: Roche, Lilly, Merck
Honoraria for advisory boards : Merck, Lilly, Roche, Astra Zeneca, Mun-
dipharma, Novartis.
8IN
THYMOMAS
N. Girard Respiratory Medicine, Reference Center for Orphan Pulmonary
Diseases, Louis Pradel Hospital, Lyon/FRANCE
The treatment of thymic malignancies is a paradigm of cooperation for the
management of rare tumors between clinicians, surgeons, and pathologists
from establishing the diagnosis to organizing the therapeutic strategy and
evaluating the prognosis. Given the rarity of thymic tumors, only few
randomized trials have been available and current recommendations are
mostly based upon small-size cohorts, retrospective data, and expert consen-
sus. The current histologic classification of thymic epithelial tumors distin-
guishes thymomas (types A, AB, B1, B2, B3) and thymic carcinomas. These
subtypes are based upon the morphology of epithelial cells (with an increas-
ing degree of atypia from type A to thymic carcinoma), the relative propor-
tion of the non-tumoral lymphocytic component (decreasing from types B1
to B3), and resemblance to the normal thymic architecture. Beyond histol-
ogy, treatment recommendations are mostly based upon the Masaoka staging
system, which integrates the degree of tumor invasion and represents the
most significant prognostic factor of overall survival. Surgery is the corner-
stone of the management of thymic tumors, both ensuring the initial his-
topathologic diagnosis and staging, and the first step of the therapeutics. At
least 10 different surgical approaches to the thymus have been described.
Robotic surgery is currently under evaluation for small-size thymomas.
Radiotherapy is mostly used as adjuvant treatment, and currently integrates
the use of multi-field arrangement and three-dimensional treatment planning.
Postoperative radiotherapy is recommended in incompletely resected thymo-
mas, but is controversial for completely resected stage II-III tumors. Thy-
momas are sensitive to chemotherapy including combinations of cisplatin
either with adriamycin and cyclophosphamide or etoposide and ifosfamide.
Chemotherapy is indicated both as an induction treatment for marginally-
resectable tumors and as the exclusive treatment for non-resectable, meta-
static, and recurrent tumors. An alternative option may be the use of
octreotide and prednisone in octreoscan-positive lesions. Targeted therapies
also represent a promising approach in specific molecular subsets of tumors.
Disclosure: The author has declared no conflicts of interest.
9IN
IMPROVING SURVIVAL IN LS-SCLC AND ES-SCLC WITH
RADIOTHERAPY
C. Faivre-Finn Department of Clinical Oncology, Christie Hospital NHS
Trust, Withington, Manchester/UNITED KINGDOM
Small-cell lung cancer (SCLC) constitutes 10-15% of all newly diagnosed
lung cancers. At the time of diagnosis, approximately 30% of patients with
SCLC will have limited-stage disease (LS-SCLC or stage I-III according to
the new TNM classification), and most long-term disease-free survivors
come from this group. Whilst the incidence of small cell lung cancer has
reduced over the last twenty years, the prognosis of the disease remains poor.
Major advances include improvements in RT techniques, the use of prophy-
lactic cranial irradiation (PCI) for all stages of SCLC and the improved
association of chemotherapy (CT) and RT. It is unlikely that future advances
in the treatment of SCLC will relate to standard CT. It is crucial that patients
with SCLC are given the opportunity to participate in clinical research in
order to continue to improve the survival of this disease. Ongoing clinical
trials addressing RT related questions include the CONVERT and the
CREST studies. CONVERT is a European phase III trial in LS-SCLC
comparing twice daily thoracic RT (45 Gy in 30 fractions starting with the
second cycle of cisplatin and etoposide) to a higher dose of conventional
radiation (66 Gy in 33 daily fractions over 6.5 weeks starting with the second
cycle of cisplatin and etoposide). The aim is to establish a standard of care
in good performance status LS-SCLC. A similar study is ongoing in the US.
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CREST is a Dutch Phase III trial randomising patients with ES-SCLC
responding to CT between thoracic RT and no thoracic RT followed by PCI
if appropriate. Molecular studies are ongoing aiming to gain improved
insight into the molecular biology of SCLC, discover and/or validate candi-
date biomarkers for response, resistance to or toxicity of systemic treatment
and radiation. There is now a concerted effort within the research community
to understand the molecular mechanisms that underpin the molecular path-
ways in cancer. It is hoped that this understanding will lead to the develop-
ment of targeted therapies that will not only prove efficacious but also less
toxic than more conventional CT treatments. In combination with newer
techniques such as conformal RT and better imaging, it is hoped that the rates
of long term survivors will increase significantly in the future.
Disclosure: The author has declared no conflicts of interest.
10IN
CIRCULATING LUNG CANCER CELLS
J. Mazie`res Department of Pneumology, Larrey Hospital, CHU Toulouse,
Toulouse/FRANCE
Tumor molecular characteristics are becoming crucial for determining the
better treatment for lung cancer patients. These data are usually obtained
from resected tumor or biopsies. Data are thus collected at the beginning of
the disease whereas many genetic abnormalities that can lead to acquired
drug resistance may emerge during treatment. Tumor sampling cannot be
repeatedly proposed during treatment to monitor changes in tumor charac-
teristics. Moreover most of the tumor samples are issued from the lung
primitive tissue and do not give complete information about the metastatic
potential of the tumor. Tumor cells are known to circulate in the blood of
patients with metastatic cancer suggesting that their detection might be useful
to obtain tumor-derived biological markers. Potential interest of the isolation
of lung cancer circulating cell are the following: -Diagnosis of lung cancer
by a non invasive method in high risk patients -Prognostic marker as the
presence of CTC is associated with shortened survival -Marker of treatment
efficacy by monitoring the blood tumor cell count during the treatment
-Analysis of tumor characteristics by performing cell and molecular biology
on isolated cells. There is no consensus on the optimal protocol for isolation
of circulating tumor DNA. Different procedure have been studied and
recently published recently: - magnetic beads conjugated antibodies against
epithelial-cell adhesion molecule (EpCAM). - microfluidic-based device
(called the CTC-chip) that can isolate, quantify, and analyze circulating
tumor cells from a blood sample. -ISET based on tumoral cell size. We will
focus on the potential role of CTC isolation for treatment optimization and
particularly on the monitoring of EGFR mutation during lung cancer evolu-
tion before and after treatment. We will develop different devices available
for CTC isolation and the perspectives concerning this very promising and
timely topic.
Disclosure: The author has declared no conflicts of interest.
11IN
PRINCIPLES OF MODERN RADIOTHERAPY FOR THE
NON-RADIATION ONCOLOGIST
M. Brada The Royal Marsden NHS Foundation Trust, The Institute of
Cancer Research, Sutton/UNITED KINGDOM
European Lung Cancer Conference Principles of Modern Radiotherapy for
the non radiation oncologist. Professor Michal Brada The Institute of Cancer
Research and The Royal Marsden NHS Foundation Trust, UK Radiotherapy
(RT) remains an effective curative and palliative treatment for localised lung
cancer and is generally delivered as photons (x-rays) by linear accelerator.
The standard technique is described as 3 dimensional conformal radiotherapy
(3DCRT) which aims to concentrate high dose to the tumour with minimum
dose to surrounding normal tissues and this is achieved by using multiple
shaped beams conforming to the shape of the tumour. The principle of
advanced techniques is better avoidance of normal tissues to allow dose
escalation without increasing treatment toxicity particularly to the lung.
Intensity modulated radiotherapy (IMRT), a variant of 3DC RT can shape
radiation to avoid adjacent critical normal structures and deliver differential
doses to various parts of the tumour (“dose painting”). Proton therapy can be
considered as potentially more conformal RT having the same biological
effect. Visualisation of the tumour close to the actual treatment with image
guided techniques (IGRT) and the use of “adaptive” RT improve the
accuracy of treatment further. One of the main challenges for NSCLC RT is
tumour motion and this can be dealt with using gating or tracking techniques
sparing more normal lung. Small localised tumours can currently be treated
to higher doses with more accurate often gated treatment techniques and this
is described as stereotactic body radiotherapy (SBRT) which achieves
excellent local control. The principles of the new techniques, their applica-
tion and the clinical results will be illustrated. Lung cancer RT is currently
at the forefront of innovation of RT technology with a great potential for
improved results combining novel techniques with dose escalation and with
biological targeted agents modifying radiation response.
Disclosure: The author has declared no conflicts of interest.
12IN
SCLC: DRUGS AND TARGETED THERAPIES
P. Baas Department of Thoracic Oncology, The Netherlands Cancer Insti-
tute, Amsterdam/NETHERLANDS
Small Cell Lung Cancer (SCLC) represents about 15% of all lung cancers
diagnosed annually. It is characterized by early dissemination; good initial
response to chemotherapy and its aggressive growth. SCLC is considered to
be a systemic disease since 60-7-% of the patients present with metastatic
disease. SCLC is responsive to many different chemotherapeutics and new,
targeted agents but rapidly develops drug resistance. For LS the standard in
Europe and the US is still the combination of concurrent chemo-radiother-
apy. Key is to keep the overall treatment time as short as possible to prevent
repopulation of the tumor cells and development of resistance to chemother-
apy. To improve outcome in SCLC many studies have examined the addition
of a third agent to the cisplatin-etoposide backbone. Drugs like taxanes,
thalidomide, vaccins BEC2 and topotecan have unfortunately not resulted in
an improved survival but only added more toxicity. Since many patients will
have recurrence of the disease, many different schedules of new drugs and
targeted agents have been tested in second line. Of these topotecan is the only
drug approved by the FDA for this indication. One of the new approaches is
to test promising drugs in a “window of opportunity”. The EORTC lung
cancer group is testing a multi-target tyrosine kinase inhibitor agent
(sunitinib) in patients with ES disease. The drug is given as single agent in
the first line with close follow-up to find early responses or patients who
progress. It is postulated that inhibition of multiple signaling pathways in
cancer cells might lead to quick responses and limited toxicity. Other groups
(CALGB) are combining sunitinib with cisplatin-etoposide to determine
optimal dose en response rate. Since SCLC has a high degree of vascular-
ization and VEGF expression, monoclonal angiogenesis inhibitors like bev-
acizumab have been tested in phase II setting with cisplatin-etoposide. The
response observed were interesting (1-year OS 49%) and has resulted in a
randomized phase 3 study. During the presentation on overview of all
recently tested drugs (amrubicin; Hedgehog inhibitors; pemetrexed; irinote-
can etc) and new approaches will be given.
Disclosure: P. Baas has been advisor for Merck Sharp Dohme and Hospira
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13IN
THE MANAGEMENT OF BRAIN METASTASES
R.O. Mirimanoff Radiation Oncology, Centre Hospitalier University Vau-
dois, Lausanne/SWITZERLAND
Brain metastases occur in 20-50% of NSCLC and 50-80% of SCLC. In this
review, we will look at evidence-based medicine data and give some perspec-
tives on the management of BM. We will address the problems of multiple BM,
single BM and prophylactic cranial irradiation. Recursive Partitioning Analysis
(RPA) is a powerful prognostic tool to facilitate treatment decisions. Dealing
with multiple BM, the use of corticosteroids was established more than 40 years
ago by a unique randomized trial (RCT). Palliative effect is high (80%) as well
as side-effects. Whole brain radiotherapy (WBRT) was evaluated in many RCTs
with a high (60-90%) response rate; several RT regimes are equivalent, but very
high dose per fraction should be avoided. In multiple BM from SCLC, the effect
of WBRT is comparable to that in NSCLC but chemotherapy (CXT) although
advocated is probably less effective than RT. Single BM from NSCLC occurs in
30% of all BM cases; several prognostic classifications including RPA are very
useful. Several options are available in single BM: WBRT, surgery (SX),
radiosurgery (RS) or any combination of these. All were studied in RCTs and
will be reviewed: the addition of WBRT to SX or RS gives a better neurological
tumour control, has little or no impact on survival, and may be more toxic.
However omitting WBRT after SX alone gives a higher risk of cerebro-spinal
fluid dissemination. Prophylactic cranial irradiation (PCI) has a major role in
SCLC. In limited disease, meta-analyses have shown a positive impact of PCI in the
decrease of brain relapse and in survival improvement, especially for patients in
complete remission. Surprisingly, this has been recently confirmed also in extensive
disease. Experience with PCI for NSCLC is still limited, but RCT suggest a
reduction of BM with no impact on survival. Toxicity of PCI is a matter of debate,
as neurological or neuro-cognitive impairment is already present prior to PCI in
almost half of patients. However RT toxicity is probably related to total dose and
dose per fraction. Perspectives : Future research should concentrate on : 1) combined
modalities in multiple BM. 2) Exploration of treatments in oligo-metastases. 3)
Further exploration of PCI in NSCLC. 4) Exploration of new, toxicity-sparing
radiotherapy techniques (IMRT, Tomotherapy etc).
Disclosure: The author has declared no conflicts of interest.
14IN
TARGETING LUNG CANCER INVASION AND METASTASIS:
LESSONS FROM THE PAST, CURRENT STATUS AND NEW
DIRECTIONS
O. Gautschi Medical Oncology, University Hospital, Bern/SWITZERLAND
Many cases of cancer death are related to metastasis. Therefore, pharmacological
inhibitors of cancer cell metastasis have substantial clinical potential. One of the
earliest steps in the process of metastasis is cancer cell invasion into surrounding
normal tiussue and into the blood stream. Invasion is mediated by many different
factors, including matrix metalloproteinases (MMP), focal adhesion kinases
(FAK), and Src family kinases (SFK). All these molecular drug targets are
currently under clinical investigation. MMP inhibitors have already been tested
in phase III trials, including patients with lung cancer. One of the largest trials
was BR.18, testing the MMP inhibitor BMS-275291 in combination with
carboplatin and paclitaxel in patients with advanced NSCLC. An update on more
recent clinical data with MMP inhibitors will be provided at the meeting.
Members of the SFK regulate adhesion and migration by cooperation with FAK
and integrin receptors. In humans, the SFK include c-Src, Yes, Fyn, Lyn, Lck,
Hck, Fgr, and Blk. Whereas c-Src, Yes and Fyn are ubiquitously expressed,
other SFK members are expressed predominatly in hematopoetic cells. c-Src is
frequently expressed and activated in primary SCLC and NSCLC. Several Src
inhibitors, including dasatinib, saracatinib, bosutinib, and KX2-391, are cur-
rently investigated in clinical trials. These compounds, as well as other Src
inhibitors, will be discussed in detail at the meeting. Additional topics will
include the potential mechanisms of drug sensitivity and/or resistance, the
interaction between Src and EGFR, as well as the current knowledge of
combination therapies, including Src inhibitors, radiation and chemotherapy. At
last, the current status of FAK inhibitors in the clinic will be summarized. (Grant
support: Swiss Cancer League and Bernese Cancer League).
Disclosure: O. Gautschi: Advisory boards by Amgen, Astrazeneca, Bayer,
Eli Lilly, Merck Serono, Novartis and Roche
15IN
THE NEW FRONTIERS IN SURGERY IN T4 TUMORS AND
METASTATIC DISEASE, INCLUDING SUPERIOR SULCUS
D. Grunenwald Thoracic Surgery, University of Paris Hoˆpital Tenon,
Paris/FRANCE
The 7th edition of the TNM staging system for lung cancer, edited under the
auspices of the International Association for the Study of Lung Cancer (IASLC)
carries several critical breakpoints. Among them, an improved specificity of T4
component, and a better definition of metastatic disease should affect the medical
practice. New frontiers in surgery have been established since T4 tumors
associated with N0-N1 nodal disease henceforth become stage IIIA, thus open-
ing new perspectives, particularly for superior sulcus tumors. Regarding the T4
descriptors from the 7th edition of the TNM staging system for lung cancer,
consistent series of extended resections have been reported in different situa-
tions. Proximal tumors from the lower lobe developed around the inferior
pulmonary vein may involve the atrial wall of the heart. In some cases a left atrial
resection can be performed. Low stages in nodal status were associated with
increased survival (p 0.0013). Invasion of the SVC by a T4 tumor in the right
upper lobe led surgical teams to attempt lobectomies or pneumonectomies
extended to the vena cava. A multicentric international review of prosthetic
replacement after superior vena cava resection for non small cell lung cancer in
28 patients (N2 involvement in 50%) showed morbidity and mortality rates of
39% and 14%, respectively. Overall 5-year survival rate was 15%. A bronchial
carcinoma from the right lung extended to the lower part of the thoracic trachea,
and/or the tracheal carina can be resected in selected patients. Long-term
survivals have been observed in 15 to 23% of the cases. The best local control
for resectable tumors is achieved by surgical operation, provided the resection is
complet and respecting oncologic principles. Recently reported experiences of
enbloc vertebrectomy demonstrate feasability of these challenging procedures.
Conclusion: Recent advances in patient’s care and surgical techniques allowed
surgeons to become more aggressive, and to propose extended resections in locally
advanced non-small cell lung cancer, with favorable long-term survival rates. The 7th
edition of TNM staging system adapted to these progress, by classifying T4N0-1
tumors in a “surgical” category, stage IIIA.
Disclosure: The author has declared no conflicts of interest.
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SURGERY STILL HAS A ROLE TO PLAY IN STAGE III
NSCLC
P. De Leyn Departmentof Thoracic Surgery, University Hospital Leuven,
Leuven/BELGIUM
Most patients with stage III have mediastinal lymph node (LN) involvement.
For stage IIIA-N2 disease a combination of chemotherapy with surgery
and/or radiotherapy will be the best strategy. There remains controversy on
the role of surgical multimodality treatment due to the lack of fully convincing
randomized trials and the diversity of phase II studies. The main reason for this
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controversy can be explained by the fact that N2-disease is a very heterogeneous
entity with a broad spectrum of metastatic LN involvement. The two randomized
trials failed to show a survival benefit for the surgical treated cohort. In the
Intergroup trial, potentially resectable N2-disease was included. In the EORTC
study, patients with irresectable N2-disease were included. In this study, induc-
tion chemotherapy did not convert unresectable disease into resectable disease as
illustrated by the low complete resection rate (50%) in the surgery arm – and, not
unexpectedly, did not result in better outcome compared with radiotherapy.
However, in the Intergroup trial disease free survival was significantly higher in
the surgical cohort and the 5-year survival was doubled (36%) compared to the
radiotherapy arm when pneumonectomy could be avoided. Moreover, both trials
observed substantial long-term survival in patients with mediastinal downstag-
ing. Prediction of complete resection and downstaging seems to be essential in
the setting of combined surgical multimodality. Baseline, patients with stage
IIIA should be evaluated by a multidisciplinary team including an experienced
thoracic surgeon in thoracic oncology assessing baseline resectability. Bulky,
extracapsular and/or multilevel disease are contraindicating surgical multimo-
dality treatments. After induction treatment, restaging should be performed.
Mainly patients with evidence of response in the primary tumor and LNs will
benefit from surgical exploration. PET-CT and invasive mediastinal techniques
are indicated. Patients should be carefully reassessed including new pulmonary
function tests with diffusion capacity. We believe that in experienced centers,
selected patients with N2-disease may benefit from surgical multimodality
treatment.
Disclosure: The author has declared no conflicts of interest.
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SURGERY STILL HAS A ROLE TO PLAY IN STAGE III
NSCLC
No abstract received at time of going to press.
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SURGERY HAS NO ROLE TO PLAY IN STAGE III NSCLC
B. Putnam Department of Thoracic Surgery, Vanderbilt University Medical
Center, Nashville/USA
Given: Surgery has no role to play in stage III (N2) NSCLC. The manage-
ment of clinically staged IIIA (N2) NSCLC challenges the clinician with the
heterogeneity of the local disease and the variable incidence of regional and
systemic metastasis. Patients with cStage IIIA (N2) NSCLC should be
preferentially entered into a prospective clinical trial. In the absence of such
a trial, chemoradiotherapy would be considered standard. The North Amer-
ican Intergroup 0139 phase III study of concurrent chemotherapy and
radiotherapy (CT/RT) vs. CT/RT followed by surgical resection (S) for stage
IIIA (pN2) NSCLC was designed to evaluate the role of resection after
chemotherapy and radiation therapy. Pneumonectomy accounted for 14/15
postoperative deaths and may have compromised overall survival. The study
showed that no significant survival advantage CT/RTS compared to CT/RT
alone. Although progression free survival was better with resection after
CT/RT, morbidity and mortality were excessive. S might be considered in fit
patients; however, the survival with resection is no different than with
CT/RT alone, and the potential extent of the resection cannot be predicted.
Patients with persistent biopsy-proven N2 disease after induction therapy
have poor survival and are not operative candidates. Down-staging with
CT/RT (changing from cN2 to cN0) may identify patients with the potential
for better survival who would not need resection. The role of resection after
CT/RT for more limited stage IIIA is unclear and probably unsafe. Resection
following CT/RT over and above that achieved with CT/RT alone, may
improve local control, but the resection itself would carry significant operative
and perioperative risk for the general population of patients so treated. Subset
analysis of INT 0139 suggests lobectomy after CT/RT may carry survival
advantage, but the analysis is underpowered and may subject patients to
unnecessary surgery and significant perioperative morbidity. Future treatment
for stage IIIA (N2) NSCLC requires consistent excellent clinical staging,
identification of specific biological characteristics for more directed therapy, and
consideration of the risk and benefit ratio of all therapeutic modalities.
Disclosure: The author has declared no conflicts of interest.
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SURGERY HAS NO ROLE TO PLAY IN STAGE III (N2)
NSCLC
J. Jassem Oncology and Radiotherapy, Medical University, Gdansk
POLAND
The role of surgery in stage III NSCLC has long been debated. Stage III lung
cancer is the most heterogeneous subset of patients, as it ranges from T3N1
category, generally amenable to surgery, to T4N3 tumors, where surgery has
definitely no role. The most controversial category is that including patients with
ipsilateral mediastinal nodal metastases (IIIA-N2). Whereas surgery is techni-
cally feasible in some of these patients, most of them will relapse despite
apparently curative resection. Strategies that have been hoped to improve
prognosis in N2 patients include induction chemotherapy or chemoradiotherapy.
However, despite early positive studies, no large randomized trial demonstrated
improved survival with these approaches as compared to surgery alone or
surgery followed by chemotherapy. Results of studies investigating the role of
postoperative chemotherapy are inconsistent; nevertheless this method is cur-
rently considered the standard of care in patients with regional lymph node
involvement. Two large phase III studies compared directly multimodality
treatment including surgery versus non-surgical approaches in stage IIIA (N2)
patients. In the first study, patients were assigned to surgery or radiotherapy after
response to induction chemotherapy1. Both disease-free survival and overall
survival did not differ between the two study arms. The second study compared
concurrent chemotherapy and radiotherapy followed by resection versus defin-
itive concurrent chemotherapy and radiotherapy without resection2. Despite
increased disease-free survival in the surgery arm, there was again no survival
benefit of resection in the intent-to-treat analysis. This negative outcome was
partly attributed to increased treatment-related deaths of respiratory causes in
patients subjected to surgery. It is expected that the introduction of new staging
system for lung cancer may better select candidates for various therapeutic
strategies in NSCLC patients. Currently, given lower toxicity of radiotherapy,
there is however no strong rationale for using surgery in patients with proven
stage IIIA N2 disease.
References
1. Albain KS, et al. Lancet 2009;374:379.
2. van Meerbeeck JP, et al. J Natl Cancer Inst 2007;99:442.
Disclosure: The author has declared no conflicts of interest.
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STAGE IV: TARGETED THERAPY AS FIRST LINE
TREATMENT - YES
R. Pirker Department of Internal Medicine I, Medical University of Vienna,
Wien/AUSTRIA
Systemic chemotherapy is established in all stages of NSCLC. Further
improvement in the systemic therapy is anticipated through targeted thera-
pies, either as single modality or in combination with chemotherapy. Tar-
geted therapies currently focus on inhibition of both growth factor receptor
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systems and angiogenesis. Several targeted agents have been shown to
improve outcome in patients with advanced NSCLC. Cetuximab added to
chemotherapy increased survival of patients with advanced NSCLC in the
FLEX trial. A meta-analysis of randomized trials confirmed the benefit of
cetuximab. In selected patients with advanced non-squamous NSCLC, bevaci-
zumab added to chemotherapy increased progression-free survival (PFS) in two
trials and survival in one of these trials. EGFR-directed tyrosine kinase inhibitors
(erlotinib, gefitinib) have shown efficacy in patients with advanced NSCLC
previously treated with chemotherapy. In the first-line setting in advanced
NSCLC, gefitinib administered until disease progression resulted in superior
PFS compared to up to 6 cycles of carboplatin plus paclitaxel in patients with
EGFR activating mutations. Erlotinib was also shown to improve PFS and
survival when given as a maintenance therapy in selected patients with advanced
NSCLC. Thus targeted therapies have resulted in clinically relevant improve-
ments in the management of patients with advanced NSCLC. These improve-
ments have to be seen in the context of both a difficult to treat disease and the
high frequency of NSCLC. Targeted therapies active in advanced NSCLC also
lend themselves for evaluation in earlier stages of NSCLC with the primary aim
of cure. Future research will focus on the characterization of biomarkers for
selection of those patients who benefit most, the optimal scheduling of targeted
agents with chemotherapy, and the characterization of new targets. Targeted
therapies eventually will allow an individualized therapy based on patient
characteristics, molecular tumor features, convenient administration, costs and
patient preference. In conclusion, targeted therapies have been shown to benefit
patients with advanced NSCLC, have led to a better understanding of the biology
of lung cancer, and will continue to stimulate both basic and clinical research.
Disclosure: R. Pirker: Honoraria for Consultant/Advisory Board: Merck
Serono, Astra Zeneca, Roche, Eli Lilly Speaker’s fee: Merck Serono, Astra
Zeneca, Roche, Eli Lilly.
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STAGE IV: TARGETED THERAPY AS FIRST LINE
TREATMENT - NO
G.V. Scagliotti Thoracic Oncology Unit, University of Turin, Orbassano/
ITALY
Targeted agents are extremely active to treat homogeneous cancer patient
population which harbour a specific molecular abnormality or profile, or
express a specific receptor or antigen. In advanced NSCLC phase III studies,
collectively including more than 20.000 unselected patients, in which tar-
geted therapies were added to platinum-based doublets, in the vast majority
of these studies no progression-free (PFS) or overall survival (OS) improve-
ment was observed. The anti-VEGF monoclonal antibody bevacizumab was
the first targeted agent to prolong survival when added to a first-line doublet
in advanced NSCLC. However grade  3 adverse events occurred at a
significantly higher rate in the bevacizumab-containing arm including bleed-
ing, hypertension and proteinuria. A total of 15 treatment-related deaths
occurred in the bevacizumab/chemotherapy arm, including 5 from pulmonary
hemorrhage. A second bevacizumab study demonstrated an improvement in
response rate and progression-free survival (PFS) but no statistically significant
improvement in OS. More recently in phase III studies a detrimental activity in
squamous cell carcinoma of the lung of two VEGFR multiple tyrosine kinase
inhibitors, sorafenib and motesanib, has been demonstrated when added to
carboplatin and paclitaxel. The anti-EGFR monoclonal antibody cetuximab
when added to cisplatin and vinorelbine and in maintenance after chemotherapy
improved modestly OS but not PFS. Any attempt to identify through molecular
markers or specific a molecular profile patients which can most benefit from
bevacizumab and cetuximab have failed. Two papers reported about the use of
EGFR-TKIs as first-line therapy in selected patients with advanced NSCLC.
Both studies showed significant improvements in response rate and PFS in
patients whose tumors had EGFR mutations. A Spanish group screened over two
thousands patients for the presence of EGFR mutations, that were more frequent
in females, adenocarcinomas and non-smoking patients. Patients who presented
an EGFR mutation were treated with upfront erlotinib with median survival of
27 months but, more importantly, OS in EGFR mutated tumors did not vary if
patients received EGFR-TKIs front- or second-line.
Disclosure: G.V. Scagliotti: honoraria from AstraZeneca, Eli Lilly, Sano-
fiaventis and Roche.
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STAGE III: COMBINED TREATMENT - SEQUENTIAL
R. Dziadziuszko Department of Oncology and Radiotherapy, Medical Uni-
versity of Gdansk, Gdansk/POLAND
A combination of chemotherapy and radiation has become the standard man-
agement in locally advanced inoperable (stage III) non-small cell lung cancer
(NSCLC). Available evidence indicates higher efficacy of concomitant versus
sequential chemo-radiation. However, the magnitude of benefit is relatively
modest (4.5% absolute survival benefit at five years) and achieved at the expense
of increased toxicity, particularly acute esophagitis. Given large tumor bulk,
frequent comorbid conditions and advanced age in a proportion of stage III
patients, the choice of concomitant versus sequential treatment should be well
balanced. Precise and uniformly adopted criteria of patient evaluation for either
treatment strategy are lacking. Recent report indicates that approximately 60% of
stage III NSCLC patients under the age of 75 would not be candidates for
concurrent approach. These patients may clearly benefit from sequential treat-
ment as compared to radiotherapy alone. Recent clinical trials exploring dose,
fractionation, volume and technique of radiation delivery in stage III NSCLC
will be discussed, with emphasis on choice of concurrent versus sequential
chemoradiotherapy in the study designs. Issues of patient selection based on
molecular predictive factors and incorporation of targeted therapies into treat-
ment strategy are poorly studied and warrant more attention.
Disclosure: The author has declared no conflicts of interest.
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STAGE III: COMBINED TREATMENT - CONCURRENT
D. De Ruysscher Department of Radiation Oncology (Maastro Clinic),
Maastricht University Medical Center  GROW Research Institute, Maas-
tricht/NETHERLANDS
After having established the superiority of induction chemotherapy followed
by radiotherapy (RT) over RT alone, several randomized studies and two
meta-analyses have clearly demonstrated a superior survival with concurrent
chemo-radiation compared to sequential administration. The survival at 5
years increased from about 10 % with sequential chemo-radiation to approx-
imately 15 % with the concurrent approach. This improved survival has been
attributed to improved local tumour control (LC) without affecting distant
metastases. This improved survival is at the expense of a higher incidence of
severe, though reversible oesophagitis, occurring in 20-30 % of the patients
for 3-6 weeks. No increased lung toxicity was observed. Also in concurrent
chemo-radiation it is of utmost importance to avoid treatment delays. In a
large series of the Radiation Therapy Oncology Group (RTOG), it was
demonstrated that each day of treatment prolongation beyond about 6.5
weeks resulted in a 2 % decrease of survival. Concurrent chemotherapy and
radiotherapy is only safe in patients with no or limited co-morbidities, who
are relatively young and have adequate organ functions. In a prospective,
population-based study, we could estimate that only about 40 % of the
patients with stage III lung cancer are suitable for the concurrent approach.
For the other, sequential chemotherapy and radiotherapy remains a reason-
able alternative. Because of the still high local tumour recurrence rates in
non-surgical series, patients with resectable N2 disease were randomized
between surgery and definitive chemo-radiation after induction concurrent
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chemo-radiation in the Lung Intergroup Trial 0139. Survival was similar in
both arms, although local tumour progression was approximately reduced by
50 % by the addition of surgery. Ongoing research focuses on the integration
of concurrent chemo-radiation with targeted agents, the possibility to deliver
full-dose chemotherapy with radiotherapy, increasing the radiotherapy dose,
patient selection to individualise therapy and the role of prophylactic cranial
irradiation (PCI) to decrease the incidence of brain metastases.
Disclosure: The author has declared no conflicts of interest.
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24IN
HOW SHOULD WE USE T?
R. Rami-Porta Thoracic Surgery, Hospital Mutua de Terrassa, Terrassa/
SPAIN
The seventh edition of the tumour, node and metastasis (TNM) classification for
lung cancer introduced several changes in the T component: T1 is divided into
T1a (2 cm or less in greatest dimension) and T1b (more than 2 but not more than
3 cm); T2 is divided into T2a (more than 3 but not more than 5 cm) and T2b
(more than 5 but not more than 7 cm); T2 greater than 7 cm is reclassified as T3;
T4 by additional nodule(s) in the same lobe of the primary tumour is reclassified
as T3; and M1 by additional nodule(s) in another ipsilateral lobe is reclassified
as T4. Malignant pleural effusion is now under the M1a category. Tumour size
has much more relevance than it had in the previous editions. Five tumour-size
groups with significantly different prognosis are defined in contrast to the
previous two-size groups. Because tumour size has an important prognostic
impact, its measurement is essential to classify the tumour correctly. Patients
who are potential candidates for radical treatment have a computed tomography
(CT) scan of the chest and upper abdomen. Tumour size is measured on the CT
scan and the greatest dimension recorded. This is usually done on the two-
dimension axial slices, but if the CT has software with possibilities for coronal
and sagital reconstructions, the craneo-caudal size should be checked as it may
be the greatest and the one that should count to determine tumour size.
Atelectasis and pneumonitis that comprise less than the entire lung and reach the
hilum are T2 descriptors, and if they comprise the entire lung, T3 descriptors.
Tumour size is not easy to measure in these cases. Integrated CT and positron
emission tomography (PET) is useful to differentiate tumour from collapsed lung,
and may help to record the precise tumour size and the extent of atelectasis. Unless
the endobronchial tumour is clearly visible on CT scan, distance from the carina is
best determined at bronchoscopy. This is an important measurement performed
during the clinical phase of staging, and it is likely to be the most reliable, because
the pathologist will not be able to measure it unless the surgical specimen includes
the carina, too. Within the possibilities of each multidisciplinary team, the most
accurate and reliable methods should be applied in the clinical staging of lung cancer
to determine the T component of the classification.
Disclosure: The author has declared no conflicts of interest.
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MULTIPLE NODULES IN THE LUNGS
P.E. Postmus Pulmonary Diseases 4a50, VU University Medical Center,
Amsterdam/NETHERLANDS
The revison of the classification of lung cancer – UICC 7 – has brought a
number of changes for classifying patients with nodules in the lungs. Based
on the large database of the IASLC it became clear that patients with a
nodule or nodules in the same lobe as the primary tumor have a better
prognosis that is better than of patients with T4 tumors (old classification)
and more or less identical to patients with T3 tumors. Comparable changes
were implemented for patients with a nodule or nodules in the same lung as
the primary tumor but in a different lobe. These patients have a better
prognosis than M1 (old classification) cases and behave more like T4 tumors.
Furthermore of all patients with signs of metastases outside the affected lung
the ones with nodules in the contralateral lung have a slightly better outcome
than other case with M1 disease, therefore this group was split up in M1a and
M1b. Staging of patients is especially useful for defining the prognosis of a
case and can as such be of help in making clinical decisions on potential
valuable treatments for the individual patient. As the UICC 7 classification is
based on retrospective analysis of a large number of cases from all kinds of
databases it was impossible to fine-tune this aspect of staging of lung cancer.
For example it was impossible to differentiate between single and multiple
nodules in the same or in the contralateral lung. In this session cases will be
demonstrated with multiple nodules in the lung of lungs and potentially
approaches will be discussed.
Disclosure: The author has declared no conflicts of interest.
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STAGING OF SMALL CELL LUNG CANCER
F.A. Shepherd Department of Medicine, Division of Medical Oncology and
Hematology of the University Health Network, Princess Margaret Hospital
and University of Toronto, Toronto/CANADA
The first staging system for small cell lung cancer (SCLC), introduced by the
Veterans’ Administration Lung Study Group (VALSG) divided SCLC into
two subgroups termed “Limited” and “Extensive” Disease. Limited Disease
(LD) was characterized by tumors confined to one hemi-thorax, although
local extension and ipsilateral, supra-clavicular nodes could also be present
if they could be encompassed in the radiation field of the primary tumor. All
other patients were classified as extensive disease (ED). In 1989, the
International Association for the Study of Lung Cancer (IASLC) recom-
mended that LD should be expanded to include patients with tumors limited
to one hemithorax with regional lymph node metastases, including hilar,
ipsilateral and contralateral mediastinal and ipsilateral and contralateral
supra-clavicular nodes. They also recommended that patients with ipsilateral
pleural effusion (cytology positive or negative) should be considered to have
LD in the absence of extra-thoracic metastases. The TNM (tumor, node,
metastasis) staging systems of the American Joint Committee on Cancer
Staging (AJCC) and the Union Internationale Contre le Cancer (UICC) are
also applicable to SCLC, but are used less frequently, particularly in the
non-surgical setting. The IASLC database contained 12,620 eligible cases of
small cell histology with TNM staging available for 8088 patients. Clinical
staging: Increasing clinical T and N categories, using the 6th edition TNM
system are associated with progressively lower survival. In the IASLC
proposal for the 7th edition, the presence of a pleural effusion will be
considered as M1 disease. In the SCLC database, the survival of LD patients
with effusion (cytologically negative or positive) was intermediate between
that of LD patients without effusion and ED patients, and the survival of LD
patients with cytologically positive effusions was superior to that of ED
patients (p0.0001). Surgical Staging: Of the 12,620 eligible SCLC cases,
349 had undergone surgical resection and full pathologic TNM staging was
available for 262 patients. Increasing T and N categories were associated
with worsening survival. TNM classification: The proposals made by the
IASLC for the 7th edition of the TNM staging system also appear to have
relevance to SCLC. The Small Cell Lung Cancer Subcommittee of the
IASLC Lung Cancer Staging Committee has recommended that TNM
staging be applied in SCLC and that stratification by TNM stage be
incorporated into clinical trials in Stage I-III SCLC. For prospective staging
validation studies, more information must be collected to define the N
category more clearly and to determine whether there is a difference in
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prognosis for patients with cytology negative or positive pleural effusions
and for patients with pericardial effusions.
Disclosure: The author has declared no conflicts of interest.
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CONSEQUENCES OF THE NEW STAGING SYSTEM
J-P. Sculier Soins Intensifs et Oncologie Thoracique, Institut Jules Bordet,
Bruxelles/BELGIUM
The new system proposed by the IASLC staging project has introduced
multiple changes in the TNM classification of lung cancer, taking into
account tumour size in the T descriptors, site of other lung nodules,
introduction of a new M1a category and a better grouping of the TNM
subsets, proposing a new thoracic lymph node map, extending its application
to other histological type than non-small cell lung cancer (small cell lung
cancer, carcinoid tumours). All those changes have practical operational and
prognostic consequences. Operational consequences consist in a better ap-
proach of the therapeutic management of lung cancer patients with the
following considerations. For stage I, whatever the histological type, the
main treatment will be surgery; the role of adjuvant chemotherapy in
non-small cell lung cancer remains to be defined. For stage II, treatment will
be based on surgery and adjuvant cisplatin-based chemotherapy; in case of
stage IIB by satellite nodule in the same lobe, the role of adjuvant chemo-
therapy has to be assessed. For stage III, treatment will be multimodal,
combining, surgery, radiotherapy and/or chemotherapy; the new system does
not allow selecting the therapeutic approach on the only basis of the TNM,
particularly concerning thoracic irradiation; it requires a multidisciplinary
discussion. The role of the new universal mediastinal lymph node map and
the concept of nodal zones have to be validated. For stage IV, medical
treatment (chemotherapy, biological agents) will be proposed; sites of
metastases such as brain involvement have to be considered in some patients
and, in the future, molecular tests such as EGFr mutations might be other
important operational factors. In term of prognosis, the new staging system
is applicable for all types of histology, including carcinoid tumours. In
addition, non-anatomical prognostic factors have been validated in the very
large series of cases provided by the data basis. Those are performance
status, sex, age and histological subtype. Other potential useful factors are
some routine biological tests and the SUVmax measured on the primary
tumour on PET scan; they require prospective validation by adequate studies
with multivariate models taking into account the other known independent
prognostic factors.
Disclosure: The author has declared no conflicts of interest.
NOVEL THERAPEUTIC AGENTS
28IN
TARGETING THE M-PHASE: FOCUS ON PLK-1 AND
AURORA B
F. Solca, D. Rudolph, U. Guertler Department of Pharmacology, Boehr-
inger-Ingelheim, RCV GmbH & Co KG, Vienna/AUSTRIA
Tubulin-binding anti-mitotic agents (e.g. taxanes and vinca alkaloids) rep-
resent established treatment modalities in cancer therapy. Some of their
limitations, in particular side effects such as neuropathy, are based on their
effects on microtubule function in interphase cells. Non-structural compo-
nents of the mitotic machinery, such as Aurora kinases or Polo-like kinase 1
(Plk1), which are exclusively expressed in dividing cells, are therefore
considered to be attractive drug targets for cancer therapy. Plk1 regulates
multiple steps in mitosis including centrosome maturation and separation,
bipolar spindle formation and cytokinesis. Inhibition of Plk1 leads to the
formation of monopolar spindles, prolonged mitotic arrest in prometaphase
followed by apoptotic cell death due to activation of the spindle assembly
checkpoint (SAC), a mitotic checkpoint that delays the onset of anaphase
until all chromosomes have attached to a bipolar spindle and are ready for
segregation. BI 6727 is a potent and selective Plk1 inhibitor (IC50 0.8 nM).
It inhibits proliferation of a broad panel of cancer cell lines irrespective of
their oncogenome signature (EC50  11-37 nM) and shows excellent
anti-tumor activity in multiple xenograft models of human cancer. Its distinct
pharmacokinetic profile characterized by a high volume of distribution and a
long terminal half-life indicates sustained tissue exposure. BI 6727 is
currently in Phase II clinical trials. While Plk1 inhibitors, Aurora A inhibitors
as well as tubulin binders lead to activation of the SAC, Aurora B inhibitors
have a distinct mode of action. Inactivation of Aurora B abrogates the SAC
and causes premature mitotic exit without cytokinesis, resulting in polyploid
cells that eventually stop further DNA replication. BI 811283, a potent
inhibitor of Aurora B kinase (IC50  9 nM), blocks proliferation in various
human cancer cell lines (EC50  2-14 nM) and induces the characteristic
polyploid phenotype. Hallmarks of senescence as well as a slow onset of
apoptosis in a small fraction of cells have been observed. Excellent in vivo
activity of BI 811283 has been demonstrated in multiple cancer xenograft
models in nude mice. Phase I clinical trials with this inhibitor are currently
ongoing.
Disclosure: F. Solca: Boehringer Ingelheim employee; D. Rudolph: Boehr-
inger Ingelheim employee; U. Guertler: Boehringer Ingelheim employee
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GLI INHIBITORS/HEDGEHOG PATHWAY INHIBITORS
D. Jablons Thoracic Surgery, UCSF Helen Diller Family, San Francisco/
USA
Hedgehog (Hh) and Wnt signaling pathways play key roles during embry-
onic development and postembryonic stem cell regulation. Aberrant activa-
tion of Hh and Wnt signaling is thought to arm normal stem cells with
proliferative and anti-apoptotic armor, setting the stage for carcinogenesis
with its hallmark of destructive processes: invasion, progression and distant
micrometastatic spread. Targeted inhibition of aberrantly activated Hh sig-
naling may lead to the suppression or killing of cancer stem cells awakened
from biological dormancy by aberrant Hh activation and propelled forward
by deranged Hh signaling. Targeted inhibition at cell membrane level of Hh
pathway has shown promising preclinical and clinical anti-cancer activity in
basal-cell carcinoma (BCC) and medulloblastoma suggesting its potential
clinical applications in the treatment of multiple cancers through possible
suppression of cancer stem cells. However, recent reports about noncanoni-
cal Gli activation through alternative pathways such as RAS or TGF
suggest the potential importance of Gli function as a therapeutic target. We
hypothesize that blockade of Gli function results in inhibition of Hh pathway
downstream activity, which in turn halt the proliferation of Gli-activated
cancer cells. We screened a set of compounds based on their ability to
interfere the Gli dependent transcription activity in an in vitro system. We
demonstrate that the identified hit compound efficiently inhibits Gli depen-
dent transcription activity. More importantly, the hit compound suppressed
cancer cell proliferation in a Gli-dependent manner compared to the less
effectiveness of upstream Hh inhibitor cyclopamine in such situations in
vitro and inhibited tumor growth in vivo, suggesting a more effective cancer
therapeutic strategy of blocking Gli function, a key control point of down-
stream oncogenic pathway activation.
Disclosure: The author has declared no conflicts of interest.
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FORETINIB: A MULTIKINASE AXL/MET INHIBITOR
L. Liu Translational Research, GlaxoSmithKline, King of Prussia/USA
MET and AXL are membrane-bound receptor tyrosine kinases (RTKs),
whose frequent deregulation in human cancer is associated with poor
prognosis and an aggressive cancer phenotype. Activation of MET promotes
cellular proliferation, migration and invasion and confers resistance to
HER-targeted agents in a subset of tumors including lung and breast.
Foretinib (GSK1363089) is an RTK inhibitor with potent activity (IC50
values 8 nM) against MET, AXL and VEGFR2 that is currently in phase
I/II clinical trials for gastric, papillary renal and hepatocellular carcinomas.
Foretinib demonstrated potent antitumor activity in MET-amplified tumor
lines and tumor xenograft models. In MET amplified MKN45 gastric tumor
cells and xenografts, foretinib inhibited phosphorylation of MET and sup-
pressed phosphorylation of AKT and ERK in a dose-dependent manner.
Foretinib alters expression of genes involved in RTK cross-talk, PI3K and
MAPK signaling, cell motility and survival both in vitro and in vivo, and
exhibits a gene expression profile similar to that of a MET-selective inhib-
itor. In addition, HER1/2 amplified tumor cell lines with MET-amplification
or over-expression that were resistant to HER-targeted agents lapatinib and
erlotinib were sensitive to combination therapy with either of these agents
and foretinib. AXL contains a kinase domain closely related to MET and an
extracellular domain resembling that of neural cell adhesion molecules. AXL
overexpression is associated with poor prognosis and increased invasiveness
of breast, lung, ovarian, renal, glioma and other cancers. Foretinib potently
inhibited AXL phosphorylation and restored lapatinib and trastuzumab
sensitivity in multiple HER2-positive, ER-positive breast cancer cell lines
overexpressing AXL. Furthermore, treatment of these cells with siRNA to
AXL or HER2 restored sensitivity to lapatinib or foretinib, respectively,
suggesting cross-talk between AXL and HER2. These data demonstrate that
foretinib is a potent inhibitor of MET and AXL that may be an effective
therapy for cancers with MET and/or AXL overexpression. Additional
clinical studies of foretinib as a single agent and in combination with
lapatinib and erlotinib are warranted.
Disclosure: L. Liu: The author is a stock holder and employee of Glaxo-
SmithKline
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TARGETING ALK-REARRANGED NON-SMALL CELL
LUNG CARCINOMA
A.J. Iafrate1, E. Kwak2, Y. Bang3, B. Solomon4, A. Shaw2, D.R. Camidge5,
S.H. Ou6, R. Maki7, R. Salgia8, J. Clark2 1Department of Pathology,
Massachusetts General Hospital, Boston/USA, 2Cancer Center, Massachu-
setts General Hospital, Boston/USA, 3Internal Medicine, Seoul National
University Hospital, Seoul/KOREA, 4Medical Oncology, Peter MacCallum
Cancer Centre, East Melbourne/AUSTRALIA, 5Medical Oncology, Univer-
sity of Colorado Health Sciences Center, Denver/USA, 6Medicine-Hematol-
ogy/Oncology, Chao Family Comprehensive Cancer Center, UC Irvine
Medical Center, Orange/USA, 7Medicine, Memorial Sloan Kettering Cancer
Center, New York/USA, 8Medicine, University of Chicago, Chicago/USA
Rearrangement of the ALK gene has recently been described in a subset of
non-small cell lung carcinoma (NSCLC), resulting in oncogenic fusion genes
most commonly partnering with the EML4 gene. ALK-positive cases possess
a distinct profile, with the majority of cases occurring in never or light
smokers, and being associated with a younger age (median age 55 vs. 65 in
ALK-negative cases), and associated with distinct histologic characteristics,
including signet ring cell morphology in many cases. The overall prevalence
of ALK-positive cases is approximately 4%, but is significantly higher in
populations enriched in younger non-smoking patients. Rejecting both
KRAS and EGFR-mutant cases, which appear mutually exclusive of ALK-
positivity, allows further enrichment of ALK-positive cases.
The effectiveness of targeting ALK in these patients has been tested in a phase
I trial of PF-02341066, a small molecule inhibitor of the ALK and MET receptor
tyrosine kinases. Prospective screening of NSCLC samples with an ALK FISH
break-apart probe has allowed the enrollment of a molecularly defined cohort,
treated at the recommended Phase 2 dose (orally at 250mg BID). Clinical
responses were determined using RECIST with radiographic studies repeated
every 8 weeks. Approximately 1,000 NSCLC patients have been screened to
identify70 ALK-positives. With few exceptions, patients had adenocarcinoma
histology and were never or former smokers. The median number of prior lines
of therapy was 3 (range, 0-7). To date, the response rate (complete  partial
responses) is approximately 65%; the median progression-free survival has not
been reached. Radiological responses typically were observed at the first or
second restaging CT scan.
Based on the promising results of this trial, a Phase 3 study has been initiated
with PF-02341066 in ALK-positive cases. Prospective identification of molec-
ularly defined cohorts can be achieved in the setting of a phase 1 clinical trial,
and thereby expedite the development of targeted cancer therapies.
Disclosure: J. Iafrate: I have been a paid consultant to Pfizer in the
development of companion diagnostics for PF-02341066 ($10,000). I have
been a member of the Pfizer advisory board in the development of PF-
02341066; B. Solomon: Research funding to laboratory to study ALK in
NSCLC from Pfizer; All other authors have declared no conflicts of interest.
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HOW TO MANAGE STAGE I DISEASE
P. Van Houtte Department of Radio-oncology, Institut Jules Bordet, Brus-
sels/BELGIUM
Surgery is considered to be the cornerstone in treating patients with stage I
NSCLC. Indeed, a lobectomy or an anatomical segmentectomy in selected
cases coupled with a lymph node dissection is considered to be the reference.
Nevertheless, stage I NSCLCL is a more complex issue: there is a wide range
of clinical situation related to the tumor extent, size or location and the
patient co morbidities. Today, there are several alternatives to surgery for
occult lung cancer: cryosurgery, endoluminal brachytherapy or phototherapy.
For larger tumors, stereotactic body radiotherapy (SBRT) or radiofrequency
are two modalities challenging surgery for high-risk patients. What are their
advantages and drawbacks? Surgery allows having a pathological diagnose
and may include a lymph node dissection; its limit is mainly related to the
patient physiological status. A wedge resection is less optimal with a higher
rate of local relapse. Radiofrequency is an invasive procedure with the risk
of pneumothorax. SBFRT has the advantage to be a non-invasive approach.
Tumor location and size are the limits of SBRT and radiofrequency (not to
close to the mediastinal structures). Two arguments often presented against
SBRT is the absence of histological diagnosis and nodal sampling. In the
PET-CT era, the rate of positive nodes is less than 10% in the absence of
mediastinal uptake; the number of isolated nodal relapse is relatively low in
the different published series confirming the observation of conventional
external radiotherapy with limited field. In the absence of tissue confirma-
tion, there is a risk treating benign disease but using strict criteria, positive
PET-CT, history of tobacco smoking, successive CT enlargement, this
probability is very low and the outcome of patients with or without tissue
diagnosis is very similar in the different published series. The current data for
the different modalities yields very similar results but we must be aware of
the limitations of many reported series: short follow-up, wide varieties of
cases (recurrent disease, primary tumor, second primary and even metastatic
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deposit). In the absence of phase III trials, treatment decision should be
individualized base taking into account patient condition, tumor location and
the local expertise.
Disclosure: The author has declared no conflicts of interest.
33IN
HOW IMPORTANT IS LYMPH NODE DISSECTION IN
STAGE I AND II?
P. De Leyn Department of Thoracic Surgery, University Hospital Leuven,
Leuven/BELGIUM
Accurate staging in patients with non-small cell lung cancer (NSCLC) is critical
since it provides prognostic information and guides the choice of treatments.
There are international followed guidelines on preoperative lymph node (LN)
staging. However, it is remarkable how much variability there exists in intra-
operative LN evaluation. For intra-operative LN evaluation different techniques
are used, ranging from simple visual inspection of the unopened mediastinum to
an extended bilateral LN dissection. In 2006, the European Society of Thoracic
Surgeons made guidelines on intraoperative lymph node staging for NSCLC
(Lardinois, 2006). For complete resection of NSCLC, a systematic nodal
dissection (SND) is recommended in all cases. The mediastinal, hilar and (in
case of lobectomy or segmentectomy) interlobar LNs are dissected and put in
different vials with separate labeling. The highest removed mediastinal LN
should be identified. Despite the systematic use of PET-CT and invasive
techniques as indicated by recent guidelines (De Leyn, 2008) systematic nodal
dissection will detect positive N1 and N2 nodes in 19% of patients with clinical
stage I NSCLC (Cerfolio, 2009). It remains unclear whether SND on itself
improves survival. In a meta-analysis, mediastinal LN dissection was associated
with improved survival (pooled hazard ratio 0.78 [confidence interval: 0.65 to
0.93]) compared to nodal sampling in patients undergoing resection for early
stage I-IIIA NSCLC (Wright, 2006). A subgroup analysis by stage was not
conducted due to the possibility of stage migration in the complete mediastinal
LN dissection group (Will Rogers phenomenon). A recent meta-analysis on the
use of adjuvant chemotherapy after complete resection of NSCLC showed clear
benefit in patients with N1 and N2-disease. So, by performing SND, more
patients will be accurately staged and treated. Nowadays, VATS lobectomy
combined with SND is performed for early stage NSCLC.
Conclusion: SND is important in stage I – II NSCLC. A meta-analysis
showed better survival over nodal sampling. Moreover, SND refines staging
allowing identification of patients that will benefit from adjuvant chemother-
apy. The beneficial role of SND is not available with other local therapies
such as radiofrequency ablation or stereotactic radiotherapy.
Disclosure: The author has declared no conflicts of interest.
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NEOADJUVANT VERSUS ADJUVANT CHEMOTHERAPY
E. Felip, P. Martı´nez Medical Oncology, Vall d’Hebron University Hospital,
Barcelona/SPAIN
Approximately one-third of NSCLC patients are diagnosed with early-stage
disease. For these patients surgery is the most effective treatment. However,
a high percentage of patients relapse and die of their disease. Adjuvant
platinum-based chemotherapy is now standard treatment in completely
resected patients with stage II and III, with a 5-year absolute survival benefit
of approximately 5%. The role of neoadjuvant chemotherapy remains un-
clear in early-stage disease. Several trials have assessed the use of neoadju-
vant chemotherapy, but none of these trials were conclusive to demonstrate
a benefit in survival. In a systematic review, which included 1,507 patients
randomized to neoadjuvant chemotherapy or surgery alone, there was a trend
to improve survival with neoadjuvant chemotherapy in a range of benefit
similar to adjuvant approach. The NATCH trial is a phase 3 randomized,
multicenter trial which compares surgery alone (S arm), or 3 cycles of
neoadjuvant carboplatin/paclitaxel followed by surgery (Neo arm), or sur-
gery followed by the same chemotherapy regimen (Adj arm). This trial is the
first to have Adj and Neo chemotherapy arms in its design, and to allocate
patients to the Adj arm before surgery. Eligible patients had to have clinical
stage IA with tumor size2 cm, IB, II or T3N1 NSCLC considered
resectable by the attending thoracic surgeon. The primary end point was
DFS. A total of 624 patients were randomized (S212, Neo201 and
Adj211 patients); 75% of patients had clinical stage I. Only 66% of the
patients allocated to Adj arm received the planned treatment as compared to
97% of the patients in the Neo arm. Patients in the Neo arm had a
non-significant trend toward longer DFS than those assigned to S arm (5-year
DFS 38.3% vs. 34.1%; HR 0.92; P0.176). Five-year DFS rates were 36.6%
in the Adj arm vs. 34.1% in the S arm (HR 0.96; P0.74). Median OS was
48.8, 55.2 and 50.3 months for S, Neo and Adj arms, respectively. In
summary, in clinically-staged resectable NSCLC, more patients are able to
receive neoadjuvant than adjuvant chemotherapy. The NATCH trial was not
powered to address the benefit of adjuvant chemotherapy in resected patients.
In the trial neoadjuvant chemotherapy yields a trend toward improved
disease-free survival when compared to surgery alone.
Disclosure: All authors have declared no conflicts of interest.
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FITNESS FOR RADICAL TREATMENT. ERS-ESTS
GUIDELINES
A. Charloux Service de Physiologie et d’Explorations Fonctionnelles, NHC,
University Hospital of Strasbourg, Nouvel Hopital Civil BP 426, Strasbourg/
FRANCE
The objective of the task force was to develop up-to-date clinical guidelines on
fitness for surgery and chemo-radiotherapy. Evidence supporting each recom-
mendation was graded according to the Scottish Intercollegiate Guidelines
Network Grading Review Group. Regarding the preoperative evaluation of the
lung resection candidate, all available information was integrated in a functional
algorithm (Eur Respir J 2009; 34: 17–41). The first step is a cardiologic
assessment based on validated index estimates of patient’s risk. Patients at low
cardiologic risk or with an optimized cardiologic treatment could proceed with
pulmonary evaluation. Spirometry and diffusion capacity of the lung for carbon
monoxide (DLCO) assessment is recommended in all patients. All patients with
either forced expiratory volume in one second (FEV1) or DLCO or both below
80% of predicted should ideally undergo a formal cardiopulmonary exercise test
(CPET) with peak oxygen consumption (VO2) measurement. However, since
many centres may have logistic problems in systematically performing this test,
a low-technology exercise test, preferentially stair climbing test (or shuttle walk
test) may be used as a screening test. Patients showing low performance at these
tests should perform a formal CPET. Patients with peakVO2 lower than 35% of
predicted value or 10 ml/kg/min and those with predicted post-operative (ppo)
FEV1 or ppoDLCO or both lower than 30% of predicted values in association
with ppoVO2peak lower than 35% of predicted value or 10 ml/kg/min are
regarded at prohibitive risk for major lung resection (lobectomy or pneumonec-
tomy) and other therapeutic options should be considered. The ppo values
calculation is based on the number of segments to be resected before lobectomy,
and on scintigraphic or quantitative CT studies before pneumonectomy. After a
careful selection based on cardiac and pulmonary parameters, patients unable to
perform exercise tests should be regarded as high-risk patients and monitored in
advanced care management setting. Contrary to lung resection, we were unable
to recommend any specific test, cut-off value, or algorithm before radio-
chemotherapy due to the lack of data.
Disclosure: The author has declared no conflicts of interest.
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BIOLOGICAL MARKERS FOR SELECTING PATIENTS
FOR CHEMOTHERAPY
No abstract received at time of going to press.
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HOW FAR CAN WE MINIMISE SURGERY FOR STAGE I?
H. Asamura Division of Thoracic Surgery, National Cancer Center Hospi-
tal, Tokyo/JAPAN
The history of lung cancer surgery is that of “down-sizing” of the extent of
pulmonary parenchyma which are to be removed together with a primary
lung cancer lesion. The evolution of lung cancer surgery has been well
described with several important surgical epochs. These included the first
successful pneumonectomy by Graham at the Barnes Hospital in St. Louis,
the concept of “radical pneumonectomy” [1] and “radical lobectomy” [2] by
Cahan at the Memorial Hospital in New York, and the randomized, phase III
study comparing the surgical outcome of lobectomy and sublobar resections
by North American Lung Cancer Study Group [3]. Through these, lobectomy
with lymph node sampling/dissection has been respected as the present-day
gold standard for the resection of lung cancer. The randomized study by
North American Lung Cancer Study Group is the only one randomized study
in the thoracic surgical community that directly compared the prognosis and
postoperative pulmonary function between lobectomy and sublobar resec-
tions for patients with T1N0M0 lung cancer less than 3 cm in diameter. The
results of the study showed that the prognosis of patients undergoing
sublobar resection was significantly worse than those undergoing lobectomy,
and the local recurrence rate for sublobar resection was also three times
higher. Although the following retrospective studies have suggested at least
the equivalent outcome after sublobar resection, there has been no definitive
demonstration of non-inferiority of sublobar resections by a fair, non-biased,
randomized study. On the other hand, owing to the advent of refined chest
CT images with higher resolution and CT screening programs, smaller lung
cancers are being encountered in our practice more frequently [4, 5].
Furthermore, the preoperative work-up for the surgical candidates has been
sophisticated together with new technologies such as PET scan. In these
situations, we have become able to deal with patients with the “true” early
stage lung cancers, and therefore, the clinical significance and importance of
sublobar resection need to be revised by definitive clinical trials. For these
reasons, two large scaled studies are underway across the ocean in US and
Japan. Both studies are targeting peripheral lung cancers less than 2 cm in
diameter without nodal involvement, and the accrual of more than 1,000
patients is planned with primary endpoint of over-all survival and secondary
endpoint of postoperative pulmonary function. The future international/
regional collaboration must be encouraged to draw meaningful conclusions
from these studies. The down-sizing of the extent of lymph node dissection
is another aspect of the issues in minimizing the lung cancer surgery. The
extent of the lymph node dissection generally has included the ipsilateral
pulmonary hilum and mediastinum. However, the recent studies have sug-
gested that the more efficient dissection could be achieved according to the
location of the primary tumor [6]. According to the definition by ESTS
(European Society of Thoracic Surgeons), such selective lymph node dis-
section is called as “lobe-specific systematic node dissection”, where it reads
“The mediastinal tissue containing specific lymph node stations are excised,
depending on the lobar location of the primary tumor” [7]. The future studies
should focusing upon more precise demonstration and larger accumulation of
the evidence that indicate the prognostic equivalence between lobectomy and
sublobar resection as well as between systematic and lobe-specific lymph
node dissection for lung cancer.
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STEREOTACTIC RADIOTHERAPY: THE NEW
STANDARD?
B.J. Slotman1, F.J. Lagerwaard2, C.J.A. Haasbeek3, S. Senan4 1Department
of Radiation Oncology, VU University Medical Center, Amsterdam/NETH-
ERLANDS, 2Radiation Oncology, VU University Medical Center, Amster-
dam/NETHERLANDS, 3Radiation Oncology, VU University Medical Center,
Amsterdam/NETHERLANDS, 4Department of Radiation Oncology, VU Uni-
versity Medical Centre, Amsterdam/NETHERLANDS
Background: Based on our experience with stereotactic radiotherapy (SRT) in
600 treated NSCLC pts, the role of SRT as the preferred treatment in
inoperable pts and as an alternative treatment for operable pts will be discussed.
Methods: This analysis pertains to 457 Stage I NSCLC pts, referred from 70
Dutch centers, treated between 2003 and 2009. Pts treated for double or
recurrent tumors were excluded. Evaluations before and regularly after SRT
included CT-scans and QoL evaluation. There were 287 T1N0 (63%) and
170 T2N0 (37%) tumors. Mean age was 73 years. All underwent 18FDG-PET
staging; 85% of pts were medically inoperable and 15% refused surgery.
Pathological confirmation of malignancy was obtained in 35% of pts. All
others had new and/or growing FDG-PET-positive lesions and CT-charac-
teristics of malignancy. The following risk-adapted SRT schemes were used:
3x20 Gy (n186;41%) for T1 tumors, 5x12 Gy (n195;43%) for T1 tumors
adjacent to the thoracic wall/mediastinum or T2 tumors, and 8x7.5 Gy
(n76;17%) for lesions adjacent to the pericardium or hilus.
Results: Median survival was 36 months (95% CI 30-42). Local failure was
seen in 13 pts (2.8%), resulting in an actuarial local failure-free survival rate of
91.6% at 3 yrs. Regional recurrences occurred in 31 pts (6.8%). Actuarial
regional-free survival at 3 yrs was 87.4%. Fifty-eight pts (12.7%) developed
distant metastases. Actuarial distant failure free survival was 75.6% at 3 yrs.
Survival and failure rates were not different in pts with or without histological
confirmation of malignancy (p0.37). On multivariate analysis, survival was
correlated with pre-SRT performance score (p0.01), lung function (p0.03)
and Charlson comorbidity score (p0.02). Treatment was well tolerated, with
fatigue (27%) being the most frequent early side effect, followed by dyspnea,
cough, nausea and chest wall pain (each 5%). Late toxicity included chronic
chest wall pain in 12 pts (3%), G3 radiation pneumonitis in 10 pts (2%), and
rib fractures in 4 pts (1%).
Conclusions: SRT results in high control rates with acceptable toxicity. It
has become the new standard of care for inoperable Stage I NSCLC pts. SRT
should be discussed as an alternative to surgery, particularly as pts with an
increased risk of surgical mortality can now be identified.
Disclosure: B.J. Slotman: Research funding from Varian medical systems;
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HOW CLOSE ARE WE TO CUSTOMIZING
CHEMOTHERAPY IN EARLY NSCLC?
J. Souglakos Department of Medical Onoclogy, University General Hospital
of Heraklion, Heraklion/GREECE
Surgery alone is considered as the standard of care for patients with operable
non–small-cell lung cancer (NSCLC). However, despite complete resection,
5-year survival rates have been disappointing, since one half of the patients
will develop relapse and die from the disease. Cisplatin-based adjuvant
chemotherapy offers a relatively small but statistical significant reduction in
risk of death (approximately 4%) at 5 years. The disappointing results of
long-term survival among patients with non-small cell lung cancer (NSCLC)
may reflect the lack of knowledge of the ways in which molecular abnor-
malities of neoplastic cells affect responsiveness to anticancer therapy. For
example, resistance to platinum compounds occurs partially because of
detoxification or efficient repair of damaged DNA by the numerous members of
the nucleotide excision repair (NER) system, including the endonuclease exci-
sion repair cross-complementing 1 (ERCC1). Clinical studies have demonstrated
that response and survival of patients with advanced NSCLC improved in the
presence of low ERCC1 expression. Moreover, data suggest that polymorphisms
of ERCC1 Asn118Asn (C_T), ERCC2 Lys751Gln (A_C), and Asp 312Asn
(G_A) may be associated with clinical outcome. Other trials suggest that specific
genetic signatures are associated with prognosis in early-stage NSCLC. For
example, three-gene signature (CSF1, EGFR, and CA IX) was associated with
prognosis in early-stage squamous cell carcinoma, while a four-gene model
based on expression of WNT3a, ERBB3, LCK, andRND3 could discriminate
patients with poor prognosis lung adenocarcinomas.
Moreover, the identification of specific pathways which provide survival
advantage or increased metastatic potential could help in the customization
of treatment for patients with early stages NSCLC. For example, LKB1
inactivation in tumors with KRAS mutations leads to increase metastatic
potential, in vitro studies. LKB1 inactivation is one of the most common
genetic events in NSCLC and its significance in correlation with the KRAS
mutations have never been studies in clinical samples. Overall, the remark-
able advances in the understanding of NSCLC biology have not yet been
translated into real benefit for patients with operable NSCLC.
Disclosure: The author has declared no conflicts of interest.
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EGFR MUTATIONS: CURRENT STATUS
R. Rosell1, M. Taron1, T. Mora´n2, M.A. Molina3, C. Costa3, S. Benlloch3, B.
Massuti4 1Medical Oncology Service, Catalan Institute of Oncology, Bada-
lona/SPAIN, 2Oncology Service, Catalan Institute of Oncology, Hospital
Germans Trias i Pujol, Badalona, Barcelona/SPAIN, 3Medical Oncology
Service, USP Dexeus University Institute, Barcelona/SPAIN, 4Oncology
Service, Hospital General de Alicante, Alicante/SPAIN
Non-small-cell lung cancer (NSCLC) driven by EGFR mutations occurs
predominantly in never-smokers, women and non-squamous cell histologies.
In the European population, the overall frequency of EGFR mutations is
15-17%; however, this can reach 40% in never-smokers, compared to 10%
in former smokers and 5% in current smokers. In females, the probability of
finding mutations is 30%, compared to 10% in males. The predominant
histological subtype of adenocarcinoma could have some influence on the
frequency of EGFR mutations although more clinical data is needed. A large
prospective study in patients with EGFR mutations showed that response to
erlotinib was 70%, progression free survival was 14 months, and median
survival was 27 months. Acquired resistance has been related to the presence
of the EGFR T790M mutation, and specific inhibitors of the T790M
mutation are promising. Additionally, the overexpression of MET has been
reported to be relevant. The detection of T790M is a technical issue that can
be solved with an adequate laboratory assay. We have detected EGFR double
mutations (T790M plus deletions or L858R) in 35% of pretreatment biopsies
from 129 NSCLC patients and observed a negative correlation with progres-
sion free survival to erlotinib. The baseline gene expression of other receptor
tyrosine kinases, such as MET, AXL, IGF-1R and IL-6 did not influence
erlotinib outcomes. Erlotinib can cause double-strand breaks that are repaired
mainly by homologous recombination. In experimental models, erlotinib
sensitivity is highly influenced by BRCA1 status. In our experience, low
levels of BRCA1 mRNA can prolong progression free survival to 27 months.
In the multivariate analysis of progression free survival, only T790M,
BRCA1 and PP2A/C were independent prognostic markers. In the multivariate
analysis of survival, only T790M and BRCA1 were identified as independent
markers. Based on our findings, we do not believe that T790M is the main cause of
acquired resistance. Rather, we speculate that the amplification of the pathway of
H2AX/RNF8/RNF168/RAP80/BRCA1 could be a main cause of resistance to
protracted treatment with erlotinib. At present, we are investigating the role of
BRCA1 SUMOylation and sensitivity to erlotinib.
Disclosure: All authors have declared no conflicts of interest.
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EGFR FISH: CURRENT STATUS
I.I. Wistuba Departments of Pathology and Thoracic/Head and Neck Medical
Oncology, University of Texas MD Anderson Cancer Center, Houston/USA
Molecular classification directing personalized treatment of NSCLC will be
essential to achieve meaningful improvements in patient outcomes. Strate-
gies for patient selection using molecular diagnostic tests have the potential
to increase the efficacy of molecular targeted therapy by optimizing and
monitoring response to treatment. EGFR tyrosine kinase inhibitors (TKIs)
have been demonstrated to significantly improve survival of NSCLC patients
compared to best supportive care. Mutations and increased gene copy
number of the EGFR gene have been associated with favorable response to
EGFR-TKIs in NSCLC. While testing for EGFR mutations is being widely
used as predictor of response and progression-free survival in NSCLC
patients treated with EGFR TKI therapy, the molecular analysis of EGFR
copy number using fluorescent in situ hybridization (FISH) methodology is
still restricted to clinical trials. EGFR increased copy number by FISH (high
polysomy and gene amplification) using the criteria developed by the
University of Colorado Cancer Center, US, has demonstrated favorable
survival outcomes after EGFR-TKI therapy in some clinical trials (i.e.,
BR.21 and ISEL), while it has demonstrated no improved benefit in survival
with similar treatment in others (i.e., INVITE, INTEREST and TRIBUTE).
This variability could be the result of multiple factors, including cross-study
difference (i.e., patient population and trial design) as well as differences in
the methodology used by the various laboratories for performing and inter-
preting the EGFR FISH assay. This assay has multiple technical challenges
at pre-analytical (sample collection and processing) and analytical (hybrid-
ization technique and scoring of probe signals) levels which may lead to
different interpretations of the results. Therefore, in order to prospectively
validate the clinical usefulness of EGFR FISH assay as a predictor of
outcome in EGFR-TKI treated NSCLC patients, studies will need very
highly standardized FISH testing procedures. Finally, the complex biology of
NSCLC, especially in the advanced stage, poses additional difficulties for an
in situ genomic test, including among others, tumor heterogeneity, differ-
ences between primary tumors and metastases, and potential differences
between chemotherapy naı¨ve and treated tumors.
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KRAS AND OTHER MUTATIONS: CURRENT STATUS
W. Pao Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Cen-
ter, Nashville/USA
Treatment decisions for patients with lung cancer have historically been
based upon tumor histology. However, with the emergence of new
targeted agents, information about the molecular composition of tumors
has become increasingly important. Here, we will review current knowl-
edge about molecular subsets of non-small cell lung cancer that could
have direct clinical relevance vis-a`-vis targeted therapies. Subsets are
defined by ‘driver mutations’ in EGFR, ALK, HER2, BRAF, KRAS,
PIK3CA, AKT1, and MEK1. Treatment tailored according to the genetic
makeup of individual tumors involves a paradigm shift but hopefully will
lead to substantial therapeutic improvements.
Disclosure: W. Pao: Consultancy: MolecularMD, AstraZeneca, Bristol-
Myers Squibb, Symphony Evolution Research funding: Exelixis, SGX Phar-
maceuticals Patent: EGFR T790M testing
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MOLECULAR AND PROTEOMIC ANALYSES OF SERUM
P.C. Mack Department of Internal Medicine Hematology/Oncology, Uni-
versity of California, Davis Campus, Sacramento/USA
In advanced NSCLC, routine detection of biomarkers predictive of
response to therapy has proven highly challenging. Impediments to
accurate detection include: limited availability of tumor specimens for
correlative analysis; tumor heterogeneity and formalin-induced DNA
artifacts. Fresh tissue is rarely acquired from patients presenting with
metastatic NSCLC. Archival specimens, while sufficient for pathological
diagnosis, are often too minimal for additional correlative studies. These
limitations are not applicable to analysis of patient plasma or sera.
Baseline blood specimens are available from essentially all consenting
patients, and on-treatment or post-treatment draws are often obtainable.
Collection of patient plasma is easily standardized, limiting variability
from handling, and can be stored frozen in aliquots. Investigations into
the clinical utility of blood-based tumor markers are ongoing on a number
of fronts. Proteomic analysis of serum, such as those presented by
Taguschi et al (JNCI, 2007), suggest that MALDI-TOF mass spectrom-
etry can be used to generate profiles for selection of patients likely to
benefit from EGFR tyrosine kinase inhibitors. This algorithm is currently
being evaluated in the Southwest Oncology Group (SWOG) trial S0709:
“A Phase II Selection Design of Carboplatin/Paclitaxel/Erlotinib or
Erlotinib Alone in Advanced Non-Small Cell Lung Cancer (NSCLC)
Patients with Performance Status 2 (PS 2) Selected by Serum Proteomics”
to enrich for patients with serum profiles associated with clinical benefit.
Shed tumor DNA in peripheral circulation is another potential source of
predictive information. Studies using highly sensitive mutation detection
techniques have identified the presence of KRAS and EGFR mutations in
shed tumor DNA from NSCLC patients. We have recently demonstrated
that the presence of EGFR mutations in plasma can predict significantly
improved tumor response rates and progression-free survival (Mack et al
JTO 2009). Multiplex profiling of plasma or serum cytokines, ligands,
growth factors, soluble receptors and angiogenic factors may also yield
prognostic, predictive or pharmacodynamic information with clinical
utility.
Disclosure: P.C. Mack: Speaker honorarium DxS LTD
EARLY NSCLC CONTROVERSIAL ISSUES
44IN
NEW TRIALS IN EARLY DISEASE COMPARING
SURGERY AND RADIATION
F.J. Lagerwaard Radiation Oncology, VU University Medical Center, Am-
sterdam/NETHERLANDS
Surgery has long been the undisputed treatment of choice in patients
presenting with Stage I non-small cell lung cancer (NSCLC), while radio-
therapy has been reserved for medically inoperable patients or those refusing
surgery. Stereotactic radiotherapy (SRT), which is characterized by the use
of ablative doses of radiation typically delivered in 3-5 fractions, achieves
local control rates in excess of 90% for patients with stage IA peripheral
tumors. Despite the very high radiation doses used, major toxicity is limited
to approximately 5% of patients who were treated for peripheral tumors.
Despite the lack of randomized data comparing conventionally fraction-
ated radiotherapy with SRT, a majority of members of the European
Society for Therapeutic Radiology and Oncology now consider SRT to be
their treatment of choice for patients with inoperable stage I NSCLC
[Widder J, pESTRO 2008]. The growing interest in evaluating SRT in
patients fit to undergo surgery has generated controversy in some quar-
ters. An excellent outcome was reported after SRT in a cohort of operable
patients [Onishi 2007], and has prompted the initiation of phase II trials
in this subset of operable patients. The results of the Japanese Clinical
Oncology group 0403 trial, where accrual has already been completed,
and the RTOG study 0618 in operable patients are awaited. However, an
open discussion on choice of treatment can only take place after a
randomized comparison. Two such prospective phase III trials comparing
SRT with surgery for Stage IA NSCLC cancer are currently ongoing: the
randomized Dutch ROSEL trial and the international STARS (Stereotac-
tic Radiosurgery vs. Surgery) trial. Although both trials are broadly
supported by the thoracic oncology community, patient accrual has thus
far been slow. Some of the challenges facing these prospective trials will
be discussed during the meeting.
Disclosure: F.J. Lagerwaard: The VU University medical center has a
research agreement with Varian medical systems
45IN
SOLITARY PULMONARY NODULES: DIAGNOSIS AND
MANAGEMENT
F.J.F. Herth Department of Internal Medicine, Pneumology and Critical
Care Medicine, University of Heidelberg, Heidelberg/GERMANY
Lung cancer is diagnosed in approximately 220 000 people each year in the
United States and is the leading cause of cancer death (incidence rate
72/100000). The need to work up and manage pulmonary nodules is
encountered with increasing frequency in chest medicine.. Imaging with CT
is very useful in the evaluation of lung cancer, but it lacks the sensitivity and
specificity to firmly establish a diagnosis on its own. For taking treatment
decisions regarding chemotherapy or surgical resection, tissue diagnosis is
essential in most patients’. Similarly, while PET scanning is more sensitive
than CT scanning in finding lung lesions, there are too many false positives
to allow treatment decisions to be consistently based on PET imaging alone.
As a result, while imaging plays a key role in the algorithms used to manage
lung cancer, often a tissue diagnosis will be required. Bronchoscopy has been
used in evaluating solitary pulmonary nodules (SPNs) and masses for more
than 30 years. In patients with such nodules, the diagnostic procedure is
usually performed as a transbronchial biopsy (TBBX) under fluoroscopic
guidance. The yield depends greatly on the size and location of the abnor-
mality and generally on the ability to visualize the lesion fluoroscopically.
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Nodules that are too small to be visualized by conventional fluoroscopy
during the procedure pose a particular problem. What are needed, therefore,
are new methods for navigation and localization, independent of visualiza-
tion by fluoroscopy, but still dependent on the technical skills of the
bronchoscopist. The first promising new technologi therefore are the avail-
able navigation systems. On the other hand, thin bronchoscopes have been
used in clinical practice and can be advanced to more peripheral bronchi than
the conventional bronchoscope. However, it is difficult to identify the route
to a pulmonary peripheral lesion under direct vision within the limited
bronchoscopic examination time. Therefore, before performing bronchos-
copy confirmation of the route to be used for the advance of the broncho-
scope by CT is very important. Also here new approaches like virtual
bronchoscopy based guidance system will increase the yield of the diagnostic
workup of solitary pulmonary nodules
Disclosure: The author has declared no conflicts of interest.
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PROGNOSTIC AND PREDICTIVE MARKERS FOR
SELECTING PATIENTS
M. Taron Medical Oncology Service, Institut Catala d’Oncologia, Bada-
lona, Barcelona/SPAIN
As we have previously shown (Rosell et al, PlosOne 2007), BRCA1 RNA
expression levels in surgically resected NSCLC patients is an independent
prognostic marker of survival. In addition, BRCA1 expression has also
shown to be predictive: patients with high BRCA1 expressing tumors are
sensitive to antimicrotubule drugs and resistant to cisplatin, and vice versa.
Based on these findings, the Spanish Lung Cancer Group (SLCG) conducted
a pilot study (SCAT; Spanish Customized Adjuvant Therapy in completely
resected pN1/pN2 NSCLC) where patients (n83) were prospectively
treated with adjuvant chemotherapy according to BRCA1 RNA levels in the
tumor specimens (assessed by real time quantitative PCR). Patients with low
levels (lowest tercile) were treated with gemcitabine/cisplatin; patients with
intermediate levels (middle tercile) were treated with docetaxel/cisplatin; and
patients with high levels (highest tercile) were treated with docetaxel alone.
As an exploratory analysis, Rap80 and Abraxas mRNA expression levels
were also analyzed. For the entire population, median disease-free and
overall survival were 22 and 43 months, respectively. In this study, no
significant differences were observed in DFS and OS according to the three
different groups of adjuvant treatment, showing the positive impact of
selection by BRCA1 expression, even in patients treated with docetaxel
alone. As a result of this pilot study, the SLCG opened a phase III
randomized trial in completely resected pN1/pN2 NSCLC with a control
arm, where patients are treated with adjuvant docetaxel/cisplatin chemother-
apy, and an experimental arm, where patients are treated according to
BRCA1 levels of expression, as previously described. At present, a total of
179 patients have been included from a planned total of 432 patients. PORT
has been considered for N2 patients. Additional markers will be analyzed:
EGFR and k-ras gene mutation status, as well as the expression of several
DNA-repair genes.
Disclosure: The author has declared no conflicts of interest.
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DO WE NEED CHEMOTHERAPY IN STAGE 1
NON-SMALL CELL LUNG CANCER?
N. Thatcher Department of Medical Oncology, Christie Hospital NHS
Foundation Trust, Manchester/UNITED KINGDOM
Introduction The new TNM(7) staging system upstages large T2(b) N0M0
tumours from IB to IIA , T2(a) NIM0 are downstaged from IIB to IIA and
T4N0,NI are downstaged from IIIB to IIIA ,with increased survival for the new
clinical IB , IIa disease(Detterbeck et al., Chest 2009). Adjuvant therapy based
on TNM6 The main controversy is the benefit or otherwise of treating 1B
disease. In general adjuvant treatment for 1A is not recommended but is
recommended for suitable patients with stage II and IIIA. The recommendation
is based on the Western adjuvant trials of cisplatin (LACE metaanalysis) which
revealed a worse survival in stage IA, HR 1.4 and only 0.93 in IB, but in stages
II, HR was 0.83 and IIIA also 0.83 (Pignon et al., J Clin Oncol 2008).In Japan
adjuvant tegafur-uracil is used, a meta-analysis mostly of stage 1 ,adenocarci-
noma patients was associated with improved 5 and 7 year survivals p0.001, but
the patients are not widely representative of a Western population(Hamada et al.,
J Clin Oncol 2005). Two trials raised the issue of platinum based CT in stage IB.
The CALGB trial with carboplatin paclitaxel showed no overall survival benefit
p0.12. In an unplanned subgroup analysis there was no improvement with
primary tumours 4cms HR was 0.69 p0.04(Strauss et al J Clin Oncol 2008).
The JBR10 trial has recently been updated and continues to show a benefit for
cisplatin vinorelbine, HR0.78, p 0.04, unlike the IALT update (Butts et al
J Clin Oncol 2010; Arriagada et al J Clin Oncol 2010). In stage 1B patients HR
was 1.03, p  0.87, when tumours  0.02. For the larger  4cms tumours the
HR was 0.66 versus 1.73 for smaller tumours, but p values for both were non
significant. Conclusion Adjuvant treatment for stage 1A is not recommended, for
1B disease a positive routine practice recommendation is problematic. There are
trials recruiting stage 1 patients and will allow the benefit or otherwise of
adjuvant treatment to be prospectively analysed.
Disclosure: N. Thatcher: adjuvant- BMS, Roche GSK honoraria
SUPPORTIVE AND PALLIATIVE CARE
48IN
PREDICTION AND PREVENTION OF BONE METASTASES
No abstract received at time of going to press.
49IN
SUPPORTIVE TREATMENT: ANTIEMETICS AND
NEUTROPENIA
M.S. Aapro Oncology, Institut Multidisciplinaire d’Oncologie, Genolier/
SWITZERLAND
Supportive care needs of lung cancer patients are several, related to the
underlying disease and its complications, including treatment induced neu-
tropenia and vomiting. Chemotherapy regimens used for non-small cell lung
cancer are rarely a cause for febrile neutropenia in more than 10% of the
patients, while this is more frequent in small-cell lung cancer regimens.
However, many of the studies excluded the not so rare patient with on-going
infection or a high-risk, like past infection and on-going obstructive lung
disease. The use of antibiotic prophylaxis to prevent infection and infection-
related complications in cancer patients at risk of neutropenia remains a
matter of debate. Current guidelines consistently advocate a risk threshold of
20% for routine G-CSF support in patients. We hope that the updated
European guidelines for the use of G-CSF will be ready in April at this
meeting. Despite the relevant progress achieved in the last 20 years, vomiting
and, especially, nausea, continue to be two of the most distressing side effects
of cancer chemotherapy. On June 2009 the European Society of Medical
Oncology (ESMO) and the Multinational Association of Supportive Care in
Cancer (MASCC) organized a new Consensus Conference on Antiemetics in
Perugia. This is a particularly relevant field for those treating lung cancer, where
a highly emetogenic drug like cisplatin continues to play a major role. Aprepi-
tant, a potent and selective antagonist of the neurokinin (NK)1 neurotransmitter
receptor is recommended to be part of a 3-drug preventative antiemetic regimen
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including single doses of a 5-HT3 receptor antagonist and dexamethasone given
before highly emetogenic chemotherapy (MASCC level of consensus: High;
MASCC level of confidence: High; ESMO level of evidence: I; ESMO grade of
recommendation: A ). No studies address the issue of whether palonosetron is
superior to other 5-HT3 receptor antagonists when an NK1 receptor antagonist is
used as recommended by guidelines. The Perugia committee was split on the
topic if palonosetron should be recommended as the 5-HT3 receptor antagonist
of choice in prevention of cisplatin-induced acute nausea and vomiting, while
this was accepted for anthracycline or other moderately emetogenic chemother-
apy when an NK1 receptor antagonist is not used.
Disclosure: M.S. Aapro is a consultant or speaker for Amgen, GSK, Helsinn,
JnJ, Merck, Roche, Sandoz, sanofi aventis, Vifor
50IN
HOW TO MANAGE THE SIDE-EFFECTS OF
CHEMOTHERAPY
T. Mora´n1, V. Quiroga2, S. Cros1, L. Capdevila1, A. Martinez1, C. Buge´s1,
R. Rosell3 1Oncology Service, Catalan Institute of Oncology, Hospital
Germans Trias i Pujol, Badalona, Barcelona/SPAIN, 2Oncology Service,
Institut Catala` d’Oncologia, Hospital Germans Trias i Pujol, Badalona,
Barcelona/SPAIN, 3Medical Oncology Service, Catalan Institute of Oncol-
ogy, Badalona/SPAIN
Anaemia in patients with cancer may be attributed to multiple factors. This
anaemia is related to chemotherapy in approximately 60% of patients, while
other causes have to be evaluated in 40% of the patients. Alternative
mechanisms to chemotherapy may contribute to anaemia development, such
as anaemia of chronic disease, blood loss, bone marrow infiltration, nutri-
tional deficiency and haemolysis. Different modulators can mediate in the
physiopathology of the anaemia: the production of IL-1 / , TNF and
1-antitrypsin may reduce EPO production, suppress BFU-E and CFU-E and
also impair iron utilization. The prevalence of anaemia in cancer patients
varies depending on the type of cancer. The European Cancer Anaemia
Survey evaluated 15,367 patients for up to 6 months. The prevalence of
anaemia during follow up was 68% (Hb 12 g/dL) and 39% (Hb  10
g/dL). The prevalence of anaemia by treatment status was 40% in patients
not receiving treatment, and 75% in patients under chemotherapy.
Fatigue is a common symptom in patients receiving chemotherapy: almost
100% of patients experience fatigue at some point in the disease. Decreased
levels of Hb and increase in fatigue have a direct impact on quality of life.
Mild and moderate anaemia has been related to greater symptom burden,
lower functioning and decline in quality of life.
The goals of recombinant EPO for the treatment of cancer-induced anaemia
are the improvement of Hb levels, the reduction of blood transfusions and the
improvement of quality of life. Different reviews of the literature have
demonstrated a benefit in the improvement of fatigue related to increased Hb
levels and decreased need for blood transfusions.
Controversy in EPO administration arises from different studies that dem-
onstrate an increased risk of thromboembolic disease, cardiovascular events
and tumor progression. These events do not appear to affect survival using
labelled dosage and clinical indications. Nevertheless, the clinician may have
to balance the risks and benefits of using EPO therapy.
Disclosure: All authors have declared no conflicts of interest.
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HOW TO MANAGE THE SIDE-EFFECTS OF RADIATION
M. Werner-Wasik Radiation Oncology, Jefferson Medical College/Kimmel
Cancer Center, Philadelphia/USA
Acute esophagitis, AE, is a common side effect for patients receiving radiation
therapy (RT) for thoracic tumors. Concurrent chemo-RT or hyperfractionation
result in a 15-25% rate of severe (RTOG Grade 3) AE. Severe AE typically
peaks 4-8 weeks from beginning of RT. Rare late esophageal damage, typically
stricture, develop 3-8 months post-RT. There seems to be no threshold for RT
dose association. Some risk of acute esophagitis occurs in the intermediate dose
range(30-50 Gy) and an increasing effect is observed for higher doses. Doses of
74 Gy standard fractionated RT have been delivered in clinical trials with
concurrent carboplatin and paclitaxel. Constant burning, unrelated to the act of
swallowing and localized in the lower part of esophagus is more likely related to
the reflux than to the AE.Incidental irradiation of the stomach, and associated
gastritis symptoms, may occur when a lower-lobe lung mass is treated. Single
institution studies suggested a benefit to amifostine in decreasing esophagitis, but
a large cooperative group phase III randomized study of 243 patients by the
RTOG did not confirm this. No amelioration of esophagitis was demonstrated
with glutamine or sucralfate. Therefore treatment remains supportive, with diet
modification, analgesia and fluid replacement if necessary. Neutropenia worsens
AE symptoms. Conformal avoidance of esophagus or part of its circumference
in radiation planning is beneficial. No single dosimetric or biologic parameter
has been identified as a reliable predictor of radiation pneumonitis (RP).
Limiting V20 (volume of both lungs receiving a dose of at least 20 Gy) to the
max. of 37% remains a useful guideline for patients receiving standard RT.
IMRT and/or proton RT may lower RP risk, but more investigation is necessary.
Preliminary data indicate that increased FDG uptake in normal lung during RT
may predict subsequent RP. Management of RP is entirely supportive. Infectious
pneumonia, tumor recurrence, interstitial pneumonitis have to be excluded.
Prednisone 60 mg for 1-2 weeks, followed by a slow taper of 10 mg per week
and maintenance on 20 mg for a prolonged time is necessary. Esophageal
infection such as candidiasis or herpes simplex may mimic AE. Preexisting
gastroesophageal reflux may worsen symptoms of AE.
Disclosure: The author has declared no conflicts of interest.
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52IN
DISCOVERING NEW MUTATIONS IN LUNG CANCER
AND NEW TARGETED THERAPIES
F. Ciardiello1, F. Morgillo2 1Dipartimento di Internistica Clinica e Speri-
mentale “F. Magrassi A. Lanzara”, Second University of Naples, Naples/
ITALY, 2Dipartimento Medico-Chirurgico di Internistica Clinica e Speri-
mentale “F. Magrassi E A. Lanzara”, Seconda Universita` degli Studi di
Napoli, Naples/ITALY
The last changes in cancer management have been obtained thanks to the data
from tumor biology. Recently, a chromosome translocation has been recognized
in approximately 5% of non-small cell lung cancer (NSCLC) patients, which
generates fused mRNA encoding the amino-terminal half of tyrosine kinase
echinoderm microtubule-associated protein like-4 (EML4) ligated to the intra-
cellular region of the receptor-type anaplastic lymphoma kinase (ALK). EML4-
ALK oligomerizes constitutively in cells and becomes activated to exert a
marked oncogenicity. Suppression of ALK enzymatic activity could be an
effective treatment strategy against this tumor. On the other side, the introduction
of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) into the management of NSCLC patients has been associated with an
objective response in 10-20% of patients. Subsequent studies have shown that
patients responsive to such drugs have tumors containing somatic activating
mutations in the EGFR gene, which have already been established in the clinic
as valid predictors of increased sensitivity to EGFR TKIs. Although impressive
clinical and radiological responses have been observed in these patients, tumor
progression occurs. The two most commonly mutated oncogenes identified as
predicting mechanisms of resistance encode for EGFR itself and KRAS. A
secondary mutation in the EGFR gene indeed, named T790M, is thought to
cause steric hindrance and impair the binding of TKIs; therefore a novel class of
irreversible TKIs are currently under development to overcome this problem. By
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contrast, even though KRAS mutations were identified in NSCLC tumors more
than 20 years ago, only recently the clinical value of KRAS tumor status has
been appreciated and somatic mutations of the gene have been assessed as a
mechanism of de-novo resistance to EGFR tyrosine-kinase inhibition in patients
with NSCLC. Basal and post-treatment tumor specimens will be needed to
establish molecular profiles for each patient with NSCLC. In addition, novel,
highly sensitive technology will be required to detect these mutations. In this
way, treatment strategies in NSCLC are becoming increasingly tailored to the
individual, and may set an example for other areas of oncology.
Disclosure: All authors have declared no conflicts of interest.
53IN
THE BIOLOGICAL SIGNIFICANCE OF TARGETED
THERAPIES: THE DEVELOPMENT OF MTOR INHIBITORS
F.R. Khuri, S.S. Ramalingam, T.K. Owonikoko, S-Y. Sun, H. Fu Thoracic
Oncology, Winship Cancer Institute, Atlanta, GA/US
Clinical trials conducted in selected patient populations have led to the approval
of nine novel agents, three of them targeted, for non-small cell lung cancer
(NSCLC) in the last twenty years. A recent evaluation of patients with stage
IIIB/IV NSCLC diagnosed between 1988 and 2005 through the linked SEER-
Medicare data base indicated that the utility of these agents has penetrated the
US population as a whole. The development of targeted therapies has varied
significantly from the development of classical and even novel therapeutic
agents. Strategic approaches that have been highly successful in the development
of agents for specific malignancies based on the principles of oncogene addiction
have resulted in imatinib for CML and GIST tumors and gefitinib and erlotinib
for EGFR-mutant lung cancer. Nonetheless, recent studies have shown that the
number of molecular genetic changes in primary lung cancers can total fifty or
greater, and while a series of new mutations have been identified in a small but
meaningful subpopulation of lung cancer patients, such as those targeting
EML4-ALK translocation, other approaches have proceeded along the lines of
targeting selected convergence pathways for the treatment of advanced, refrac-
tory lung cancer. In many of these cases, initial approaches have shown that
agents such as mammalian target of rapamycin (mTOR) or PI3 kinase inhibitors,
which may have limited activities as single agents, could perhaps be better
developed in combination with cytotoxic therapies in selected patient popula-
tions. While these agents, such as the mTOR inhibitors are active in down-
regulating metabolic activities of certain tumors, as was recently shown in a
phase IB pre-operative trial of everolimus in resectable NSCLC, only modest
progress has been made to date in selecting those patient populations likely to
respond to combinations of PI3K/mTOR axis inhibitors and cytotoxic agents.
Explorations of combinations in the front line with platinums and taxanes and in
the second line with either pemetrexed, docetaxel or erlotinib are ongoing.
Disclosure: The author has declared no conflicts of interest.
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RANDOMIZED TRIALS IN PATIENTS WITH EGFR
MUTATIONS
T. Mok Department of Clinical Oncology, The Chinese University of Hong
Kong, Prince of Wales Hospital, Hong Kong/CHINA
Iressa Pan-Asia Study (IPASS) is the first randomized study that showed
EGFR-TKI to be equally effective as chemotherapy in a clinically selected
population with a high incidence of EGFR mutation. We enrolled 1217 patients
from 9 countries in Asia to receive gefitinib (n609) carboplatin/paclitaxel
(n608). Gefitinib demonstrated superior PFS compared with chemotherapy
(HR 0.74; 95% CI 0.65-0.85; p0.0001). Tumor samples from 437 patients
were evaluated for EGFR mutation and 59.7% was positive. PFS in EGFR
mutation positive patients was longer for gefitinib than for chemotherapy (HR
0.48 95% CI 0.36-0.64; p0.0001); in EGFR mutation negative patients PFS
was longer with chemotherapy (HR 2.85 95% CI 2.05-3.98; p0.0001). A
Korean study (First-SIGNAL) with similar design randomized 313 non-/light
smokers with adenocarcinoma to either gefitinib or gemcitabine/carboplatin. The
study support the IPASS finding that EGFR mutation-positive patients having a
higher tumor response rate and longer PFS. Two randomized studies from Japan
have compared EGFR TKI with chemotherapy in patients with EGFR muta-
tiona˜€, Mitsudomi et al randomized 177 chemotherapy-naı¨ve patients with
EGFR mutation positive adenocarcinoma to either gefitinib or docetaxel/cispla-
tin. Tumor response rate was 62.1% and 32.2% for EGFR TKI and chemother-
apy, respectively, while the PFS was significantly in favor of the EGFR TKI
(HR.49 95% CI 0.34 to 0.70 p0.001). Kobayashi et al (2009) conducted a
similar study and reported tumor response rate of 74.5% and 29.0% respectively.
Consistent with other studies, HR for PFS was 0.357 (95% CI 0.252-0.507
p0.001). Results from other similar studies comparing erlotinib with chemo-
therapy EURTAC study from Spain and OPTIMAL from China will available
in the near future. Including IPASS there are four randomized studies that
confirm the efficacy of first line EGFR TKI in patients with EGFR mutation. It
has become clear that EGFR TKI is one of the standard first line therapy.
Disclosure: T. Mok: Advisory Board: Astrazeneca, Roche, Eli Lilly, Merck,
Pfizer, Eisai Honorarium: Astrazeneca, Roche, Eli Lilly, Pfizer
55IN
MICRORNAS IN LUNG CANCER
M. Skrzypski Department of Oncology and Radiotherapy, Medical Univer-
sity of Gdansk, Gdansk/POLAND
MicroRNAs (miRs) are a new class of molecules involved in gene expression
regulation. These short RNA chains (19-25bp) exert their effect through
binding to target sequences on mRNA. Depending on the degree of comple-
mentarity microRNA may silence a target gene altogether or result in
expression fine tuning of whole gene groups. This permissiveness of inter-
action places miRs in the centre of gene expression regulation.
MiRs expression assessment have been thus proposed as a basis for molecular
diagnostic tests in the following applications: (1) lung cancer screening - miR
detection in blood or serum; (2) prognostic tests for selection of high risk patients
for adjuvant treatment after surgery; (3) predictive tests for choosing chemo-
therapy for patients with advanced disease. Additionally, miRs are potential
targets for therapeutics. Feasibility of miR detection in blood have been dem-
onstrated in a few cancer types. Such diagnostic test might greatly enhance the
radiological screening or even provide an alternative screening method. Cancer
specific expression of certain miRs make them particularly useful for these
purposes. Several studies suggested prognostic relevance of miRs in lung cancer,
e.g. miR146b, miR-155, miR-21, miR-191 and miR-15a in squamous cell lung
cancer (Beer at al, 2009), or a 5-miR expression profile reported by Yu et al,
2008 in NSCLC. Interestingly there are differences in miR expression between
histological types of NSCLC, which may preclude joint data analysis from different
histologies. This and other methodological aspects of miR studies will be discussed
in detail. Finally, new data indicate the feasibility and robustness of miR expression
analysis in formalin fixed paraffin embedded samples (FFPE). If confirmed, such
tests might become wildly applicable in routine oncology practice.
In terms of predictive value of miRs for chemotherapy response, preliminary
data suggest that certain miR expression profiles may predict chemosensi-
tivity in cancer cell lines.
Finally, anti-miR agents, e.g. locked nucleic acids (LNAs) will soon be
investigated within clinical trials. Given the promising results in animals and
safety data in humans, efficacy results are eagerly awaited.
Disclosure: The author has declared no conflicts of interest.
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WORKSHOP: RADIATION
56IN
THE QUESTION OF VOLUME
L. Gaspar Department of Radiation Oncology, University of Colorado
Cancer Center, Aurora/USA
The incidence and severity of treatment related pulmonary toxicity is associated
with the dose and volume of normal lung irradiated. It is common for lung
cancer patients to present with large bulky tumors. Current North American
cooperative group studies are comparing various radiation dose intensity regi-
mens for both small and nonsmall cell lung cancer. With the increase in tumor
dose there is invariably an increase in the dose to surrounding normal lung.
Retrospective studies indicate that the actuarial incidence of symptomatic pneu-
monitis is more than 30% with combined modality therapy. There are radiation
dosimetry variables that are associated with the later development of pulmonary
toxicity. For example, the relationship between V20 (the percent of normal lung
receiving 20 Gy or more), and mean lung dose with pulmonary toxicity have
been well documented. There is also a correlation with cytokines such as
TGF1, normal lung irradiated and subsequent pulmonary toxicity. Efforts have
been undertaken to minimize this toxicity by intensity modulated radiation
treatment and pharmacological manipulation. Other possibilities include pre-
radiation chemotherapy or adaptive radiation treatment, i.e. replanning patients
during radiation treatment if their tumor has decreased in size. Prospective
studies are in development to test these options.
Disclosure: The author has declared no conflicts of interest.
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THE QUESTION OF DOSE
No abstract received at timerof going to press.
58IN
THE QUESTION OF FRACTIONATION
D. Ball Radiation Oncology, Peter MacCallum Cancer Centre, East Mel-
bourne/AUSTRALIA
Empirically it has been found that the delivery of a radical course of radiotherapy
as multiple small doses (fractionation) over a period of 6 to 7 weeks maximizes
the therapeutic ratio by allowing the administration of total doses high enough to
have some chance of sterilizing the cancer, and at the same time minimizing the
risk of serious morbidity in incidentally irradiated late reacting tissues, which are
particularly sensitive to changes in dose per fraction. Other theoretical benefits
include reoxygenation of hypoxic tumours as regression occurs, and synchroni-
zation of clonogens in radiosensitive phases of the cell cycle. In patients with
non-small cell lung cancer (NSCLC), attempts to increase the total dose further
by reducing the dose per fraction without significantly altering overall treatment
time (hyperfractionation) have demonstrated that it is feasible, but without
improving survival. But if hyperfractionation is combined with a reduction in
overall treatment time, as in the CHART study, there is an improvement in local
control and survival, even though the total dose (54 Gy) was lower than in the
control arm (60 Gy). This is an important observation, as it is consistent with
accelerated repopulation being a cause of treatment failure in NSCLC. We do
not know however if CHART is more or less effective than concomitant
chemoradiation. Further, if the benefits of CHART are reliant on the epidermal
growth factor receptor (EGFR), could they be duplicated using conventional 2
Gy fractions and EGFR blockade? Fractionation is less important if the total
dose of radiotherapy falls short of the maximally tolerated dose, as in palliative
treatments; or if late reacting critical tissues are excluded from the high dose
region, as in the treatment of peripherally situated stage I NSCLC using image
guidance and multiple beam arrangements or arcs. However, the use of large
doses per fraction has been associated with serious toxicity in the treatment of
tumours located close to the mediastinum or brachial plexus. In these settings,
can we justify hypofractionation when the safer and well established alternative
of conventional fractionation is available?
Disclosure: D. Ball: I am a member of advisory boards for Lilly Oncology
and Astra Zeneca.
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THE QUESTION OF INDUCTION OR CONSOLIDATION?
F. Mornex1, N. Girard2 1De´partement de Radiotherapie Oncologie, Centre
Hospitalier Lyon Sud, Pierre Benite/FRANCE, 2Respiratory Medicine, Ref-
erence Center for Orphan Pulmonary Diseases, Louis Pradel Hospital,
Lyon/FRANCE
Radiotherapy is one of the major therapeutic options in thoracic oncology.
Chemoradiotherapy is the standard treatment for unresectable locally-advanced
non-small cell lung cancer. Concurrent chemoradiation leads to a significant
survival benefit when compared to exclusive radiotherapy or sequential chemo-
radiation, owing to a better local, rather than systemic, tumor control. Current
modalities of radiation in this setting include three-dimensional conformal
treatment planning, allowing dose escalation and combination with most recent
chemotherapy agents to occur. Most of the time, during concomitant chemora-
diation, chemotherapy reduction dosages must be achieved to preserve a good
patient tolerance. In order to deliver higher doses of chemotherapy and to
increase systemic control rates, several investigators developed mixed therapeu-
tic sequences, associating induction and/or consolidation chemotherapy, before
and/or after concurrent chemoradiation. Overall, results from phase II-III studies
indicate that both induction and consolidation strategies are feasible and may
increase local and systemic tumor control. Even if some recent data suggested a
potential benefit on progression-free survival with consolidation, available meta-
analyses concluded that no significant differences exist between induction and
consolidation regarding overall survival. In a routine practice setting, we strongly
favor induction chemotherapy, which (1) allows the initiation of the treatment
sequence while preparing the patient for radiotherapy with shorter delays, (2)
may facilitate radiotherapy through tumor control and GTV decrease, (3) leads
to select most appropriate patients that do not present with early progression and
(4) allows to test the tumor chemosensitivity. Future developments of induction
and consolidation treatment in locally-advanced non-small cell lung cancer
consists of evaluating new systemic agents, including targeted therapies. Even if
maintenance with EGFR tyrosine kinase inhibitors has been disappointing in this
setting, a better selection of patients and the use of monoclonal antibodies may
provide more promising results.
Disclosure: All authors have declared no conflicts of interest.
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CLINICAL OUTCOMES AND TREATMENT PLANNING
STRATEGIES FOR ADVANCED-STAGE NON-SMALL CELL
LUNG CANCER (NSCLC) TREATED BY INTENSITY
MODULATED RADIATION THERAPY (IMRT) OR
3DIMENTIONAL CONFORMAL RADIATION THERAPY
(3DCRT) WITH CONCURRENT CHEMOTHERAPY (CCT)
R. Komaki Radiation Oncology, UT MD Anderson Cancer Center, Houston/
USA
Background: IMRT has been used in our institution to treat locally ad-
vanced NSCLC for which the dose-volume constraints for 3D conformal
therapy (3DCRT) could not be met. The purposes of this study are 1) to
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review the clinical outcomes and 2) to establish corresponding clinical
guidelines for IMRT treatment planning.
Materials and methods: Clinical data were reviewed for lung cancer
patients treated with IMRT at our institution from 2002-2005. The patient
cohort included those who had stage III-IV NSCLC, and who had definitive
concurrent chemoradiation. Patients were excluded if they had a history of
major lung surgery, prior chest radiotherapy, or mixed 3DCRT and IMRT
plans. Clinical outcomes and major toxicities including pneumonitis and
esophagitis were analyzed based on medical records and clinical follow-up.
IMRT treatment plans and dosimetric parameters were reviewed. Guidelines
for IMRT treatment planning were developed based on the existing clinical
outcome and dosimetry data.
Results: In total, 87 patients were included in this study. The median
follow-up time was 10 months (range, 1.1-43.8 months). 61% of patients
were treated to a dose range of 63-66 Gy (see Table 1). The 2-year
locoregional control, disease free survival, and overall survival were 41%,
23%, and 57%, respectively. The rate of grade 3 and higher treatment-related
pneumonitis at 12 months was 11%. The rate of grade  acute esophagitis
was 34%. In achieving effective IMRT treatment plans, mean lung dose and
the volume of normal lung receiving low-dose radiation were used as
important constraints to minimize pulmonary toxicity. The number of IMRT
beams should be limited within the range of 5-7 beams, with the beam angles
being carefully selected to spare healthy lung. The other physical parameters
that affected low-dose radiation and were thus considered during IMRT
treatment planning included the number of MLC segments and monitor units
used.
Conclusions: IMRT with CCT may be an effective and safe modality in
treating advanced-stage NSCLC with concurrent chemotherapy. Dose distri-
butions for IMRT treatments should be carefully planned considering normal
tissue toxicity and minimization of exposure to healthy lung.
Disclosure: The author has declared no conflicts of interest.
THE NEW ERS/IASLC/ATS CLASSIFICATION OF
LUNG ADENOCARCINOMA
61IN
INTRODUCTION AND PATHOLOGY
E. Brambilla1, W. Travis2 1De´partement D’Anatomie et Cytologie
Pathologiques, University Hospital Grenoble, Grenoble/FRANCE, 2Depart-
ment of Pathology, Memorial Sloan Kettering Cancer Center, New York/USA
Despite advances in molecular understanding of carcinogenesis steps of this
tumor in the past decade, there remains a need for a universally accepted
criteria for adenocarcinoma subtypes in particular bronchioloalveolar carci-
noma (BAC). The specific aim and project objectives were to develop a
multidisciplinary subclassification of lung adenocarcinoma defining clinical
/ histologic, radiologic, molecular subtypes of lung adenocarcinoma and to
propose an international standard for histologic subclassification of lung
adenocarcinoma, the backbone of the multidisciplinary classification. The
major changes in this classification include : 1) Cessation of the use of the
term BAC. This old concept of BAC now appears in 5 different places in the
classification 2) Addition of a category of minimally invasive adenocarci-
noma (MIA). Patients with small solitary (usually less than 2 cm) adenocar-
cinoma with an invasive area of less than 5 mm can have 100% 5-year
survival. 3) The category of mixed subtype adenocarcinoma is dropped
because it was comprizing 90% of our diagnosis, invasive subtypes are now
declined in predominant patterns with other patterns defined with a percent-
age in tumor. 4) The former mucinous BAC now called mucinous adeno-
carcinoma with lepidic pattern represents the first most important variant of
adenocarcinoma. 5) This classification will make recommendations regard-
ing the diagnosis of adenocarcinoma versus other non small cell lung
carcinoma in small biopsies and cytology. The distinction between squamous
cell from large cell and adenocarcinoma rests on a panel of special stains
including mucin and immunohistochemical markers including TTF1, CK5-6
and P63 in small biopsies with an appearance of non small cell lung
carcinoma (NOS). A number of gene mutations, gene copy number increase
and molecular pathways have been associated strongly with each of the
histological adenocarcinoma patterns, containing potential therapeutic targets.
Disclosure: All authors have declared no conflicts of interest.
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THE NEW ERS/IASLC/ATS CLASSIFICATION OF LUNG
ADENOCARCINOMA: RADIOLOGICAL ASPECTS
K. Garg Diagnostic Radiology, University of Colorado at Denver and
Health Sciences Center, Denver/USA
There is a widely divergent clinical, radiologic, molecular and pathologic
spectrum within lung adenocarcinoma. Despite remarkable advances in
understanding of this tumor in the past decade; there remains a need for a
universally accepted criteria for adenocarcinoma subtypes, in particular
bronchioloalveolar carcinoma (BAC). The use of the term BAC encompasses
a broad spectrum of tumors ranging from solitary small peripheral lung
tumors with a 100% 5-year survival to widespread advanced disease with a
10% 3-5 year survivals, with widely varying use of terminology. The
widespread availability of MDCT and abundance of new information ob-
tained especially from low-dose CT lung cancer screening programs, have
increased our understanding of the management and types of small peripheral
lung nodules, in particular, the subsolid pulmonary nodules. Subsolid nod-
ules are now known to frequently represent the histologic spectrum of
peripheral adenocarcinomas. Pending revisions in multidisciplinary classifi-
cation of these lesions, this includes premalignant atypical adenomatous
hyperplasia (AAH), carcinoma in-situ or bronchiolalveolar carcinoma (AIS/
BAC), minimally invasive (MIA) and invasive adenocarcinoma. Thin section
CT has emerged as a new biomarker for lung adenocarcinoma subtypes.
GGO nodule correlates with lepidic growth and better clinical outcome than
part-solid or solid nodules. Pure GGO lesions are typically FDG-PET
negative whereas more aggressive and invasive tumors manifesting as solid
or part-solid lesions are metabolically active. Key messages from radiology
lecture are: 1) The term BAC is confusing and it should no longer be used
in reference to adenocarcinoma manifesting as GGO. The new terms pro-
posed for the adenocarcinoma subtypes that cause this pattern are AIS/MIA
and lepidic predominant adenocarcinoma 2) Mucinous adenocarcinoma (pre-
viously called BAC) is usually a solid tumor or as consolidation (not GGO).
3) Multiple lesions – careful description of each lesions is desirable because
multiple synchronous/metachronous primaries are not uncommon (which
may show different sizes and attenuation patterns).
Disclosure: The author has declared no conflicts of interest.
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SURGERY
P.E. Van Schil1, H. Asamura2, T. Mitsudomi3, V. Rusch4, M. Tsuboi5
1Department of Thoracic and Vascular Surgery, Antwerp University Hospi-
tal, Edegem/BELGIUM, 2Division of Thoracic Surgery, National Cancer
Center Hospital, Tokyo/JAPAN, 3Thoracic Surgery, Aichi Cancer Center
Hospital, Nagoya/JAPAN, 4Department of Thoracic Surgery, Memorial
Sloan-Kettering Cancer Center, New York/USA, 5Thoracic Surgery & On-
cology, Tokyo Medical University & Hospital, Tokyo/JAPAN
Although no prospective, randomized trials exist comparing surgery and radio-
therapy in early stage lung cancer, surgical treatment has traditionally been
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considered the treatment of choice. After a prospective randomized trial of the
Lung Cancer Study Group published in 1995, comparing lobectomy to lesser
resections for peripheral T1N0 lesions, lobectomy became the procedure of
choice and the minimal resection to be performed. Stimulated by large screening
programmes for lung cancer, the role of sublobar resection is currently being
reconsidered for very early lung cancer. This particularly applies to non-solid or
part solid ground glass opacities on chest computed tomography which mostly
correspond to adenocarcinoma in situ (AIS) or minimally invasive adenocarci-
noma (MIA) in the new ERS/IASLC/ATS classification. Most experience has
been gained in Japan where thoracic surgeons deal with small lung lesions for a
prolonged period of time. Specific interest centers on lung nodules  2 cm.
Already in 1995, Noguchi presented a novel classification for small adenocar-
cinomas subdividing them in an alveolar replacement and non-replacement type.
In non-randomized studies sublobar resections, wide wedge resection or ana-
tomical segmentectomy, were found to be valid oncological procedures in
specific subgroups. Recently, treatment algorithms were proposed for lung
nodules  2cm which are classified in the 7th TNM edition as T1a tumors. In
some specific subgroups lymph node sampling rather than systematic nodal
dissection may be appropriate. For AIS or MIA having an excellent prognosis,
lymph node sampling or dissection may not be required. Specific guidelines for
frozen section examination of these lesions have to be developed. Multiple lung
adenocarcinomas are not a contra-indication for surgical exploration when they
are considered to be multiple, early stage primary tumors without evidence of
mediastinal lymph node invasion. However, before sublobar resection can
readily be recommended as standard treatment for early stage lung cancer 
2cm, the results of ongoing randomized trials in Japan and the USA are awaited
for. These studies will also provide a deeper insight in the behavior and clinical
characteristics of these tumors.
Disclosure: All authors have declared no conflicts of interest.
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HOW TO MEASURE T STATUS, DIFFERENT IMAGING
TECHNIQUES, DIFFERENT IMAGING METHODS
W. De Wever Department of Radiology, University Hospitals Leuven,
Leuven/BELGIUM
Measurement of lung tumor is important for staging and follow-up. Especially in
the new lung cancer system, tumor size has become a major descriptor in T
staging. (Multi-detector) Computer Tomography is a widely used imaging
technique to determine the size of tumor. Tumor measurement can easily
performed using electronic rulers on diagnostic monitors. Window settings (lung
versus mediastinal window) can influence measurement of tumor size. The same
windows should be used on subsequent examinations to measure any lesions.
Measurements obtained using lung settings are more accurate irrespective of
collimation than measurements obtained using soft tissue settings. Slice thick-
ness, reconstruction algorithm and tube current can also affect size measurement
of solid nodules. Slice thickness of 1.25 mm and high-spatial-resolution algo-
rithms are recommended when measuring tumor size. Tumor can be measured
in an uni- (minimal versus maximal) or bidimensional way. This can be done on
transverse or on reformatted images. Measurements of tumor size on CT are
often inconsistent, especially in small tumors ( 3 cm). This can also lead to an
incorrect interpretation of tumor response. Measurement differences are greatest
when the edge of the lesion is irregular, speculated or when the tumor consists
of ground-glass attenuation components. The interobserver variability is larger
than the intraobserver variability. Consistency can be improved if the same
reader performs serial measurements for any one patient. Computer aided
diagnosis is a very promising tool in the measurement of tumor size. Measure-
ment of unidimensional lesion size with the computer method is more accurate
than reader measurement and can be considered significant when estimating the
outcome of therapy in a patient. Semiautomatic volumetry of lung tumor is
sufficiently accurate and repeatable.
Disclosure: The author has declared no conflicts of interest.
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NEW NON-INVASIVE IMAGING TECHNIQUES IN LUNG
CANCER (EXCLUDING PET)
O. Lucidarme Service de Radiologie Centrale, Groupe Hospitalier Pitie´
Salpeˆtrie`re, Paris/FRANCE
Many clinical trials of modern therapies have shown that targeted therapy may
not lead to substantial tumor volume reduction, especially soon after therapy.
Hence conventional measurements of the tumor size change may be insensitive
or markedly delayed even when there may be substantial therapeutic effect.
Thus, the clinical use of targeted therapies leads to develop new imaging
methods that are able to assess the microcirculation or the cellularity of the
tumor. This is the role of the different functional imaging techniques that use
indirect method to provide surrogate markers of the microcirculation or of the
microscopic cellular organization of the tumor. Dynamic imaging of the micro-
circulation using either DCE MRI, or functional CT are all based on the same
principle which consists of injecting a known amount of contrast agent and
obtaining the curve of signal intensity change over the time. The enhancing
curve provides information on blood flow, on capillary surface, on endothelial
permeability and on the volume of the extracellular, extravascular space. Diffu-
sion weighted MRI provides information on tissue cellularity, and the integrity
of cellular membranes by measuring the random motion of the water molecules
(apparent diffusion coefficient: ADC) in tissue which is modified by interactions
with hydrophobic cellular membranes. Then vascular changes and necrosis or
cellular lysis induce by treatment will lead to decrease dynamic parameters
and/or to increase water diffusion and corresponding ADC values respectively.
There are now convincing data to support their usages for monitoring response
to a variety of treatments mainly for brain tumors, but also for liver, kidney,
rectal or breast cancers. However these techniques remain considerably more
complex than conventional anatomical imaging. Their limitations must be
known and they still require validation, ideally against clinical outcome before
allowing their adoption as established surrogate end points of drug effects.
The principles of functional MRI and CT in oncology, results expected, their
limitations and studies testing these techniques will be presented and discussed.
Disclosure: The author has declared no conflicts of interest.
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HOW SHOULD PET–CT INFLUENCE OUR DECISION
MAKING?
J. Vansteenkiste Respiratory Oncology Unit, University Hospital Gasthuis-
berg, Leuven/BELGIUM
The 1st clinical report on FDG-PET in thoracic oncology came out in 1990
(Kubota, JNM 1990). Over the last 20 years, the technique has revolutionised
the imaging of lung cancer. We will discuss three of the settings where the
findings have impacted on clinical decision making. In the assessment of
solitary pulmonary nodules, PET-CT is proven to be superior to CT alone in
several studies and meta-analyses (Fischer, Lancet Oncol 2001). For lesions
1 cm, however, current PET scanners are at their limitation of sensitivity,
and other algorithms with CT follow-up are proposed (MacMahon, Radiol-
ogy 2005). In lesions 1 cm, the added value of PET is highest for lesions
with an intermediate probability of cancer (i.e. between 5 and 60%) (Gould,
Chest 2007). Several studies and meta-analyses also convincingly demon-
strated that NSCLC staging is improved use of PET-CT (Fischer NEJM
2009). This is due to more accurate non-invasive locoregional lymph node
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(LN) staging than with CT alone, because PET-CT orients LN tissue
sampling techniques, and due to improved extrathoracic staging. Some – but
not all – randomised studies have shown a reduction of invasive procedures
and of futile surgery (Van Tinteren, Lancet 2002; Viney JCO 2004; Maziak
Ann Int Med 2009).Whether improved treatment outcomes are due to stage
migration (Morgensztern, JTO 2008) or better choice of therapeutic modal-
ities (Wauters, 2010) remains unsolved. A 3rd setting is the assessment of
induction therapy in combined modality treatment for stage III (Vansteenk-
iste, Lancet Oncol 2004). This is more difficult, as quantification of FDG-
uptake is needed here, in contrast with previous indications. The performance
of PET-CT in assessment of LNs is not as good as at initial LN staging.
Therefore, tissue sampling tests (echo-endoscopy, mediastinoscopy) play an
important role. Apart from LN downstaging, the other important element in
prediction of outcome after combined modality treatment (CMT) is patho-
logic response in the primary tumour. The latter is far better predicted by
PET than by CT, and consequently PET-response was related to outcome in
several prospective studies. A combination of LN downstaging by tissue tests
and tumour response by PET may be one of the most powerful predictors of
outcome after CMT (Dooms, JCO 2008).
Disclosure: The author has declared no conflicts of interest.
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67IN
SURGERY FOR MPM; EXTRAPLEURAL PNEUMONECTOMY
(EPP) VS PLEURECTOMY/DECORTICATION (P/D)
M. Tsuboi Thoracic Surgery & Oncology, Tokyo Medical University &
Hospital, Tokyo/JAPAN
Standard treatment for all but localized malignant pleural mesothelioma
(MPM) is generally not curative. Although some patients will experience
long-term survival with aggressive treatment approaches, it remains unclear
if overall survival (OS) has been significantly altered by the different
treatment modalities or by combinations of modalities. The goal of surgery
in the multimodality treatment approach is to achieve a macroscopic com-
plete resection, with adjuvant therapies directed at residual microscopic
disease. For patients who are eligible candidates, surgical resection plays an
important role. Both extrapleural pneumonectomy (EPP) and pleurectomy/
decortication (P/D) have evolved for the surgical treatment of MPM. How-
ever, the optimal procedure for resection of malignant pleural mesothelioma
is controversial. Knowledge of the similarities and differences between the
two operations that have evolved-EPP and P/D-is prerequisite to understand-
ing the complex issues associated with patient selection, diagnosis, patho-
logic staging, preoperative assessment, perioperative management, and ad-
juvant treatment. Both operations are technically complex. Overall survival
reported in a recent multicenter analysis of these two operations supports the
use of P/D for early stage MPM provided that a complete resection is
feasible; otherwise EPP will confer a survival advantage. For stage II disease,
however, EPP demonstrates a possible advantage. The focus in stage III
disease should remain on the ability to achieve macroscopic complete
resection, rather than N2 disease. P/D can provide palliative relief from
symptomatic effusions, discomfort caused by tumor burden, and pain caused
by invasive tumor. Operative mortality from P/D is less than 2%, while
mortality from EPP has ranged from 6% to 30%. For patients who undergo
P/D, local recurrence (within the surgically operated hemithorax) is the most
common form of recurrence. For patients who have undergone EPP, the
pattern of recurrence is predominantly a combination of local and distant
failure. The local recurrence rates, however, seem to be lower than rates seen
after P/D. At present, the choice of operative mode should be tailored to the
extent of primary disease, patient co-morbidities, and type of multimodality
therapy planned.
Disclosure: The author has declared no conflicts of interest.
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THE ROLE OF RADIOTHERAPY IN MALIGNANT
PLEURAL MESOTHELIOMA TREATMENT
C. Le Pechoux1, A. Paumier1, D. Planchard2, J. Margery2, P. Ruffie2
1Department of Radiotherapy, Institut Gustave Roussy, Villejuif/FRANCE,
2Department of Medicine, Institut Gustave Roussy, Villejuif/FRANCE
Malignant pleural mesothelioma (MPM) is a rare tumour of great concern to
chest physicians and oncologists because of its difficult pathological diag-
nosis and poor prognosis with median survival time ranging from 9 to 17
months. Radiation oncologists may take care of such patients in 3 situations:
- as prophylaxis to reduce the risk of parietal seeding along the drainage sites
after drainage or thoracoscopy
- as adjuvant post-operative treatment in an attempt to improve locoregional control
after resection in a subgroup of selected patients with early-stage disease
- and for palliation of symptoms for patients with painful chest wall
infiltration or nodules.
The role of radiotherapy in the prevention of parietal seeding was at first
explored in a small randomized trial which concluded that prophylactic drain site
radiotherapy, could prevent the development of subcutaneous metastasis. Other
small randomized trials have not confirmed these results. Concerning post-
operative radiotherapy after extra-pleural pleuro-pneumonectomy (EPP), data
from the literature are limited, and come mostly from retrospective studies or
phase II prospective studies. Post-operative irradiation should only be proposed
in clinical trials, as a part of multimodal treatment. Conformal radiotherapy has
been used in recent phase II prospective studies. According to the dose and
technique used, the local recurrence rate may vary between 13% and 50%. The
ability to cover fully all the areas at risk of recurrence, is limited by dose
constraints to the surrounding normal structures (heart, liver, contralateral lung
and spinal cord). Preliminary results of intensity-modulated radiotherapy in the
adjuvant setting seemed particularly promising as they could provide good local
control and protect organs at risk. However, severe pulmonary toxicity has also
been reported so that it should not be recommended outside of clinical trials.
Further studies are needed to establish better the role of radiotherapy. Recent
studies have underlined the importance of radiotherapy technique both in
terms of local control and toxicity. A randomized multicenter European
study is ongoing to answer the question of adjuvant post-operative radio-
therapy after EPP (SAKK study).
Disclosure: All authors have declared no conflicts of interest.
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SYSTEMIC TREATMENT AND MOLECULAR PATHWAYS
R.A. Stahel Klinik und Poliklinik fu¨r Onkologie, Universita¨tsspital, Zu¨rich/
SWITZERLAND
The treatment of malignant pleural mesothelioma continues to be a challenge.
The palliative effect of combination chemotherapy and potential benefit of early
versus late chemotherapy has been documented from studies using mitomycin C,
vinblastine and cisplatin. The MS01 trial comparing the outcome of patients
treated with active symptom control alone or symptom control with either MVP
or vinorelbine was unable to demonstrate a significant difference in quality of
life or survival, however an exploratory analysis suggested a survival advantage
for the vinorelbine group. Based on the results of a phase III trial and the
registration of pemetrexed, its use in combination with cisplatin has become the
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preferred choice of chemotherapy. Phase II studies and the results of the
pemetrexed international expanded access program suggest similar activity when
pemetrexed is combined with carboplatin. Vinca alkaloids also have activity in
malignant pleural mesothelioma. Studies include the use of vinorelbine alone or
in combination with cisplatin and vinflunine. The role of second line chemo-
therapy and optimal choice of agent needs to be defined. Gefitinib and erlotinib
were found to have no clinical activity. In contrast, clinical signals were reported
with the multitargeted tyrosine kinase inhibitors vatalanib, sorafenib and sutinib
prompting further clinical studies with this group of agents. While an earlier
randomized phase II study of bevacizumab in combination with cisplatin and
gemcitabine was negative, the agent is currently investigated in combination
with platin and pemetrexed. Other agents under investigation are bortezomib and
vorinostat. Molecular studies identified inactivation of the neurofibromatosis-2
(NF2/merlin) signaling and of INK4a/ARF gene to be key events in tumorigen-
esis. Inactivation of NF2 signaling is due to gene mutation or functional
inactivation of the protein which may depend, e.g., on PTEN deletion or
overexpression of CPI-17 oncogene. NF2 signaling involves the mam-
malian Hippo cascade which inhibits YAP activity by phosphorylation.
YAP is a transcription factor promoting tumorigenesis when active.
Amplification of chromosomal 11q22 region including YAP was identi-
fied in a subset of mesothelioma, indicating an additional way of NF2
signaling inactivation.
Disclosure: The author has declared no conflicts of interest.
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SPIRAL CT
R.J. van Klaveren Pulmonology, Erasmus MC, Rotterdam/NETHERLANDS
When lung cancer is intercepted in its early stages, lung cancer can be treated
with a surgical resection. However, most patients present when they are symp-
tomatic and in an advanced disease stage. The hypothesis is that if a larger
proportion of the lung cancer cases could be detected in an early stage, this might
translate into an improved outcome. Randomized controlled trials in the 1970s
and 1980s did not validate this principle. With the advent of new technology and
the introduction of low-dose multidetector computer tomography, new hopes
have been raised. In order to address the effectiveness and cost-effectiveness of
LDCT screening for lung cancer, several observational cohort studies and
randomised clinical trials have been launched. A major drawback of current
screen regimens is, however, that they lead to a high rate of false positive test
results and to low positive predictive values. This translates into high rates of
subsequent work-ups, costs, loss of quality of life, potential morbidity and low
acceptance of these screening programs among the public. Although lung cancer
screening and surgical resection for early stage lung cancer may offer a potential
curative treatment, it is not free of complications. Therefore, the number of
participants with a false positive test result in a screening program should be as
low as possible. In the Dutch-Belgian low-dose multi-detector CT lung cancer
screening trial (NELSON) a novel screening strategy has been used based on the
size of new nodules and the volume doubling times of existing nodules with
growth by semi-automated software only, without use of PET, FNA or evalua-
tions after antibiotics. This reduced the proportion of test positives to only 2%.
In conventional regimens the proportion of test positives ranges from 15-50%.
The NELSON nodule management strategy will increase the acceptance of
possible future screening programs. However, CT screening for lung cancer
should still be regarded as investigate and needs to be confirmed in well-
designed randomized controlled trials before implementation on a large scale.
Disclosure: The author has declared no conflicts of interest.
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DO WE NEED TO SCREEN PERSONS EXPOSED TO
ASBESTOS?
N. van Zandwijk ADRI/Bernie Banton Centre/, University of Sydney, Syd-
ney/AUSTRALIA
Asbestos, a group of naturally occurring mineral silicates, was introduced
into our environment approximately a century ago. Specific properties such
as resistance to corrosive and thermal effects and increased tensile strength
have resulted in its introduction into over 3000 products. Asbestos readily
breaks into small, easily inhaled fibers that may elicit lung fibrosis, (asbes-
tosis), lung cancer and malignant mesothelioma. In most industrialized
countries asbestos has been banned from work and home environments but
current widespread use of asbestos in developing countries indicates that the
epidemic of asbestos-related disease will continue to grow in the decades to
come. Asbestos-exposed individuals have justifiable anxiety about their
future. In some countries monitoring of individuals with occupations involv-
ing asbestos exposure has been effectuated. Unfortunately surveillance with
radiographic examinations and pulmonary function tests has been shown of
little value. At the same time studies attempting to define biomarkers for
early detection have shown that Soluble Mesothelin-related Protein, Os-
teopontin and Megakaryocyte-Potentiating Factor aren’t sensitive enough to
be introduced in the clinic (1). It has become clear that even in high-risk
populations significant variations in cancer risk exist. More accurate risk
prediction is expected to assist in balancing potential risks and benefits of
screening. Risk models for lung cancer prediction have been developed and
easily obtained clinical information can be used to identify individuals, who
may benefit from increased surveillance (2). Thus, future screening studies in
asbestos-exposed individuals are expected to concentrate on subgroups with
very high risk. A better definition of high risk in combination of sophisticated
radiographic and biomarker techniques are new tools to be tested and will
hopefully assist in preventing the lethal consequences of asbestos exposure.
1. Pass HI. Semin Thorac Cardiovasc Surg, 2009; 2. Spitz MR et al. J Natl
Cancer Inst, 2007.
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MOLECULAR SCREENING
C. Mascaux1, G. Anthoine2, N. Peled1, V. Ninane3, A. Burny4, J. Sculier5,
F.R. Hirsch6 1Department of Medical Oncology, University of Colorado
Cancer Center, Anschutz Medical Campus, Aurora/USA, 2Intensive Care
and Thoracic Oncology, Institut Jules Bordet, Brussels/BELGIUM, 3Pneu-
mology, CHU Saint-Pierre, Brussels/BELGIUM, 4Laboratory of Molecular
and Cellular Biology, Faculte´ Universitaire des Sciences Agronomiques de
Gembloux (FUSAGx), Gembloux/BELGIUM, 5Department of Intensive Care
and Thoracic Oncology, Jules Bordet Institute, Brussels/BELGIUM, 6Med-
icine-Oncology, University of Colorado Cancer Center, Aurora/USA
Recent technological advances have made it possible to study molecular events
preceding the development of invasive cancer. It is expected that molecular
studies will identify biomarkers for early detection of lung cancer, by using more
readily obtainable biologic samples (blood, sputum, exhaled breath) being
applicable to large-scale cost effective screening in high-risk groups. Recently,
our group defined transcriptomic profiles by miRNA and mRNA for detecting
pre-cancerous stages and invasive lung cancer. We performed gene expression
profiling in 122 biopsies at all successive stages from normal bronchial epithe-
lium of smokers, through all intermediate stages, to lung invasive squamous cell
carcinoma. We obtained a signature of 382 genes, which allows for the discrim-
ination of malignant and premalignant bronchial tissue (invasive and pre-
invasive lesions at high-risk to progress) from benign one (normal tissue and
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low-grade lesions which very rarely evolving toward cancer), with a sensitivity
and specificity of 93% and 88%. In parallel, our group studied miRNA a subset
of 60 samples from the transcriptomic study. MiRNA patterns of expression
were able to segregate high-grade preneoplastic lesions (severe dysplasia and
CIS) and SCC from the low-grade lesions (metaplasia, mild and moderate
dysplasia) with sensitivity and specificity up to 83% and 100%, respectively. The
mRNAs and miRNAs profiles differentially expressed between these stages are
thus potential tools for early detection of lung cancer at pre-invasive stages. An
ongoing study aims to validate our findings in a prospectively collected inde-
pendent set of fresh frozen bronchial biopsies. Afterwards, we will select
candidate mRNAs and miRNAs from bronchial biopsies studies and assess them
in prospectively collected plasma from the same cohort. Detecting these biomar-
kers in plasma would be a potential approach for non-invasive screening of lung
cancer. As also studying volatile organic compounds in exhaled breath from the
same patients, we propose a clinical strategy for early detection of lung cancer
by combining a plasma test based on detection of selected RNAs by RT-PCR
together with exhaled breath test, expecting that these two non-invasive tests
detect early lung cancer with a very high sensitivity and specificity.
Disclosure: F.R. Hirsch: Advisory Boards: AstraZeneca, Merck Serono,
BMS/Imclone, Syndax, Pfizer, Boehringer-Ingelheim, Lilly Oncology, GSK,
OSI/Genenetech/Roche Research Funding: AstraZeneca, OSI, Genentech,
Syndax, Biogen-Idec, Ventana-Roche, Merck, Genmab. All other authors
have declared no conflicts of interest.
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PROGNOSTIC FACTORS IN STAGE III NSCLC
T. Berghmans Medicine, Institut Jules Bordet, Brussels/BELGIUM
The overall prognosis of lung cancer is poor. During the last decade, there were
an increasing number of articles related to the study of survival prognostic
factors (PF) in NSCLC. For this presentation, we selected only those dealing
specifically with stage III NSCLC. Among the published potential PF, some
variables are more consistently associated with survival. The prognostic role of
disease stage was recently confirmed within stage III NSCLC patients in the very
large international study performed by the IASLC, proposing a new TNM
classification. Respective 5-year survival rates for clinical stage IIIA and IIIB
were 19% and 7% (p  0.0001). Other PF in stage III NSCLC have been
proposed in a heterogeneous literature e.a. due to variations in the populations,
to the type of treatment or to the variables taken into consideration for the PF
analyses. The most frequently reported PF were performance status, age, some
characteristics of the primary tumour (size, local extension) or of the mediastinal
lymph node involvement (N stage, number of metastatic nodal stations) and the
objective response to treatment. Unfortunately, none of these clinical PF are
accurate enough to perform meaningful individual prognosis. Their utility stays
principally in the comparison of different groups of patients or in the choice of
stratification criteria for clinical studies. The prognostic role of new biological
markers has been assessed in a few heterogeneous studies of limited sample size,
not all comparing biological to clinical factors in multivariate survival analyses.
Although not uniformly reported, some PF were suggested: apoptotic index,
bcl-2, p53, hMSH2 (a mismatch repair gene), Fas or the rhTRAIL DR5 receptor.
The prognostic role of the metabolic tumoural activity measured by the SUV on
18F-FDG-PET was suggested in a literature meta-analysis of small retrospective
studies, needing confirmation in prospective studies taking into account classical
PF. Conclusion: Disease stage and performance status are the most prominent PF
in stage III NSCLC, while other clinical and therapeutic variables have some
prognostic value. Biological factors and SUV are new promising PF, their
definitive role being to be confirmed in stage III NSCLC.
Disclosure: The author has declared no conflicts of interest.
74IN
OPTIMISING THE SYSTEMIC THERAPIES IN A
MULTIMODAL APPROACH
K. O’Byrne Oncology, St James Hospital, Dublin/IRELAND
Despite significant advances in the optimisation of care for resected and
advanced non-small cell lung cancer, the most controversial area of man-
agement centres around locally advanced disease. Recent randomsied con-
trolled trials have failed to show an improvement in survival for patients
undergoing surgical resection following either chemoradiotherapy or versus
radiotherapy following induction chemotherapy for stage IIIA, N2 positive
disease. As a result of these trials chemoradiotherapy has been adopted as the
treatment of choice for proven N2 disease. There are, however other
considerations. In the aforementioned randomised trials patients that under-
went a lobectomy appeared to have an improved outcome. A recent meta-
analysis of 5 studies presented at the British Thoracic Oncology Group
demonstrated that radiotherapy provided no advantage over surgery with a
trend to better outcomes for surgery. There is also mounting evidence that the
zonal distribution of N2 disease may have a role in determining who should
undergo surgery based on survival outcomes. Therefore in certain N2 patient
populations surgery followed by adjuvant chemotherapy /- post-operative
radiotherapy may result in the optimal long term survival. For the patient
with unresectable N2 or N3 disease the optimal treatment based on current
evidence is concurrent chemoradiotherapy. Tumour volume, however, has a
direct effect on outcome with long term survival being unlikely with a
tumour diameter 4 cms. The role of induction chemotherapy in reducing
tumour burden prior to radical radiotherapy or the use of shrinking field
radiotherapy as the tumour responds to chemoradiotherapy in improving
patient outcomes has not been tested in randomsied controlled trials. Finally
there may be a role for surgery in T4 tumours involving a mediastinal
structure such as the aorta or vena cava as part of a multi-modal approach.
Looking to the future chemoradiotherapy incorporating agents such as
pemetrexed and cetuximab requires optimisation. Also meta-analysis con-
firms that three drug regimens have higher response rates than two drug
regimens. Their use in the neoadjuvant and adjuvant settings may improve
outcomes for resected and unresectable locally advanced non-small cell lung
cancer.
Disclosure: K. O’Byrne: I have received honoraria for lectures and advisory
board work and have participated in clinical trials with Merck Serono and
Lilly Oncology
75IN
IMPROVING THE THERAPEUTIC RATIO OF
CHEMORADIATION: BIOLOGY MEETS TECHNOLOGY
D. Zips1, S. Appold1, M. Baumann2 1Radiation Oncology/ Oncoray, Tech-
nische Universita¨t Dresden / University Hospital and Medical Faculty,
Dresden/GERMANY, 2Department of Radiation Oncology, University Hos-
pital and Medical Faculty, Dresden/GERMANY
Better understanding of the biological determinants and advanced radiation
technology led to improved outcome after chemoradiation in patients with
lung cancer. Milestones were the optimization of time-dose-fractionation and
schedules of combined therapies, introduction of functional imaging for
treatment planning and monitoring of response, novel radiation techniques as
well as implementation of image-guidance allowing high-precision delivery
and control for respiratory motion. Advances in imaging and radiation
technology have been shown to be not only useful to increase the radiation
dose to the tumour but also to spare normal tissues. Equally important for the
progress in radiotherapy were fundamental insights into the cellular and
molecular mechanisms of radiation response of tumours and normal tissues.
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Together, biology-driven optimization embedded into high-tech radiotherapy
represents a promising environment for further developments.
Disclosure: D. Zips: Research grants by Siemens, Bayer Schering, Boehr-
inger Ingelheim Austria. Honoraria by Merck, Astra Zeneca. Member of the
Lilly advisory board radiotherapy; S. Appold: Clinical reviewer for ESTRO-
Equal. Honoraria from Merck; M. Baumann: Research grants by Siemens,
Bayer Schering, Boehringer Ingelheim Austria. Honoraria by Merck, Astra
Zeneca.
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WHICH PATIENTS ARE CANDIDATES FOR SURGERY?
W. Weder Division of Thoracic Surgery, University Hospital Zurich, Zurich/
SWITZERLAND
Stage III disease is characterised by its heterogeneity. It includes patients
with locally advanced tumor with infiltration of the chest wall or the
mediastinum in combination with lobar lymph node metastasis (T3, N1) or
tumors infiltrating organs or central structures such as trachea, aorta, vertebra
(T4) and on the other hand tumors of any size located within the lung
parenchyma with metastasis to the mediastinal lymph nodes either ipsilateral
(N2) or contra lateral (N3).
Furthermore N2 or N3 disease is not a uniform entity and encompasses a
broad spectrum of metastatic lymph node involvement from microscopic
disease found unexpectedly at surgery to multilevel bulky lymph node
involvement. Treatment recommendations in some subgroups are relatively
clear in others discussed controversially and differ between institutions.
Treatment recommendations especially for surgery have to be balanced with
risk of morbidity and mortality and this again differs quite largely between
institutions. The heterogeneity of Stage III disease and the difference in
treatment related mortality and morbidity of surgically treated patients is a
dilemma for giving a brief recommendation who the surgical candidates are.
There are a few basic rules for surgical treatment of lung cancer. In general,
patients profit from surgery only, when resection is complete with free
resection margins. Complete resection of metastatic lymph nodes is more
problematic to define but is defined to be in those cases in which the highest
mediastinal lymph nodes are free. Several studies confirm this definition by
showing a superior long term survival in those patients who fulfil these
criteria.
When the question has to be answered, who is a candidate for surgery in
Stage III disease and then it is advisable to differentiate between T3/T4
tumors from N2 disease.
Tumors with infiltration into the chest wall or the mediastinum are recom-
mended to be radically resected by a lobectomy including chest wall
resection and mediastinal lymph adenectomy. Adjuvant chemotherapy is
recommended in physically fit patients. Adjuvant radiotherapy is indicated
when the resection margin is not clear. Theses patients may achieve a five
year survival within a range of up to 40 – 50%.
Patients with infiltration of the carina, aorta or spine are potential candidates
as well but should be treated by surgeons with a high experience with these
procedures to avoid a high treatment related morbidity or even mortality.
More and more of these resections are done after induction chemo or
chemo-radiotherapy and it has been shown that surgical morbidity is not
increased.
None of the other stages of NSCLC led to a more controversial discussion
regarding the overall management than N2 disease. Depending on the
experience of the team responsible for treatment decisions, different algo-
rithms are applied. Due to the lack of fully convincing randomized trials the
diversity of phase II studies and especially the heterogeneity of the study
population, it is not surprising that the available evidence is interpreted
differently and discussed controversially. Survival data may differ widely
between studies and an explanation is often elusive. Patient selection is
among other factors the key for differences in outcome. Unfortunately N2
disease is often imprecisely described. Several authors have proposed that
N2 disease should be divided into subgroups. For example Robinson pro-
posed 4 subgroups (1. Incidental nodal metastasis found on final pathology,
2. Nodal metastasis recognized intraoperatively, 3. Nodal metastasis recog-
nized by prethoracotomy staging, 4. Bulky or fixed multistation N2 disease).
The question, whether N2 disease can be considered resectable, cannot be
answered easily since several co-founding factors play a role. The question
includes at least for different aspects. The first aspect is regarding the
technical resectability. The surgeon has to answer if the affected lymph
nodes are completely removable from a macroscopic standpoint. This ques-
tion is a prerequisite and is typically answered by analysing images espe-
cially the CT or PET/CT by an experienced surgeon. Further tests such as
mediastinoscopy may be needed for final evaluation. The second and even
more critical aspect relates to the question if local resection is useful for the
patient since N2 disease may be the tip of an iceberg and indicate more than
just locally advanced disease, a disease with systemic spread of tumor cells
to other organs. The third aspect regarding the usefulness of resection is the
response rate of the tumor and mediastinal lymph nodes to neoadjuvant
chemo- or chemoradiotherapy. Finally the fourth aspect has to take into
account the risk benefit ratio for the patient regarding the treatment. It is
relevant for the decision making to evaluate to what risk the patient is
exposed when a lobectomy or pneumonectomy is performed after neoadju-
vant therapy.
When the question has to be answered if N2 disease is resectable or in other
words when surgery is indicated or not, subgroups can be defined which
allow a clear answer and most oncologists, surgeons and radiotherapists
might agree. One subgroup is N2 metastasis found unexpectedly during
surgery. If a radical resection of the tumor as well of the lymph nodes is
possible and tolerated by the patient, surgery should be completed and
adjuvant therapy is recommended. On the other hand in cases of bulky
multistation N2 at initial diagnosis and especially after neoadjuvant therapy,
surgery is not indicated since the patient will not experience a profit. The
main controversy occurs in cases with initially diagnosed N2 disease at either
a single or in some adjacent stations but surgically resectable. These patients
are recommended either to undergo neoadjuvant chemo- or chemo-radio-
therapy followed by surgery. Definitive chemo-radiotherapy is reserved for
those who are not completely resectable or high perioperative mortality.
However the term resectable is not clearly definable on preoperative imaging
and depends from the expertise and subjective judgement of the surgeon.
Despite the fact that two randomized trials did not show a survival benefit in
the arm which included surgery after chemo-radiotherapy in comparison to
chemo-radiotherapy alone there remain some open questions. The North
American intergroup 0196 trial reported a treatment related mortality of
7.9% in the surgical arm in comparison to 2.1% in the medical arm. The
mortality was especially high in pneumonectomies with 26%. Despite this
unusually high mortality the 5 year survival in the surgical arm in those
patients with complete clearance of the mediastinal lymph nodes was 41%
and significantly higher. Furthermore patients who underwent a lobectomy
experienced a significantly better survival than non-surgical patients. Taken
into account that other centres report much lower perioperative mortality
even in pneumonectomies after neoadjuvant therapy the role of surgery has
to be considered at least in centres with a high expertise. We reported
recently a 3% mortality rate in 172 pneumonectomies after chemoradiother-
apy for stage III disease treated in two different centers.
In the EORTC trial reported by van Meerbeck there was also no survival
benefit in the surgical arm in comparison to the chemoradiotherapy alone
arm and the overall 5-year survival was 16.4months. However 50% of the
patients had an incomplete resection and the patients which were included
had irresectable N2 at study entry. In the multicenter phase II SAKK
study reported by Betticher patients with N2 disease and treated by
neoadjuvant chemotherapy and surgery the 5-year overall survival was
superior with 27.6 months. This outcome was even better in those patients
who experienced a complete remission of the mediastinal nodes and
underwent surgery.
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It is of importance that patients who present with N2 disease should be
evaluated by a multidisciplinary team including an experienced surgeon in
thoracic oncology in order to select patients for the appropriate treatment
either in a study protocol or an individualised regimen which respects the
local expertise. Further aspects and other data will be discussed in detail
during the conference.
Disclosure: The author has declared no conflicts of interest.
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INDUCTION TREATMENT – CHEMOTHERAPY OR
CHEMORADIATION?
J.P. van Meerbeeck Department of Respiratory Medicine, University Hos-
pital, Ghent/BELGIUM
Concomitant chemoradiotherapy at systemic doses results in superior out-
come compared to sequential chemoradiotherapy, at the cost of a moderately
increased toxic morbidity and is considered the present standard. Three
randomised trials have compared chemotherapy and chemoradiotherapy as
induction regimen in stage III NSCLC proceeding to surgery; 1 more is
ongoing and 1 has been prematurely closed due to a lack of accrual (table).
Ongoing Korean and Swiss trials compare the optimal intensity of induction
treatment. Taken together, these trials suggest that induction chemoradio-
therapy results in better rates of resectability, pathological downstaging and
pathological complete remissions than chemotherapy alone, without signif-
icantly affecting overall or progression-free survival survival. Our present
systemic induction treatment is still poor. It is unclear whether new cytotoxic
drugs will result in an improved outcome, as most third generation drug
containing induction combinations seem to have a similar activity in locally
advanced disease. Many’s expectations are turned towards an incremental
effect of adding a targeted biological agent to the standard induction
treatment, either during or following radiotherapy. The latter approach was
not successfull in a trial conducted by SWOG, wherein patients with stage III
were treated with consolidation docetaxel after chemoradiotherapy and then
randomised between gefitinib, a small molecule oral inhibitor of the Epider-
mal Growth Factor Receptor (EGFR) and placebo. A detrimental effect of
gefitinib was observed. Early data on the concomitant use of chemoradio-
therapy and cetuximab and bevacizumab are promising and need randomised
confirmation. Several retrospective and single institutional prospective series
show an improved rate of pathological complete remission with higher total
doses of radiotherapy, administered concomitantly with standard cisplatin-
based combination chemotherapy, suggesting that an improvement in local
control is likely to be mostly obtained by improvements in the radiotherapy
delivery Current practice guidelines allocate a category 1 evidence to definite
concomitant cisplatin-based chemoradiation in selected patients with stage
III NSCLC.
Disclosure: The author has declared no conflicts of interest.
78IN
HOW TO RESTAGE A PATIENT AFTER A
PREOPERATIVE TREATMENT
G. Stamatis Thoracic Surgery and Endoscopy, Ruhrlandklinik, Essen/
GERMANY
Multimodal treatment concepts have become a therapeutic option for patients
with stage IIIA and in selected cases stage IIIB NSCLC. An important
question remains whether a better local control and survival are obtain by
induction treatment and surgery compared to standard chemoradiotherapy.
Complete resection is an essential factor in the potential of cure, therefore, an
important aim of restaging procedures in these patients will be to guide the
multidisciplinary decision on whether the patients is a candidate for surgery.
For T4 tumors the re-evaluation of tumor viability and metastatic spread in
the surrounding structures remains a challenge for anatomic imaging because
the reduction of tumor size, which does not occur immediately after cell
death, is used as a diagnostic criterion. Morphologic and functional changes
in PET/CT scans before and after induction treatment can provide the
clinician with information about the prediction of response of the primary
tumor. The percentage of remaining FDG signal normalized to the initial
SUV has turned out as a better variable for prediction of response. In some
cases a VATS procedure before surgery is helpfull to define tumor ivasion
and local operability. A major concentration on these restaging issues is
warranted since is now agreed that sterilisation of the mediastinal lymph-
nodes after induction therapy has an impact on the prognosis of patients with
stage IIIA-N2 disease, and accurate staging after therapy may rationally
guide diverse therapeutic interventions in these patients. At the present time,
neither CT, PET nor PET/CT scans are accurate enough to make final further
therapeutic decisions for mediastinal nodal involvement. An invasive tech-
nique providing cytohistological information is still recommended at the
present time by the European Society of Thoracic Surgeons (ESTS). Endo-
scopic (EBUS-FNA or/and EUS-FNA) or surgical (mediastinoscopy, remediastinos-
copy, VATS) invasive procedures may be utilized the precise choice depending on
the availability of the technique and expertise of the centre.
Disclosure: The author has declared no conflicts of interest.
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THE MORBIDITY OF SURGERY AFTER INDUCTION
TREATMENT
A.J. Torres, J.R. Jarabo, J. Calatayud, A.M. Go´mez, E. Ferna´ndez, R.M.
Sa´nchez, F. Hernando Department of Surgery, Thoracic Surgery Unit, Hos-
pital Clinico San Carlos, Complutense University of Madrid, Madrid/SPAIN
Surgical treatment offers the best chance for patients with early stages of
non-small cell lung cancer (NSCLC). In IIIA-B staged patients multimodality
treatment including surgery may be feasible in selected cases. Induction chemo-
(CT) or chemoradiotherapy (CRT) has gained acceptance even in early staged
cases. The effect of induction therapy on postoperative outcomes remains
unclear. Some authors (Roberts 2001) shown that neoadjuvant CT increased
life-threatening surgical complications, whereas other reports do not find an
increasing in postoperative complications after CT (Perrot 2005). Furthermore,
the widespread agreement among thoracic surgeons trying to avoid pneumonec-
tomies due to their association with complications after induction treatment
(Martin 2001) remains debatable according with recent reports (Takedo 2006,
Mansour 2007). . Factors as pulmonary function tests (PFTs), cardiac function,
performance status, age and comorbidity probably determine the deleterious
effect of neoadjuvance on surgical outcomes. It has been reported a decrease in
the percent diffusion capacity of the lung for diffusion of carbon monoxide
(LDCO) after CT or CRT.
Recent reports suggest that preoperative doses of 60 Gy are safe (Sonett 2004,
Cerfolio 2009, Milman 2009), obtaining important therapeutic benefits without
higher rates of postoperatory complications as bronchopleural fistula.
In conclusion, several items must be kept in mind when designing a
multimodality approach to NSCLC:
- A selection process by a multidisciplinary team, with a great role of a
specialized oncological thoracic surgeon.
- Identification of underlying comorbidities with a special attention to PFTs
(including LDCO).
- A correct restaging after induction treatment to identify persisting N2
disease.
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- Special surgical care (reinforcement of bronchial stump, avoidance of
pneumonectomy (especially right), use of steroids postoperatively, and
optimal medical management).
Disclosure: All authors have declared no conflicts of interest.
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OPTIMAL TREATMENT FOR PS2 PATIENTS
No abstract received at time of going to press.
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OLIGOMETASTASES: THE POINT OF VIEW OF THE
SURGEON
B. Passlick Department of Thoracic Surgery, University Medical Center
Freiburg, Freiburg/GERMANY
Considering oligometastatic NSCLC two different situations should be
considered. First patients with intrathoracic metastasis either to the same lobe
(2010 classified as T3) or to a different ipsilateral lobe (2010 classified as
T4). In surgical series patients with ipsilateral additional nodules can be
encountered in about 4 - 5% of the cases. Patients with additional nodes in
the same lobe have a relatively good 5-year survival rate up to 28%.
Similarly, patients with T4-tumors due ipsilateral metastases have a 5-year
survival rate of 22%. Depending on the co-morbidity and the functional
reserve an anatomic resection (lobectomy) in combination with a segmen-
tectomy or wedge-resection is regarded as the treatment of choice.
The second group of patients with oligometastatic lung cancer are patients
with extrathoracic metastatic disease. They represent almost 10% of all M1
patients. Among those 5% will have metastases to the brain, 4% to the
adrenal glands, 2% to the bones and up to 1% will have single liver
metastasis.
Looking at the patients with brain metastasis several prognostic factors have
been identified: nodal status positive versus negative), performance status,
and primary tumor symptoms (yes or no). In patients with metachronous
single brain metastasis a long-term survival can be reached in 16 - 20% of the
cases. In our own institution a long-term survival of more than 40% has been
reached in patients with complete resection and negative mediastinal nodes.
The same long-term survival rates can be reached in patients with single
adrenal metastasis. In patients with single ipsilateral adrenal metastasis this
can be done in combination with the lobectomy, in all other patients
laparoscopic adrenalectomy is the treatment of choice.
In summary, patients with oligometastatic non-small cell lung cancer are
rare. If probably staged (PET-CT) a complete resection of the primary tumor
and all metastatic disease is recommended. An important prerequisite for a
long-term outcome is a negative mediastinum. An adjuvant systemic che-
motherapy is mandatory.
Disclosure: The author has declared no conflicts of interest.
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OLIGOMETASTASES: THE POINT OF VIEW OF THE
RADIOLOGIST
H. Choy, S.K. Jain Department of Radiation Oncology, University of Texas
Southwestern Medical Center, Dallas/USA
Since Halsted’s initial description of the contiguous spread of cancer, data
illustrating long term, disease free survival in patients with metastases led to
Hellman’s proposed theory of oligometastases. His theory described a
disease state with a limited number of metastases that had not evolved to
widespread disease. If this is the case, one could implement aggressive local
therapy as curative-intent treatment for oligometastases. Surgical resection
data for pulmonary metastases has illustrated improvements in survival, with
a 5 year and 10 year overall survival (OS) of 36% and 25% respectively.
Based on this improvement in survival with aggressive local control (LC),
radiotherapy has also been explored for select patients. Newer techniques,
such as stereotactic body radiation therapy (SBRT) that involves precise
delivery of an “ablative” tumorcidal dose is now being investigated. This
advanced form of radiotherapy involves meticulous treatment planning with
accurate patient positioning and immobilization, daily imaging, and sophis-
ticated tumor motion control. Because of success with SBRT in the treatment
of primary lung tumors, this technique is now being applied in the oligo-
metastatic setting. Phase II data from Rochester illustrated that 49 patients
with 121 metastatic lung lesions had a 3 year actuarial LC rate of 91%. Mean
OS time was 23.4 months and treatment was tolerated well with 2% grade 3
toxicity. Data from Germany showed that 61 patients with lung metastasis
treated for 71 lesions with SBRT had a 2 year actuarial LC rate and OS rate
of 73.7% and 65.1% respectively. Hoyer et al. published phase II data
assessing SBRT in colorectal metastasis with 12 patients with pulmonary
mets treated to 45 Gy in 3 fractions. Two year actuarial LC rate was 86%.
Recently, a multi-institutional, prospective phase I/II trial evaluating SBRT
in patients with 1-3 lung metastases treated to 60 Gy illustrated an actuarial
2 year LC rate of 96%, median survival of 19 months, and grade 3 toxicity
rate of 8%. In the oligometastatic setting, these studies suggest that SBRT is
both well tolerated and effective, with results comparable to metastectomy,
and could be a valuable non-invasive treatment option for patients.
Disclosure: All authors have declared no conflicts of interest.
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THE ROLE OF FIRST-LINE TARGETED THERAPIES
C. Gridelli Division of Medical Oncology, “S.G. Moscati Hospital”, Avel-
lino/ITALY
Molecularly targeted therapies have recently extended the therapeutic op-
tions available for the treatment of patients with advanced non-small-cell-
lung cancer (NSCLC). Currently two types of therapeutic targets are devel-
oped: vascular endothelial growth factor (VEGF) and its receptors and
epidermal growth factor receptor (EGFR). Bevacizumab is the first mono-
clonal antibody (mAb) against VEGF which in combination with chemo-
therapy compared to chemotherapy alone, as first line treatment, has shown
to increase by two months the median survival of advanced non squamous
histology NSCLC patients. Other antiangiogenic agents, including sorafenib,
VEGF-trap and ASA404 are being tested in ongoing clinical trials which
could to clarify their role in the management of NSCLC. Targeting the EGFR
has played a central role in advancing NSCLC research, treatment, and
patient outcome over the last several years. EGFR inhibition in NSCLC
cancer is achieved via small molecular tyrosine kinase inhibitors (TKIs),
such as erlotinib or gefitinib; or mAbs such as cetuximab. Cetuximab has
show that when added to first line chemotherapy significantly prolongs
survival compared to chemotherapy alone (FLEX trial). Trials incorporating
TKIs with chemotherapy in first line treatment, failed to produce a survival
benefit. The identification of patients that are likely to benefit from EGFR
TKI therapy is a priority for patients with advanced NSCLC. Previous,
uncontrolled clinical trial have suggested that first-line treatment with ge-
fitinib would be efficacious in selected patients with NSCLC. At the molec-
ular level, most patients with partial or complete responses to TKIs harbored
specific mutations in the gene that encodes EGFR. Recently in a large phase
III trial (IPASS) in chemotherapy-naive Asian patients with adenocarcinoma
who were never smokers or former light smokers, gefitinib was more
effective than carboplatin plus paclitaxel in prolonging progression-free
survival. In a prespecified subgroup analysis, EGFR-mutation-positive status
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is a strong predictor of a better outcome with gefitinib. The EURTAC trial
assessing the role of erlotinib in EGFR mutated tumors is ongoing. Despite
the recent therapeutic improvements, the overall survival for most patients
with advanced-stage disease remains modest, and clinical trials that investi-
gate the activity of novel agents, and incorporate patient selection based on
clinical and molecular factors, are required.
Disclosure: C. Gridelli: Honoraria as speaker bureau and advisory board
member for Roche, Merck-Serono
84IN
CUSTOMIZING SYSTEMIC THERAPY IN PATIENTS
WITH ADVANCED LUNG CANCER
P. Germonpre´ Pneumology Service, Antwerp University Hospital, Edegem/
BELGIUM
Until recently non-small cell lung cancer (NSCLC) was considered as a
single disease entity, whereby the treatment decissions were mainly based on
the stage of the tumor, and the performance status and comorbities of the
patient. Currently we are at the dawn of customized treatment for advanced
NSCLC based prognostic and predictive charateristics of both the patient or
the tumor. A growing body of evidence shows that tumor-specific biomar-
kers can predict response to therapy in NSCLC. However most of these
predicitve biomarkers still require validation in phase III trials of customized
treatment. Histology has recently emerged as a potential predictive factor for
treatment with EGFR-TKIs or pemetrexed. In patients with an adenocarci-
noma the response rates for EGFR TKIs are higher (without necessarily
translating into superior survival), while three large phase III trials demon-
strated that the pemetrexed efficacy differs significantly according to NSCLC
histology. However we should move beyond histology as a predictive
marker, as it is clear that underlying molecular factors are responsible for
these findings. The IPASS trial proved that a molecular selection based on
EGFR mutation status is superior in terms of predicting benefit from
treatment with EGFR TKI. The sensitivity to pemetrexed on the other hand
seems to correlate to the thymidylate synthase expression (high expression in
squamous cell carcinoma, low expression in adenocarcinoma and variable
expression in large cell carcinoma). Although the relationship between DNA
repair systems and survival in NSCLC patients treated with cisplatin-based
chemotherapy has been extensively studied, prospective validation of mo-
lecular selection based on these molecular markers is lacking. Currently such
a trial using BRCA1 and RAP80 as genetic markers is ongoing. Bevaci-
zumab-containing regimens are contraindicated in patients with squamous
cell NSCLC because of an increased risk of inducing life-threatening
hemoptysis. Patient rather than tumor-related factors are also correlated with
treatment-related toxicities. For example, a deficiency of serum cytidine
deaminase activity is associated with the occurence of early severe toxicities
with gemcitabine.
Disclosure: The author has declared no conflicts of interest.
85IN
MAINTENANCE THERAPY
S. Novello1, M. Giaj Levra1, E. Capelletto2, S.G. Rapetti2 1Thoracic On-
cology Unit, University of Turin, Ospedale San Luigi, Orbassano/ITALY,
2Thoracic Oncology Unit, University of Turin, Orbassano/ITALY
Maintenance Therapy for patients (pts) with metastatic non–small cell lung
cancer (NSCLC) the 5-year survival rate is equal to 2.8%, leaving an unmet
medical need for this population. According to the recently released ASCO
Clinical Practice Guideline Update cytotoxic chemotherapy should be
stopped at disease progression or after 4 cycles in pts whose disease is not
responding to treatment and, also in case of response, doublet cisplatin-based
chemotherapy should not be administered for no more than 6 cycles.
Maintenance therapy (first-line treatment is continued or switched to another
agent beyond 4-6 cycles) is gaining recognition as a possible approach, as
clinical trials have demonstrated a survival benefit. Early (maintenance
therapy) versus delayed (at the time of progression) administration of
docetaxel was tested in a randomised study: median progression-free survival
(PFS) significantly favored early docetaxel with a trend of a better overall
survival (OS). Pemetrexed (pem) was tested in a phase III study as a
maintenance therapy (vs placebo) in pts with advanced NSCLC who did not
progress after 4 cycles of platinum-based doublet chemotherapy. PFS was
significantly longer with pem (4.3 vs 2.6 mo; hazard ratio [HR]  0.50). OS
was also significantly improved (13.4 vs 10.6 mo; HR  0.79) and pem was
generally well tolerated during long-term exposure. A pre-planned subset
analysis showed in non-squamous histology a survival benefit of 5 months
(HR 0.70) for pts treated with pem. Erlotinib (erl) in the maintenance setting
was explored in two phase III studies. In one of these 889 pts who had not
progressed on 4 cycles of platinum-based chemotherapy were randomized to
maintenance with erl or placebo. Maintenance therapy with erl resulted in a
better disease control rate at 12 weeks (40.8% vs 27.4%), with a statistically
significant improvement in PFS (12.3 weeks vs 11.1 weeks) compared with
placebo (HR  0.71; p  .000003) and in OS (12 vs 11 mo, HR 0.81). The
available evidence support the maintenance approach for pts (with response
or stable disease) without relevant clinical toxicities and asking to continue
therapy. For those pts with clinical relevant toxicity with first line therapy or
preferring a treatment holiday and monitoring, starting timely second line
remains an appropriate alternative.
Disclosure: All authors have declared no conflicts of interest.
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THE IDENTIFICATION OF NOVEL TARGETS FOR
DEVELOPING NEW CLINICAL TRIALS
J. Mazie`res Department of Pneumology, Larrey Hospital, CHU Toulouse,
Toulouse/FRANCE
Continuing progress in basic cancer research and drug development has led
to discoveries of new agents or strategies for molecular targeting in novel
cancer therapies. These new agents suppress tumour growth through multiple
mechanisms such as cell cycle control, activation of tumour suppressor
genes, essential signal pathway blockage, tumour vaccines, tumour micro-
environment modification, etc. Rapid translation of these exciting discoveries
into clinical practice requires timely support to accommodate the special
needs of novel cancer therapy development. In the field of lung cancer,
molecular targets or processes such as EGFR, IGFR, ALK, angiogenesis
have been well identified and studied from bench to bedside with an impact
on patient survival. Nevertheless, some of the new drugs have been disap-
pointing essentially due to the absence of biomarker-based patients selection.
Patient selection should be considered as early as possible in the drug
development process. This may be followed by a recruitment expansion only
in selected patients at higher doses to interrogate biological hypotheses.
Moreover, the dose-limiting toxicities of targeted therapies are frequently
markedly different from those of cytotoxic anticancer drugs. Target modu-
lation can be assessed by phase 0 clinical trial that are designed to evaluate
the pharmacodynamic effect of a new drug that is expected to be correlated
with its clinical activity. In addition to the shift in the initial phase of drug
development, the design of phase II and III studies may also need to change
to adapt clinical development to the needs of modern drug development
without compromising assessment of relevant end points, especially in
confirmatory pivotal trials. Randomized phase II studies in selected patient
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populations employing various dose levels, guided by biomarkers of activity
and randomized assignment of potential responders to either the study drug
or placebo and withdrawal of subjects who do not benefit because of disease
progression, may help to optimize classical phase II studies. Enrichment of
patients in phase III studies may be an essential tool to prevent negative
trials. Demonstration of benefit based on hard clinical end points is also
considered to be pivotal for modern innovative drugs. The paradigm shift in
the development of novel anticancer drugs is the change from widely used
chemotherapy to drugs for selected patient populations or even for niche
indications. A very tight collaboration among clinicians, basic researchers
and pharmaceutical companies is mandatory in order to investigate new
potential target and to design new relevant clinical trials. Some examples of
new targets, new clinical trial and optimization of translational research will
be discussed.
Disclosure: The author has declared no conflicts of interest.
87IN
THE ROLE OF ANTI-ANGIOGENIC AGENTS (TKIS)
M. Reck Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf/
GERMANY
Dysregulation of angiogenesis in solid tumors enables tumor growth and
metastasis. Receptors that mediate angiogenesis, and their ligands, have been
identified; among these, vascular endothelial growth factor (VEGF) and its
receptor tyrosine kinase play a central role. First-Line Treatment: In a
randomized phase III trial (ESCAPE trial) the addition of sorafenib to
standard chemotherapy didnt improve overall survival (OS) or progression-
free survival (PFS) but was associated with a higher mortality rate in patients
with squamous cell lung cancer histology (Scagliotti 2008). Results of a
second randomized trial (NEXUS trial) are awaited. Cediranib at a dose of 30
mg combined with chemotherapy did improve response rate (RR) and PFS
but was associated with unacceptable toxicity (Goss 2009). Second-Line
Treatment: Combination of vandetanib and docetaxel showed a statistical
significant improvement in PFS, RR and a trend in OS compared to docetaxel
(Herbst 2009). However two additional trials which compared the combina-
tion of vandetanib and pemetrexed with pemetrexed and vandetanib with
erlotinib didnt meet the primary endpoint of statistically significant PFS
prolongation (de Broer 2009, Natale 2009). In two similar randomized phase
III trials the VEGFR-TKI BIBF1120 is evaluated either in comb. with
docetaxel or with pemetrexed compared to docetaxel or pemetrexed. The
primary endpoint of both trials is significant prolongation of PFS. Sunitinib
which has shown a median PFS of 12.0 weeks and a median OS of 23.4
weeks (Socinski 2008) has been investigated in a randomized trial in comb.
with erlotinib compared to erlotinib. Results are awaited for 2010. In heavily
pretreated patients sorafenib has shown improvement in PFS in a randomized
phase II trial compared to placebo (Schiller 2008). Currently a randomized
phase III trial compares the efficacy of sorafenib with placebo in patients
failing at least two lines of previous chemotherapy. Conclusion: The role of
antiangiogenic TKI in treatment of NSCLC hasnt been defined yet and is
currently investigated in a large number of randomized trials. One of the
most important challenges for the future is the identification of predictive
markers which might help to select patients who benefit from treatment with
these new drugs.
Disclosure: M. Reck: I have received honoraria for lectures from Hoff-
mann-La Roche, Lilly, Merck and AstraZeneca. I served on the Advisory
Board of Hoffmann-La Roche, Lilly, Merck and AstraZeneca.
88IN
PREDICTIVE MARKERS OF TUMOR RESPONSE
B. Besse Department of Medicine, Institut Gustave Roussy, Villejuif/
FRANCE
In the last decade, treatment of non-small-cell lung cancer (NSCLC) was
steadily improved by optimizing cytotoxic chemotherapy and integration of
targeted therapies. Further improvements could be expected by individual-
izing therapy based on predictive biomarkers. To date, the “quest” for the
perfect predictive molecular marker has been mainly based on retrospective
database with 2 types of technology. (1) High throughput technology;
Despite huge efforts and millions of Euros spent worldwide each year to
identify predictive biological signatures, there has been limited progress and
only one signature (Metagene) is being evaluated prospectively; (2) single
biomarker approach; we may distinguish such a biomarker in 3 categories of
therapeutic agents: cytotoxic agents, tyrosine kinase inhibitors and antian-
giogenic agents. In the ‘cytotoxic setting’, DNA repair pathways have
provided the most promising biomarkers for cisplatin resistance, as the
expression of ERCC1 & MSH2 or the level of BRCA1 mRNA. Others
candidate biomarkers such as the cell cycle regulator p27, class III -tubulin
or thymidylate synthase had been linked to a benefit of chemotherapy. With
regard to targeted therapies, specific activating mutations located in the
tyrosine kinase domain of the epidermal growth factor receptor (EGFR) are
associated with an improved response to EGFR-directed tyrosine kinase
inhibitors (TKIs) in NSCLC patients. In contrast, mutations in KRAS or
c-Met amplification are associated with resistance to EGFR-directed TKI
therapy. EML4-ALK variant seems to be a good candidate for ALK inhib-
itors. Although antiangiogenic therapies are actively studied in NSCLC, no
predictive biomarker has been identified so far and the patients’ selection still
rely on clinical and pathological profile. Because many biomarkers have only
been characterized in retrospective studies, prospective validation in well
designed clinical trials is mandatory. Important issues are availability of
sufficient tumor material, validation of detection methods, and confirmation
of the survival benefit in properly designed clinical trials. According to the
present promising data, individualized therapy based on tumor features is
feasible and may improve outcome of patients with NSCLC in the future.
Disclosure: The author has declared no conflicts of interest.
89IN
MOVING FORWARD IN THE FIELD OF NEW ORAL
INHIBITORS
F. Cappuzzo Department of Medical Oncology, Istituto Clinico Humanitas
IRCCS, Rozzano, Milan/ITALY
Non-small cell lung cancer (NSCLC) remains the main cause of cancer death in
the world. Unfortunately, at the time of diagnosis, the vast majority of patients
have a metastatic disease and a definitive cure is not achievable. Currently, the
standard treatment consists in platinum-based chemotherapy, with the addition
of the anti-vascular endothelial growth factor (VEGF) monoclonal antibody
bevacizumab in certain patients. Recent advances in the knowledge of cancer
biology led to the identification of several potential molecular targets that play a
key role in cancer development and progression. Selective targeting of cancer
cells based on their molecular phenotype can provide effective anti-cancer
activity avoiding the commonly experienced side effects induced by chemother-
apy. Moreover, many of the agents under investigation have the advantage of
oral administration. Among these agents, the reversible Epidermal Growth
Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIs) gefitinib and erlotinib
demonstrated to produce dramatic and durable response in some patients with
NSCLC, particularly in those harbouring an activating mutation of the EGFR
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gene. Four large phase III randomized trials comparing standard chemotherapy
versus gefitinib in chemonaive NSCLC demonstrated the superiority of gefitinib
at least in terms of progression free survival, in EGFR mutant patients.. These
data strongly support EGFR testing in NSCLC together with an early usage of
EGFR-TKIs in individuals with an EGFR mutation. Specific molecular events,
including the presence of EML4-ALK fusion gene, could be responsible for the
lack of sensitivity to anti-EGFR strategies observed in some patients and even in
EGFR mutants, after an initial response, all patients inevitably acquire resistance.
Therefore, new oral agents are under investigation, including ALK inhibitors,
cMET inhibitors and the new class of irreversible EGFR-TKIs. Preclinical and
clinical data suggested that such agents are effective in patients with specific
biological characteristics highlighting the importance of incorporating prospec-
tive molecular genotyping into clinical trials of novel targeted agents.
Disclosure: The author has declared no conflicts of interest.
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90O
CXCR4 OVER-EXPRESSION BY IMMUNOHISTOCHEMISTRY
(IHC) HERALDS POOR OUTCOME IN METASTATIC NSCLC
S. Otsuka, A. Klimowicz, K. Kopciuk, S. Petrillo, E. Stolte, M. Konno, W.
Boland, D. Morris, T. Magliocco, G. Bebb Tom Baker Cancer Centre and
University of Calgary, Calgary/CANADA
Background: CXCR4, a G protein coupled chemokine receptor, and its
ligand, stromal cell derived factor-1 (SDF-1), play a critical role in organ
specific tumor metastasis. In vitro, CXCR4 expression has been shown to
correlate with migration, invasion and adhesion. High CXCR4 expression in
resected tumors is associated with poorer clinical outcome, but its effect on
outcome in advanced non-small cell lung cancer (NSCLC) has not been
explored. We investigated the effect of CXCR4 expression on outcome in
stage IV NSCLC.
Methodology: After ethical approval was obtained, demographic details,
clinical variables and outcome data were gathered on NSCLC patients
diagnosed at the Tom Baker Cancer Centre (TBCC) from 2003 to 2006
(Glans-Look Lung Cancer Database). Formalin-fixed paraffin embedded
tumor specimens were obtained from patients diagnosed with stage IV
NSCLC and tissue arrays (TAs) generated. Specimens were randomly
assigned into tester and validator cohorts. CXCR4 expression within NSCLC
cells was analyzed by IHC (Epitomics) using the HistoRx PM-2000 platform
then correlated with clinical outcome. CXCR4 high expression cutoff was
determined as mean expression plus 1 SD. Statistical analysis was performed
using the Kaplan-Meier method, multivariate analysis and Spearman’s rank
correlation.
Results: Between 2003-2006, 832 patients were diagnosed with stage IV
NSCLC with 303 tissue samples available, 200 suitable for TA generation. The
overall survival of patients whose tumors were suitable for TA generation was
similar to the general cohort. Automated IHC for CXCR4 was successfully
completed on the tester cohort of 103 patients. High expressers (10.7% of the
tested stage IV patients) had a significantly poorer clinical outcome with a
median overall survival (MOS) of 2.7 months vs 6.1 months for the low
expressers (P0.0001). CXCR4 over-expression was associated with squamous
histology, smoking history and a higher rate of brain metastases.
Conclusions: CXCR4 is expressed in most NSCLC tumors. CXCR4 over
expression is associated with significantly poorer survival in stage IV NSCLC
patients. Our results suggest that novel therapeutic strategies, possibly involving
anti-CXCR4 drugs, should be tested in CXCR4 over-expressers. Staining on a
validation cohort is underway and full data will be presented.
Disclosure: All authors have declared no conflicts of interest.
91O
NESTIN EXPRESSION IN NON-SMALL CELL LUNG
CANCER AND ITS RELEVANCE WITH PROGNOSTIC
SIGNIFICANCE
C. Zhenguang1, W. Tao2, L. Honghe1, Y. Xuhui3, X. Peng3 1Thoracic
Department, 1st Affiliated Hospital of Sun Yat-sen University, Guangzhou/
CHINA, 2Center for Stem Cell Biology and Tissue Engineering, Sun Yat-sen
University, Key Laboratory for Stem Cells and Tissue Engineering, Ministry
of Education, 1st Affiliated Hospital of Sun Yat-sen University, Guangzhou/
CHINA, 3Center for Stem Cell Biology and Tissue Engineering, Sun Yat-sen
University, Key Laboratory for Stem Cells and Tissue Engineering, Ministry
of Education, 1st Affiliated Hospital of Sun Yat-sen University, Guangzhou/
CHINA
Background: As an intermediate filament protein and important neural stem
cell marker, nestin has been detected in several progenitor cells during
development. Recent reports indicated nestin may be re-expressed under
neoplastic transformation and exerted its activity by linking to malignant
characteristics so that nestin could be a new and simple diagnostic tool for
evaluation of tumor prognosis. Investigation to the association of nestin
expression with prognosis in non-small cell lung cancer (NSCLC) would
enable the use of nestin as a biomarker of the disease.
Methods: Using immunohistochemistry method, we investigated the expres-
sion of nestin in 52 cases of NSCLC specimens and also successfully
detected nestin expression in three NSCLC cell lines by immunocytochem-
istry staining, RT-PCR and western blot. Next, we analyzed association of
nestin expression with clinical and pathological characteristics of NSCLC
and assessed its influence on patients’ prognosis. Moreover, we revealed
nestin expression in A549 and H460 cell lines, blockaded nestin expression
by shRNA-mediated knockdown, and demonstrated the variety of tumor
cells proliferation, apoptosis and subcutaneous growth in vivo.
Results: Nestin expressed in tumor cells of 86.5% samples and three NSCLC
cell lines. When the median histoscore of nestin was used as cutoff value
(8.4), significant differences of nestin expression could be observed between
poor and well differentiation (p  0.007) or between adenocarcinoma and
squamous cell carcinoma (p  0.000). The median survival time of the
patients with a low nestin expression was more than 60 months as compared
with 23 months among those with high nestin expression (p  0.003). This
difference corresponded to a 3.42-fold increased risk of dying for patients
with high nestin expression (p  0.009) and remained significant in multi-
variate analysis (hazard ratio, 3.366; p  0.034) independent of other
clinicopathological features. Stable siRNA-mediated knockdown nestin ex-
pression decreased proliferation and increased apoptosis of A549 and H460
tumor cells prominently. In vivo, knockdown of nestin expression inhibited
growth of A549 and H460 cells when implanted as tumor xenografts.
Conclusions: Our results identified nestin expression in NSCLC tissues and
cell lines. Knockdown of nestin expression revealed down-regulation of
proliferation and up-regulation of apoptosis in NSCLC cell lines. Nestin
might be a strong and independent favorable prognostic marker for NSCLC.
Disclosure: All authors have declared no conflicts of interest.
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OVEREXPRESSION OF THE SIGNAL TRANSDUCER VAV1
IS A PROGNOSTIC FACTOR IN RESECTABLE NON
SMALL CELL LUNG CANCER PATIENTS
E. Sapir1, G. Laizer2, S. Katzav2, U. Izhar3, E. Pikarsky4, G. Amir5, N.
Peylan Ramu1 1Oncology and Radiation Therapy, Hebrew University,
Hadassah Medical Center, Jerusalem/ISRAEL, 2Department of Experimental
Medicine and Cancer Research, Hebrew University, Hadassah Medical
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Center, Jerusalem/ISRAEL, 3Thoracic Surgery, Hebrew University, Hadas-
sah Medical Center, Jerusalem/ISRAEL, 4Pathology, Hebrew University,
Hadassah Medical Center, Jerusalem/ISRAEL, 5Patology, Hebrew Univer-
sity, Hadassah Medical Center, Jerusalem/ISRAEL
Background: Better knowledge of the molecular abnormalities and their
effects on responsiveness to therapy may improve our ability to predict and
eventually improve long term survival of resectable non small cell lung
cancer (NSCLC). Remarkable advances in the understanding of NSCLC
biology have been made, including alterations in gene products directly
related to drug activity. Physiological expression of Vav1 is restricted to the
hematopoietic system, where its best-known function is as a GDP/GTP
nucleotide exchange factor, an activity strictly controlled by tyrosine phos-
phorylation downstream of cell surface receptors. We previously found that
Vav1 is widely expressed in lung cancer and plays a critical role in its
pathogenesis. Thus, Vav1 expression could define a subset of tumors that is
signified by specific clinical characteristics.
Methods: We retrospectively collected clinical and pathological information
of 140 patients with resectable NSCLC treated at the Hadassah Medical
Center. We prepared a tissue microarray containing 3 tumor and 3 normal
lung cores from each case. Immunohistochemical staining for Vav1 protein
expression was performed and analyzed by automated image analysis by the
Ariol SL50 robotic image analysis system.
Results: From 8/1994 until 12/2001, 140 patients (pts) with NSCLC under-
went wedge resection (7), lobectomy (105) or Pneumonectomy (28). Pts’ age
range: 40 - 84 years. M/F ratio: 2/1 and 81% had non squamous disease.
Stage I - 46%, II - 34% and III 20%. Additional therapy included adjuvant
radiotherapy in 17 pts and neoadjuvant chemotherapy in 3 pts. Presently 39
pts (28%) are well and alive. We divided the pts into 3 groups according to
VAV1 protein expression: To examine the effect of gene expression on
survival of patients we used the Cox model. The median survival for each
group was: Low-39.5, Medium-36, High-64 months. HR (High vs. Low and
Medium groups) was 0.63 with p - 0.04. These results were also demon-
strated by the Kaplan-Mayer curves.
Conclusions: 1. Overexpression of Vav1 indicates higher overall survival in
resectable NSCLC. 2. VAV1 may be identified as a potential therapeutic
target and an instrument for decision making for therapy
Disclosure: All authors have declared no conflicts of interest.
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METHYLATED SHOX2 DNA IN BRONCHIAL LAVAGE – A
HIGHLY SPECIFIC MOLECULAR TUMOR MARKER FOR
LUNG CARCINOMA
B. Schmidt1, V. Liebenberg2, D. Dietrich2, M.J. Walshaw3, T. Schlegel2, C.
Kneip2, T. Liloglou4, M. Fleischhacker5, C. Witt1, J.K. Field4 1Medizinische
Klinik m.S. Pneumologie, Charite´-Universita¨tsmedizin, Berlin, Berlin/
GERMANY, 2Product Development, Epigenomics AG, Berlin/GERMANY,
3Respiratory Medicine, Liverpool Heart and Chest Hospital Trust, Liver-
pool/UNITED KINGDOM, 4Roy Castle Lung Cancer Research Programme,
University of Liverpool Cancer Research Centre, Liverpool/UNITED
KINGDOM, 5Medizinische Klinik m.S. Onkologie Und Ha¨matologie,
Charite´-Universita¨tsmedizin, Berlin, Berlin/GERMANY
In patients with suspected lung cancer the objective of the diagnostic workup
is to establish a definitive diagnosis using the least invasive diagnostic
procedures. Especially when conventional methods like histology and cytol-
ogy cannot establish the diagnosis, molecular tests may provide additional
information to clinicians and pathologists. A lung specific tumor marker with
a low rate of false positive results could be of clinical value by speeding up
the existing workup and avoiding laborious and eventually risky procedures.
Objective: The goal of this retrospective study was to evaluate DNA
methylation of the SHOX2 gene as a tumor marker to detect malignant lung
disease in patients with suspected lung cancer using a bronchial lavage
material obtained for cytology and confirm results from an earlier study in a
larger and independent study population. Methods: Bronchial lavage speci-
men from 475 subjects undergoing workup for suspected lung cancer, 257
patients with lung carcinoma and 218 control samples from patients with
non-malignant lung disease were included in the study. The samples were
obtained at two European centers (Charite´ Berlin and University of Liver-
pool). SHOX2 methylation was measured by quantitative real-time PCR.
Results: DNA methylation of SHOX2 was shown useful for distinguishing
lavage specimen of patients with lung carcinoma from samples of patients
without malignant disease with high specificity. A ROC analysis of the test
performance exhibited an AUC of 0.86 [95% confidence interval, 0.83-0.89].
At a specificity of 99% [3/218 without disease] the tumor marker showed a
sensitivity of 55% [141/257 with malignant lung disease] in this population
comprised of the major histological lung cancer subtypes. Squamous cell
carcinoma alone was detected at an even better sensitivity of 71% 66⁄93 at the
same high specificity. Conclusion: These results show that detection of
SHOX2 gene methylation in bronchial lavage specimens taken from patients
with suspected lung cancer is a promising tumor marker to identify patients
with lung carcinoma. The development of a diagnostic test based on this
marker and a clinical study for its prospective performance evaluation are
currently ongoing.
Disclosure: V. Liebenberg: I am an employee of Epigenomics AG, Berlin,
Germany; D. Dietrich: I am an employee of Epigenomics AG, Berlin, Germany;
T. Schlegel: I am an employee of Epigenomics AG, Berlin, Germany; C. Kneip:
I am an employee of Epigenomics AG, Berlin, Germany; J.K. Field: The work
presented was performed without financial interest requiring disclosure. Never-
theless, currently negotiations regarding an Advisory board membership are
ongoing and might lead to such a relationship in future. All other authors have
declared no conflicts of interest.
94O
GENE EXPRESSION PROFILES IN NON-SMALL CELL
LUNG CANCER (NSCLC) AND IN CORRESPONDING
HEALTHY LUNG TISSUES IN SMOKERS VS.
NON-SMOKERS
A. Szymanowska-Narloch1, M. Skrzypski2, M. Taron3, H. Dienemann4, W.
Rzyman5, M. Jarzab6, T. Muley7, E. Jassem1, R. Rosell8, J. Jassem2 1De-
partment of Allergology, Medical University of Gdansk, Gdansk/POLAND,
2Department of Oncology and Radiotherapy, Medical University of Gdansk,
Gdansk/POLAND, 3Medical Oncology Service, Catalan Institute of Oncol-
ogy, Badalona, Barcelona/SPAIN, 4Department of Thoracic Surgery, Uni-
versity of Heidelberg, Heidelberg/GERMANY, 5Department of Thoracic
Surgery, Medical University of Gdansk, Gdansk/POLAND, 6Department of
Tumor Biology, Center of Oncology Maria Sklodowska-Curie Memorial
Institute Branch Gliwice, Gliwice/POLAND, 7Translational Research Unit,
University of Heidelberg, Heidelberg/GERMANY, 8Medical Oncology Ser-
vice, Catalan Institute of Oncology, Badalona/SPAIN
Background: About 5-15% of all lung cancer patients are non-smokers.
Defining biological factors of NSCLC development in patients not subjected
to cigarette smoke carcinogens is of particular importance. The aim of this
study was to compare expression of key genes related to etiology of NSCLC
in smoking vs. non smoking patients in tumor samples and in corresponding
healthy lung tissue.
Methods: We analyzed snap frozen tumor samples from 85 surgically
treated NSCLC pts (39 non-smokers and former smokers and 46 smokers),
with corresponding 70 normal lung tissue samples (from 32 and 38 pts,
respectively). Expression of 21 genes (including genes associated with
smoking, kinases, hormonal receptors, growth factor receptors, transcription
factors, genes indirectly involved in HPV infection pathways and other) was
assessed by RT-PCR with the use of microfluid cards (MFC). Analysis of
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RT-PCR was performed with relative quantification 2-CT. Subunit 18S,
POLR2A and ESD were used as normalization genes.
Results: Expression of 11 genes was higher in healthy lung tissues compared
to tumors: PgR (p0.0000), TGFBR2 (p0.00000), TGFBR3 (p0.0000),
AR (p0.0001), EPHB6 (p0.0001), RRAD (p0.0001), AHR
(p0.0003), ESR1 (p0.0006), IGF2 (p0.0014), DLG1 (p0.0016) and
CSF1R (p0.0048), whereas 6 genes showed higher expression in tumors:
BIRC5 (p0.0000), AKR1B10 (p0.0001), CHRNA6 (p0.0001),
CDKN2A (p0.0001), SOX9 (p0.0001) and ESR2 (p0.002). Five genes
were significantly overexpressed in tumors of non-smokers vs. smokers: PgR
(p0.0001), RRAD (p0.0001), AR (p0.0006), CSF1R (p0.0009) and
TGFBR2 (p0.002), whereas one (BIRC5) was downexpressed (p0.0007).
Conclusions: Gene expression in NSCLC is strongly related to smoking
history. Overexpression of PgR and AR in tumors suggests possible hor-
monal dependence. Some other molecular distinct features may prompt new
treatment strategies.
Disclosure: All authors have declared no conflicts of interest.
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RELIABLE CLASSIFICATION OF NON-SMALL CELL
LUNG CARCINOMA USING A NOVEL MICRORNA-BASED
APPROACH
W.H. Westra1, J.A. Bishop1, H. Benjamin2, H. Cholakh3 1Pathology, The
Johns Hopkins University School of Medicine, Baltimore/USA, 2Pathology,
Rosetta Genomics Ltd, Rehovot/ISRAEL, 3Pathology, Rosetta Genomics Inc.,
Philadelphia/USA
Background: Advances in targeted lung cancer therapy now demand accu-
rate classification of non-small cell lung cancer (NSCLC). MicroRNAs
(miRNAs) are recently-discovered short, non-coding genes that play essen-
tial roles in tissue differentiation during normal development and tumori-
genesis. For example, hsa-miR-205 is a miRNA that is highly expressed in
lung squamous cell carcinomas (SqCCs) but not in non-squamous lung
carcinomas. The differential expression of miRNAs could be exploited to
distinguish squamous from non-squamous tumor types.
Methods: 102 resected NSCLCs were classified as SqCC or adenocarcinoma
(AC) based on their histologic features and immunohistochemical profiles
(p63, TTF-1 and Napsin). Corresponding pre-operative biopsies/aspirates
that had been originally diagnosed as poorly differentiated NSCLCs were
available for 21 cases. A qRT-PCR diagnostic assay which measures the
expression level of hsa-miR-205 was used to classify the carcinomas as
SqCC or AC based solely on expression levels. The two sets of diagnoses
were compared.
Results: Using conventional methods of lung cancer classification (i.e.
microscopy and immunohistochemistry), 52 resected lung carcinomas were
classified as SqCCs and 50 as ACs. There was 100% concordance between
the histologic diagnoses and miRNA-based diagnosis. MiRNA profiling also
correctly classified 20 of the 21 preoperative biopsy specimens.
Conclusions: MiRNA profiling is a highly reliable strategy for accurately
classifying NSCLCs. Indeed, classification is consistently reliable even in
small aspirates and biopsies of poorly differentiated tumors. Confirmation of
its reliability across all tumor grades and specimen types (aspirates, biopsies
and resections) represents an important step towards broad application.
Quantitative separation of squamous and non-squamous NSCLCs may not
only directly benefit patients by individualizing oncologic therapy, but will
enhance objectivity among those trials correlating clinical endpoints with
defined pathologic variables.
Disclosure: W.H. Westra is a consultant for Prometheus Laboratories Inc.
This lab markets miRNA technology for the classification of lung cancer.
Funding for travel has been provided by Rossetta Genomics. H. Benjamin:
Authors affiliated with Rosetta Genomics are full-time employees and/or
hold equity in the company, which develops microRNA based diagnostic
products and may stand to gain by publications of these findings; H.
Cholakh: Authors affiliated with Rosetta Genomics are full-time employees
and/or hold equity in the company, which develops microRNA based
diagnostic products and may stand to gain by publications of these findings.
All other authors have declared no conflicts of interest.
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COMBINED TARGETING OF AROMATASE AND
EPIDERMAL GROWTH FACTOR RECEPTOR IN
NON-SMALL CELL LUNG CANCER
I. Kritikou1, E. Giannopoulou2, A.K. Koutras2, H. Kalofonos2 1Clinical
Oncology Laboratory, Department of Medicine, University of Patras,
Patras/GREECE, 2Department of Medicine, Division of Oncology, Clinical
Oncology Laboratory, University of Patras, Patras/GREECE
Background: Targeted therapy provides an exciting project for treatment of
non small cell lung cancer (NSCLC). Aromatase catalyses the final step of
estrogen synthesis in several tissues including lung. EGFR signaling is
implicated in cell proliferation and metastasis. Cross-talking between these
pathways has been reported. The aim of this study is to evaluate the
antitumor effect of the combined inhibition of aromatase and EGFR.
Material and methods: In vitro experiments were performed on H23, H358
and A549 NSCLC cell lines. Exemestane and erlotinib were applied. Cell
proliferation was measured by MTT assay and cell death by annexin V/
propidium iodide assay. Cell migration was determined by boyden chamber
assay. pEGFR status was estimated using an appropriate ELISA kit and
EGFR location was detected by immunofluorescence.
Results: Exemestane and erlotinib, either alone or in combination, inhibited
cell proliferation, through an increase in cell apoptosis. However, the
combination of the agents had a synergistic effect only on H23 cells. The
tested agents and their combination inhibited migration of H23 cells. Ex-
emestane inhibited H358 cell migration whereas erlotinib reversed this
effect. No change was found on cell migration of A549. Further, pEGFR
levels were increased by exemestane in H23 cells and decreased in A549
cells. These experiments are in progress for H358 cells. Moreover, it was
found that EGFR translocated in mitochondria after exemestane application
in H23 cells while erlotinib reversed this effect. These experiments are
ongoing for H358 and A549 cells.
Conclusions: Although each agent alone exerted an antitumor effect on the
proliferation of all cell lines, their combination had a synergistic effect on
H23 cells. Exemestane activated EGFR pathway in H23 cell line suggesting
the treatment of these cells should include an anti-EGFR agent.
Disclosure: All authors have declared no conflicts of interest.
97PD
IMMUNOHISTOCHEMISTRY WITH MUTATION
SPECIFIC ANTIBODIES DETECTING THE STATUS OF
EGFR MUTATIONS IN NON-SMALL-CELL LUNG
CANCER
J. Yu1, D. Li2 1Cell Biology, Cell Signaling Technology, Danvers/USA,
2Pathology, Second Xiangya Hospital, Changsha/CHINA
Background: Activating mutations within the tyrosine kinase of epidermal
growth factor receptor (EGFR) are found in approximately 10-30% of
non-small-cell lung cancer (NSCLC) patients and the association between
EGFR mutations and response to EGFR tyrosine kinase inhibitors (TKIs) in
NSCLC has been consistently confirmed in a number of studies. Deletions in
exon 19 and the L858R substitution in exon 21, accounting for approxi-
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mately 90% of all EGFR mutation, are the best characterized sensitizing
mutations in adenocarcinoma (AC). This study was designed to evaluate
immunohistochemistry (IHC) with mutation specific antibodies to detect
mutant EGFR proteins in NSCLC for patient selection to TKI therapy.
Design: We have screened 410 cases of paraffin embedded NSCLC patient
tumor samples, which included 330 cases of AC and 80 cases of other types
of NSCLC, by IHC using total EGFR antibody and exon 19 delE746_A750
and L858R mutation specific antibodies. The result was confirmed by DNA
sequencing. In addition, we compared patient response to TKIs with the IHC
staining result in 32 patients who were treated by TKI prior the screening.
Result: Screening a panel of the tumor samples with the mutation specific
antibodies showed the sensitivity of the IHC assay is 86% and the specificity is
99% as compared with direct and mass spectrometry based DNA sequencing.
Among these, there were 32 advanced disease cases treated by Iressa until
disease progression. In three month following up: 1 case complete response
(CR), 8 cases partial response (PR), 2 cases stable disease (SD), 21 cases
progression of disease (PD). The total effective rate (CRPR) was 28.1% and
disease control rate (CRPRSD) was 34.4%. 9 of the 32 cases (28.1%) were
IHC positive: 1 CR, 7 PR, 1 SD. Total effective rate (CRPR) of IHC positive
cases was 88.9% and disease control rate (CRPRSD) was 100.0%.
Conclusion: IHC with mutation specific antibodies to detect mutant EGFR
proteins is a rapid, specific and cost efficient methodology. The positive
staining is not just highly correlative to the sequencing result, but also
correlative to tumor response to TKIs.
Disclosure: All authors have declared no conflicts of interest.
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QUANTITATIVE ANALYSIS OF PLASMA DNA IN
RESECTABLE NSCLC, CHRONIC INFLAMMATORY
RESPIRATORY DISEASES AND HEALTHY CONTROLS
A. Szpechcinski1, K. Maszkowska-Kopij2, W. Kupis3, E. Puscinska4, P.
Bielen5, T. Orlowski3, P. Sliwinski5, J. Chorostowska-Wynimko1 1Labora-
tory of Molecular Diagnostics and Immunology, National Institute of Tuber-
culosis and Lung Diseases, Warsaw/POLAND, 2Outpatient Department,
National Institute of Tuberculosis and Lung Diseases, Warsaw/POLAND,
3Department of Thoracic Surgery, National Institute of Tuberculosis and
Lung Diseases, Warsaw/POLAND, 4Department of Lung Diseases, National
Institute of Tuberculosis and Lung Diseases, Warsaw/POLAND, 5Depart-
ment of Diagnosis and Treatment of Respiratory Failure, National Institute
of Tuberculosis and Lung Diseases, Warsaw/POLAND
Background: minute amounts of free-circulating DNA are present in
plasma of healthy individuals, whereas increased levels are found in
malignant pathologies including non-small cell lung cancer (NSCLC).
Intensified cell death processes seem to play a crucial role in release of
genomic DNA into a bloodstream. Thus, quantitative analysis of plasma
DNA might be useful for monitoring of treatment effectiveness in
NSCLC by indication patient’s physiological response. However, it
remains questionable whether the elevated release of free-circulating
DNA into the bloodstream of NSCLC patients results from malignancy or
chronic respiratory inflammation.
Methods: plasma samples were collected from 30 NSCLC patients (I-IIIA)
before and after surgery, patients with chronic inflammatory respiratory
diseases (30 COPD, 30 sarcoidosis, 20 asthma), and 25 healthy volunteers in
order to free-circulating DNA extraction and real-time PCR quantification.
Results: NSCLC group showed significantly higher mean plasma DNA con-
centration with respect to patients with chronic respiratory inflammation and
healthy controls (12.10 vs. 3.90 vs. 2.85 ng/ml, respectively; p0.001). Further-
more, drastic increase in plasma DNA levels up to mean 68.74 ng/ml was observed
a week after the primary tumor resection. Most NSCLC patients with no disease
recurrence during 6-12 month follow-up demonstrated reduced plasma DNA levels
with respect to presurgical plasma DNA concentration values.
Conclusions: NSCLC is associated with elevated concentration of free-
circulating DNA in plasma, and chronic respiratory inflammation does not
seem to contribute to this phenomenon. We speculate that postsurgical
trauma causes drastic increase in plasma DNA levels, whereas a trend
towards reduction of free-circulating DNA amount is observed in relapse-
free patients. The study is to be continued and the groups extended.
Disclosure: All authors have declared no conflicts of interest.
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IMPACT OF CENTRAL REVIEW WITH UNDERTAKING
OF IMMUNOHISTOCHEMISTRY ON THE DIAGNOSIS OF
LUNG CANCER
H. Charalambous1, C. Charalambous2 1Medical Oncology, Bank of Cyprus
Oncology Centre, Nicosia/CYPRUS, 2Histopathology, Nicosia General Hos-
pital, Nicosia/CYPRUS
Introduction: Increasingly with more multidisciplinary team working in
Lung Cancer, central review of initial histopathology reports is being
undertaken. This allows for site specialized Lung pathologists to review the
histology specimens and also for Immunohistochemistry (IHC) to be under-
taken in central pathology laboratories. This is especially important in the
sub-classification of Lung Cancer, not only into Small cell Lung Cancer
(SCLC) or Non Small cell Lung Cancer (NSCLC), but also for the subclas-
sification of NSCLC into squamous (sq) and non-squamous types (non-sq),
which now has major therapeutic implications.
Methods: Between 2006 and 2009, following referral to one clinical oncologist
(HC) with the diagnosis of Lung Cancer, all histopathology specimens coming
from private histopathologists in Cyprus (without site specialization for Lung
Cancer and without IHC being undertaken) were referred for central review to a
specialized Lung pathologist (CC) in the Nicosia General Hospital. This was
undertaken in 34 cases. Comparison was made between the initial histology
diagnosis and the final diagnosis following central review and IHC.
Results: There was concordance for 20 out of 34 specimens (59%). There
were 7 major changes in diagnosis (21%): 2 NSCLC changed into SCLC, 2
SCLC into lymphoma, 1 lymphoma into adenocarcinoma, 1 adenocarcinoma
into mesothelioma and 1 carcinoid into metastasis from bladder cancer.
There were also 7 cases (21%) where the subclassification of NSCLC
changed, 4 from sq to non-sq, 1 from non sq to sq, whilst 2 changed but
remained non squ. There were also 2 cases (6%) where only NSCLC
classification was used in the original report. Hence in total for 14 patients
(41%) there were potential treatment implications as a result of this review.
See main results in table underneath.
Conclusion: This study shows the importance of undertaking central
review including IHC for all patients referred with an initial diagnosis of
lung cancer.
Disclosure: All authors have declared no conflicts of interest.
Private/Primary H&E
Diagnosis
Final Histopathology
Diagnosis
Adeno 10 Adeno 8
Squ 1
Mesothelioma 1
SCLC 9 SCLC 7
Lymphoma 2
Squ 5 Squ 1
Adeno 4
NSCLC 4 SCLC 2
Adeno 2
Lymphoma 1 Adeno 1
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EVALUATION OF ERCC1, BRCA1, THYMIDYLATE
SYNTHASE (TS), CLASS III BETA TUBULIN(BTUBIII),
P53R2, RRM2 IN STAGE I-III NON-SMALL CELL LUNG
CANCER (NSCLC): A TISSUE MICROARRAY (TMA)
STUDY
F. Grossi1, C. Genova1, E. Rijavec1, D.F. Merlo2, S. Salvi3, M. Mannucci2,
M. Taviani4, L. Morelli5, G.B. Ratto5, M. Truini3 1Medical Oncology,
National Institute for Cancer Research, Genoa/ITALY, 2Epidemiology and
Biostatistics, National Institute for Cancer Research, Genoa/ITALY, 3Pathol-
ogy, National Institute for Cancer Research, Genoa/ITALY, 4Thoracic Sur-
gery, University of Genoa, Genoa/ITALY, 5Thoracic Surgery, National
Institute for Cancer Research, Genoa/ITALY
Previous studies have shown that high levels of BRCA1, TS and bTubIII and
low levels of ERCC1 and RRM1 expression are associated with poor
prognosis in NSCLC patients (pts) treated with surgery alone. Also, clinical
studies suggest that ERCC1, RRM1, BRCA1 and bTubIII expression is
associated with resistance to several agents. Tumor tissue samples from 82
pts with stage I-III NSCLC who underwent surgery between 7/2005 - 3/2007
were analyzed. Viable tumor was sampled in triplicate for TMA analysis, and
slides were stained by immunohistochemistry (IHC) with antibodies against
ERCC1, BRCA1, TS, bTubIII and P53R2, RRM2 (subunits of RRM). All
tissue arrays were examined and independently scored by two observers
(M.T. and S.S.), blinded to the patients. The score was calculated using the
following formula: (1 I) x PC, where I represents the staining intensity and
PC represents the percentage of tumor cells that stained at each intensity,
respectively. A categorical value (positive vs negative) was used for statis-
tical analyses of marker expression. In addition, IHC expression profiles
were correlated with clinicopathological features. During a median follow-up
time of 41 months (range 28-54), a total of 13 deaths was observed. In
univariate analysis, P53R2 expression was significantly higher in adenocar-
cinoma compared to squamous samples (mean score 59.3 vs 4, p0.01),
whereas TS expression was significantly higher in squamous tumors (mean
score 39.2 vs 3.1, p0.03). bTubIII expression was significantly higher in
stage I vs stage II pts (mean score 200.2 vs 49.2, p0.023). No significant
association was seen between ERCC1, BRCA1, RRM2 expression and any
clinicopathological features. The small number of deaths is insufficient for
meaningful prognostic evaluation. In conclusion, this study confirms the differ-
ent expression of TS in adenocarcinoma compared to squamous pts and suggests
a possible role of p53R2 as a marker for histological differentiation. The
significantly higher expression of bTubIII in stage I compared to stage II pts may
explain a stage-specific different efficacy of adjuvant chemotherapy.
Disclosure: All authors have declared no conflicts of interest.
101PD
THE DETECTION OF CIRCULATING TUMOR CELLS IN
LUNG CANCER PATIENTS
J. Klein1, J. Srovnal2, Z. Kolar3, J. Skarda3, P. Skalicky1, T. Janaskova4, M.
Hajduch2 1The 1st Department of Surgery, University Hospital Olomouc,
Czech Republic, Olomouc/CZECH REPUBLIC, 21Laboratory of Experimen-
tal Medicine, University Hospital Olomouc, Czech Republic, Olomouc/
CZECH REPUBLIC, 3Department of Pathology, University Hospital Olo-
mouc, Czech Republic, Olomouc/CZECH REPUBLIC, 4Department of
Pneumology, Hospital Ostrava-Vı´tkovice, Ostrava/CZECH REPUBLIC
Objectives: The role of circulating tumor cells (CTC) and nucleic acids in
prognostication in non-small cell lung cancer patients is controversial, but
may be better defined with advancing technologies of detection of such cells
or free tumor DNA with higher precision, and improved clinical-pathological
correlations. Biomarker measurements of the minimal tumor cell dissemina-
tion disease have the potential to monitor the molecular status of tumors
without invasive tumor biopsy, at the time of treatment selection.
Patients: This is a pilot study to test for the presence of circulating tumor
cells (CTC) samples of the peripheral blood, blood from vv. pulmonales and
bone marrow in 21 lung cancer patients undergoing curative surgery.
Methods: We used real-time RT-PCR method for absolute gene expression
quantification of carcinoembryonic antigen (CEA), epidermal growth factor
receptor 1 (EGFR1), human telomerase reverse transcriptase (hTERT),
palate, lung and nasal epithelium associated (PLUNC) and hepatocyte
growth factor receptor (c-met).
Results: All tested markers are characterized by high specificity and sensi-
tivity for CTC detection in lung cancer patients. CTC positivity using CEA
was found in 40% (8/20) of vv.pulmonales blood samples, in 43% (9/21)
samples of peripheral blood and 52% (11/21) samples of bone marrow.
Using EGFR we detected CTC positivity in 25% (5/20) of vv.pulmonales
blood samples, in 10% (2/21) samples of peripheral blood and 43% (9/21)
samples of bone marrow.
Conclusions: This pilot study shows that the CTC detection in lung cancer
is technically possible and high specific and sensitive markers for the
monitoring of CTC are available. The clinical relevance of this minimal
tumor cell dissemination is under permanent debate. It is our hope that
validation of postoperative persistence or re-appearance of tumor cells may
help to identify patients in need of an adjuvant systemic therapy. Optimal-
ization of the panel of specific tumour markers and evaluation of their
validity in monitoring of the minimal residual disease in lung cancer patients
need to be investigated in larger studies.
Disclosure: This study was supported by grant IGA MZCR NS 10285-3
2009. All authors have declared no conflicts of interest.
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INHIBITION OF CARMA3 IMPAIRS LYSOPHOSPHATIDIC
ACID-INDUCED LUNG CANCER CELL MIGRATION AND
INVASION THROUGH NF-KAPPAB
J. Sun1, J. Cai2, Y. Feng3 1Department of Molecular Cellular Oncology, The
University of Texas M.D. Anderson Cancer Center, Houston/USA, 2Surgery,
Wenzhou Medical University Affiliated No.2 Hospital, Wenzhou/CHINA,
3Oncology, Tianjin Medical University Cancer Institute and Hospital, Tian-
jin/CHINA
Lung cancer is the leading cause of cancer deaths in both women and men
in the United States and throughout the world. Lung cancer can be triggerd
by lysophosphatidic acid (LPA). LPA is a type of G protein-coupled receptor
ligand, and a bioactive mediator that induce cell proliferation, migration,
invasion, and production of angiogenic factors in lung cancer cell lines. LPA
activates NF-kappaB, which is an important transcription factor and plays
critical roles in tumorigenesis, such as migration and invasion. We have
previously reported that CARMA3 (CARD and MAGUK domain-containing
protein 3) is indispensable in LPA-induced nuclear factor kappa B (NF-
kappaB) activation in mouse embryonic fibroblast cells. However, it remains
unknown whether the CARMA3 plays an important role in LPA-induced
lung cancer cell migration and invasion. In the present study, using
CARMA3 shRNA, we knockdowned its protein expression level in lung
cancer cell lines. Consistent with previous reports, we found that down-
regulation of CARMA3 strikingly impaired LPA-induced IKK activity and
NF-kappaB activation in lung cancer cells. In addition, in vitro transwell
migration and matrigel invasion assays demonstrated that CARMA3 shRNA
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significantly attenuated LPA-induced lung cancer cell motility and invasive-
ness. Together, our results provide the evidence that CARMA3 serve as a
critical regulator in LPA-induced, NF-kappaB-mediated lung cancer cell
migration and invasion. Therefore, we speculate that CARMA3 may repre-
sent an attractive therapeutic target for lung cancer cell and many other
alignancies.
Disclosure: All authors have declared no conflicts of interest.
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CLINICAL AND BIOLOGICAL FEATURES ASSOCIATED
WITH EML4-ALK FUSION GENE IN NON SMALL CELL
LUNG CANCER
C. Choi1, S.H. Jang2, Y.I. Hwang2, J.H. Jung3, Y.Y. Lee4, J.C. Lee4
1Department of Pulmonary and Critical Care Medicine, Asan Medical
Center, Seoul/KOREA, 2Division of Pulmonary, Allergy and Critical Care
Medicine, Hallym University Sacred Heart Hospital, Anyang/KOREA, 3De-
partment of Internal Medicine, Seoul National University Bundang Hospital,
Seongnam/KOREA, 4Department of Internal Medicine, Korea Cancer Center
Hospital, Korea Institute of Radiological & Medical Science, Seoul/KOREA
Purpose: The EML4-ALK fusion gene has been detected in 5-7% of lung
adenocarcinomas. We evaluated the incidence, prognosis and the char-
acteristics of ALK-rearranged non-small cell lung cancers and the opti-
mal diagnostic modality to detect ALK rearrangements in routine clinical
practice.
Experimental design: Seven hundred and nine surgical specimens of non-
small cell lung cancer from two institutions were analyzed. To identify ALK
rearrangements immunohistochemistry were performed. We also examined
ALK rearrangements by fluorescent in situ hybridization (FISH). The clin-
icopathologic characteristics of tumors with and without ALK reaarangemets
were compared. EGFR and KRAS mutations were determined by DNA
sequencing.
Results: We identified 49 (6.9%) non-small cell lung cancer with ALK
rearrangements within our cohort by immunohistochemistry. Forty-three
(87.8%) of the 49 EML4-ALK tumors were adenocarcinomas. ALK
reaaranement was associated with never smoking (p  0.001) and female
(p  0001). Among 372 cases ALK rearrangement was identified by FISH
in 9 (2.4%) cases. Eight (88.9%) was negative in immunohistochemistry.
Patients in the EML4-ALK fusion gene in adenocarcinoma had no effect on
progression free survival and overall survival.
Conclusions: The patients most likely to harbor EML4-ALK are never
smokers with adenocarcinoma. But EML4-ALK was not prognostic factor.
Disclosure: All authors have declared no conflicts of interest.
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VALUE OF EGFR GENE MUTATION ANALYSIS IN
CHINESE NON SMALL CELL LUNG CANCER PATIENTS
M. Sun1, L. Shen2, X. Cai2, H. Chen3, X. Du2, X. Zhou1 1Tissue Bank,
Department of Pathology, Fudan University Shanghai Cancer Center,
Shanghai/CHINA, 2Department of Pathology, Fudan University Shanghai
Cancer Center, Shanghai/CHINA, 3Department of Thoracic Surgery, Fudan
University Shanghai Cancer Center, Shanghai/CHINA
EGFR inhibitors Erlotinib and Gefitinib are of very important in treating late
stage adenocarcinoma of lung due to a longer survival related to EGFR
mutation, more frequently in Asian, female and non smoker patients, al-
though EGFR inhibitor has not been used as first choice treatment for
advanced Asian patients. We included 92 Chinese cancer patients into the
study of EGFR mutation. Among them 60 were lung cancer and the others
were either the patients without clear diagnosis or necessary for differenti-
ation diagnosis including 11 supraclavicular lymph node biopsies, 7 Endo-
bronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-
TBNA) for mediastinal masses and 14 masses of different other sites. EGFR
mutation was checked. Thirty nine out of 92 patients possessed mutation in
EGFR gene (42.39%, 39/92). In lung cancer patients the mutation counted
46.67% (28/60) and it increased to 58.14% (25/43) in adenocarcinoma only.
Squamous carcinoma, large cell carcinoma and poorly differentiated carci-
noma did not show any mutation in our study. In EBUS-TBNA samples
42.86% mutation (3/7) was detected, close to our mutation rate in lung
cancer. Around half mutation were located in exon 19 and around one third
in exon 21. There was a tendency of a lower exon 19 mutation in older
patient group (median age 58, 58 vs. 58,) (35.71%, 5/14 vs. 58.82%,
10/17, P0.0581) and a higher exon 21 mutation in younger group (64.29%,
9/14 vs. 23.53%, 4/17, P0.0800). The mutation in exon 19 was found more
frequent in male patients (71.43%, 10/14), while the mutation rate of exon 19
and exon 21 in female patients was comparative (43.47%, 10/23 in exon 19
and 47.83%, 11/23 in exon 21). Mutation in exon 20 was rare (4 mutations
found). A relatively high mutation rate of supraclavicular lymph node
(36.37%, 4/11) was seen, in comparison to the one in other variant sites was
low (20.00%, 4/20). One exon 19 mutation of a metastatic adenocarcinoma
located in uterus muscle layer was detected. Our data suggest that EGFR
mutation analysis show its value both in selection of EGFR TKI treatment
and in differentiation diagnosis of some common metastasis lesions. In Asian
patients group, mutation analysis in EBUS-TBNA samples demonstrates to
be of important in providing treatment hint.
Disclosure: All authors have declared no conflicts of interest.
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DOMINANT-NEGATIVE AGGREGATION OF P53 AS A
NOVEL MECHANISM OF TUMOUR SUPPRESSOR GENE
INACTIVATION
J. Xu, J. Reumers, J. Couceiro, F. Rousseau, J. Schymkowitz Switch
Laboratory, Vrije Universiteit Brussel, Brussels/BELGIUM
It remains largely unexplained why the most aggressive p53 missense
mutations possess dominant-negative activity, why they often display gain of
oncogenic activity and why the presence of these mutants leads to lifetime
extension and accumulation of p53 in tumours. Here we show, both in
cultured cells and in murine and human tumours, that the dominant-negative
activity of p53 mutants is tetramer-independent and instead results directly
from the increased aggregation propensity of these mutants. Upon aggrega-
tion, mutant p53 is able to induce the co-aggregation of the wild type p53 and
its family members p63 and p73 into cellular inclusions. Aggregation
explains equally well the lifetime extension and accumulation of both mutant
and wild type p53 in tumours, as suppression of the aggregation propensity
in these mutants fully restores wild type p53, p63 and p73 activity. Finally,
we classify patient data from the literature according to aggregating versus
non-aggregating mutants and find a significant difference in the second hit
(loss of heterozygosity) and clinical outcome both with respect to therapeutic
response and long-time survival. The poorer clinical outcome of patients
with aggregating mutants suggests that gain-of-function is also a conse-
quence of aggregation and that inhibition of p53 aggregation might be a
valuable therapeutic strategy.
Disclosure: All authors have declared no conflicts of interest.
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PROGNOSTIC IMPORTANCE OF P27KIP1 EXPRESSION
IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
S. Ariad1, J. Freedman1, I. Lazarov1, A. Bolotin2, N. Sion-Vardy3 1Depart-
ment of Oncology, Soroka University Medical Center, Beer Sheva/ISRAEL,
2Department of Epidemiology, Ben Gurion Unversity of the Negev, Beer
Sheva/ISRAEL, 3Department of Pathology, Soroka University Medical Cen-
ter, Beer Sheva/ISRAEL
Introduction: Tumor node metastasis (TNM) staging and histological grad-
ing are acceptable classification systems for lung cancer (LC), but not
satisfactory to predict prognosis. p27Kip1 (p27) plays an important role in
cancer cell cycle regulation by inhibiting cyclin–CDK complex activity in
the nucleus. Recent evidence however, suggests that under certain condi-
tions, p27 may function as an oncogene rather than a tumor suppressor gene.
Although most studies in LC patients indicated that loss of p27 protein
expression diminishes chance of survival, some investigators reported oppo-
site findings. We assumed that this discrepancy could be attributed to the
inclusion of different groups of patients, lack of stratification by histological
grade, or non-standardized methodology.
Patients and methods: Ninety-two patients of all stages with previously
untreated non-small cell lung cancer (NSCLC) were included. Tumors
diagnosed as adenocarcinoma were evaluated for grade. The IHC localiza-
tion of p27 was scored through a semiquantitative method. IHC studies were
also performed for p53, and Pirh2. The association between p27 H-Score
values and time-to-progression (TTP) and overall survival (OS) was ana-
lyzed with population-averaged, panel-data models by using generalized
estimation equations (GEE). TTP and OS time were analyzed with Cox
proportional hazards regression models.
Results: The mead H-Score value for p27 was equal to 91.2  83.7. The
relationship between p27 H-Score to TTP or OS time was polynomial for
both. Short TTP in patients with metastasis or whose tumors progressed
during the eight-month period after diagnosis was statistically associated
with overexpression of Pirh2 (P  0.001). In patients whose tumors pro-
gressed later, long TTP was associated with LC of the non-adenocarcinoma
type (P  0.027), p27 H-Score (P  0.032), and well-differentiated adeno-
carcinoma (P  0.047). None of the parameters was found to correlate with
OS time.
Conclusions: The interpretation of p27 H-Score has to be collaborated with
other clinico-pathological parameters which indicate metatasis or may pre-
dict TTP. The non-linear relationship may reflect different biological effects
of p27 on cell proliferation.
Disclosure: All authors have declared no conflicts of interest.
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USING REAL TIME (RT)-PCR FOR GLUTATHIONE-S-
TRANSEFRASE P1 (GSTP1) GENE TO MEASURE FREE
CIRCULATING DNA IN PATIENTS (PTS) WITH
ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
L.E. Raez1, E.S. Santos2, T. Talebi1, C. Quintero1, G. Walker1, E. Lopez1, M.
Farias1, R. Singal1 1Sylvester Comprehensive Cancer Center, University of
Miami Miller School of Medicine, Miami/USA, 2Oncology, University of
Miami, Miami/USA
Purpose: Measurement of free circulating DNA (free DNA) as predictor for
chemotherapy response (complete: CR, partial: PR, stable: SD or progres-
sion: PD) in newly diagnosed patients (pts) with advanced non-small cell
lung cancer (NSCLC). There is evidence that tumors shed DNA into the
blood stream and the plasma DNA concentrations increase in pathological
situations associated with cell death.
Material and methods: Every two cycles of chemotherapy, free DNA was
measured (ng/ml) in blood samples from NSCLC patients by real time
(RT)-PCR for Glutathione-s-transefrase P1 (GSTP1) gene. Nonparametric
tests were used to examine the relationship between baseline DNA level and
patient characteristics (Wilcoxon rank sum test: WRST) and to test changes
from baseline after two treatment cycles (Wilcoxon signed rank test: WSRT).
Results: We enrolled 32 pts, all treated with platinum-based chemotherapy.
Baseline data were available for 26 pts: 19 males, 23 White, and 16 Hispanic.
All pts had stage III/IV and 19 were adenocarcinomas. Responses were: PR:
27%, SD: 58% and PD: 12%. No association was found between baseline
FCDNA and age ( 68 v  69, p0.200), gender (p0.954), ethnicity
(p0.385), PS (0 v 1⁄2, p0.732), stage (p0.978), histology (adenocarci-
noma vs. other, p0.386), or smoking history (p0.648). Measurements
after 2 treatment cycles were available for 13 pts. Nine patients had higher
levels of free DNA after 2 cycles of chemotherapy compared with baseline,
while 4 showed a decrease. The difference was marginally significant,
p0.080, (WSRT). No association was found between baseline free DNA
level and response following 2 treatment cycles: p0.545, Kruskal-Wallis
test comparing 7 patients with PR against 15 with SD and 3 with PD. Change
in free DNA was not associated with response: p0.316 comparing 4 PR and
9 SD (8) or PD (1); p0.445.
Conclusion: We have documented here important changes in the amount of
free DNA in NSCLC patients on chemotherapy, however, these changes
have not achieved statistical significance yet. Results increasing the number
of pts and number of samples per pt as per protocol will be presented in the
meeting.
Disclosure: All authors have declared no conflicts of interest.
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SNIP1 EXPRESSION CORRELATES WITH THAT OF RB
AND HDAC1 IN PRIMARY LUNG CANCERS AND
INTERFERES RECRUITMENT OF HDAC1 TO RB IN
VITRO
H. Jeon1, J.Y. Park2, J. Fukuoka3, J. Jen4 1Department of Biochemistry &
Cell Biology, Kyungpook National University, School of Medicine, Deagu/
KOREA, 2Department of Internal Medicine, Kyungpook National University,
School of Medicine, Deagu/KOREA, 3Lab of Anatomic Pathology, Toyama
University Hospital, Toyama/JAPAN, 4Department of Pulmonary and Crit-
ical Care Medicine, Mayo Clinic, Rochester/USA
Smad nuclear interacting protein 1 (SNIP1) regulates gene expression
through interactions with multiple transcription regulators. The Rb tumor
suppressor gene plays a critical role in controling cell proliferation and
differentiation. It recruits HDAC1 protein into the E2F complexes to repress
transcription. Phosphorylation of Rb by Cdk4/6 and Cdk2 displaces HDAC
from the pocket domain and releases its transcriptional repression activity.
In here, we show that SNIP1, Rb and HDAC1 were significantly coexpressed
in lung cancer tissues in a tissue microarray containing 300 non-small cell
lung cancers. There was a strong correlated expression between staining for
SNIP1 and Rb, SNIP1 and HDAC1 (P0.00003, P0.00006, respectively).
Functionally, SNIP1 competes with HDAC1for binding Rb and reducing
HDAC1 activity. We found that phosphorylation of Rb was reduced by
knockdown of SNIP1. Knockdown of SNIP1 caused reduction of tumori-
genesis of lung cancer cells. These findings suggest that SNIP1 is involved
in the Rb/HDAC1 chromatin remodeling pathway and may play a role in
lung cancer progression.
Disclosure: All authors have declared no conflicts of interest.
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FTIR SPECTROSCOPY OF A549 CELLS TREATED WITH
PMF: STRUCTURAL CHANGES IN DNA AND CELL
MEMBRANE
G.A. Ahmed1, F.A. Khorshid2, T.A. Kumosani2 1Biochemistry, King Abdu-
laziz University-Faculty of Science, Jeddah/SAUDI ARABIA, 2Biochemistry,
King Fahd Medical Research Centre-King Abdulaziz University-Faculty of
Science, Jeddah/SAUDI ARABIA
Cancer becomes one of the leading causes of death in many countries all over
the world. PMF (new natural product extracted from PM 701) has been
proved recently as selective anticancer agent. FTIR spectra of human lung
cancer cells (A549) treated with PMF for different time intervals ranging
from 5min up to 24hr were examined. The results revealed that characteristic
bands alterations were identified in the apoptotic cells arising from cellular
protein, lipid and DNA, there were specific changes that affected the
secondary structure of proteins in the apoptotic lung cells appeared in the
FTIR spectra confirmed with the second derivative analysis. The dominant
protein structure shifts from -helix in the control cancer cells (untreated) to
parallel -sheet and random coil structure indicating modification protein
secondary structure in the apoptotic cells treated up to 24 hr and these
changes in the secondary structure of proteins are time dependant. In addition
the total cellular lipid content increases starting from the first 5 to 15 min up
to 24hr of treatment while the amount of DNA decreases dramatically during
treatment with PMF as observed in difference spectrum. A characteristic
internucleosomal ladder of DNA fragmentation was observed with A549
cells treated with PMF for 30 min. Moreover, the pH values were recorded
for all samples during the time of treatment, at all times of treatment, the pH
values increased significantly after adding PMF to A549 cells the maximum
value was obtained at 2hr of treatment.
Disclosure: All authors have declared no conflicts of interest. pectroscopy
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TARGETING ER-GOLGI HOMEOSTASIS IS AN
ADVANTAGEOUS THERAPEUTIC STRATEGY IN
LUNG CANCER
V. Zismanov1, L. Drucker2, M. Gottfried3 1Lung Cancer Research Labora-
tory, Meir Medical Center, Kfar Saba/ISRAEL, 2Oncogenetic Laboratory,
Meir Medical Center, Kfar Saba/ISRAEL, 3Lung Cancer Unite Oncology,
Meir Medical Center, Kfar Saba/ISRAEL
Heat shock protein 90 (Hsp90) is a molecular chaperon essential for folding
and stability of multiple oncogenes and an established target in cancer
therapeutics (lung included). Misfolded proteins accumulate in the ER,
induce ER stress, and activate response pathways such as the ubiquitin
proteasome system (UPS), which orchestrates turnover of cellular proteins
and histone deacetylases (HDACs) that critically recruit misfolded protein
aggregates (un-degradable by UPS), into dedicated organelles. Indeed,
Hsp90 inhibition causes unfolded proteins accumulation and ER stress. The
therapeutic efficacy of such inhibition may be augmented by co-administer-
ing it with other drugs that disrupt response signals that enable ER-Golgi
homeostasis. We aimed to examine the effect of combined treatment of
Hsp90 antagonist with proteasome or HDAC inhibitors on human lung
cancer cell lines fate (viability, proliferation, cell cycle, death, death mode)
and ER-Golgi homeostasis (protein synthesis, UPR, autophagy, other Hsps,
FOXO). Hsp90 inhibitor (17-DMAG) co-administration with HDAC inhib-
itor (PTACH) or proteasome inhibitor (Velcade) yielded a synergistic in-
crease in apoptosis of lung cancer cell lines. Reduced viability was demon-
strated in all cell lines with all drug combinations except 17-DMAG and
PTACH co-administered to H1299 cells. Interestingly, combined 17-DMAG
and PTACH induced elevated H1299 viability despite the increased cell
death. We hypothesized that this phenomenon may result from increased
H1299 proliferation and in accordance determined higher levels of PCNA in
treated cells. Analyses of ER stress markers (BiP, CHOP, and pJNK) in the
treated cancer cells are underway. Our findings provide proof-of-concept that
targeting ER-Golgi homeostasis is therapeutically beneficial in lung cancer
cell lines.
Disclosure: All authors have declared no conflicts of interest.
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NR2E1 INHIBITS CELL PROLIFERATION IN LUNG
SQUAMOUS CELL CARCINOMAS BY REGULATING
ENTRY TO CELL CYCLE
D. Barh1, P. Sindhurani2, A. Bhattacharjee3 1Centre for Genomics and
Applied Gene Technology, Institute of Integrative Omics and Applied Bio-
technology (IIOAB), Nonakuri/INDIA, 2Centre for Genomics and Applied
Gene Technology, Institute of Integrative Omics and Applied Biotechnology
(IIOAB), Nonakuri/INDIA, 3Bioinformatics Laboratory, Department of Bio-
technology and Bioinformatics, North Eastern Hill University, Shillong/
INDIA
Objective: Orphan nuclear receptor and transcription regulator NR2E1
(TLX) regulates neural stem cell proliferation and self-renewal through
Wnt/beta-catenin pathway [PMID: 20010817] and mutations in the gene
have been implemented for bipolar disorder [PMID: 18205168]. Recently,
NR2E1 promoter has been found hyper-methylated and can be considered as
methylation marker in lung squamous cell carcinomas (LSCCs) [PMID:
18162535]. NR2E1 upregulates SIRT1 expression [PMID: 19555662] and
interacting with histone demethylase (LSD1) and HDACs (HDAC3,
HDAC5), it regulates PTEN, P21, and CDK-inhibitor transcription [PMID:
18391013, PMID: 17873065] and thereby it may regulate cell cycle and cell
proliferation. NR2E1 also interacts with GSPT1, HSP90AB1, and MED1. This
study was aimed to explore the role NR2E1 plays in LSCC tumorigenesis.
Methods: In silico approaches were used in this analysis. Briefly, an
experimentally validated NR2E1 promoter (600 bp) was retrieved using
Genomatix “Gene2Promoter” module. Thereafter CpG and transcription
factor (TF) binding sites within this sequence were predicted using respec-
tively, Methylator and MATCH programs. Lung and cell cycle specific
affected TFs due to hyper-methylation were identified by comparing Methy-
lator and MATCH results. VisANT and Osprey tools were used for protein-
protein interaction network based functionality analysis using NR2E1, its
promoter binding TFs, and NR2E1 interacting proteins.
Results: Twenty one CpG sites are predicted to be hyper-methylated and
there are at least 4 lung and 8 cell cycle specific TF binding sites (including
E2F, MYB) found with in NR2E1 promoter sequence. Two cell cycle
specific TFs (E2F and YY1) and one lung specific TF (NF1) are affected
due to hyper-methylation. Key nodes and shortest pathway analysis from
protein-protein and TFs-interaction network based functionality analysis
shows that NR2E1 inhibits cell proliferation by regulating entry to cell
cycle.
Conclusions: Our results suggest that NR2E1 is a negative regulator of cell
growth and proliferation that exerts it function by regulation entry to cell
cycle.
Disclosure: All authors have declared no conflicts of interest.
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CORRELATION OF FACTOR XIII ACTIVITY WITH
CELL-TYPES AND STAGES OF NON-SMALL CELL LUNG
CANCER
J.H. Kim1, I.B. Suh2, K.H. Jung1, G.Y. Hur3, S.Y. Lee3, S.Y. Lee4, J.J.
Shim3, K.H. In4, K.H. Kang3, S.H. Yoo4 1Department of Internal Medicine,
Korea University Ansan Hospital, Ansan/KOREA, 2Department of Clinical
Pathology, Kangwon National University Hospital, Chuncheon/KOREA,
3Department of Internal Medicine, Korea University Guro Hospital, Seoul/
KOREA, 4Department of Internal Medicine, Korea University Anam Hospi-
tal, Seoul/KOREA
Background: Factor (F) XIII is a thrombin-activated plasma transglutami-
nase zymogen, which has been reported to support hematogenous tumor cell
metastasis. The purpose of this study is to examine the correlation of FXIII
activity with cell-types and stages of non-small cell lung cancer (NSCLC),
comparing with healthy subjects.
Methods: Forty-seven NSCLC patients were enrolled; 22 adenocarcinoma,
17 squamous cell carcinoma, and 8 undifferentiated NSCLC; 5 stage I, 1
stage 2, 21 stage III, and 20 stage IV. Age-, gender-, and smoking status-
matched healthy subjects were selected from participants of The Korean
Health and Genome Study, an ongoing population-based prospective cohort
study. FXIII activity was measured using fluorescence based protein arrays.
Fabricated amine modified glass slides were incubated with fibrinogen, and
diluted plasma was mixed with reaction buffer including CaCl2 and throm-
bin. Then reaction mixture was applied to the array wells and the FXIII
catalyzed incorporation of pentylamine into fibrinogen was probed with
Cy3-conjugated streptavidin and scanned with a fluorescence scanner. The
FXIII activity was expressed as relative fluorescence units (RFU).
Results: The FXIII activity of the NCSLC group (78.73.8 RFU,
meanSEM) was significantly higher than that of the Healthy group
(63.22.3 RFU) (p0.03). In the subgroup analysis, FXIII activities were
significantly different among adenocarcinoma (89.28.9 RFU), squamous
cell carcinoma (70.35.2 RFU), undifferentiated NSCLC (52.43.7 RFU)
and Healthy groups (p0.015, by Kruskal-Wallis test). FXIII activity in the
adenocarcinoma NSCLC group was significantly higher than those of other
cell types and Healthy groups (p0.05). The stage IV group (76.88.7 RFU)
showed significantly higher FXIII activity than other stages and Healthy
groups (p0.05). The FXIII activity of stage IV adenocarcinoma group
(95.710.7 RFU) was significantly high, comparing with other cell type-
stage combinations and Healthy group (p0.05).
Conclusions: FXIII activity showed correlation with cell types and stages of
NSCLC, suggesting potential roles of FXIII in progression and metastasis of
NSCLC.
Disclosure: All authors have declared no conflicts of interest.
113P
ACCURACY OF CYTOLOGY IN THE IDENTIFICATION
OF HISTOLOGIC SUBTYPE IN NON-SMALL CELL LUNG
CANCER (NSCLC)
M. Tiseo1, R. Nizzoli1, A. Guazzi1, M. Bartolotti1, F. Gelsomino1, M.
Majori1, L. Ferrari1, M. De Filippo1, E.M. Silini1, A. Ardizzoni2 1Medical
Oncology, Parma Hospital, Parma/ITALY, 2Medical Oncology, Parma Uni-
versity Hospital, Parma/ITALY
Background: The importance of histological sub-typing for non small cell
lung cancer (NSCLC) has recently increased due to the emerging differences
in the medical treatment between squamous and non-squamous cancer. Many
NSCLCs present at diagnosis in advanced stage and diagnosis is often
obtained by fine needle aspirate (FNA) cytology. In this study we investigate
how reliable is FNA cytology diagnosis in sub-typing NSCLCs as compared
to histology.
Methods: From 2002 up to 31/03/2009, a total of 875 cytological exams for
lung cancer suspicion have been performed. 369 patients had a cytological
(MGG stain/- PAS/PAP) diagnosis of primary NSCLCs on trans-bronchial
needle aspirate (TBNA) or trans-thoracic needle aspirate (TTNA) samples by
an experienced cytologist (RN, AG). Of these patients, 171 (46%) underwent
a parallel or subsequent histological diagnosis (HE /- HIC) on bronchial
biopsy or major surgery as performed in blind and independently by
dedicated pathologists (EMS).
Results: Of 171 cases investigated for comparison, at cytology 151 (88%)
had a specific subtype diagnosis (90 adenocarcinoma, 56 squamous cell
carcinoma, 5 large cell carcinoma), and 20 cases (12%) were defined as
NSCLC not otherwise specified (NOS). At histology, 155 had a specific
subtype diagnosis (87 adenocarcinoma, 60 squamous cell carcinoma, 4
adeno-squamous carcinoma, 2 large cell carcinoma, 1 small cell carcinoma,
1 mesothelioma) and 16 cases (9%) resulted NSCLC NOS. Concordance
between cytology and histology was found in 118 (80%) cases. Predictive
value of cytologic diagnosis was 84% for adenocarcinoma and 79% for
squamous cell carcinoma.
Conclusions: On the basis of the high concordance between cytology and
histology, our data indicate that cytology in expert hands is reliable for both
identifying lung malignancy and NSCLC sub-typing. FNA cytology is
acceptable for diagnosis and treatment planning in most cases and especially
when other more invasive approaches are unfeasible.
Disclosure: All authors have declared no conflicts of interest.
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ROLE OF NUCLEAR MORPHOMETRY IN DIAGNOSIS OF
SPUTUM CYTOLOGICAL ATYPIA IN SMOKERS
R. Kulshrestha1, V. Vijayan2 1Pathology, Vallabhbhai Patel Chest Institute,
Delhi/INDIA, 2Respiratory Medicine, Vallabhbhai Patel Chest Institute,
Delhi/INDIA
Background: Cytological atypia of exfoliated cells in sputum has been
shown to be associated with both prevalent and incident lung cancer.
However the clinical utility of sputum cytological atypia remains uncertain
to date. One reason for this is the subjective classification of sputum cytology
by pathologists into normal with or without squamous metaplasia, mild
atypia, moderate atypia, severe atypia and carcinoma with lack of clear
criteria between the grades.
Methods: We reviewed the sputum samples submitted to Pathology depart-
ment, Vallabhbhai Patel Chest Institute over a five year period from 2005 to
date. Total of 1304 samples were received for sputum cytology evaluation in
smokers. On the basis of cytology these cases had been classified into (i)
Normal, (ii) Inadequate/unreadable, (iii) Inflammatory expectorate, (iv) In-
flammatory expectorate with atypia, (v) Carcinoma. In cases with atypia
nuclear morphometry was done using the Nikon 90i microscope and image
analyzer. The nuclear area, nuclear perimeter and nuclear shape of the
atypical cells was assessed and compared to mature squamous epithelial cells
in the control group.
Results: Of the total 1304 specimen received, 189 cases, 14.49% were
within normal limits, 296 cases 22.69% were inadequate/unreadable, inflam-
matory expectorate was seen in 674 cases, 51.69%, Inflammatory expecto-
rate with atypical cells was present in 127 cases, 9.74% and diagnosis of
carcinoma was made in 18 cases, 1.38%. Nuclear morphometry for grading
of atypia revealed an increase in nuclear size in moderate atypia when
compared to control. Further increase in atypia was associated with nuclear
pyknosis, hyperchromasia and bizarre shape of cells with increase in nuclear
cytoplasmic ratio.
Conclusion: Sputum cytology is a simple cost effective noninvasive method
of assessment of the central airway lesions. In smokers it can detect
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cytological atypia which when accurately graded using nuclear morphome-
try, may prove to be the much needed marker for lung cancer in this high risk
population.
Disclosure: All authors have declared no conflicts of interest.
PREVENTION, EARLY DETECTION,
EPIDEMIOLOGY AND TOBACCO CONTROL
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PROGNOSTIC FACTORS OF DISEASE RECURRENCE
AND OVERALL SURVIVAL IN ELDERLY VERSUS
YOUNG PATIENTS IN SURGICALLY RESECTED
NON SMALL CELL LUNG CANCER
B. Al-Alao1, E.N. Mc Govern1, V.N. Young1, K. O’Byrne2 1Cardiotho-
racic, St. James’s Hospital, Dublin/IRELAND, 2Oncology, St James Hospi-
tal, Dublin/IRELAND
Introduction: Prognostic factors for overall survival and disease free sur-
vival in elderly patients after surgical resection are not well described. We
report the outcomes in elderly (older than 70 years) and young (70 years or
less) with stage I-III non small cell lung cancer (NSCLC) after surgical
resection.
Methods: A retrospective study of patients diagnosed with NSCLC after
surgical resection at major cancer centre from 1998 to 2008. Demo-
graphic, pathologic, treatment, and follow-up data were collected. Re-
currence rates and overall survival were calculated by the Kaplan-Meier
method. Potential prognostic factors were examined by Cox regression
multivariate analysis.
Results: Of the 593 patients included in the study, 204 were older than 70
years at diagnosis. In this elderly cohort, the median age was 74 years (range,
70-104 years) and 74 of them were women (36.3%). Clinical and pathologic
characteristics were not statistically different between the elderly and
younger cohorts, with the exception that older patients were more likely to
have Lobectomy and Sub-lobar resections (90.7% versus 75.1%, p 0.0001)
and less likely to have multiple lymph nodes involved (19.1% versus 26.2%,
p  0.03) compared with the younger cohort. In the elderly cohort, while
male gender (HR 1.6;p0.05) and intra-tumoural vascular invasion (ITVI)
(HR 2.24;p0.003) were both associated with overall mortality, only lym-
pho-vascular space invasion was a predictor of disease recurrence (HR
2;p0.05). In comparison, in the younger cohort; while several risk factors
has been associated with increased overall mortality (male gender (HR
1.6;p0.008)), smoking status (HR 2;p0.05), ITVI (HR 1.9;p0.003),
larger tumour size (HR 3.7;0.001), multiple lymph nodes involvement (HR
2.23;0.002)), only smoking status (HR 2.24;p0.003) and ITVI (HR
1.4;p0.05) were correlated to disease recurrence.
Conclusions: Although overall survival was similar in both cohorts, disease
recurrence was significantly different. Certain risk factors can play different
prognostic role in different age groups for overall and disease free survival.
Treatment options should be tailored according to age.
Disclosure: All authors have declared no conflicts of interest.
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SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR
RECEPTOR: A NEW INDEPENDENT RISK MARKER OF
RESPIRATORY CANCER
A. Langkilde1, T.W. Hansen2, S. Ladelund1, A. Linneberg3, O. Andersen1,
S.B. Haugaard1, J. Jeppesen4, J. Eugen-Olsen1 1Clinical Research Centre,
Copenhagen University, Hvidovre Hospital, Hvidovre/DENMARK, 2Clinical
Physiology, Copenhagen University, Faculty of Health Sciences, Hvidovre
Hospital, Hviodvre/DENMARK, 3Research Centre for Prevention and
Health, Copenhagen University Hospital, Glostrup, Glostrup/DENMARK,
4Department of Medicine, Glostrup University Hospital, Glostrup/
DENMARK
Introduction: Biomarkers of low-grade inflammation may predict cancer
development. Recently, we found elevated plasma levels of the inflam-
matory marker soluble urokinase plasminogen activator receptor (suPAR)
to be associated with increased risk of cancer development in the general
population. In this study we tested whether increased baseline plasma
suPAR levels are related to development of more specific cancer types in
the general population.
Participants and methods: 2528 individuals from the population based
Danish MONICA10 study, aged 41, 51, 61, and 71 years were included
and followed for a median of 12.6 years, during which 368 developed
cancer. Cancer cases were diagnosed according to ICD10 codes. Subjects
with incident cancer at baseline were excluded. suPAR levels were
measured using a commercially available ELISA (suPARnostic, Viro-
Gates, Denmark).
Results: During the follow-up, respiratory (n57), gastrointestinal (n100),
and other cancer types (n211) were registered. Baseline median suPAR
level was 4.01 ng/ml (range 1.34 to 17.80). In Cox regression analyses using
age as underlying time and adjusting for time since blood sampling, alcohol,
sex, smoking, and BMI, an increase of 1 ng/ml suPAR was associated with
hazard ratios (HR) of 1.60 (95% CI: 1.23-2.09, P0.001) for respiratory,
0.92 (95% CI: 0.69-1.24, P0.59) for gastrointestinal, and 1.32 (95% CI:
1.12-1.56, P0.001) for other cancer types. Plasma suPAR levels remained
associated with respiratory cancer (HR 1.49, 95% CI: 1.11-2.00, P0.009)
and other types of cancer (HR 1.40, 95% CI: 1.17-1.67, P0.001), after
additional adjustment for the inflammatory markers C-reactive protein
(hsCRP) and leukocyte numbers.
Conclusion: Elevated plasma suPAR levels correlate with increased risk
of developing respiratory cancer and other cancer types, but not with
gastrointestinal cancer in the general population. Our findings imply that
different disease mechanisms underlie respiratory and gastrointestinal
cancer development. The finding that suPAR is associated with respira-
tory cancer independently of age and smoking suggests that inclusion of
suPAR in screening programmes may identify individuals at high risk of
developing lung cancer.
Disclosure: O. Andersen: Ove Andersen is mentioned as inventor on a
patent on suPAR and prognosis owned by Copenhagen University Hos-
pital Hvidovre, Denmark. S.B. Haugaard: Steen B Haugaard is mentioned
as inventor on a patent on suPAR and prognosis owned by Copenhagen
University Hospital Hvidovre, Denmark. J. Eugen-Olsen: Jesper Eugen-
Olsen is co-founder, board member, and shareholder of ViroGates,
Denmark, the company that produces the suPARnostic assay All other
authors have declared no conflicts of interest.
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ABSTINENCE AND EFFECTIVENESS OF SMOKING
CESSATION PROJECT: EXPERIENCES OF INDIAN
CANCER NGO ABOUT PREDICTABLE FACTORS
P.D. Shankpal, V. Sankpal Community Care, HAOI, Dhule/INDIA
Aims: Cigarette smoking is the single biggest avoidable cause of death and
disability in developing countries. Smoking cessation programs are non-
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existent in Indian healthcare system. Smoking behavior is multifactorial.
Motivation is a fundamental aspect in smoking cessation.
Objectives: 1] To assess effectiveness and factors associated with outcome
of the smoking-cessation program 2] Investigate timeframe of the quit-
tobacco rate from the beginning of the project to one year after quitting.
3] Analyze predictable factors of smoking cessation.
Methods: 188 non-filtered tobacco-users from rural India were enrolled in
the project. This retrospective study was based on motivation, depen-
dence, conviviality with smokers and tobacco abstinence after one year.
This QUIT-Smoking project was carried out by 3 counseling sessions per
week. Subject-evaluation was done bi-monthly. Sex, age, smoking pat-
tern, previous attempts to quit, education, marital status, psychological
background, other addictions and nicotine dependence through the Fag-
erstrom Test for Nicotine Dependence (FTND) were evaluated as predic-
tors of abstinence by univariate analysis. Individual counseling done for
behavioral modification by psychologist were conducted.
Results: Total of 239 smokers were willing to quit, but 153 completed
study. Mean age of participants was 4, previous attempts to quit was
recorded in 78%, umber of cigarettes 31/day, FTND 5.99 2.11. 123
subjects reported abstinence at one year. Reduced abstinence was asso-
ciated more in females [93%, p0.03]. Mean age at beginning of
smoking habits was 16 years. Co-morbidities in study group were as
follows: respiratory disease 60%; cardiovascular disease 13%; de-
pression 38%. Main reasons for cessation efforts: health: 62%, family/
society pressure: 23%, children: 4% and economy: 11%. Dependence was
high in 73%. QUIT-success rate in young smokers 35 yrs was 22%,
whereas rate 65 years of age was 40%. In our project, 30% participants
with tobacco-addicts stopped smoking. 68% Quit smoking by end of this
project. Sustained quit rates after 12 months increased from 16% to
approximately 41% during the first year of this program.
Conclusions: Our NGO project “STOP-QUIT & Live Long” successfully
motivated 62% of subjects to stop smoking within one year. Unavailabil-
ity of nicotine replacement therapies reduced our success rate. Abstinence
was more difficult in young male smokers with depression. Counseling/
motivation were highly effective in reducing incidence of thoracic can-
cers in the long-term. Our experience/data suggests the need for com-
bined efforts by IASLC, ESMO & community NGO’s working in the
tobacco control field. The ELCC 2010 Conference must expedite such
NGO initiatives in resource-poor nations.
Disclosure: All authors have declared no conflicts of interest.
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ASSESSING THE KNOWLEDGE OF TWO LUNG CANCER
RELATED FACTORS IN HOSPITAL STAFF SMOKERS
WILLING TO QUIT
J.E. Alonso, A. Sanchez, B. Gallego, I. Herrero, E. Chacon, S. Bello
Respiratory Service, Hospital Miguel Servet, Zaragoza/SPAIN
Aim: Knowledge is a key point in primary prevention in lung cancer. We
consider two different classes of factors in this prevention, depending on
the possibility of intervention or not. In a group of hospital staff smokers
attending a tobacco cessation clinic we asked about their knowledge on
tobacco and radon as lung cancer etiologic factors.
Methods: 197 smokers attending a 6 months hospital-based tobacco cessa-
tion programme were included in our study. They belonged to a university
teaching tertiary hospital and were part of the staff. It included doctors,
nurses and auxiliary personnel. We specifically asked about cancer risk of
tobacco, radon knowledge and cancer risks of radon. Subgroups of smokers
knowing these risks were analyzed and also some potential variables that
could explain these differences were studied.
Results: 63 smokers (32%) finally succeed at 6 months follow up point. At
the initial inclusion 140 smokers (70%) knew about the risk of lung cancer
related to the cigarettes. 35 smokers (18%) had heard about radon. 2 smokers
(1%) knew about the radon related lung cancer risk.
Conclusion: There is still room to insist in tobacco cessation specially
arguing on lung cancer risks in nature or home environment that are
sometimes difficult to modify. Even in a hospital setting there’s a significant
proportion of smokers ignoring the lung cancer risk related to tobacco.
Disclosure: All authors have declared no conflicts of interest.
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CARCINOMAS OF LUNG & TOBACCO USE: SUPPORTIVE
CARE NEEDS IN ASIAN COMMUNITY TO BRING DOWN
MORTALITY/MORBIDITY
V.P. Shankpal Community Medicine, Health Alert Organisation of India,
Dhule/INDIA
Issues: This is Phase-IV continuation of our NGO-Project in Indian-
adolescents. Studied influence of counseling on reduction in tobacco-
smoking eventually reducing lung-cancer-incidence. 218 deaths/year due
to lung-cancer. Crude-Tobacco-smoking socially accepted in rural/tribal
India. From May 2007 our NGO conducts project “BIDI [Locally made
crude-Indian-tobacco] OR HEALTH”. Aims to reduce tobacco-products-
consumption & provide de-addiction guidance/counselling.
Methodology: 11 villages from rural India included. Total-participants 511,
age 14-24. Tobacco-addicts graded clinically. Counseling-effect monitored
for four-months. Counseled for cause tobacco-use, educational/social factors.
Conducted 20 follow-up-sessions during course of study.
Results: Of 511 tobacco-users 493 continued to participate. [18 drop-
outs]. 32% COPD & respiratory disorders, 12% Tuberculosis. 8 health-
care personals from rural-Govt-clinics trained in counseling with com-
munity-leaders. 431 participants showed positive-attitude towards
quitting tobacco use. Of these 431, 410 smokers quit habit of tobacco. 21
able to abstain for short-period but eventually restarted habit. Post-
project-surveillance showed need for community help & Rehabilitation.
Of 431 who responded positively majority [394] adolescents started using
tobacco due to peer-pressure [84%], imitation of tobacco-advertising on
media/films/TV [11%].
Conclusion: NGO-activists with scientific knowledge/expertise are only
available resource for influencing cancer incidence in India. They act as
channel to implement Supportive cancer care/prevention-programmes.
NGOs should utilize this approach to reduce cost-factor in cancer-control-
strategies & better de-addiction-facilities in rural/tribal areas where qualified
Oncologists are rarity.
Recommendations: Developing-nations have little manpower/resources/
technologies in de-addiction. Nicotine replacement therapies are expensive
& available in metro-cities only. Government must carry out supportive-
care-programmes with NGO-counsellors to bring down mortality/morbidity
of lung-cancer. Anti-tobacco-activists trained in counseling provide better
cancer care with reduced cost. We intend to form an Umbrella group of
anti-cancer activists to workout more planned approach to this issue at 2nd
European Lung Cancer Conference Geneva 2010.
Disclosure: All authors have declared no conflicts of interest.
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USEFULNESS OF A FAST ACCESS INVESTIGATION UNIT
FOR LUNG CANCER DIAGNOSIS
J. Sanz-Santos1, F. Andreo1, E. Monso1, J. Bechini2, M. Llatjo´s3, E. Cas-
tella3, I. Guasch1, P. Lopez de Castro1, F. Caro4 1Pneumologia, Hospital
Universitari Germans Trias i Pujol, Badalona/SPAIN, 2Radiologia, Hospital
Universitari Germans Trias i Pujol, Badalona/SPAIN, 3Anatomia Pato-
logica, Hospital Universitari Germans Trias i Pujol, Badalona/SPAIN,
4Pulmonologia, Hospital Maria Ferrer, Buenos Aires/ARGENTINA
Aim: To evaluate the usefulness of a fast-track diagnosis unit for lung cancer
after 42 months of being established.
Patients and method: Patients with suspected lung cancer (who could be
investigated in a outpatient setting) were recruited from the e-department,
hospitalization or from their GP and them referred to the unit (by fax, phone or
e-mail). Within a week they were seen by a pulmonologist. After a first
evaluation diagnosing and staging test were carried out in a quick access. Once
the patients were diagnosed they were referred to oncology, radiotherapy and/or
thoracic surgery department after being reviewed in a multi-disciplinary-weekly
meeting. Time from the first visit to diagnosis as well as histologic type, diagnostic
method, age, gender, tobacco exposure and TNM classification were recorded.
Results: 678 patients were seen from Oct 2005 to Apr 2009. Of these, 361 (54.7%)
were found to have a thoracic malignancy. For the group of patients having lung
cancer (337 cases) the mean age was 65.3 yrs (SD 10.5), mostly men (87%),
smokers or ex-smokers (91.8%) with a mean smoking exposure of 54.6 packs/yr.
Adenocarcinoma was the most common histologic type accounting for 118
(33.5%) of the total with no differences on gender and smoking status. Second
histologic type was squamous cell carcinoma: 89 (25.3%) cases. The most
common diagnosis methods were: fiberoptic bronchoscopy (48.1%), endobron-
chial ultrasound bronchoscopy (EBUS) (20.2%), surgery (14.8%) and transtho-
racic needle aspiration (8.8%). For the cases of NSCLC, in a third part (36.3%)
were found to be resectable (stage I and II) and for a quarter of them (26.6%) to
have distant metastasis.
The median time to diagnosis was 12.5 days (IQR:5-27). Delays were related to
stage (advanced stages were diagnosed earlier) and with the diagnosis method:
fiberoptic bronchoscopy was the fastest method (mean time 8 days, IQR 4-14),
and surgery was the slowest (mean time 65 days, IQR 47-109).
Conclusion: Although there is not evidence that delays in the diagnosis of lung
cancer are related to prognosis there are other reasons for what delays have to be
avoided. In our experience, a fast access investigating unit for lung cancer diagnosis
improves management centralizing efforts and avoiding redundant tests.
Disclosure: All authors have declared no conflicts of interest.
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CHARACTERISTICS OF THORACIC MALIGNANCIES
OCCURRING AFTER SOLID ORGAN TRANSPLANTATION
C. Genebes1, L. Brouchet2, B. Lepage3, N. Kamar4, L. Rostaing4, A. Didier1,
J. Mazie`res1 1Department of Pneumology, Larrey Hospital, CHU Toulouse,
Toulouse/FRANCE, 2Department of Thoracic Surgery, Larrey Hospital,
CHU Toulouse, Toulouse/FRANCE, 3Department of Statistics, CHU Tou-
louse, Toulouse/FRANCE, 4Department of Nephrology, Rangueil Hospital,
CHU Toulouse, Toulouse/FRANCE
Background: Chronic immunosuppression after solid organ transplantation is
associated with an increased risk of developing malignancies. The purpose of
this study was to determine the clinical characteristics and the outcome of
thoracic malignancies in patients who underwent solid organ transplantation.
Methods: Among a cohort of 2780 patients transplanted in our institution and
followed between 1984 and 2009, 24 patients (0.86%) developed a lung cancer.
Demographic characteristics, risk factors for lung cancer, cancer characteristics
and transplantation characteristics were analyzed. A survival analysis was done.
Results: Twenty-four patients were included (21 men and 3 women, median
age 61.2 year). Twenty-two patients were smokers. The most frequent
anatomopathologic types were squamous cell carcinoma (46%) and adeno-
carcinoma (37%). The median time period between transplantation and the
diagnosis of lung cancer was 6.6 years. Ten lung malignancies occurred after
kidney transplantation (0.5%), 8 after liver transplantation (1.3%) and 6 after
heart transplantation (2.8%). Seven patients underwent surgery, 3 radiother-
apy, 4 chemotherapy and 5 radio-chemotherapy. The median survival was
1.2 years ranging from 6 months for stage IV to 3.7 years for stage I.
Conclusion: Solid organ transplantation is associated with a high risk of lung
cancer. Survival of lung cancer in our study population is not inferior from
the one in non transplanted patients. Screening lung cancer in this high-risk
population should be considered to make an earlier diagnosis. In our study
surgery allows to obtain favorable survival results.
Disclosure: All authors have declared no conflicts of interest.
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THE RISK OF LIFELONG DNA DAMAGE CAUSED BY
LUNG CANCER AMONG RURAL MALE SMOKERS WHO
BEGIN AT TEENAGE
E.O. Odiase Tobacco Control, SmokeFree Foundation, Abuja/NIGERIA
Goals: To examine the effect of smoking on lung cancer risk and entire DNA
damage in a relatively large number of rural men, many of whom are poor
and started smoking as teenagers.
Methods: We followed 50,232 men, ages 25 to 50 years, through a community-
based tobacco control outreach programme with questionnaires both in English
and the local language to the North western and North eastern Nigerian Cohort
Study in 2002/2003, through December 2007. We estimated relative risk (RR) of
lung cancer associated with different measures of smoking initiation, duration,
and intensity adjusting for confounding variables. We conducted analyses on the
entire study population, among men who had smoked for at least 15 years,
among non drinkers, and separately for each geo-political zone.
Results: Altogether, 10,240 men were diagnosed with lung cancer. Com-
pared with never smokers, men who smoked for at least 15 years and who
smoked 10 cigarettes or more daily had a higher RR. In contrast, men who
had smoked for at least 15 years, but started after their 19th birthday, did not
experience an increased lung cancer risk. The increased RR associated with
smoking was observed among nondrinkers of alcohol, men with and without
a family history of lung cancer in both geo-political zones in Nigeria.
Conclusion: Our results support the notion that men who start smoking as
teenagers and continue to smoke for at least 15 years may increase their lung
cancer risk with dramatic and lifelong DNA damage.
Disclosure: The author has declared no conflicts of interest.
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POLYMORPHISMS IN MICRORNA BIOSYNTHETIC
GENES AND LUNG CANCER RISK: A MULTI-STAGE
CASE-CONTROL STUDY
G. Jin, J. Kim1, H. Jeon1, J.Y. Park2 1Department of Biochemistry and Cell
Biology, Kyungpook National University School of Medicine, Daegu/
KOREA, 2Department of Internal Medicine, Kyungpook National University,
School of Medicine, Deagu/KOREA
Based on the important role of microRNA (miRNA) biosynthesis genes in
carcinogenesis, we hypothesized that polymorphisms in the miRNA biosyn-
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thesis genes may modulate susceptibility to lung cancer. To test this hypoth-
esis, we conducted a two-stage study to evaluate the associations between
single nucleotide polymorphisms (SNPs) in the miRNA biosynthesis
genes and the risk of lung cancer. In stage 1 of the study, 24 SNPs in the
11 miRNA biosynthesis genes (DROSHA, DGCR8, RAN, XPO5, DI-
CER, AGO1, AGO2, HIWI, GEMIN3, GEMIN4, and TRBP) were
genotyped in 100 lung cancer patients and 100 healthy controls using a
sequenome mass spectrometry-based genotyping assay. One promising
SNP (AGO1 rs636832AG) was selected for stage 2 of the study, and
genotyped by a melting-curve analysis using fluorescence-labeled hybrid-
ization probes in an independent set of 552 cases and 552 controls. The
AGO1 rs636832AG exhibited highly consistent results between the two
stages of the study. In combined analysis, the 636832AG was associ-
ated with a significantly decreased risk of lung cancer in a dose-
dependent manner (Ptrend  6.0 	 10
-4). Individuals with at least one
rs636832G allele were at a significantly decreased risk of lung cancer
compared with those with the AA genotype (adjusted odds ratio  0.67,
95% confidence interval  0.53-0.84, P  4.0 	 10-4). This finding
suggests that the AGO1 rs636832AG might be a useful marker for
determining the susceptibility to lung cancer and that the AGO1 gene
might be involved in the development of lung cancer.
Disclosure: All authors have declared no conflicts of interest.
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GENETIC POLYMORPHISMS IN ATM, ERCC1, APE1 AND
IASPP GENES AND LUNG CANCER RISK IN A
POPULATION OF SOUTHEAST CHINA
Q. Deng, L. Sheng, D. Su, S. Ma Radiation Oncology, Zhejiang Cancer
Hospital, Hangzhou/CHINA
Polymorphisms in DNA repair and apoptosis genes are suspected to alter
the individual susceptibility to develop lung cancer. We investigated the
relationship between polymorphisms in ATM (A60G), ERCC1
(Asn118Asn), APE1 (Asn148Glu), and iASPP (A67T) and the risk of
developing lung cancer. A case-control study was conducted with 315
lung cancer patients and 315 cancer-free controls, matched on age and
sex. Genotypes were detected using the ABI 7500 real-time PCR system.
The association between genotype and lung cancer risk was evaluated by
computing the odds ratios (ORs) and 95% confidence intervals (CIs) from
multivariate unconditional logistic regression analysis with adjustment
for gender, sex and smoking status. The T/T homozygote in ERCC1
(Asn118Asn) was correlated with a strong statistically significant in-
creased risk of developing lung cancer (adjusted OR2.44; 95%
CI1.13-5.28; P0.023), especially lung adenocarcinoma (adjusted
OR3.18) and small cell lung cancer (adjusted OR6.08). For iASPP
(A67T), smokers with at least one T allele (A/T  T/T) were more likely
to develop lung cancer compared to those who did not carry the T allele (95%
CI, 1.07-2.84, P0.026). Subjects carrying the G allele in APE1 (Asn148Glu)
had a decreased risk of lung cancer (P0.05), which showing a protective effect.
Our results suggest that polymorphism Asn118Asn in ERCC1 increases the risk
of lung cancer. The effect is especially for lung adenocarcinoma and small cell
lung cancer. The iASPP A67T polymorphism may contribute to the early-onset
of lung cancer in smokers. However, polymorphism of the APE1 (Asn148Glu)
plays an important role in protecting against developing lung cancer, especially
for smokers.
Disclosure: All authors have declared no conflicts of interest.
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IDENTIFICATION OF GENETIC ALTERATIONS IN LUNG
CANCER PATIENTS IN SOUTH INDIAN POPULATION, INDIA
V. Balachandar1, S. Mohanadevi1, M. Arun1, A. Karthick Kumar1, P.
Manikantan1, P. Velmurugan1, K. Sasikala1, S. Sudha2, S.N. Dharwatgar3
1Human Molecular Genetics Laboratory, Department of Zoology,
Bharathiar University, Coimbatore/INDIA, 2Department of Biotechnology,
Karpagam University, Pollachi/INDIA, 3Department of Biotechnology, KLE
Medical University, Bangalore/INDIA
Lung cancer (LC) is the leading cancer in incidence and mortality
worldwide. Tobacco smoking is a major established risk factor for lung
cancer, contributing to 10-fold or higher risks in long-term smokers. The
aim of the present study was to identify the chromosomal alterations (CA)
in LC patients and compare with their smoking status. In our study, a total
of 34 LC patients have been selected (36 to 61 years) with known
smoking status and equal number of normal, healthy controls. After
signing a consent form, both groups (patients and controls) provided a
blood sample (5 ml) to establish cell culture. In 25 patients random
numerical and structural aberrations were identified. Structural aberra-
tions predominated, consisted of deletions, translocation, inversion and
mosaicism of various chromosomes. Our study has detected 1, 3, 4, 5, 7,
13, 18 and 21 suggested that these chromosomal scratches are prevalent
in LC patients. In comparison to the patients, control subjects expressed
very low levels of major CA (P0.005). Statistically significant results
were observed in smokers compared with non smokers. In the present
study, the high frequency of chromosomal rearrangements designates a
potential role for mitotic indiscretion coupled with the centromere in lung
cancer patients. Therefore, the survival rate of chromosome alterations in
lymphocytes might be used as a biomarker to identify populations at high
risk for lung cancer. Identification of chromosome alterations may be
helpful in devising better therapeutic strategies in future.
Disclosure: All authors have declared no conflicts of interest.
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METABOLOMIC PROFILING OF LUNG
ADENOCARCINOMA
C.D. Hoang1, M. Wu2, Y. Xu1, G. Peltz1, R. Merritt1, R. Whyte1, J. Shrager1
1Cardiothoracic Surgery, Stanford University, Stanford/USA, 2Anesthesia,
Stanford University, Stanford/USA
Objective: We hypothesized that accumulation of specific metabolites precedes
morphologic changes in lung tumors during malignant transformation, and that
this may be exploited to develop a lung cancer biomarker.
Methods: We performed metabolomic profiling on 9 fresh-frozen speci-
mens from patients with proven adenocarcinoma. The following tissues
from each patient were analyzed: tumor, adjacent-to-tumor tissues, and
normal lung. The metabolites were extracted by a methanol chloroform
technique and separated liquid chromatography. They were analyzed
using a 6520 hybrid Q-TOF mass spectrometer (Agilent). Mass Profiler
Professional software was used for statistical analysis and metabolite
profiling. To identify a metabolite of interest, the retention time and
elemental composition data were searched against databases: METLIN
Personal Metabolite. After multiple data filtering steps we derived a lung carcinoma-
specific metabolomic fingerprint. We performed metabolic network analysis to
assess which gene(s) may be associated with the metabolomic biosignatures.
Results: We detected 2232 unique metabolites in the tumor specimens,
1795 in the adjacent-to-tumor specimens, and 1613 in the normal lung.
Comparing tumor and normal lung samples, 201 metabolites were sig-
nificantly over-expressed and 105 were under-expressed in the tumor
tissue. The metabolic biosignature for the tumor group was highly distinct
from the other lung regions by several fold change. The metabolites
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within the tumor-specific signature included the following families:
lactate, amino acids, phospholipids, eicosanoids, and glycine derivatives.
In particular, multiple phosphatidylethanolamines showed dramatic dif-
ferential expression in tumor tissues compared to normal lung. Metabolic
network analysis suggests that the altered metabolite levels could affect
critical cellular functions, including: cell signaling, growth and invasive-
ness.
Conclusion: Metabolomic analysis identified metabolites that were uniquely
found in human lung adenocarcinomas. The specific metabolic biosignature
of lung adenocarcinoma could suggest novel biomarkers for use in diagnosis,
as well as suggest altered molecular pathways contributing to the pathogen-
esis of lung cancer.
Disclosure: All authors have declared no conflicts of interest.
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THE CLINICAL CHARACTERISTICS OF FAMILIAL LUNG
CANCER (FLC) BY POPULATION SCREENING
A. Vanags, I. Strumfa, A. Gardovskis, V. Borosenko, A. Abolins, G.
Trofimovics, J. Gardovskis Hereditary Cancer Institute, Riga Stradins
University, Riga/LATVIA
Introduction: Although smoking is the main risk factor of lung cancer (LC),
there is increasing evidence of the role of hereditary factors. While the search
for the responsible mutations is going on, the diagnostics of FLC depends on clinical
data.
Aim: To test the possibility of diagnosing FLC by clinical criteria in
population screening (PS) approach.
Materials and methods: PS was carried out in a territorial unit of Latvia,
reaching 18642 (76.6%) participants. Adult persons filled out the ques-
tionnaire reporting the presence, localisation and age of diagnostics of
malignant tumours in kinsmen. Hereditary cancer syndromes were sought
for according to international assessment criteria. Adjustment consulta-
tions were carried out. The FLC was diagnosed on the basis of 3 LC cases and
suspected on the basis of 2 cases in mutually first-degree relatives. Descriptive
statistics was performed by CIA software.
Results: The applied criteria revealed 13 cases of FLC and 93 – of
suspected FLC (sFLC) corresponding to population frequency 0.07%
[95% confidence interval  0.04-0.12] and 0.50% [0.41-0.61], resp. The
FLC/sFLC pedigrees had high frequency of LC (table), higher proportion
of early-onset cases (15.0% [11.1-20.3] vs. 8.3% [7.1-9.6] in the popu-
lation), low spouse correlation of 2.5% [0.7-8.6%], tumour anticipation.
FLC/sFLC constituted 12.9% [11.5-14.6] but FLC – 2.4% [1.8-3.2] of all
reported LC cases.
Conclusions: The clinical criteria based on the number of LC cases among
blood relatives ensure the identification of reasonable number of families
subjected to high LC load. The LC frequency in sFLC affected in single
generation is lower than in FLC, although high. FLC/sFLC show higher
frequency of early-onset cases but age as a diagnostic criterion does not
identify group with higher LC frequency.
Disclosure: A. Vanags: This work was supported by ESF project 2009/0147/
1DP/1.1.2.1.2./09/IPIA/VIAA/009 and Interreg IIIB NI-008; A. Gardovskis:
This work was supported by Interreg IIIB NI-008; V. Borosenko: This work
was supported by Interreg IIIB NI-008; J. Gardovskis: This work was
supported by ESF project 2009/0147/1DP/1.1.2.1.2./09/IPIA/VIAA/009
and Interreg IIIB NI-008 All other authors have declared no conflicts of
interest.
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THORACIC TUMOURS ELECTRONIC DATABASE:
A PORTUGUESE PROJECT
A.M. Figueiredo1, M.T.A.S. Almodovar2, S. Valente3, V. Hespanhol4, F.
Barata5 1Pneumologia, Centro Hospitalar de Coimbra, Coimbra/
PORTUGAL, 2Servic¸o Pneumologia, Instituto Portugues de Oncologia,
Lisboa/PORTUGAL, 3Pneumologia, Centro Hospitalar Cova da Beira,
Covilha˜/PORTUGAL, 4Pneumologia, Hospital S. Joa˜o, Porto/PORTUGAL,
5Pneumologia Oncolo´gica, Centro Hospitalar de Coimbra, Coimbra/
PORTUGAL
Background: Lung cancer is the most deadly cancer in the world due to high
incidence and poor response to treatment. Epidemiologic data are essential to
compare treatments and outcomes in these patients. The oncologic section of
the Portuguese Respiratory Society (PRS) exists for 25 years gathering
together Portuguese doctors and other health professionals working with lung
cancer patients.
Description: In order to improve the epidemiologic, demographic and
clinical data collection, and to assist the treatment decisions, an on-line
electronic database was developed, in compliance with current legislation
regarding data protection. This password protected base can be accessed
through the PRS website (http://tumorestoracicos.sppneumologia.pt/). The
database is intended to achieve two main goals: To provide each Centre
dealing with thoracic tumours a user-friendly standardized registry of the
epidemiologic and clinical data, from diagnosis to death. The clinician is
allowed to add data at any time after the initial registry of the patient
(treatments performed, progression, follow-up and death). This database also
provides descriptions of the staging criteria, node maps, makes an automatic
staging of the patient and provides links to the main guidelines. It also allows
automatic reports of every patient and provides automatic or personalized
statistical treatment of all the data. The second goal is to gather the data from
all the Centres and provide an epidemiologic overview of all the patients
treated in Portugal with thoracic tumours. New fields can be added to
integrate new data whenever justified.
Results: This project was established at the end of 2007 and the database was
released in October 2009. This base has by now been approved by 18
Table. Frequency of Lung Cancer in FLC/sFLC Pedigrees
by Selection Criteria
Group
Frequency/
FLC
95% CI/
FLC
Frequency/
sFLC
95% CI/
sFLC
Basic 25.5 19.3–32.8 17.2 15.0–19.7
Single generation 28.6 18.9–40.7 15.4 12.3–19.1
Multiple generations 23.4 16.0–32.9 18.7 15.6–22.2
Early-onset pedigrees
defined by presence
of at least 1 case of
lung cancer before
the age of 50
27.5 18.9–38.1 17.7 14.3–21.8
Pedigrees lacking lung
cancer cases before
the age of 50
23.4 15.3–34.0 16.8 14.0–20.1
Early-onset cancer in
single generation
31.3 19.9–45.3 15.5 10.9–21.4
Early-onset cancer in
multiple generations
21.9 11.0–38.8 19.6 14.9–25.5
Late-onset cancer in
single generation
20.0 7.0–45.2 15.4 11.5–20.3
Late-onset cancer in
multiple generations
24.2 15.2–36.2 18.0 14.2–22.6
Abbreviations: FLC, familial lung cancer; CI, confidence interval; sFLC, sus-
pected familial lung cancer.
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Institutions and the patients are already being registered. We expect this
registration to become systematic in 2010.
Conclusions: Our project aims to improve data collection on lung cancer
while helping to uniform treatment decisions.
Disclosure: All authors have declared no conflicts of interest.
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AN EPIDEMIOLOGIC COMPARISON STUDY OF LUNG
CANCER IN THE SAN JOAQUIN VALLEY OF
CALIFORNIA BY GENDER, RACE AND HISTOLOGICAL
SUBTYPES
A.M. Emtiazjoo, M.W. Peterson, P.K. Mills Department of Medicine, Uni-
versity of California at San Francisco, Fresno Medical Education program,
Fresno/USA
Background: Both genetic and environmental factors influence lung cancer
risk, however, the impact of these variables on histological subtypes of lung
cancer is less studied. We compared the incidence of lung cancer in San
Joaquin Valley of California (SJV) with the rest of the state by gender,
race/ethnic groups and histological subtypes. We chose SJV for comparison
to the rest of California due to its known poor quality of air, and agricultural
related pollution.
Methods: A descriptive epidemiologic analysis of lung cancer was con-
ducted using data from the National Cancer Institute (NCI) Surveillance,
Epidemiology and End Results program (SEER) for the diagnosis years
2000-2006. Age adjusted lung cancer incidence rates (AAIR) and associated
95% confidence intervals were calculated for lung cancer histological sub-
types for the San Joaquin Valley of California (SJV) compared to the rest of
the state. Comparisons between the two geographic regions were made based
upon gender, race/ethnicity, and histological subtypes.
Results: A total of 121,365 incident lung cancers were included in the
analysis. Overall, the AAIR was higher in the SJV than the rest of the state.
Rates were higher in males than females and in Blacks compared to other
race/ethnic groups and these patterns persisted for squamous cell carcinoma
and adenocarcinoma of the lung. However, white males (WM) experienced
the highest AAIR for small cell lung cancer (SCLC) compared to any other
subgroup and this was particularly true among WM in the SJV. In addition,
the AAIR of bronchoaveleolar lung cancer were lower in the SJV compared
to the rest of the state and were found to be higher in both white females
(WF) and black females (BF) compared to other gender and race/ethnicity
subgroups.
Conclusion: There is a significant difference in the incidences of lung cancer
and its histological subtypes among the different genders, race/ethnicity and
geographical zones. This study strongly suggests the presence of a different
set of risk factors for the different histological subtypes of lung cancer.
Disclosure: All authors have declared no conflicts of interest.
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EARLY DETECTION OF LUNG CANCER IN THE
REPUBLIC OF KOSOVO
B. Osmani, G. Zhuri, Z. Bujupi, R. Mehmeti, P. Rashiti Oncology, Clinic for
Lung Diseases, Prishtina/ALBANIA
Despite rapid development of diagnostic and therapeutics methods, lung
cancer still remains a big challenge of contemporary medicine. According to
various recent studies, results shows that a higher number of people die from
lung cancer than any other kind of cancer.
Our results: Clinic for Lung Disease is reference institution for lung cancer
in the Republic of Kosovo. Within a period of 2 years 245 patients were
diagnosed with lung cancer and treated. 191 patients or 78% were with non
small cell lung cancer (NSCLC) 54 patients or 22% were with small cell lung
cancer (SCLC). Patients age is as follows: 40 years old – 3 patients 41–60
years old – 106 patients  60 years old – 82 patients.
Histopathologic types: Squamous carcinoma 158 ( 83% ) Adenocarcinoma
30 ( 16%) Large Cell 3 (1%) STAGING II – 17 patients IIIA – 24 patients
IIIB – 113 patients IV – 37 patients.
Treatment protocols: Surgical treatment – 15 (8 %) Chemotherapy – 154
(80%) No treatment (symthomatic) – 23 (12%). Small cell lung cancer: 54
Patients: Male – 48 Female – 6 According to localization: Right sided – 31
Left sided – 23. Age: 40 years old – 2 patients (4%) 41–60 years old – 26
patients (48%) 60 years old – 26 patients (48%) As limited disease – 18 As
spread disease – 36.
Treatment: – Surgical – No treatment, Chemotherapy 49 (91%), Symptom-
atic therapy 5 (9%).
Disclosure: All authors have declared no conflicts of interest.
131P
THE INFLUENCE OF MALIGNANCY AND REFERRING
DEPARTMENT ON SMOKING CESSATION SUCCESS
P.M. Putora1, F. Baty2, P. Ludwig2, G. Rogenmoser3, L. Plasswilm4, M.
Brutsche2 1Klinik Fu¨r Radio-onkologie, Kantonsspital St. Gallen, St.
Gallen/SWITZERLAND, 2Department of Pneumology, Kantonsspital St.
Gallen, St. Gallen/SWITZERLAND, 3Lungeliga, Lungenliga St. Gallen, St.
Gallen/SWITZERLAND, 4Kantonsspital St. Gallen, Department of Radia-
tion-Oncology, St. Gallen/SWITZERLAND
Background: Smoking cessation programs are often under-utilized. This is
usually the case with patients with malignant disease including lung cancer.
Possibly, some physicians deem cancer patients less fit for smoking cessation
programs, perhaps due to life expectancy issues. Our aim was to analyse
whether cancer patients did differently in smoking cessation programs.
Method: We retrospectively analysed 635 patients that had at least one
smoking cessation consultation at the Kantonsspital St. Gallen between 2006
and 2009. Factors that were analysed included their diagnosis list, whether
the patients had a malignancy and specifically whether patients had lung
cancer. Another factor we included in the analysis was the referring depart-
ment. Using logistic regression and Pearson’s Chi-squared test, we tested the
influence of these factors on the success of the smoking cessation program.
Results: Of evaluable patients 8% (42/546 pts) had lung cancer and 12%
(53/441 pts) had a other malignant disease. The 1-month quit rate was 54%,
55%, 44% for patients with non-malignant disorders, lung cancer and other
malignancy respectively (Chi-square test: p  0.73). Malignancy as a
parameter also had no effect on the success rate: 48% with and 54% without
cancer (Chi-square test: p  0.72). Of the 441 patients, where a referring
department could be identified, only 5% (21 pts) were referred from the
oncology department. As expected, a difference could not be determined.
There was no difference in the success rate between patients from medical
and surgical departments. A factor that stood out was the motivational stage.
In the Prochaska stage “active”, the success rates were much higher than in
the low-motivated patients (OR: 12.3 [2.6 - 89.9]).
Conclusion: We could demonstrate that lung cancer patients do not do worse
in a smoking cessation program than patients with other malignancies or
non-malignant diseases. Also, the referring department had no effect on the
smoking cessation success rate. Our conclusion is that the diagnosis of lung
cancer is no reason to expect the patient doing worse in a smoking cessation
program. Therefore we recommend all treating physicians in pneumo-
oncology to consider smoking cessation programs for all of their patients.
Disclosure: All authors have declared no conflicts of interest.
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QUIT-TOBACCO: A DECADE OF ABSOLUTE
DEDICATION IN LUNG CANCER PREVENTION
IN RURAL INDIA
P.D. Shankpal, V. Shankpal Community Care, HAOI, Dhule/INDIA
Issues: Indian farmers/adolescents use crude-tobacco leading to high inci-
dence of inflammatory airway-diseases. It is a priority issue due to high
mortality/morbidity. Developing nations have less expertise in tobacco-
de-addiction. We used community volunteers to reduce tobacco consumption
de-addiction (QUIT-tobacco project).
Methodology: Eleven villages from rural India are included in the program;
n320, age 14–37.
Tobacco-addicts were graded clinically in this 16-months project. Users were
counseled about tobacco consumption, educational/social factors. Traditional
faith-healers community-leaders were incorporated for better impact.
Results: 16 dropped out of the project. Volunteers from our NGO are trained
in counseling. A total of 289 participants showed a positive attitude towards
quitting tobacco and 250 subjects quit tobacco. We noticed that 39 subjects
were able to abstain for a short period but eventually restarted the habit.
Post-project surveillance showed the need for community help rehabilitation.
Of 289 who responded positively, the majority [261] of adolescents started
using tobacco due to peer pressure [84%], imitation of tobacco advertising in
the media [14%], or were influenced by movies, TV [58%].
Conclusion: Community-NGO volunteers are a channel to implement a
tobacco-control program. Other NGOs should utilize our approach to reduce
the cost in tobacco control and achieve better impact in rural/tribal areas
where qualified oncologists are rare.
Recommendations: Developing nations have little manpower/resources/
technologies for tobacco control. Government/NGOs could address inflam-
matory airway-diseases interventional programs within available resources
and by above approach.
Disclosure: All authors have declared no conflicts of interest.
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RISK OF RECURRENCE AND OVERALL SURVIVAL OF
SURGICALLY RESECTED NON SMALL CELL LUNG
CANCER IN ELDERLY PATIENTS
B. Al-Alao1, E.N. Mc Govern1, V.N. Young1, K. O’Byrne2 1Cardiotho-
racic, St. James’s Hospital, Dublin/IRELAND, 2Oncology, St James Hospi-
tal, Dublin/IRELAND
Introduction: Surgery is a valid option for fit elderly patients with lung
cancer, but risk factors for overall survival and disease free survival after
surgical resection are not well described. We report the outcomes in elderly
patients (older than 70 years) with stage I-III non small cell lung cancer
(NSCLC) after surgical resection.
Methods: This is a retrospective study of patients diagnosed with NSCLC
after surgical resection at major cancer centre from 1998 to 2008. Demo-
graphic, pathologic, treatment, and follow-up data were collected. Recur-
rence rates and overall survival were calculated by the Kaplan-Meier
method.
Results: Of the 593 patients included in the study, 204 were older than 70
years at diagnosis. In this elderly cohort, the median age was 74 years (range,
70-104 years) and 74 of them were women (36.3%). Clinical and pathologic
characteristics were not statistically different between the elderly and
younger cohorts, with the exception that older patients were more likely to
have Lobectomy and Sub-lobar resections (90.7% versus 75.1%, p 0.0001)
and less likely to have multiple lymph nodes involved (19.1% versus 26.2%,
p  0.03) compared with the younger cohort. The Median follow-up of
elderly cohort, the median overall survival and the median disease free
survival were 2.9 years, 2.3 years and 2 years, respectively. While the overall
5-year survival rate was not statistically significant (23% versus 33%,
p  0.062), elderly patients had significantly lower 4-year disease free
survival rate (16% versus 30%, p0.002) when compared to the younger
cohort.
Conclusions: Although overall survival rate was similar to younger patients,
elderly patients had higher rate of limited surgical resection, more single lymph
node involvement and higher rate of disease recurrence after complete resection.
Disclosure: All authors have declared no conflicts of interest.
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ANALYSIS OF BIOMARKERS (BMS) IN THE AVAIL
PHASE III RANDOMISED STUDY OF FIRST-LINE
BEVACIZUMAB (BV) WITH CISPLATIN-GEMCITABINE
(CG) IN PATIENTS (PTS) WITH NON-SMALL CELL LUNG
CANCER (NSCLC)
M. Reck1, S.L. de Haas2, S.E. Evers3, P.D. Delmar4, C. Manegold5, S.J.
Scherer6, N.B. Leighl7 1Thoracic Oncology, Hospital Grosshansdorf,
Grosshansdorf/GERMANY, 2PDEO, F. Hoffmann-La Roche Ltd., Basel/
SWITZERLAND, 3Molecuzlar Medicine Laboratories, F. Hoffmann La
Roche, Basel/SWITZERLAND, 4PDIM, F. Hoffmann La Roche, Basel/
SWITZERLAND, 5Department of Surgery, Thoracic Oncol., Heidelberg
University, Mannheim/GERMANY, 6Biomarker and Experimental Medicine,
F. Hoffmann La Roche, Basel/SWITZERLAND, 7Medical Oncology, Princess
Margaret Hospital, Toronto/CANADA
Background: Two phase III trials, E4599 and AVAiL, have shown that
addition of Bv to platinum-based chemotherapy improved outcomes in pts
with untreated advanced NSCLC. In study E4599, analysis of several BMs
showed that intracellular adhesion molecule-1 (ICAM-1) levels may be
predictive of response to therapy and prognostic of survival, whereas pts with
high baseline vascular endothelial growth factor (VEGF) levels may have a
higher response rate to Bv. A similar exploratory BM analysis was per-
formed on baseline samples of the AVAiL trial.
Methods: In AVAiL 1,043 pts with untreated locally advanced, meta-
static or recurrent non-squamous NSCLC, ECOG PS 0/1, were random-
ised to CG q3w for up to 6 cycles plus either Bv 7.5mg/kg (n345), Bv
15mg/kg (n351) or placebo (n347). PFS was the primary endpoint.
Baseline plasma samples were collected and analysed for VEGF,
ICAM-1, vascular cell adhesion molecule-1 (VCAM-1), E-selectin and
basic fibroblast growth factor (bFGF) by ELISA. Samples were available
for 358 pts. The use of median levels across the samples to categorise
them as low and high was pre-specified as a cut-off. Simple and multiple
regression approaches as well as subgroup analyses were used to correlate
BM levels to PFS and OS.
Results: Baseline characteristics of pts with available BM samples
appeared to be balanced between the 3 treatment arms. Analysis of
ICAM, VCAM, bFGF and VEGF suggested that high baseline levels of
these markers were associated with a shorter OS compared with low
levels. When comparing PFS between the 15mg/kg Bv and placebo arms,
a trend towards a larger treatment effect was observed in pts with low
ICAM-1 levels compared with pts with high ICAM-1 levels. Comparing
OS between the 7.5mg/kg Bv and placebo arms, a trend towards a larger
treatment effect was observed in pts with high bFGF levels compared
with pts with low bFGF levels.
Conclusions: This exploratory analysis showed that BMs involved in an-
giogenic pathways may play a prognostic role in pts with advanced NSCLC.
The role of angiogenic BMs in predicting response should be further
evaluated in ongoing trials with Bv in NSCLC.
Disclosure: M. Reck: Honoraria: Hoffmann-La Roche, Lilly, Merck, Astra-
Zeneca; Advisory Board: Hoffmann-La Roche, Lilly, Merck, Astra-Zeneca
S.L. de Haas: I am an employee of F.Hoffmann-La Roche, which has funded
the conduct of the AVAIL study and biomarker analysis.
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SOLUBLE LEVELS OF VEGF-A AND VEGFR-2 IN
PATIENTS WITH ADVANCED NSCLC
R. Sirera1, E. Sanmartin2, E. Jantus2, A. Blasco3, C. Caballero4, S. Gallach5,
P. Olmo4, N. del Pozo6, R.M. Bremnes7, C. Camps8 1Molecular Oncology
Laboratory, University General Hospital, Valencia/SPAIN, 2Molecular On-
cology Laboratory, Fundacion para la Investigacion del Hospital General
Universitario de Valencia, Valencia/SPAIN, 3Medical Oncology, Cosorcio
Hospital General Universitario de Valencia, Valencia/SPAIN, 4Oncology
Service, University General Hospital, Valencia/SPAIN, 5Molecular Oncol-
ogy Laboratory, Fundacio´n para la Investigacio´n del Hospital General
Universitario de Valencia, Valencia/SPAIN, 6Oncology Sevice, University
General Hospital, Valencia/SPAIN, 7Department of Oncology, Institute of
Clinical Medicine, University of Tromsø, Tromsø/NORWAY, 8Oncology
Service, Hospital General Universitario de Valencia, Valencia/SPAIN
Introduction: Angiogenesis is an early and crucial event in NSCLC pathogen-
esis. VEGF-A is an important proangiogenic factor for novel tumor blood vessel
formation. The expression of VEGF-A in tumor cells and in tumor micro-vessels
has been reported in 30–100% of NSCLC patients. VEGFR-2 is the main
pro-angiogenic receptor for VEGF-A, and seems to play a key role in tumor-
induced angiogenesis. An increased expression of angiogenic factors in tumor or
serum/plasma is associated with metastasis and poor prognosis. The aim of this
study is to investigate the usefulness of the quantification of soluble VEGF-A
and VEGFR-2 as biomarkers in advanced NSCLC.
Patients and methods: 458 patients with advanced NSCLC (stages IIIB-IV)
treated with cisplatin and docetaxel and 89 healthy age-matched controls
were studied. Pre-treatment blood samples were collected, and plasma was
obtained. VEGF-A and VEGFR-2 protein levels were quantified using an
ELISA assay. Statistical analysis was performed using SPSS 15.0. Tests
were considered significant at p 0.05.
Results: Soluble levels of VEGF-A and VEGFR-2 were significantly higher
in patients than controls; VEGF-A: 105.92  5.30 pg/ml vs 26.17  5.35
pg/ml, respectively; p0.0001; and VEGFR-2: 8346 120 pg/ml vs 6903
144 pg/ml, respectively; p 0.0001). The areas under the ROC curve were
0.858 for VEGF-A and 0.744 for VEGFR-2, indicating that both variables
are suitable diagnostic-biomarkers, allowing the discrimination between
controls and patients. Patients with high VEGFR-2 plasma levels (75 per-
centile) show a significantly longer time to progression (TTP, p0.029). On
the other hand, high levels of soluble VEGF-A (75 percentile) correlates with
a poor overall survival (OS, p0.026). A subgroup characterized by a
combination of high levels of soluble VEGF-A and low levels of soluble
VEGFR-2 had the worse prognosis regarding TTP (p0.042) and OS
(p0.003), when compared with other possible combinations of markers.
Conclusions: Soluble levels of VEGF-A and VEGFR-2 are significantly
higher in NSCLC patients than in age-matched controls. The combination of
both variables, allow the identification of a NSCLC subgroup with a poorer
prognosis, which may benefit from additional anti-angiogenic therapy.
Disclosure: All authors have declared no conflicts of interest.
136O
EXPRESSION OF VEGF LIGANDS AND RECEPTORS IN
TUMOR VERSUS STROMAL CELLS IN NSCLC:
PROGNOSTIC VALUE
E. Jantus1, E. Sanmartin1, R. Sirera2, A. Blasco3, R. Guijarro4, T. Donnem5,
S. Al-Saad6, L. Busund7, R.M. Bremnes8, C. Camps9 1Molecular Oncology
Laboratory, Fundacion para la Investigacion del Hospital General Univer-
sitario de Valencia, Valencia/SPAIN, 2Molecular Oncology Laboratory,
University General Hospital, Valencia/SPAIN, 3Medical Oncology, Cosorcio
Hospital General Universitario de Valencia, Valencia/SPAIN, 4Thoracic
Surgery, Consorcio Hospital General Universitario de Valencia, Valencia/
SPAIN, 5Institute of Clinical Medicine, Uniersity of Tromso, Tromso/NOR-
WAY, 6Institute of Medical Biology, Universitu of Tromoso, Tromso/NOR-
WAY, 7Institute of Medical Biology, University of Tromso, Tromso/
NORWAY, 8Department of Oncology, Institute of Clinical Medicine,
University of Tromsø, Tromsø/NORWAY, 9Oncology Service, Hospital Gen-
eral de Valencia, Valencia/SPAIN
Background: In tumor angiogenesis there is a complex interplay between
endothelial, stromal, and tumor cells. One of the most important signalling
pathways in angiogenesis is initiated by binding of VEGF ligands to its
receptors. This study analyses correlations between the expression of VEGF
ligands and receptors in tumor cells and tumor stroma in samples from
resectable non-small cell lung cancer (NSCLC) patients.
Methods: Primary tumor tissues (n84) from NSCLC patients (I -IIIA)
were used in this study. The most representative areas of tumor, stroma and
normal tissue were carefully selected. RNA was extracted from 2 sampled
cores (0.6 mm) using a standard protocol and RT-PCR was performed using
TaqMan® probes. Relative quantification was calculated using actin-b as
endogenous control. Results were normalized against a calibrator sample
(NCI-H23 cell line). Normalization against normal tissue is under study.
Statistical analysis were considered significant at p0.05.
Results: Significant differences between tumor and stroma expression were
found for VEGFR-1, 3 and neuropilin-1 (NRP-1). Analysis according to
histological subtypes [squamous (SCC) vs. adenocarcinoma], show signifi-
cant differences in expression for: PlGF and VEGFR-2 (in tumor) and
VEGF-A, VEGFR-2,3, NRP-1 (in stroma). Survival analyses revealed that
patients co-expressing lower levels of VEGFR-2 in tumor and higher stromal
levels of VEGF-A had significantly worse prognosis (p 0.017).
Conclusions: Our results show the importance of tumor-stroma interactions
in the angiogenic process in this type of cancer. There are “angiogenic
profiles” that could be used as prognostic markers in NSCLC and may help
in the selection of patients that will better benefit of the anti-angiogenic
therapies. (Supported by ISCIII grant)
Disclosure: All authors have declared no conflicts of interest.
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PREDICTIVE SIGNIFICANCE OF EGFR SOMATIC
MUTATIONS AND GENE COPY NUMBER IN NSCLC
PATIENTS TREATED WITH SINGLE AGENT TYROSINE
KINASE INHIBITORS: A SYSTEMATIC REVIEW AND
META-ANALYSIS
S. Murray1, E. Evangelou2, H. Linardou3, I.J. Dahabreh4,6, P. Kosmidis5, D.
Bafaloukos3, J.P.A. Ioannidis2,6 1Department of Molecular Biology and
Genetics, Metropolitan Hospital, Athens/GREECE, 2Department of Hygiene
and Epidemiology, University of Ioannina School of Medicine, Ioannina/
GREECE, 31st Oncology Department, Metropolitan Hospital, Athens/
GREECE, 4Department of Pathophysiology, Medical School, National Uni-
versity of Athens/GREECE, 52nd Department of Oncology Hygeia Hospital,
Athens/GREECE, 6Biomedical Research Institute, Foundation for Research
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Background: The presence of somatic mutations of in the TK of EGFR and
gene copy number gain in patients with NSCLC are good candidate predic-
tive biomarkers for response to monotherapy with TKIs. We aimed to
characterize the predictive effect of these aberrations on survival outcomes
and response by systematic review and meta-analysis
Methods: We performed a computerized search of MEDLINE and Cochrane
library to identify the association between EGFR gene status and response or
survival to the TK inhibitors gefitinib and erlotinib. Study eligibility: single
agent TKI in unselected patients with advanced NSCLC. Between-study
heterogeneity was assessed with the Q statistic and inconsistency with the I2
statistic; small study effects were assessed using the Harbord/ Egger test.
Both fixed and random effects models were considered for the summary
effects. Data on OS, PFS, TTP and response rates were extracted. Random
effects meta-analyses were used to calculate summary hazard ratios and
bivariate random effects meta-analysis was used to calculate likelihood ratios
for predicting response.
Results: Of 4873 studies, 85 were eligible for at least one outcome. For
somatic EGFR mutations 20 (1373), 22 (1685), 43 (2412), 65 (3101) and for
EGFR gene gain 5 (294), 10 (822), 20 (1689), 21 (1539) studies were
evaluable for TTP, PFS, OS and response respectively. Random effects
analysis showed somatic EGFR mutations to be superior predictors of
TTP/PFS compared to gene copy gain (HR0.38; 95%CI, 0.29-0.49 vs 0.6;
95%CI, 0.46-0.79) compared to wild type. Superiority was observed for OS
(HR0.49; 95%CI, 0.42-0.57 for mutations; 0.78; 95%CI, 0.66-0.93 gene
copy). Likelihood ratios of response supported the supperiority of EGFR
mutations: LR5.6, -LR0.25 vs LR2.1, -LR0.55 for gene gain.
Effects were consistent across subgroups
Conclusions: These comprehensive meta-analyses provide large-scale empiri-
cal evidence that the improved responses observed in patients harboring somatic
mutations in EGFR are matched by survival outcomes. The data also suggests
that there is less benefit obtained by stratifying for EGFR gene copy number
Disclosure: S. Murray: Consultant or Advisory role: S Murray, AstraZeneca,
Macclesfield, United Kingdom. AstraZeneca are proprietors of Iressa® (gefitinib).
P. Kosmidis: Consultant or Advisory role: P Kosmidis, AstraZeneca, Maccles-
field, United Kingdom. AstraZeneca are proprietors of Iressa® (gefitinib).
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INCREASED THYMIDYLATE SYNTHASE (TS) GENE
COPY NUMBER IN NSCLC
M.W. Wynes1, R. Dziadziuszko2, S. Singh3, D. Christoph4, J. Ranger-Moore5,
B. Szostakiewicz6, K. Dziadziuszko7, W. Eberhardt8, J. Jassem9, F.R. Hirsch10
1Medicine-division of Medical Oncology, University of Colorado Denver,
Aurora/USA, 2Department of Oncology and Radiotherapy, Medical Univer-
sity of Gdansk, Gdansk/POLAND, 3Translational Diagnostics, Ventana
Medical Systems Inc., Tucson/USA, 4Internal Medicine, University Hospital
of Duisburg-Essen, Essen/GERMANY, 5Biostatistics and Data Management,
Ventana Medical Systems Inc., Tucson/USA, 6Department of Oncology and
Radiotherapy, Medical University of Gdansk, Gdansk/POLAND, 7Depart-
ment of Radiology, Medical University of Gdansk, Gdansk/POLAND, 8De-
partment of Internal Medicine (cancer Research), West German Cancer
Centre Universita¨tsklinikum Essen, Essen/GERMANY, 9Oncology and Ra-
diotherapy, Medical University, Gdansk/POLAND, 10Medicine-Oncology,
University of Colorado Cancer Center, Aurora/USA
Background: High TS expression may associate with poor prognosis and
confer resistance to antifolates, particularly pemetrexed. TS is essential for
DNA synthesis and for de novo production of dTMP. This study determined
TS gene copy number in NSCLC, especially with regard to histology, and
evaluated the prognostic influence of TS gene copy number.
Methods: TS was evaluated on a tissue microarray containing triplicate
samples from 189 patients (pts) who underwent surgery using an exper-
imental silver in situ hybridization (SISH) assay (Ventana Medical
Systems, Inc., Tucson, AZ). Results were obtained for 124 pts (66%).
This group included 83% males, 60% squamous cell carcinomas (SCC)
and 25% adenocarcinomas (AC). The pathological stages were I: 39%, II:
25% and III: 30%, IV: 5% and unknown: 1%. A certified pathologist
counted signals in 50 nuclei/core and determined the mean TS copies/
nucleus/core. The average of the triplicate cores was compared to the
highest core of same pt. The highest core was used for further analyses
due to better relationship to parameters tested.
Results: Median gene copy number in the population was 2.5 (1.4-9.6)
while mean was 2.7 (1.0). Nine cases (7%) had 4 genes/nucleus and
1 had clusters. Gene copy number significantly differed (p0.04) by
histology: AC median 2.2 (1.6-4.5) mean 2.5 (0.7); SCC 2.5 (1.4-9.6),
2.8 (1.2); NOS/other 2.9 (1.5-3.4), 2.7 (0.6). Using 2.5 as a cut-off,
32% of ADs, 50% of SCCs and 68%of NOS/others were positive. For TS
4, 7/9 pts were SCC and 2/9 AD. Kaplan-Meier analysis using median
cut-off revealed no relationship between TS copy number and PFS
(p0.45) or OS (p0.40). Similar results were obtained using adjusted
Cox regression analysis and examining TS as a continuous variable; PFS
(HR 0.96, p0.77) or OS (HR 0.94, p0.70). No relationship between
TS and PFS (p0.56) or OS (p0.37) was found after stratification by
histology (SCC vs. non-SCC).
Conclusions: TS gene copy number is increased in primary tumors from
NSCLC pts. Many SCC tumors had high TS gene copy number, but others
did not. TS gene copy number is not associated with prognosis. Ongoing
studies will test whether TS gene copy number predicts clinical benefit from
pemetrexed and preliminary data are planned to be presented.
Disclosure: S. Singh: This author is an employee of, and has stock owner-
ship in Ventana Medical Systems Inc. J. Ranger-Moore: This author is an
employee of Ventana Medical Systems Inc. F.R. Hirsch: Advisory Boards:
AstraZeneca, Merck Serono, BMS/Imclone, Syndax, Pfizer, Boehringer-
Ingelheim, Lilly Oncology, GSK, OSI/Genenetech/Roche Research Funding:
AstraZeneca, OSI, Genentech, Syndax, Biogen-Idec, Ventana-Roche,
Merck, Genmab. All other authors have declared no conflicts of interest.
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INFLUENCE OF EVEROLIMUS AND PEMETREXED ON
THYMIDYLATE SYNTHASE EXPRESSION AS WELL AS
ON PROLIFERATION AND SURVIVAL OF NON-SMALL
CELL LUNG CANCER CELLS
B. Markova1, P.S. Ha¨hnel2, S. Herbertz3, M. Schuler4, F. Breitenbuecher1
1Innere Klinik/tumorforschung, Westdeutsches Tumorzentrum, Universita¨-
tsklinikum Essen, Essen/GERMANY, 23rd Medical Department, Johannes
Gutenberg University, Mainz/GERMANY, 3Business Unit Oncology, Novar-
tis Pharma GmbH, Pulheim/GERMANY, 4Innere Klinik und Poliklinik (tu-
morforschung), University of Essen, Essen/GERMANY
Pemetrexed is a potent inhibitor of thymidylate synthase (TS) and additional
folate-dependent enzymes, effective in treatment of non-squamous non-small
cell lung cancer (NSCLC). Preclinical data indicate that overexpression of TS
correlates with reduced sensitivity of NSCLC cells to pemetrexed. A recent
study in chemotherapy-naÃve patients demonstrated that the baseline expres-
sion of the TS gene and protein were significantly higher in squamous cell
carcinoma as compared to adenocarcinoma. Against this background we hy-
pothesized that the allosteric mTOR inhibitor everolimus (RAD001) could
increase the efficacy of pemetrexed in squamous NSCLC by lowering TS levels.
To this end, we used a panel of cell lines representing squamous- and adeno-
carcinoma histology. Thymidylate synthase mRNA and protein levels were
measured by qRT-PCR and western bloting, respectively. Biological end points
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were proliferation, apoptosis and clonogenic survival of the cells. Surprisingly,
no correlation between histology and TS expression levels was observed.
Treatment with pemetrexed significantly induced TS mRNA and protein levels.
RAD001 treatment did not modulate TS mRNA expression, but protein levels
were reduced. RAD001 was able to prevent pemetrexed-induced upregulation of
TS mRNA in some cell lines. However, the antiproliferative activity of pem-
etrexed was not enhanced in co-treatment experiments with RAD001. Surpris-
ingly, combining pemetrexed and RAD001 considerably reduced pemetrexed-
induced apoptosis. These results were further supported by colony formation
assays, which revealed increased clonogenic survival under treatment with
RAD001 and pemetrexed as compared to pemetrexed alone. These data indicate
that strategies based on RAD001 and pemetrexed combinations require careful
preclinical assessment.
Disclosure: S. Herbertz: Employed by Novartis Pharma GmbH. All other
authors have declared no conflicts of interest.
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DETECTION OF CIRCULATING TUMOUR CELLS (CTCS)
IN NON-SMALL CELL LUNG CANCER (NSCLC) BY
CELLSEARCH AND ISET TECHNOLOGIES
M. Krebs1, R. Sloane1, L. Priest1, L. Lancashire2, J. Hou3, G. Clack4, A.
Hughes4, C. Dive3, F. Blackhall5 1Clinical and Experimental Pharmacology
Group, Paterson Institute for Cancer Research, Manchester/UNITED
KINGDOM, 2Cep, PICR, Manchester/UNITED KINGDOM, 3Clinical &
Experimental Pharmacology, Paterson Institute for Cancer Research,
Manchester/UNITED KINGDOM, 4Discovery Medicine, AstraZeneca,
Manchester/UNITED KINGDOM, 5Department of Medical Oncology,
Christie Hospital NHS Trust, Manchester/UNITED KINGDOM
Background: Circulating tumour cells (CTCs), a key intermediary in me-
tastasis offer potential utility as prognostic, predictive and/or pharmacody-
namic biomarkers. We compared the ability of CellSearch and ISET (Isola-
tion by Size of Epithelial Tumours) technologies to enumerate and
characterise CTCs in NSCLC patients.
Methods: CellSearch enriches CTCs by EpCam based immunomagnetic
capture. Permeabilised cells were labelled with DAPI and antibodies to
cytokeratins and CD45. ISET CTC detection is by size exclusion and CD45
negative selection. Baseline clinical samples, processed to GCLP standards,
were collected from stage III/IV, chemo-na¨ive patients according to ethically
approved clinical protocols. Parallel blood samples were analysed by both
technologies.
Results: 26 patients were analysed (4 stage IIIA, 8 stage IIIB, 14 stage IV
disease). 6/26 patients (23%) had 2 CTCs/7.5ml blood (CTC#) by
CellSearch. Median CTC# was 0 (meansd 516, range 0-78). Mean CTC
# detected by stage is shown in Table1 By ISET, 20/26 (77%) patients had
2 CTC#. Median CTC# was 29 (meansd 90206, range 0-1045). Mean
CTC# by stage is shown in Table1. Ten patients (6 Stage IV, 4 Stage IIIB
patients) had evidence of circulating tumour microemboli (CTMs), not
identified by CellSearch. CTCs/CTMs were confirmed as malignant by
positive staining for EpCam, cytokeratin, epidermal growth factor receptor
and/or TTF1.
Conclusions: CTCs were identified in NSCLC patients by both technologies
but with higher frequency and prevalence by ISET. CTM identification by ISET
supports conceptualised mechanisms of tumour invasion. The prognostic signif-
icance of circulating cells enriched by ISET is unclear and will be explored
regarding clinical outcome. Combinations of technologies are clearly needed to
detect heterogeneous circulating cells and the potential to identify predictive
biomarkers and understand further the biology of metastasis is highlighted.
Disclosure: All authors have declared no conflicts of interest.
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CLINICOPATHOLOGIC CHARACTERISTICS AND
SURVIVAL OUTCOMES OF THREE RARE SUBTYPES
OF ADENOCARCINOMA (PAPILLARY CARCINOMA,
ACINAR CARCINOMA, SIGNET-RING CELL CARCINOMA)
THAT HAVE BEEN ASSOCIATED WITH HISTOLOGICAL
CHARACTERISTICS OF EML4-ALK NSCLC
S.H. Ou1, A. Ziogas2, J.A. Zell1 1Medicine-Hematology/Oncology, Chao
Family Comprehensive Cancer Center, UC Irvine Medical Center, Orange/
USA, 2Epidemiology, University of California Irvine, Irvine/USA
Background: Several rare subtypes of adenocarcinoma including signet-ring
cell carcinoma (SRCC), acinar carcinoma (AC), and papillary carcinoma
(PC) have been described in the EML4-ALK positive NSCLC. We investi-
gated the clinicopathologic characteristics and survival outcome of these
adenocarcinoma subtypes.
Methods: Retrospective population-based analysis of 3 adenocarcinoma
subtypes diagnosed histologically in the California Cancer Registry
(CCR) between 1989 and 2006 with comparison to adenocarcinoma of the
lung.
Results: 1241 cases of PC, 379 cases of AC, and 262 cases of SRCC are
compared to 50089 cases of adenocarcinoma of the lung. The median age
of SRCC patients is significantly younger than adenocarcinoma patients
(64 vs. 67; p  0.0001). More than half of PC and AC patients are
females. Close to half of AC patients (48.6%) present with stage I disease
while 49.2% of SRCC patients present with stage IV disease. There is no
significant difference in the distribution of AC and SRCC among the 4
major ethnicities but Asians have a higher proportion among PC as
compare to adenocarcinoma. Among patients with known smoking status,
SRCC patients have the highest proportion of never-smokers (30.8%)
while only 11.0% of adenocarcinoma patients are never-smokers. The
median overall survival (OS) for AC patients is 68 months, 20 months for
PC patients, 10 months for adenocarcinoma patients, and 6 months for SRCC
patients. Multivariate analyses reveal AC and PC histologies are independent
favorable prognostic factors for OS while SRCC histology is an independent
unfavorable prognostic factor when compare to adenocarcinoma. AC remained
a favorable prognostic factor among stage I patients and SRCC histology
remains an unfavorable prognostic factor among stage IV patients when com-
pared to adenocarcinoma.
Conclusions: PC, AC, and SRCC are all rare subtypes of adenocarcinoma
of the lung and have different clinicopathologic features and survival
outcomes. Signet-ring cell carcinoma of the lung seems to share the most
common characteristics associated with EML4-ALK NSCLC.
Disclosure: All authors have declared no conflicts of interest.
Table 1
CellSearch ISET
No. pts with
>2 CTC/
7.5ml Blood
Meansd
CTC Number
No. pts with
>2 CTC/
7.5ml Blood
Meansd
CTC Number
Stage IIIA (n4) 0 0.5  0.6 2 19  35
Stage IIIB (n8) 1 0.6  1.1 7 61  74
Stage IV (n14) 5 10  22 11 127  274
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PROGNOSTIC VALUE OF CIRCULATING ENDOTHELIAL
CELLS EXPRESSION MARKERS IN ADVANCED NSCLC
R. Sirera1, S. Gallach2, A. Blasco3, E. Jantus2, E. Sanmartin2, N. del Pozo4,
A. Iraola4, R.M. Bremnes5, A. Berrocal6, C. Camps6 1Molecular Oncology
Laboratory, University General Hospital, Valencia/SPAIN, 2Molecular On-
cology Laboratory, Fundacio´n para la Investigacio´n del Hospital General
Universitario de Valencia, Valencia/SPAIN, 3Medical Oncology, Cosorcio
Hospital General Universitario de Valencia, Valencia/SPAIN, 4Oncology
Service, University General Hospital, Valencia/SPAIN, 5Department of On-
cology, Institute of Clinical Medicine, University of Tromsø, Tromsø/NOR-
WAY, 6Oncology Service, Hospital General de Valencia, Valencia/SPAIN
Introduction: Angiogenesis is an important process for tumor development,
growth and dissemination. Abnormal numbers of circulating endothelial cell
(CEC) and circulating endothelial progenitor cell (EPC) are present in
cancer, but their relationship with prognosis is unclear. CECs are a minute
subset of peripheral blood cells, characterized by the expression of several
surface markers like: CD146, CD31, CD133, Tie2 and CD34 (in the case of
EPCs). The aim of the study was to quantify markers associated to CECs and
EPCs by RT-PCR and to correlate them with clinicopathological variables,
response to treatment and prognosis in advanced NSCLC patients.
Patients and methods: Patients with advanced NSCLC (n 53), stage
IIIB-IV, were studied. They were treated with a combination of cisplatin and
docetaxel. Blood samples were collected before and after 3 cycles of
chemotherapy in PAXgene Blood RNA Tubes and stored at 80°C until
RNA isolation. mRNA was reverse transcribed and quantification of CD146,
CD31, CD34, CD133 and Tie2 genes by RT-PCR was performed using
TaqManaˆ primers/probes. Relative expression was calculated by Pfaffl for-
mulae, using GUSB as endogenous control. Differences were considered
significant at p 0.05.
Results: We found no correlation between the expression of the analyzed
markers and clinico-pathological variables. Compared to pre-treatment lev-
els, post-treatment expression levels of CD31 and Tie2 were significantly
reduced after chemotherapy (p0.0001 and p0.003, respectively). Consid-
ering only adenocarcinomas, we found that those patients with basal low
CD146 expression had significant better progression-free (p0.024) and
overall survival (p0.001).
Conclusion: This study shows that it is possible to detect and quantified
CEC-associated markers in peripheral blood samples. The expression of
CD146 can possibly be used as biomarker of prognosis in advanced NSCLC.
Disclosure: All authors have declared no conflicts of interest.
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PRX1 PROVIDES RESISTANCE TO DOCETAXEL-
INDUCED APOPTOSIS IN LUNG CANCER CELLS
H. Kim, S. Yang, E. Jeong Internal Medicine, College of Medicine
Wonkwang University, Iksan/KOREA
Prx1 is a major 2-Cys peroxiredoxin family member and is frequently
elevated in several human cancers including lung, oral, prostate, and breast
cancers, and this seems to confer increased treatment resistance. Although
Prx1 suppresses radiation-induced c-Jun NH2-terminal kinase (JNK) activa-
tion and apoptosis in non-small cell lung cancer (NSCLC), the precise
mechanism of chemoresistnace is not clearly known. In this study, we
investigated the role of Prx1 in docetaxel-induced apoptosis of A549 lung
cancer cells. We generated shRNA targeting Prx1 in A549 cells to test the
sensitivity to docetaxel treatment. We found that Prx1 knock-down increased
apoptotic potential through activation of caspase cascade. In addition, inhi-
bition of Prx1 by shRNA suppressed the phosphorylation of Akt and
FoxO1a, a substrate of Akt, by docetaxel treatment in A549 cells. Further-
more, PI3K inhibitor LY294002 inhibited the phosphorylation of FoxO1a
and increased the cytotoxicity of docetaxel in A549 cells. These findings
suggest that Prx1 may modulate the chemosensitivity of lung cancer A549
cells to docetaxel through suppressing FoxO1a–induced apoptosis.
Disclosure: All authors have declared no conflicts of interest.
144P
THE MMP1, MMP2 AND VEGF GENETIC
POLYMORPHISMS AS PROGNOSTIC FACTORS IN
NON-SMALL CELL LUNG CANCER
R. Suwinski1, D. Butkiewicz2, A. Drosik3, M. Gawkowska-Suwinska1, E.
Nowara4, M. Rusin2 1Radiotherapy Department, M. Sklodowska-Curie Me-
morial Cancer Center and Institute of Oncology, Gliwice Branch, Poland,
Gliwice/POLAND, 2Tumor Biology, M. Sklodowska-Curie Memorial Cancer
Center and Institute of Oncology, Gliwice Branch, Poland, Gliwice/
POLAND, 3Clinical Oncology, M. Sklodowska-Curie Memorial Cancer
Center and Institute of Oncology, Gliwice Branch, Poland, Gliwice/PO-
LAND, 4Radiotherapy Department, M. Sklodowska-Curie Memorial Cancer
Center and Institute of Oncology, Gliwice Branch, Poland, Glliwice/PO-
LAND
Purpose: To evaluate the effect of four functional MMP1, MMP2 and VEGF
gene polymorphisms on overall survival (OS) of non-small cell lung cancer
(NSCLC) patients.
Material and methods: The study included 135 patients with NSCLC
treated with radio-chemotherapy or radiotherapy alone. Genomic DNA was
isolated from frozen peripheral blood and the polymorphisms were detected
with standard PCR-RFLP. Survival in relation to genotypes was evaluated
using the Kaplan-Meier method and assessed with log-rank test. Uni- and
multivariate Cox proportional hazards model was also used.
Results: Out of four polymorphisms studied, the MMP1 1607 and VEGF
634 significantly influenced OS in NSCLC patients. Carriers of one or two
MMP1 2G alleles showed better survival compared to 1G1G homozygotes
(P  0.043). Carriers of at least one VEGF 634 C allele had higher risk of
death than GG homozygotes (P  0.008). When clinical stage was consid-
ered, only in IIIA-IIIB subgroup the influence of the polymorphisms on OS
was observed – the VEGF 634 GG homozygotes showed better survival
than GCCC carriers. Also, in patients with T3-T4 primary tumour stage,
the VEGF 634 GCCC genotype correlated significantly with an in-
creased risk of death (P  0.010), whereas the MMP1 1607 2G allele was
slightly associated with better survival. Moreover, there was statistically
significant influence of the VEGF 634 genetic polymorphism on survival
among patients who received radiotherapy only (P  0.016). Multivariate
analysis revealed that VEGF 634 genetic polymorphism was an indepen-
dent prognostic factor in the studied group.
Conclusion: Our results demonstrate that MMP1 1607 2G and VEGF
634 G alleles are associated with better overall survival in NSCLC
patients, especially among those with locally advanced disease, and suggest
that MMP1 1607 and VEGF 634 polymorphisms may serve as prognos-
tic biomarkers in NSCLC.
Disclosure: All authors have declared no conflicts of interest.
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PDGF LIGANDS AND RECEPTORS: EXPRESSION IN
TUMOR CELLS AND STROMA IN NSCLC
E. Jantus1, E. Sanmartin1, A. Blasco2, R. Sirera3, R. Guijarro4, T. Donnem5,
S. Al-Saad6, L. Busund7, R.M. Bremnes8, C. Camps9 1Molecular Oncology
Laboratory, Fundacion para la Investigacion del Hospital General Univer-
sitario de Valencia, Valencia/SPAIN, 2Medical Oncology, Cosorcio Hospital
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Laboratory, University General Hospital, Valencia/SPAIN, 4Thoracic Sur-
gery, Consorcio Hospital General Universitario de Valencia, Valencia/
SPAIN, 5Institute of Clinical Medicine, Uniersity of Tromso, Tromso/
NORWAY, 6Institute of Medical Biology, Universitu of Tromoso, Tromso/
NORWAY, 7Institute of Medical Biology, University of Tromso, Tromso/
NORWAY, 8Department of Oncology, Institute of Clinical Medicine, Univer-
sity of Tromsø, Tromsø/NORWAY, 9Oncology Service, Hospital General de
Valencia, Valencia/SPAIN
Background: Tumor angiogenesis is a complex process in which tumor,
endothelial and stromal cells are involved. The ligands and receptors of
PDGF family play an important role in this process. The aim of this study
was to analyze the expression of PDGF ligands and receptors in tumor cells
and tumor stroma in resectable non-small cell lung cancer (NSCLC) samples
and to correlate them with clinicopathological variables and prognosis.
Methods: We studied 84 resectable NSCLC samples (stage I -IIIA). The
most representative areas of tumor cells, tumor stroma and normal lung
tissue were carefully selected for building tissue microarrays (TMA) blocks.
RNA extracted from 2 cores pieces from each area. RTqPCR were performed
to analyze genes of PDGF family by TaqMan ® primers/ probes. Relative
quantification was calculated by Pfaffl formula using actin-b as endogenous
control. Results were normalized against a calibrator sample (cDNA from
NCI-H23). Normalization against normal lung tissue is under study. TTP and
OS were calculated from the date of diagnosis to the date of disease
progression, death or last follow up.Statistical analysis were considered
significant at p0.05.
Results: Significant differences between tumor and stroma expression were
found for PDGF-B, PDGFR- and -. We observed a statistical association
between lower levels of expression of PDGFR- in tumor and relapse.
Moreover, we also found a significant correlation between lower expression
of PDGF-C, PDGFR- and - in tumor and a poor differentiation grade.
Survival analyses in the SCC subgroup revealed that patients showing a
combination of high stromal PDGF-A and low tumor PDGFR- levels have
shorter overall survival than the others (p 0.019).
Conclusions: Our results show a possible prognostic role of the stroma in
tumor angiogenesis in NSCLC. There are “angiogenic profiles” that could be
used as prognostic markers and may help in the selection of patients that will
better benefit of the anti-angiogenic therapies (Supported by ISCIII grant).
Disclosure: All authors have declared no conflicts of interest.
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REGULATORY T-LYMPHOCYTE-ASSOCIATED MARKER
EXPRESSION IN RESECTABLE NSCLC: PROGNOSTIC
VALUE
R. Sirera1, M. Uso´2, S. Gallach3, A. Blasco4, E. Jantus5, E. Palomares6, R.
Guijarro7, C. Caballero6, J. Galbis8, C. Camps9 1Molecular Oncology
Laboratory, University General Hospital, Valencia/SPAIN, 2Molecular On-
cology Laboratory, Fundacio´n para la investigacio´n del Hospital General de
Valencia, Valencia/SPAIN, 3Molecular Oncology Laboratory, Fundacio´n
para la Investigacio´n del Hospital General Universitario de Valencia,
Valencia/SPAIN, 4Medical Oncology, Cosorcio Hospital General Universi-
tario de Valencia, Valencia/SPAIN, 5Molecular Oncology Laboratory, Fun-
dacion para la Investigacion del Hospital General Universitario de Valen-
cia, Valencia/SPAIN, 6Oncology Service, University General Hospital,
Valencia/SPAIN, 7Thoracic Surgery, Consorcio Hospital General Universi-
tario de Valencia, Valencia/SPAIN, 8Thoracic Surgery Service, University
General Hospital, Valencia/SPAIN, 9Oncology Service, Hospital General de
Valencia, Valencia/SPAIN
Introduction: Regulatory T-lymphocytes (Tregs) play a critical role in
immune tolerance to tumor cells. Several molecules, including CD4, CD25,
CD127, CTLA-4, IL-10 and TGF1 have been reported markers of Tregs.
Another highly specific marker for Tregs is FoxP3, a transcription factor
which appears to be a master control gene for their development and
function. The aim of this study was to determine the expression of Treg-
associated markers by RT-PCR and to correlate them with clinicopatholog-
ical and prognostic variables in NSCLC.
Patients and methods: RNA was obtained from frozen lung specimens
(tumor and normal lung) from early-stage NSCLC patients (n135). RT-
PCR was performed to analyze the expression of: CD4, CTLA-4, FoxP3,
IL10, CD25, CD127 and TGF1. Relative expression was normalized by an
endogenous gene (GUS-B) using the Pfaffl formulae. Statistical analyses
were done by SPSS 15.0 and considered significant at p0.05.
Results: Compared to normal lung tissue, tumor samples had significantly
higher expression of CD25 (x2.1) and lower expression of CD127 (x0.42),
reflecting a Treg phenotype infiltrating the tumor. In concordance, those
patients that relapsed presented significantly higher CD25 and lower CD127
levels in tumor (p0.05 and p0.006, respectively). Additionally, patients
that did not relapse presented higher levels of CD4 and CD8 (p0.004 and
p0.037, respectively), markers of infiltrating helper and cytotoxic lympho-
cytes, respectively. Survival analyses revealed that patients with high FoxP3
expression had reduced OS (p 0.028) whereas those with high CD4
expression had improved PFS (p0.007) and OS (p 0.047).
Disclosure: All authors have declared no conflicts of interest.
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COMPREHENSIVE ANALYSIS OF DNA REPAIR GENE
POLYMORPHISMS AND SURVIVAL IN PATIENTS WITH
EARLY STAGE NON-SMALL CELL LUNG CANCER
J.E. Choi1, S.Y. Lee2, H.G. Kang1, J.Y. Park2 1Department of Biochemistry
and Cell Biology, Kyungpook National University School of Medicine,
Daegu/KOREA, 2Department of Internal Medicine, Kyungpook National
University School of Medicine, Daegu/KOREA
Background: This study was conducted to analyze a comprehensive panel of
single nucleotide polymorphisms (SNPs) in DNA repair genes to determine
the relationship between polymorphisms and survival outcome of patients
with early stage non-small cell lung cancer (NSCLC).
Patients and methods: Three hundred ten consecutive patients with surgi-
cally-resected NSCLC were enrolled. Forty-eight SNPs in 27 DNA repair
genes were genotyped and their associations with overall survival (OS) and
disease-free survival (DFS) were analyzed.
Results: Individually, 6 SNPs exhibited significant associations with sur-
vival outcome. When the 6 SNPs were combined, OS and DFS were
decreased as the number of bad genotypes increased (Ptrend  0.0001 for
both). Patients with 3, and 4 or 5 bad genotypes had a significantly worse OS
and DFS compared with those carrying 0 or 1 bad genotypes (adjusted hazard
ratio [aHR] for OS  3.53, P  0.02, and aHR for DFS  3.31, P  0.006;
and aHR for OS  5.47, P  0.002, and aHR for DFS  4.42, P  0.001,
respectively).
Conclusion: These findings suggest that the 6 SNPs identified can be used
as prognostic markers for patients with surgically-resected early stage
NSCLC.
Disclosure: All authors have declared no conflicts of interest.
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POLYMORPHISMS IN THE APOPTOSIS-RELATED
GENES AND SURVIVAL OF PATIENTS WITH EARLY
STAGE NON-SMALL CELL LUNG CANCER
H.G. Kang1, H. Jeon1, S.S. Yoo1, J.Y. Park2 1Department of Biochemistry
and Cell Biology, Kyungpook National University School of Medicine,
Daegu/KOREA, 2Department of Internal Medicine, Kyungpook National
University, School of medicine, Deagu/KOREA
Purpose: This study was conducted to determine the association between
single nucleotide polymorphisms (SNPs) in apoptosis-related genes and
survival outcomes of patients with early stage non-small cell lung cancer
(NSCLC).
Methods: Three hundred ten consecutive patients with surgically-resected
NSCLC were enrolled. Twenty-five SNPs in 17 apoptosis-related genes were
genotyped by a sequenome mass spectrometry-based genotyping assay. The
genotype associations with overall survival (OS) and disease-free survival
(DFS) were analyzed.
Results: Three SNPs (TNFRSF10B rs1047266, TNFRSF1A rs4149570, and
PPP1R13L rs1005165) were significantly associated with survival outcomes
in multivariate analysis. When the three SNPs were combined, OS and DFS
were decreased as the number of bad genotypes increased (Ptrend for OS and
DFS 7	 10-5 and 1	 10-4, respectively). Patients with one bad genotype,
and patients with two or three bad genotypes had a significantly worse OS
and DFS compared with those with 0 bad genotypes (adjusted hazard ratio
[aHR] for OS  2.27, 95% confidence interval [CI]  1.22-4.21, P  0.01,
aHR for DFS  1.74, 95% CI  1.08-2.81, P  0.02; aHR for OS  4.11,
95% CI  2.03-8.29, P  8 	 10-5; and aHR for DFS  2.89, 95% CI 
1.64-5.11, P  3 	 10-4, respectively).
Conclusion: Three SNPs in apoptosis-related genes were identified as
possible prognostic markers of survival in patients with early stage NSCLC.
The SNPs, and particularly their combined genotypes, can be used to identify
patients at high risk for poor disease outcome.
Disclosure: All authors have declared no conflicts of interest.
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APPLICATION OF MASS SPECTROMETRY-BASED
SERUM PROTEOME PATTERN ANALYSIS IN
IDENTIFICATION OF LUNG CANCER PATIENTS
M.A. Pietrowska1, Ł. Marczak2, R. Suwinski3, M. Stobiecki2, J. Polan˜ska4,
A. Polan˜ski5, P. Widłak1, M. Gawkowska-Suwinska3, A. Drosik6, A.
Walaszczyk1 1Department of Experimental and Clinical Radiobiology, Cen-
ter of Oncology Maria Sklodowska Curie Memorial Institute, Gliwice/
POLAND, 2Plant Secondary Metabolites Biochemistry Group, Institute of
Bioorganic Chemistry Polish Academy of Sciences, Poznan˜/POLAND, 3Ra-
diotherapy Department, M. Sklodowska-Curie Memorial Cancer Center and
Institute of Oncology, Gliwice Branch, Poland, Gliwice/POLAND, 4Institute
of Automatic Control, Silesian University of Technology, Gliwice/POLAND,
5Institute of Computer Science, Silesian University of Technology, Gliwice/
POLAND, 6Clinical Oncology, M. Sklodowska-Curie Memorial Cancer
Center and Institute of Oncology, Gliwice Branch, Poland, Gliwice/
POLAND
Mass spectrometry-based analysis of the blood proteome is an emerging
method of clinical proteomics and cancer diagnostics. Here we performed
mass spectrometry-based serum proteome pattern analysis aimed at identi-
fying features specific for patients with non-small cell lung cancer (NSCLC).
Blood samples were collected before the start of therapy from 49 patients
with locally advanced NSCLC, 39 patients with head & neck cancer and 36
patients with colon cancer, as well as in a group of age and sex-matched
healthy controls (48 donors). Serum was isolated after blood clotting and the
low-molecular-weight proteome fraction (2-14 kDa) was analyzed using
MALDI-ToF mass spectrometry. Registered mass spectra were analyzed
using bioinformatic tools created and optimized in our group. We have
identified cancer classifiers built of multiple spectral components that dif-
ferentiated sera from analyzed groups. Classifiers built of 16-18 components
differentiated healthy persons and patients with NSCLC with about 90%
specificity and sensitivity. Furthermore, we have compared similarity of
proteome patterns specific for analyzed types of cancer. Peptide profiles
characteristic of samples from blood of patients with NSCLC and head &
neck cancer were the most similar, while samples of colon cancer were the
most different. Spectral components that are the most characteristic of
specific types of cancer have been also identified. MALDI-ToF MS-based
serum proteome pattern analysis has an obvious potential to differentiate
samples between NSCLC patients and healthy controls or patients with other
type of cancers.
Disclosure: All authors have declared no conflicts of interest.
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ACTIVITY BASED PROTEIN PROFILING OF HUMAN
LUNG ADENOCARCINOMA BIOPSIES
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Hillinger5, R. Aebersold6, W. Weder7 1Department of Surgery, Division of
Thoracic Surgery, University Hospital Zurich, Zurich/SWITZERLAND,
2Functional Genomics Center Zurich (FGCZ), UZH/ETHZ, Zurich/
SWITZERLAND, 3Department of Surgery, University Hospital Zurich, Zu-
rich/SWITZERLAND, 4Institute of Pathology, University Hospital Zurich,
Zurich/SWITZERLAND, 5Department of Thoracic Surgery, University Hos-
pital Zurich, Zurich/SWITZERLAND, 6Department of Biology, Institute of
Molecular Systems Biology (ETH) and Faculty of Science (UZH), ETH
Zurich and University of Zurich (UZH), Zurich/SWITZERLAND, 7Division of
Thoracic Surgery, University Hospital Zurich, Zurich/SWITZERLAND
Rationale Lung cancer is the leading cause of all cancer related deaths and
treatment is still suboptimal. A promising option in the search for predictive
biomarkers is a novel methodology termed Activity Based Protein Profiling
(ABPP). This technology employs so-called Activity Based Probes (ABPs)
that selectively bind to active sites of members of distinct enzyme super-
families, thereby making a direct activity read-out of a given proteome
possible. Using ABPs targeting serine hydrolases, a large and diverse class
of enzymes that have previously been linked to lung cancer development, we
introduced ABPP as a biomarker screening platform in a clinical setting.
Methods A directed mass spectrometric approach was used for qualitative
and quantitative analysis of ABP labeled proteomes. Samples were analyzed
on an FTICR mass spectrometer (LTQ-FTMS, Thermo Finnigan, Bremen,
Germany). Mass spectrometric data were searched against a recently updated
human database (UniProt) using the Mascot search engine (version 2.2).
SuperHirn v0.3 was used for label-free quantitation. Inclusion lists were
generated based on data derived from discovery-driven experiments in
data-dependent acquisition mode. Results Approximately 30 serine hydro-
lases – mostly esterases and proteases – were identified per investigated
proteome of the human lung adenocarcinoma cell line CaLu-3. Certain
enzymes like Fatty Acid Synthase (FASN) or Kallikrein-6 (KLK6) have
previously been associated with lung cancer development or lung cancer
diagnosis, respectively. However, other enzymes like Neutral cholesterol
ester hydrolase 1 (NCEH1) have not been linked to lung cancer so far or even
represent uncharacterized proteins (Abhydrolase domain-containing protein
10, ABHD10). Discussion ABPP allows a relative fast and semi-quantitative
analysis of enzymatic activity profiles in cell lines and primary human
specimen. We aim to apply the established methodology on 100 pairs of
fresh-frozen human lung adenocarcinoma biopsies and corresponding normal
lung tissues from our tumor bank and link activity profiles of serine
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hydrolases to clinical follow-up data. The results of this study will ideally
allow the discrimination of low-/ high-risk lung adenocarcinoma patients.
Disclosure: All authors have declared no conflicts of interest.
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FEASIBILITY STUDY OF GENE EXPRESSION ANALYSIS
IN BRONCHOSCOPY SPECIMENS
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Curie Memorial Cancer Center and Institute of Oncology, Gliwice/
POLAND, 3Lung Diseases Division, City Hospital, Chorzow/POLAND,
4Clinical Oncology, M. Sklodowska-Curie Memorial Cancer Center and
Institute of Oncology, Gliwice Branch, Poland, Gliwice/POLAND, 5Radio-
therapy Department, M. Sklodowska-Curie Memorial Cancer Center and
Institute of Oncology, Gliwice Branch, Poland, Gliwice/POLAND, 6Chest
Disease Hospital, Zakopane/POLAND, 7Department of Lung Diseases and
Tuberculosis, Silesian Medical University, Zabrze/POLAND
Numerous studies have shown the potential role of gene expression markers
as prognostic or predictive factor in early lung cancer. Also, in advanced lung
cancer the DNA-based analysis of EGFR mutations has been proven to be
feasible. However, only single studies use material obtained from brochos-
copy to determine gene expression-based molecular markers.
The aim of the previous study was to determine the feasibility of gene
expression analysis of multiple mRNA markers in bronchoscopy-obtained
lung cancer specimens and to verify the parameters influencing the technical
quality of the result.
We analyzed gene expression of 19 genes in 110 lung cancer specimens,
from which both RNA and DNA were isolated. Quantitative real time PCR
was carried out by ABI 7900 HT machine, with Universal Probe Library
(Roche) fluorescent probes. 11 potential prognostic/predictive markers were
analyzed (ERCC1, EGFR, BRCA1, CSF1, CA9, DUSP6, STAT1, ERBB3,
MMD, FN1, CDKN1B), with 6 reference genes and two subtype-specific
genes.
Results: More than 50 ng of RNA was obtained in 81.3% of samples, but
larger amount (1 ug) only in 44%, with median isolation efficiency 800 ng.
Very good RNA integrity (RIN 8-10) was obtained only in 12.3% of
samples, with RNA degradation partially related to the learning curve of
the cooperating physicians (correlation coefficient R0.61). Six potential
reference genes were tested, at least 3-gene set was necessary to obtain
sufficient stability of geNorm normalization index (HADHA, EIF3S10
and UBE2D2). Majority of analyzed markers showed moderate expres-
sion, except of CDKN1B, with much larger expression amplitude. We
found out that the panel of analyzed mRNAs showed significant differ-
ences when related to the expression of TTF1 and TP63 (representing
differences between SCC and AC), but these two genes were not enough
to reliably discriminate between AC and SCC specimens. Two genes,
DUSP6 and BRCA1 showed distictly discordant pattern when compared
to other analyzed genes.
Conclusions: Analysis of bronchoscopy-obtained markers demands exten-
sive optimization and probably does not allow to directly utlilize markers
selected by the analysis of bulk tissue. Study supported by N N403 290636
grant.
Disclosure: All authors have declared no conflicts of interest.
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NEGATIVE PREDICTIVE VALUE OF REAL-TIME
ENDOBRONCHIAL ULTRASOUND-GUIDED
TRANSBRONCHIAL NEEDLE ASPIRATION IN STAGING
NON-SMALL CELL LUNG CANCER
J. Sanz-Santos1, E. Monso1, F. Andreo1, M. Llatjo´s2 1Pneumologia,
Hospital Universitari Germans Trias i Pujol, Badalona/SPAIN, 2Anatomia
Patologica, Hospital Universitari Germans Trias i Pujol, Badalona/SPAIN
Aim: To evaluate the negative predictive value (NPV) of real-time
endonbronchial ultrasonography-guided transbronchial needle aspiration
(EBUS-TBNA) in stagin non-small cell lung cancer (NSCLC) .
Material and methods: We performed a prospective study including
patients who were referred for NSCLC staging through rtEBUS-TBNA
between Ap 2005 to Mar 2009. A thoracic CT scan was performed prior
to staging, mediastinal nodes with a short-axis diameter 10 mm were
considered enlarged. In patients who underwent surgery we compared the
results of rtEBUS-TBNA with post-surgical staging.
Results: 296 patients where included (mean age 63yr (SD10)). 82 (61.5%)
patients had enlarged nodes on the CT scan. Final diagnoses were adeno-
carcinoma in 124 (41.9%) patients, SCC 82 (27.7%), large-cell carcinoma 11
(3.7%) and NSCLC 79 (26./%).
A total of 803 sampling procedures were performed, 675 (84.1%) on
mediastinal nodes and 128 (15.9%) on lobar nodes. The median (IQR)
small-axis diameter of the sampled mediastinal and lobar nodes was 10
(7-10) mm and 8 (6-11) mm, respectively. The most sampled stations were
number 7 390 (48.6%), number 4R 177 (22%) and number 4L 91 (11.3%).
The result of the samples where: normal nodes (lymph tissue) in 470 (58.5%)
cases and malignancy in 243 (30.3%). In 90 cases (11.2%) samples were
unsatisfactory (blood,bronchial cells).
In 182 (61.5%) patients rt-EBUS TBNA detected N2/N3 disease , for the
other 134 (38.5%) rt-EBUS TBNA didn’t showed nodal metastasis over
N0/N1. Off these patients, 78 patients underwent surgery Comparing the
findings of postsurgical staging with rtEBUS TBNA, the absence of
N2/N3 disease was confirmed in 66 (84.6%) cases. In the other 12 cases
(15.4%) 6 cases were nodes inaccesible for EBUS, 3 had unsatisfactory
samples and 3 nodes were malignant being considered normal on rtEBUS
TBNA. In 72 cases where all nodes from stations 4R, 4L and 7 where
sampled and proper material obteined, post-surgical staging only found
N2 disease in 6 cases (8.3%).
Conclusion: In our study rt-EBUS TBNA showed a NPV of 84.6% for
staging NSCLC. Whenever satisfactory samples could be obteined and all
nodes from stations 4R, 4L and 7 could be sampled NPV reached up to
91.7%.
Disclosure: All authors have declared no conflicts of interest.
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AN INVESTIGATION OF METABOLIC DIFFERENCES IN
VARIOUS HISTOLOGICAL TYPES OF LUNG CANCER
AND THE POTENTIAL IMPLICATIONS ON TREATMENT
AND PROGNOSIS
J. Singh, J. Feeback, J. Peck, R. Shah Division of Oncology, The Cancer
Center at Research Medical Center, Kansas City/USA
Background: Positron emission tomography (PET) scanning has become
increasingly useful and important in the initial staging and diagnosis of solid
tumors, and has been studied extensively in lung cancer. The purpose of this
retrospective study was to determine whether tumors of varying histologies
can be differentiated based on PET data.
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Method: 140 patients with lung cancer were identified from the Research
Medical Center tumor registry, and data elements on these patients were
abstracted from the medical records. Demographic information, disease
characteristics, and PET SUVMAX for the largest lesion were collected.
Results: Of the 140 patients, 79 were female, and 61 were male. PET
SUVMAX was obtained for 122 of these patients. AJCC staging was
available for 98 patients. The most commonly reported histological types
were adenocarcinoma (34%) and squamous carcinoma (33%). The mean
SUV for adenocarcinoma patients was significantly lower than that of
squamous or NSCLC that was not otherwise specified.
Conclusions: 1)Our results suggest that tumors of squamous histology
exhibit higher metabolic uptake than those of adenocarcinoma histology,
which is consistent with traditional studies of tumor doubling time. 2)The
ability for PET scans to predict histology may prove useful when sufficient
tissue cannot be obtained for pathology or when a patient is unable to tolerate
a surgical staging procedure. 3)There is evidence to support the idea that PET
scanning can be used to differentiate between lung tumors of various
histology. Further research is necessary to determine the extent to which this
information would be useful in practice.
Disclosure: All authors have declared no conflicts of interest.
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BASELINE (BL) RADIOGRAPHIC CHARACTERISTICS
AND SEVERE PULMONARY HEMORRHAGE (SPH) IN
BEVACIZUMAB (BV)-TREATED NON-SMALL CELL
LUNG CANCER (NSCLC) PATIENTS (PT): RESULTS
FROM ARIES, AN OBSERVATIONAL COHORT
STUDY (OCS)
P. Kumar1, N.A. Fischbach2, J.R. Brahmer3, D.R. Spigel4, S. Beatty5, S.L.
Teng5, E.D. Flick6, A.P. Sing7, T.J. Lynch8 1Hematology, Oncology, &
Transplantation, University of Minnesota, Minneapolis/USA, 2Oncology,
Oncology Associates of Bridgeport PC, Fairfield/USA, 3Sidney Kimmel
Comprehensive Cancer Center, Johns Hopkins University School of Medi-
cine, Baltimore/USA, 4Oncology, Sarah Cannon Research Institute, Nash-
ville/USA, 5Biostatistics, Genentech, Inc, South San Francisco/USA, 6Epi-
demiology, Genentech, Inc, South San Francisco/USA, 7Biooncology,
Genentech, Inc, South San Francisco/USA, 8Oncology, Yale Cancer Center,
New Haven/USA
Background: BV (Avastin®) prolongs progression free and overall survival
in advanced NSCLC pts. ARIES, a prospective OCS, evaluates BV clinical
outcomes in a real world setting. Post hoc analyses from randomized
controlled trials suggest location and cavitation as potential risk factors for
SPH, a serious and often fatal adverse event (AE). ARIES presents a unique
opportunity to independently evaluate BL tumor characteristics and correlate
with SPH.
Methods: Pts with advanced nonsquamous NSCLC on 1st line chemotherapy
and BV enrolled. No doses, regimens or assessments were prespecified. Data
were collected electronically at BL and quarterly. SPH were reported
expeditiously. BL CT scans were requested for all pts and reviewed by an
independent review facility (IRF).
Results: NSCLC enrollment completed 06/2009. As of 09/2009, 1970 pts
had median follow-up of 9.6 mo. The IRF reviewed BL scans of 1881 pts;
1470 (78%) had 1 BL measurable (meas) tumor (0.5cm) and 49% (718)
were central; 67% had largest tumor size 3cm; 14% had cavities and 10%
had 1 cavity. BL tumor characteristics were generally similar across
subpopulations (age 70, PS 2, pts with CNS mets). Pts with a history
(Hx) of hemoptysis (n105) had more centrally located tumors, fewer
numbers of meas tumor, and larger cavity size. There are 15 (0.8%) reported
SPH events to date; 2 pts had no BL CT scan submitted and 2 pts with BL
scans had no meas tumor (1 had Hx of hemoptysis). Of the remaining 11 pts
with SPH: 8 had central tumors; 1 had cavitation (1.2cm); 0 were on
anticoagulants at BL; largest tumor size ranged from 1.8-11.6cm. There was
1 SPH in pts with 1 cavity (0.5%) and 8 in pts with central tumors (1.1%).
Conclusions: ARIES has the largest series of independently reviewed BL
scans from advanced NSCLC pts, providing an opportunity to correlate
radiographic factors with outcomes in BV treated pts. Although limited by
small numbers, the data suggest that cavitation is not predictive of SPH.
Correlation of BL radiographic characteristics with outcomes and risk factor
analysis will be presented.
Disclosure: P. Kumar: Advisory role with Genentech (compensated) and
have received honoraria from Genentech; J.R. Brahmer: Advisory role for
Genentech (compensated); D.R. Spigel: Advisory role (Genentech; uncom-
pensated); S.L. Teng: Employee of Genentech, with stock ownership in
Roche; E.D. Flick: Employee of Genentech, with stock ownership in Roche;
A.P. Sing: Employee of Genentech, with stock ownership in Roche; T.J.
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Advisory role (compensated): Genentech, Merck, Astra Zeneca, Boehringer
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EARLY RESPONSE MONITORING OF ERLOTINIB AND
SORAFENIB BY 18F-FLUORODEOXYGLUOSE AND
15O-WATER POSITRON EMISSION TOMOGRAPHY IN
NON-SMALL CELL LUNG CANCER
J.S.W. Lind1, V. Frings1, O.S. Hoekstra2, R. Boellaard1, A.C. Dingemans3,
H. Groen4, E.F. Smit5 1Pulmonary Diseases, VUMC, Amsterdam/
NETHERLANDS, 2PET Centre, VU University Medical Centre, Amsterdam/
NETHERLANDS, 3Respiratory Medicine, Maastricht University Medical
Center, Maastricht/NETHERLANDS, 4Pulmonary Diseases, University Med-
ical Center Groningen, Groningen/NETHERLANDS, 5Pulmonary Diseases,
VU University Medical Center, Amsterdam/NETHERLANDS
Purpose: Response monitoring of molecularly targeted agents remains a
challenge. This study prospectively evaluates the change in tumour meta-
bolic activity and tumour perfusion, measured by 18F-FDG- and H2
15O-PET,
in patients with advanced/metastatic non-small cell lung cancer (NSCLC)
receiving combined anti-angiogenic (sorafenib) and anti-epidermal growth
factor receptor (erlotinib) treatment, as possible early predictors of response
and outcome with targeted therapy.
Patients and methods: 18F-FDG- and H2
15O-PET were performed at base-
line and 3 weeks after starting treatment. The percentage change in tumour
metabolic activity (SUV) and blood flow (BF) were calculated. Metabolic
response (25% decrease in SUV) and perfusion response (20% decreased
in BF) after 3 weeks and RECIST after 6 weeks of treatment were correlated
with progression-free survival (PFS) and overall survival (OS) using log-
rank statistics.
Results: Complete 18F-FDG- and H2
15O-PET sets were available for 35 and
12 patients respectively. At week 3 the mean decrease in SUV was 26%
(31.4%), p0.0001. Median PFS was longer in metabolic responders (5.5
months) compared to metabolic non-responders (3.0 months), p0.037.
There was no difference in median OS. The mean percentage change in BF
was38% (60), p0.17. BF response was not associated with PFS or OS.
RECIST responders at week 6 tended towards a longer median PFS com-
pared to non-responders (14.2 versus 4.3 months, p0.052). There was no
difference in OS.
Conclusion: After only 3 weeks of treatment tumour metabolic response was
predictive for PFS in patients with NSCLC receiving sorafenib and erlotinib.
RECIST at week 6 showed only a trend. 18F-FDG-PET may, thus, allow
earlier response evaluation than RECIST. Blood flow, measured by H2
15O-
PET, was not predictive for outcome.
Disclosure: All authors have declared no conflicts of interest.
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DYNAMIC CONTRAST-ENHANCED CT IN PATIENTS
TREATED WITH SORAFENIB AND ERLOTINIB FOR
NON-SMALL CELL LUNG CANCER: A NEW METHOD TO
MONITOR TREATMENT?
J.S.W. Lind1, M.R. Meijerink2, A.C. Dingemans3, C. van Kuijk2, M. Ollers4,
D. De Ruysscher5, P.E. Postmus6, E.F. Smit7 1Pulmonary Diseases, VUMC,
Amsterdam/NETHERLANDS, 2Radiology, VUMC, Amsterdam/NETHERLANDS,
3Respiratory Medicine, Maastricht University Medical Center, Maastricht/
NETHERLANDS, 4Radiotherapy, Maastro Clinic, Maastricht/NETHERLANDS,
5Department of Radiation Oncology (Maastro Clinic), Maastricht University
Medical Center  GROW Research Institute, Maastricht/NETHERLANDS,
6Pulmonary Diseases 4a50, VU University Medical Center, Amsterdam/
NETHERLANDS, 7Pulmonary Diseases, VU University Medical Center, Am-
sterdam/NETHERLANDS
Purpose: We investigated the feasibility of serial dynamic contrast-enhanced
computed tomography (DCE-CT) in patients with advanced/metastatic non-
small cell lung cancer (NSCLC) receiving anti-angiogenic (sorafenib) and
anti-epidermal growth factor receptor (erlotinib) treatment, and correlated
tumour blood flow (BF) with treatment outcome.
Methods: DCE-CTs were performed at baseline and 3 and 6 weeks after
starting treatment. Tumour BF, calculated with the maximum-slope method,
and percentage change were measured in 23 patients (14 males; median age
59 years). Tumour BF at baseline and weeks 3 and 6 were compared using
the Wilcoxon signed-rank test; relation with RECIST and Crabb responses
was assessed using the Mann-Whitney test and associations with progres-
sion-free survival (PFS) using log-rank statistics.
Results: Mean tumour perfusion decreased from 39.2  29.9 ml/100g/min
at baseline to 15.1  16.5 ml/100g/min at week 3 (p0.001) and 9.4  15.4
ml/100g/min at week 6 (p0.001). Tumour perfusion was lower in respond-
ers versus non-responders at week 3 (4.2  7.8 versus 17.7  13.4
ml/100g/min, p0.03) and week 6 (0  0 versus 13.4  16.9 ml/100g/min,
p0.04). This was also found when incorporating tumour cavitation into
response assessment. Patients with a decrease larger than the median of 91%
at week 6 tended towards a longer PFS than those with a smaller decrease
(7.1 versus 5.7 months, p0.06).
Conclusion: Serial DCE-CTs are feasible in patients with NSCLC and
demonstrated a significant decrease in tumour BF following sorafenib and
erlotinib therapy. Moreover, early changes in tumour BF correlated with
objective response and showed a trend with PFS.
Disclosure: All authors have declared no conflicts of interest.
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EARLY PREDICTIVE VALUE POST CHEMOTHERAPY OF
METABOLIC RESPONSE ASSESSMENT USING
FLUORDEOXYGLUCOSE POSITRON EMISSION
TOMOGRAPHY (FDG-PET) IN NON SMALL CELL
LUNG CANCER
T. Meniawy, A. Davidson Medical Oncology, Royal Perth Hospital, Perth/
AUSTRALIA
Background: Recently there has been interest in the prognostic value of
baseline FDG PET SUV measured in primary tumours as well as the
predictive value of response assessment using PET metabolic response
criteria (PRESIST criteria). The last published review was in 2006.
Objectives: To assess the predictive value on survival of changes in
standardised uptake value (SUV) measured on fluordeoxyglucose positron
emission tomography (FDG-PET) before and after treatment of non-small
cell lung cancer, at either cycle 1 or 2 SEARCH.
Methods: We searched MEDLINE (January 1966 to September 2009) and
EMBASE (January 1985 to September 2009). In addition, reference lists
were hand searched for any other relevant trials.
Selection criteria: Randomised and non-randomised studies evaluating
metabolic response using at least two FDG-PET studies performed at
baseline and after one or two cycles of chemotherapy for non small cell lung
cancer, and reporting survival data for metabolic responders compared to
non-responders. Trials published after 2000 only were chosen to reduce the
effect of technological changes over time on the results.
Data collection and analysis: Two authors independently assessed trial
quality and extracted data. We performed a meta-analysis of the difference in
median overall survival between metabolic responders and non-responders as
defined by the cut-offs for metabolic response in individual studies. A
subgroup analysis of patients treated with radical or palliative interventions
was also performed
Results: Nine studies involving 426 patients were included. Six studies
involved 305 patients treated with radical radiotherapy or surgical resection,
whereas three studies involved 121 patients predominantly treated with
palliative chemotherapy. There was some heterogeneity between studies with
regards to patient characteristics, treatments received and criteria for PET
metabolic response assessments. Meta-analysis of included studies demon-
strated that metabolic responders had a median overall survival that was
significantly longer than non-responders by 13.34 months (95% CI 6.12,
20.56). Subgroup analysis also demonstrated a median overall survival that
was 19.05 months longer in metabolic responders than in non-responders
(95% CI 6.81, 31.38) in patients treated radically, and 5 months longer (95%
CI 1.82, 8.17) in metabolic responders treated with palliative intent.
Authors’ conclusions: Metabolic response assessment using changes in
standardised uptake value measured on FDG-PET are predictive of
treatment response and long-term survival in non-small lung cancer. The
shown differences in survival would suggest that early identification of
response to treatment would have clinical implications for early trial
design and personalised patient treatment management . Limitations of
data and analyses include small patient numbers, heterogeneity in PET
raw data analyses, metabolic response criteria and therapeutic interven-
tions leading to many caveats on the validity of the results. There is
individual trial specific limitations on statistical power to establish the
predictive value of PET response as an independent marker when other
variables such as age, stage, performance status and histology are
considered. We aim to conduct a systematic review and meta-analysis of
individual patient data to allow multivariate analyses and subgroup
analyses across studies. (note there is also the forrest plot of the
meta-analysis).
Disclosure: All authors have declared no conflicts of interest.
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THE IMPACT OF STAGE MIGRATION ON SURVIVAL IN
THE UICC 7 TNM-CLASSIFICATION OF LUNG CANCER
J.P. van Meerbeeck1, K. Chansky2, P. Goldstraw3 1Department of Respira-
tory Medicine, University Hospital, Ghent/BELGIUM, 2Cancer Research
and Biostatistics, Cancer Research and Biostatistics, Seattle/USA, 3Depart-
ment of Thoracic Surgery, Royal Brompton Hospital, London/UNITED
KINGDOM
Background: Change of staging classification has been associated with
improvements in stage specific survival without improvement of overall
survival (Feinstein, 1985). Aim: to estimate in patients with non-small cell
lung cancer (NSCLC), included in the IASLC staging database (Goldstraw,
2006) 1. the magnitude and direction of stage migration between the 6th and
Journal of Thoracic Oncology • Volume 5, Number 5, Supplement 1, May 2010 Abstracts
Copyright © 2010 by the European Lung Cancer Conference S63
7th edition of the UICC-TNM classification, and 2. its impact on stage
specific outcome.
Methods: Untreated NSCLC cases were extracted from the IASLC database
and classified according to the 6th and 7th edition of UICC-cTNM. Cases with
prior lung cancer were excluded from the set; only substages A and B for
stage III were detailed. Migration was estimated by calculating the rate of
patients classified in any higher or lower UICC-7 c-stage over the corre-
sponding UICC 6 c-stage. Outcome was estimated by the Kaplan-Meier
method and expressed as median survival rate (mSR) with lower and upper
95% confidence intervals (95% CI).
Results: stage distribution of 11,536 cases, classified according to UICC 6
and 7, with corresponding overall and stage specific mSR are in the table. 5
year survival rate is 21% (20-22). Overall, 1068 cases (9%) migrate, of
whom 899 (8%) to a higher and 177 (%) to a lower stage. There are no
substantial changes in mSR.
Conclusion: in this data set of untreated NSCLC cases, the change of TNM
staging classification from UICC6 to 7 results in a net migration of out of
cases, to a higher stage in most of them. The impact on outcome is however
not substantial, making a Will Rogers phenomenon unlikely.
Disclosure: All authors have declared no conflicts of interest.
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THE PROGNOSTIC SIGNIFICANCE OF FDG-PET IN
PATIENTS WITH ADVANCED NON-SMALL CELL
LUNG CANCER
S.H. Bae1, H.M. Ryoo2 1Oncology/Hematology, Daegu Catholic University
Hospital, Daegu/KOREA, 2Internal Medicine, Daegu Catholic University
Medical Center, Daegu/KOREA
Background/Aims: Positron emission tomography with [18F] fluorodeoxy-
glucose (FDG-PET) shows various levels of FDG uptake in patients with
non-small cell lung cancer (NSCLC). This study was conducted whether the
maximal standardized uptake value (SUVmax) of the primary tumor by PET
at the time of diagnosis has prognostic significance in patients with advanced
NSCLC.
Methods: A retrospective review identified 59 patients with pathologically
proven stage IIIB and IV NSCLC who underwent FDG-PET at the time of
diagnosis. All patients received systemic chemotherapy. The Cox propor-
tional hazards model was used with SUVmax and clinical data including age,
performance status, histologic cell type, hemoglobin, and number of meta-
static sites.
Results: The median overall survival of all patients was 18.3 months
(95% CI 16.0-20.6). The median survival of the 16 patients with the
primary tumor having an SUVmax  7 was not reached, whereas the
median survival of the 43 patients with the primary tumor having an
SUVmax  7 was 16.6 months (95% CI 8.7-23.6). In the univariate and
multivariated analysis, performance status and SUVmax were significant
predictors of overall survival. These finding were replicated in progres-
sion free survival.
Conclusions: The amount of FDG uptake of the primary lesions in patients
with advanced non-small cell lung cancer have a significant relation with
survival.
Disclosure: All authors have declared no conflicts of interest.
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PROGNOSTIC POTENTIAL OF F-FLURODEOXYGLUCOSE
UPTAKE IN NON-SMALL CELL LUNG CANCER PATIENTS
TREATED WITH RADICAL RADIOTHERAPY OR
CONCOMITANT CHEMO-RADIOTHERAPY
M.Y. Lin1, M. Wu1, S. Brennan1, M.P. Campeau1, D. Binns2, M. Mac
Manus1, B. Solomon3, R. Hicks2, D. Ball1 1Radiation Oncology, Peter
MacCallum Cancer Centre, East Melbourne/AUSTRALIA, 2PET Centre,
Peter MacCallum Cancer Centre, East Melbourne/AUSTRALIA, 3Medical
Oncology, Peter MacCallum Cancer Centre, East Melbourne/AUSTRALIA
Purpose: The aim of this retrospective study is to investigate the potential of
Standarized Uptake Values (SUVs) derived from F-2-deoxy-D glucose
(FDG) Positron Emission Tomography (PET) or PET/CT (computed tomog-
raphy) scans, to predict outcome in patients with non-small cell lung cancer
(NSCLC) treated with radical radiotherapy (RT) alone or concurrent chemo-
radiotherapy (CCRT).
Methods: Patients were eligible if they: had histological or cytological
evidence of NSCLC; were treated with radical RT or CCRT as their primary
treatment between January 2000 and December 2006; had pre-treatment
staging PET/ PET-CT scans; had no recent history of other malignancies; had
no prior treatment for NCSLC. Other known or potential prognostic factors
including UICC stage group, tumor histology and differentiation, smoking
status, performance status, recent weight loss and simplified co morbidity
score (SCS) were recorded. The maximum SUV (SUVmax) was defined as
the maximum pixel SUV value retrieved from the primary tumor. SUV max
was analyzed as a dichotomous variable for survival using a selected cut
point of 9.
Results: 121 NSCLC patients met the eligibility criteria for the study,
including 39 stage I patients, 13 stage II, 65 stage III, and 4 stage IV. The
mean SUVmax in stage I patients was significantly lower than that in
stage II to IV patients (11.8 versus 17.2, p0.002). In univariate analysis,
with a median follow-up of 48.7 months (range 21.8 to 79.1 months),
progression-free survival (PFS) was 32.5 months for patients with SUV-
max less or equal to 9 and 11.3 months for patients with SUVmax more
than 9 (p0.023). Disease-specific survival (DSS) was 50.2 months if
SUVmax was less or equal to 9 and 24.3 months if SUVmax was more
than 9 (p0.028).
Conclusion: In this cohort of patients, higher levels of FDG uptake were
associated with worse outcomes, but also with more advanced stage. Further
studies are required to determine if SUV is an independent prognostic factor
for survival in patients treated by non-surgical means.
Disclosure: All authors have declared no conflicts of interest.
UICC 6 UICC 7
Net
Migration
Total 11,536 (100%) 1068 (9%)
m SR 13.9 (13.5–14.3) m 0 m
c I 2673 (23%) 2115 (18%) —
m SR 43.5 (40.9–47.9) m 49.9 (45.2–55.2) m 6.4 m
c II 2176 (19%) 2731 (24%) 57 (5%)
m SR 18.3 (17.4–19.8) m 19.6 (18.2–21.0) m 1.3 m
c IIIA 3005 (26%) 3175 (28%) 170 (1%)
m SR 14.1 (13.3–15.0) m 14.3 (13.5–15.2.) m 0.2 m
c IIIB 1224 (11%) 758 (7%) 10 (1%)
m SR 9.8 (9.1–10.6) m 9.7 (8.6–10.4) m 0.1 m
c IV 2458 (21%) 2757 (24%) 318 (3%)
m SR 5.8 (5.6–6.0) m 6. (5.7–6.2) m 0.2 m
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USE OF PET/CT FOR RADIATION THERAPY PLANNING
IN LOCALLY ADVANCED LUNG CANCER: DEFINITION
OF GTV AND DOSIMETRIC ANALYSIS
B. Meduri1, G.N. Mantini2, F. De Rose1, M.N. Balducci2, V.N. Frascino2,
N.N. Dinapoli3, M.L. Calcagni4, G.N. Corbo5, T.N. Pirronti6, V.N. Valen-
tini4 1Radiotherapy, Polyclinic, Rome/ITALY, 2Radiotherapy, Polyclinic A
Gemelli, Rome/ITALY, 3Radiotherapy, Polyclinic Gemelli, Rome/ITALY,
4Radiology, Polyclinic, Rome/ITALY, 5Pneumology, Polyclinic Gemelli,
Rome/ITALY, 6Radiology, Polyclinic Gemelli, Rome/ITALY
Purpose: FDG-PET/CT is more accurate than CT alone in determining the
extent of non-small-cell lung cancer (NSCLC); this study was performed to
evaluate the impact of functional imaging on radiation therapy (RT) Gross
Tumor Volume (GTV) definition in patients with Stage III NSCLC.
Methods: Each patient underwent sequential CT and PET/CT simulation
using the same immobilization devices. Both the CT and PET/CT image data
sets were transferred to the RT treatment planning workstation for contour-
ing. For each patient, two conformal treatment plans were made: one with a
CT-based GTV (GTV-CT) and one with a PET/CT based GTV (GTV-PET).
A qualitative visual method for contouring GTV-PET was used. Dosimetric
factors and volumes of each plan were analyzed and compared. For each
patient, both GTV-CT and GTV-PET were contoured independently by a
second observer.
Results: Fifteen patients with Stage III NSCLC were studied. A clinically
significant (20%) treatment volume modification was observed between
GTV-CT and GTV-PET in 7/15 (46%) cases. Four cases resulted in a
reduction in GTV-PET volume vs GTV-CT because PET/CT was more
accurate in distinguishing tumor from atelectasis. MLD (mean lung dose),
lung V20 (the percentage of lung volume receiving 20 Gy) and lung V30
decreased in favour of PET-CT (p0.5). Three cases showed an increase in
GTV-PET volume vs GTV-CT because of an unsuspected nodal disease
detected by PET. The increase in target volumes led to a respective increase
in MLD, lung V20, lung V30. The interobserver GTV variability decreased
from a mean volume difference of 1810 cc when evaluating CT-based
treatment plans to 42 cc when the evaluation was made on PET/CT-based
treatment plans (p0.001).
Conclusion: In this group of clinical stage III NSCLC patients, fused
PET/CT and CT images in RT planning reduced the radiation exposure of
lung because it resulted in a more accurate distinction of tumor from
atelectasis or reduced risk of geographic misses detecting unsuspected nodal
disease; moreover, the use of PET/CT, reducing interobserver variability,
improved homogeneity in GTV delineation. The results of this study con-
firmed that PET/CT planning increased therapeutic ratio in RT.
Disclosure: All authors have declared no conflicts of interest.
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COMPARISON OF INSPIRATION AND EXPIRATION
BREATH-HOLD FOR NSCLC IMRT
M.Q. Hatton, B. Tahir, C. Bragg, S. Lawless, R. Ireland Department of
Clinical Oncology, Weston Park Hospital, Sheffield Teaching Hospitals NHS
Foundation Trust, Sheffield/UNITED KINGDOM
Background: To compare target coverage and lung tissue sparing between
inspiration and expiration breath-hold intensity modulated radiotherapy
(IMRT) plans for patients with non-small cell lung cancer (NSCLC).
Methods and materials: In a prospective study, seven NSCLC patients gave
written consent to undergo both a controlled 1L inspiration and an end
expiration breath-hold computed tomography (CT), which were used to
generate 5-field IMRT plans. Dose was calculated with a scatter and
inhomogeneity correction algorithm. The percentage of planning target
volume (PTV) receiving 90% of the prescription dose (PTV90), the volume
of total lung receiving  10 Gy (V10) and  20 Gy (V20) and the mean lung
dose (MLD) were compared by the Student’s paired t test.
Results: Compared with the expiration plans, the meanSD reductions for
V10, V20 and MLD on the inspiration plans were 4.03.7% (p0.031),
2.52.3% (p0.028) and 1.10.7 Gy (p0.007), respectively. Conversely,
a mean difference of 1.11.1% (p0.044) in PTV90 was demonstrated in
favour of expiration.
Conclusions: When using IMRT, inspiration breath-hold can reduce the dose to
normal lung tissue while expiration breath-hold can improve the target coverage.
The improved lung sparing at inspiration may outweigh the modest improve-
ments in target coverage at expiration. Acknowledgments Supported by a
Postdoctoral Award from the UK National Institute of Health Research, Weston
Park Cancer Charity and Sheffield Hospitals Charitable Trust.
Disclosure: All authors have declared no conflicts of interest.
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EXPERIENCE IMPROVES TRAINEE YIELD IN THE
FIBREOPTIC BRONCHOSCOPIC (FB) DIAGNOSIS OF
PRIMARY LUNG CANCER
M.M. Wilczynska, J. Bennett, B. Sutton Respiratory Medicine, Glenfield
Hospital, Leicester/UNITED KINGDOM
Introduction: FB remains a significant tool in the diagnosis of primary
lung cancer. Our audit from 2006 demonstrated a significant difference in
bronchoscopic yield between consultants and trainees. This study aimed
to reassess the same group of operators’ yield two years later.
Methods: All FBs requested via the lung cancer MDT in 2008 were investi-
gated. Collected data included: operator grade, macroscopic appearance and
diagnostic yield. The CHI-SQUARE distribution was used for data analysis.
Results: 149 FBs were requested via the lung cancer MDT. 130 patients
were diagnosed with primary lung cancer of whom 97 had a cancer
diagnosis confirmed pathologically from FB biopsies whilst the remain-
ing 33 required further investigations for pathological verification. All
FBs were preceded by staging Computed Tomography (CT) scan. There
were 26 different FB operators (most of whom were the same operators
as in 2006) with consultants performing 57% of FB (n75). Over all hit
rate for consultants and trainees was 71%. There was no significant
variation in positive diagnostic yield between consultants and trainees
(p0.694) (table 1). Macroscopically abnormal mucosa was reported in
85 FB with 80% positive yield (n68) compared to a 77% yield in 2006.
Hit rate for macroscopically visible tumour was not significantly different
(p0.44) between consultants and trainees.
Conclusions: Closer consultants’ supervision during bronchoscopy sessions
as well as experience gained during further 24 months in specialty training
improved trainees’ skills in obtaining positive samples via FB for primary
lung cancer. Given the changes in specialist training and the European
Working Time Directive, rigorous training in procedures is required and we
Fibreoptic
Bronchoscopy Consultants Trainees Total P value
2006
Positive 59 48 146 0.009
Negative 12 27
2008
Positive 55 42 130 0.694
Negative 20 13
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believe that it would be advisable to develop new guidelines for respiratory
medicine trainees in the form of mandatory logbooks to demonstrate an
appropriate level of ability.
Disclosure: All authors have declared no conflicts of interest.
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THE IMPORTANCE OF TRANSBRONCHIAL BIOPSY
CONTROLLED BY ROENTGEN-SCOPE IN THE
DIAGNOSIS OF LUNG CANCER
V. Radosavljevic, M. Obradovic, V. Milovanovic Pulmology, KBC “Beza-
nijska Kosa”, Belgrade/SERBIA AND MONTENEGRO
The aim of the study was to examine importance of transbronchial biopsy
controlled by roentgen (RO) scope in the diagnosis of lung cancer. About
30% of lung cancer presents with central localisation, and the rest (about
70%) with peripheral. A lot of skill is needed to take a good quality biopsy
tissue for pathological exam from periphery of the lung.
Material and method: Patients with suspected radiological finding of
peripheral lesions were divided in two groups. In both groups CT scan was
also performed. The first group included 30 patients in whom blind trans-
bronchial biopsy was performed, based on experience and CT localisation.
The second group also included 30 patients but in whom transbronchial
biopsy was performed and controlled by roentgen-scope.
Result: In the 1st group there were 5 (16.6%) patients with positive
pathohistological findings (3 patients with adenocarcinoma and 2 with
planocellularl carcinoma). In the 2nd group there were 12 (40%) patients
with positive pathohistological findings (7 patients with adenocarcinoma and
5 with planocellular carcinoma).
Conclusion: Our result suggests that transbronchial biopsy leaded by RO
scope has an important advantage compared to the blind method. However
higher percentage of positive pathohistological findings is needed. Our study
showed that transbronchial biopsy leaded by RO scope is a good diagnostic
method of peripheral lung lesions.
Disclosure: All authors have declared no conflicts of interest.
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THE CLINICAL VALUE OF MEDIASTINOSCOPY IN
PREOPERATIVE STAGING OF NON-SMALL CELL
LUNG CANCER
D. Kim1, H. Seok Jin2, P. Hyochae2 1Thoracic and Cardiovascular Surgery,
Eulji University Hospital, Daejeon/KOREA, 2Thoracic and Cardiovascular
Surgery, Kangnam Severance Hospital, Seoul/KOREA
Objective: Mediastinoscopy is generally performed to confirm mediastinal
lymph node metastasis and to find optimal neoadjuvant therapy candidate in lung
cancer patients. It still remains controversial whether mediastinoscopy should be
performed in all patients with resectable non-small cell lung cancer (NSCLC).
We studied the clinical value of mediastinoscopy in preoperative staging in
NSCLC.
Methods: We retrospectively studied 111 NSCLC patients who underwent
radiological evaluation and mediastinoscopy followed by surgical resection
from March 2002 to December 2004. Sensitivity, specificity, and accuracy of
each evaluation method were assessed and compared.
Results: Sensitivity, specificity, and accuracy of radiologic evaluation and
mediastinoscopy and were 62.9%, 75.8%, 64.9% and 54.3%,100%, 76.6%
respectivley. Specificity and accuracy was superior to those of radiological
evaluation (p0.01, p0.015), but absolute sensitivity of radiological eval-
uation is higher rather than mediastinoscopy although there was no signifi-
cant difference in sensitivity (p0.58). Especially, the sensitivity of medi-
astinoscopy was 23.1% in 38 patients with radiological N0/1 disease and
72.7% in 73 patients with radiological N2/3 disease.
Conclusion: Considering its invasiveness, the difficulty to reach certain node
stations, and its low sensitivity in radiological N0/1 disease, mediastinoscopy
should be selectively performed in radiological N2/3 disease rather than in all
radiological cancer stages.
Disclosure: All authors have declared no conflicts of interest.
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THE FEASIBILITY OF MEDICAL THORACOSCOPY FOR
THE DIFFERENTIAL DIAGNOSIS OF MALIGNANT
EFFUSION IN THE TUBERCULOSIS ENDEMIC COUNTRY
D. Kim, J.J. Hwang, K. Kim 1Thoracic and Cardiovascular Surgery, Eulji
University Hospital, Daejeon/KOREA
Objective: The high sensitive and accurate diagnosis is necessary to prevent
misconceiving malignant effusion as tuberculosis pleurisy in the tuberculosis
endemic country. The thoracoscopic pleural biopsy is thought ideal diagnostic
tool, but it did not gain general concept because the procedure is necessary
general anesthesia. Medical thoracoscopy has as high sensitivity as conventional
throacoscopy, and performed under local anesthesia. We thought medical tho-
racoscopy was ideal diagnostic tool for differential diagnosis of malignant
effusion in the tuberculosis endemic country.
Methods: 248 patients transferred to evaluate undetermined pleural effusion.
216 patients underwent medical thoracoscopy, cytology, and chest CT except 32
patients refused medical thoracoscopy. We analyzed safety of medical thoracoscopy
and compared sensitivity, specificity, and accuracy among three diagnostic tools.
Results: There was no mortality, and nor morbidity. Only two cases were
impossible to perform medical thoracoscopy due to severe dyspena. The final
diagnosis is malignant effusion 30.1% (n65), tuberculosis pleurisy 28.3%
(n61), parapneumonic effusion 40.7% (n88), and others 0.9% (n2).
The sensitivity of cytology, radiologic evaluation, and medical thoracoscopy
were 22.6%, 78.5%, 93.8% respectively, and the specificity were 99.3%,
91.4%, 100% respectively, and the accuracy were 75.9%, 87.5 %, 98.4%
respectively. Especially, Sensitivity and accuracy of medical thoracoscopy
are significantly higher than cytology and radiologic evaluation (p0.05).
Conclusion: The medical thoracoscopy is safe and feasible as a routine
diagnostic tool of undetermined pleural effusion. And the sensitivity and
specificity is superior to other diagnostic tools, especially it is useful to
differential diagnosis between malignant effusion and tuberculosis pleurisy.
Disclosure: All authors have declared no conflicts of interest.
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PREVALENCE, CORRELATIONS, AND PROGNOSTIC
SIGNIFICANCE OF THE PRESENCE OF MICROSCOPIC
VASCULAR INVASION FOLLOWING COMPLETE
RESECTION OF STAGE I NON-SMALL CELL LUNG
CARCINOMA. AN UNDERESTIMATED FACTOR?
E. Ruffini1, P.L. Filosso1, S. Asioli2, L. Buffoni3, A. Oliaro1 1Thoracic
Surgery, University of Torino, Torino/ITALY, 2Pathology, University of
Torino, Torino/ITALY, 3Clinical Oncology, S. Giovanni Battista Hospital,
Torino/ITALY
Objective: The significance of microscopic invasion of blood vessels (Mi-
croscopic Vascular Invasion, MVI) in patients with non-small cell lung
carcinoma (NSCLC) remains controversial. The aim of this study was to
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evaluate prevalence, correlations and the prognostic significance of MVI in
patients following complete resection of Stage I NSCLC.
Methods: From 1/1998 to 10/2008 1521 patients received resection for NSCLC
at our Institution, of whom 737 were at pathological Stage I after surgery. There
were 323 adenocarcinomas (ADK) (44%), 322 squamous cell carcinomas (SCC)
(44%), 53 bronchioloalveolar carcinomas (BAC) (7%), 29 large cell anaplastic
carcinomas (LCC) (4%). Histologic grading was: 114 G1 (15%), 279 G2 (38%)
and 344 G3 (47%). Mean tumour dimension was 36 mm. MVI was ascertained
using routine histopathological workup. Immunohistochemical staining with
antibody anti-CD34 was done to evaluate blood vessels on a selective basis.
Prevalence differences, logistic regression and survival analysis were used for
analysis.
Results: MVI was observed in 228 patients (31%). Prevalence was signifi-
cantly higher in ADK (131/323, 41%) than in SCC (80/322, 25%, p0.002).
A significant correlation was found between the presence of MVI and ADK
(OR 0.8, 95% CI 0.7-0.9) and increased tumour dimension (OR 1.1, 95% CI
1.01-1.24). Univariate survival analysis indicates that the presence of MVI
was associated with a significantly reduced 5-year survival overall (65% vs.
52%, p0.0003) and in ADK (68% vs. 54%, p0.0002) but not in SCC
(58% vs. 49%, p0.25). In a multivariate survival analysis, the presence of
MVI was a significant indicator of poor survival overall (HR 1.61, 95% CI
1.30–2.15) and in ADK (HR 2.02, 95% CI 1.36–3-02).
Conclusions: The finding of MVI in completely resected Stage I NSCLC is
not infrequent. MVI is strongly correlated with adenocarcinoma histotype and
increased tumour dimensions. The presence of MVI is an independent negative
prognostic factor, which is particularly significant in adenocarcinomas. The use
of adjuvant chemotherapy might be taken into consideration in these patients.
Disclosure: All authors have declared no conflicts of interest.
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MOLECULAR EXPRESSION OF ANGIOGENIC MARKERS
IN EARLY-STAGE NSCLC: EVALUATION OF THE
PROGNOSTIC ROLE
E. Jantus1, A. Cabrera2, R. Sirera3, M. Uso´4, S. Gallach5, A. Blasco6, A.
Berrocal7, M. Taron8, R. Rosell9, C. Camps10 1Molecular Oncology Labo-
ratory, Fundacion para la Investigacion del Hospital General Universitario
de Valencia, Valencia/SPAIN, 2Molecular Oncology Laboratory, Fundacion
para la Investigacio´n del Hospital General Universitario de Valencia,
Valencia/SPAIN, 3Molecular Oncology Laboratory, University General Hos-
pital, Valencia/SPAIN, 4Molecular Oncology Laboratory, Fundacio´n para la
investigacio´n del Hospital General de Valencia, Valencia/SPAIN, 5Molecu-
lar Oncology Laboratory, Fundacio´n para la Investigacio´n del Hospital
General Universitario de Valencia, Valencia/SPAIN, 6Medical Oncology,
Cosorcio Hospital General Universitario de Valencia, Valencia/SPAIN,
7Oncology Service, University General Hospital, Valencia/SPAIN, 8Medical
Oncology Service, Institut Catala d’Oncologia, Badalona, Barcelona/
SPAIN, 9Medical Oncology Service, Catalan Institute of Oncology, Bada-
lona/SPAIN, 10Oncology Service, Hospital General Universitario de Valen-
cia, Valencia/SPAIN
Background: NSCLC is a major cause of cancer related death worldwide.
While treatment with conventional chemotherapy has improved during the
last decade, 5 year survival is still modest. It is known that angiogenesis is
an essential event for solid tumour growth and angiogenic factors, such as
different ligands and receptors of vascular endothelial growth factor (VEGF),
seem to play a key role. Our objective was to evaluate the mRNA expression
of the family of VEGFs and VEGFRs and correlate them with disease
outcome in resectable NSCLC patients.
Methods: We performed quantitative analysis (RTqPCR) to assess the expres-
sion of VEGF-A, -B, -C, -D, PlGF, VEGFR-1, 2 and 3 in 135 frozen lung
cancer specimens from untreated NSCLC patients who had undergone surgical
resection. RNA was extracted using Trizol® and RTqPCR was performed using
TaqMan® probes. Relative quantification was evaluated using GUS-B (endog-
enous control gene) for normalization. We correlate the expression of the
angiogenic genes with clinico-pathological and survival variables. All statistical
analysis were considered significant at p0.05.
Results: We found an overexpression of PlGF in tumor vs normal tissues,
being higher in squamous cell carcinomas (SCC). There was no correlation
between VEGF-A, VEGFR-1 and VEGFR-2 with the histology or tumor
stage in our cohort. A strong positive correlation between the expression of
VEGF-A and VEGFR-1 in tumour samples (p0.000, Spearman’s test) was
found. Using the median as a cut-off value for VEGF-A and VEGFR-1, cases
were splited as high (H) or low (L) accordingly. 71.5% of patients (108/151)
have concordant results in both variables. Kaplan Meier plots show that the
group of patients expressing higher levels of VEGF-A and VEGFR-1 (HH)
had a worse prognosis (OS: p0.066, PFS: p0.098, log-rank test) than the
other groups (HL or LL).
Conclusion: In NSCLC tumour samples, PlGF is overexpressed, specially is
SCC. In addition, determination of VEGF-A and VEGFR-1 genes by
RTqPCR would be a useful clinical test to assess prognosis in NSCLC, due
to the fact that higher levels of expression of both genes correlates with
shorter OS. Supported by ISCIII grant.
Disclosure: All authors have declared no conflicts of interest.
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LUNG VOLUME REDUCTION SURGERY IN PATIENTS
WITH LUNG CARCINOMA
M. Tutic1, D. Lardinois2, P. Kestenholz1, D. Schneiter1, I. Opitz1, K. Bloch3,
E.W. Russi3, W. Weder1 1Thoracic Surgery, University Hospital Zurich,
Zurich/SWITZERLAND, 2Thoracic Surgery, University Hospital Basel,
Basel/SWITZERLAND, 3Pulmonology, University Hospital Zurich, Zurich/
SWITZERLAND
Introduction: The majority of patients with non-small cell lung cancer
(NSCLC) are lifelong heavy smokers, a considerable part of them are
functionally impaired by COPD. Complete surgical resection offers the best
chances to cure patients with early-stage NSCLC and anatomic lobectomy
with mediastinal lymph-node dissection is still considered the operation of
choice. The aim of this study is to report the experience of a single center in
patients with heavily impaired lung function due to COPD undergoing
simultaneously lung cancer surgery and LVRS and to assess postoperative
course, lung function and survival.
Methods: 33 patients (12 females), mean age (SE): 68  1,8, with
marginal lung function due to advanced emphysema ( mean FEV1: 34% 
2,1) underwent resection of preoperatively detected lesions, which were
suspicious and later proven for malignancy.
Results: Tumorresection and including Lung Volume Reduction Surgery
(LVRS) was performed in 8, unilateral LVRS in 13, anatomical segmentec-
tomy in 5, lobectomy in 5 and bilobectomy in 2 patients. The histology
revealed an adenocarcinoma in 18 patients, a squamous cell carcinoma in 7,
a large cell carcinoma in 4, a neuroendocrine tumor in 3 and a well-
differentiated chondrosarcoma in 1 patient. The tumorstaging showed 19
patients with Stage IA, 7 with IB, 2 with II A and 1 with III A- Stage. The
postoperative FEV1 improved up to 38%  2,3 (21-66%) at 3 months. In
hospital mortality was 6 % (one due to intracerebral bleeding and one due to
multiorgan failure). The 5 years survival was 60%.
Conclusion: Lung cancer surgery in selected high-risk patients with very
severe emphysema and impaired lung function is feasible and safe in an
experienced center. The in hospital mortality is low, the postoperative lung
function may be improved and the 5- years survival is acceptable.
Disclosure: All authors have declared no conflicts of interest.
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STEREOTACTIC BODY RADIOTHERAPY VERSUS
SURGERY FOR STAGE I NSCLC: A MARKOV MODEL
BASED DECISION ANALYSIS
G. Rodrigues1, A.V. Louie1, M. Hannouf2, G. Zaric2, D. Palma1, J. Mocanu3
1Radiation Oncology, London Regional Cancer Program, London/CANADA,
2Epidemiology, University of Western Ontario, London/CANADA, 3Business,
University of Western Ontario, London/CANADA
Purpose: To compare the quality-adjusted life expectancy and overall
survival in patients with stage I NSCLC treated with either stereotactic body
radiation (SBRT) or surgery.
Methods and materials: We constructed a Markov model to describe health
states after either SBRT or lobectomy for stage I non-small cell lung cancer
(NSCLC) for a 5-year timeframe. Rates of recurrence and Markov state
utilities, consistent with the four stages of the AJCC staging system, were
extracted and adapted from the literature. We report various treatment
strategy survival outcomes stratified by age, sex, and pack-year history of
smoking and compared these to an external outcome prediction tool (Adju-
vant! Online).
Results: Overall survival, cancer specific survival, and other causes of death
as predicted by our model correlated closely with those predicted by the
external prediction tool. Mean quality-adjusted life expectancy after surgery
ranged from 3.47 to 4.00 years and 3.45 to 3.97 years for SBRT for our base
cases. The SBRT associated utility threshold for preferring SBRT over
surgery assuming 80% of patients who fail locally and/or regionally received
standard salvage treatment ranged from 0.948 to 0.966 for our base cases.
Outcomes were sensitive to the utility of initial treatment, the proportion of
local and regional recurrences that were treated with standard versus pallia-
tive treatments, and the surgical and SBRT treatment related mortality.
Conclusions: The role of SBRT in the medically operable patient is yet to be
defined. Our model indicates that SBRT may offer comparable survival and
QALYs as compared to surgical resection. Well powered prospective studies
comparing surgery versus SBRT in early lung cancer are warranted to further
confirm the relative survival, quality of life and cost characteristics of both
treatment paradigms in a multiinstitutional setting.
Disclosure: All authors have declared no conflicts of interest.
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RADIOLOGICAL AND CLINICAL PNEUMONITIS AFTER
STEREOTACTIC LUNG RADIOTHERAPY: A MATCHED
COMPARISON OF 3D-CONFORMAL AND VOLUMETRIC
MODULATED ARC THERAPY TECHNIQUES
D. Palma1, S. Senan1, C.J.A. Haasbeek1, W. Verbakel1, A. Vincent2, F.J.
Lagerwaard1 1Radiation Oncology, VU University Medical Center, Amster-
dam/NETHERLANDS, 2Department of Biometrics, Netherlands Cancer In-
stitute, Amsterdam/NETHERLANDS
Purpose: Lung fibrosis is common after stereotactic body radiotherapy
(SBRT) for lung tumors, but the influence of treatment technique on rates of
clinical and radiological pneumonitis is not well-described. After implement-
ing volumetric modulated arc therapy (RapidArcTM [RA], Varian Medical
Systems) for SBRT, we compared the early pulmonary changes seen with arc
vs. conventional 3-dimensional SBRT (3D-CRT).
Methods: Twenty-five SBRT patients treated with RA were matched 1:2
with fifty SBRT patients treated with 3D-CRT. Dose-fractionations were
based on a risk-adapted strategy. Clinical pneumonitis was scored using
Common Terminology Criteria for Adverse Events, version 3.0. Acute
radiological changes three months post-treatment were scored by three
blinded observers. Relationships between treatment type, baseline factors,
and outcomes were assessed using Spearman’s correlation, Cochran-Mantel-
Haenszel tests, and logistic regression.
Results: The RA and 3D-CRT groups were well-matched. 43 patients (57%)
had radiological pneumonitis 3 months after treatment. 28 patients (37%) had
CT findings of patchy or diffuse consolidation, and 15 patients (20%) had
ground glass opacities only. Clinical pneumonitis was uncommon, with no
differences seen between 3D-CRT vs. RA in rates of grade 2/3 clinical
pneumonitis (6% vs. 4%, respectively; p0.99), moderate/severe radiolog-
ical changes (24% vs. 36%, respectively, p0.28), or patterns of CT changes
(p0.47). Radiological severity scores were associated with larger planning
target volumes (p0.09) and extended fractionation (p0.03).
Conclusions: Radiological changes after lung SBRT are common. However,
no differences in clinical or radiological findings were observed 3 months
after RA. Data with longer follow-up is awaited to exclude late changes.
Disclosure: D. Palma: Dr. Palma’s research is supported by the Canadian
Assoc. of Radiation Oncologists-Elekta Fellowship, the Ontario Institute for
Cancer Research, and the Detweiler Fellowship. The VUMC has a research
collaboration with Varian Medical Systems. All other authors have declared
no conflicts of interest.
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TREATMENT UTILIZATION AND SURVIVAL FOR
ELDERLY PATIENTS WITH STAGE I NSCLC:
A POPULATION-BASED TIME-TREND ANALYSIS
D. Palma1, O. Visser2, F.J. Lagerwaard3, S. Senan4 1Radiation Oncology,
VU University Medical Centre, Amsterdam/NETHERLANDS, 2Cancer Reg-
istry, Comprehensive Cancer Centre, Amsterdam/NETHERLANDS, 3Radia-
tion Oncology, VU University Medical Center, Amsterdam/NETHERLANDS,
4Department of Radiation Oncology, VU University Medical Centre, Am-
sterdam/NETHERLANDS
Background: Treatment options for elderly patients with stage I NSCLC
have changed dramatically in the past decade, mostly due to the introduction
of stereotactic body radiotherapy (SBRT). Treatment patterns and overall
survival (OS) in elderly patients (age 75) with stage I NSCLC were studied
in a comprehensive population-based registry in North Holland (http://
www.ikcnet.nl/IKA).
Methods: Population-based data was assessed for three eras: 1999-2001 (period
A, pre-SBRT); 2002-04 (period B, some availability of SBRT) and 2005-07
(period C, full access to SBRT). Chi-square, Kaplan-Meier and Cox Regression
were used to compare treatment patterns and OS between these periods.
Results: 842 elderly patients were diagnosed with stage I NSCLC in the
study period. Primary treatment was surgery in 299 (36%), radiotherapy (RT)
in 264 (31%) and neither in 279 (33%). The proportion of patients under-
going RT increased significantly (26% in period A vs. 36% in period C;
p0.01), which corresponded to a decrease in patients receiving no treat-
ment. Median survival for all patients increased from 16 months in periods
A and B to 21 months in period C. On multivariate analysis, factors
predictive of improved OS were T1 disease (vs. T2, HR 0.55 95% CI
0.45-0.67), pathological confirmation of disease (vs. clinical diagnosis, HR
0.31; 95% CI 0.21-0.46), and treatment in period C (vs. period A, HR 0.68
95% CI 0.56-0.83). This improvement in OS was confined to patients treated
with RT (HR 0.67 95% CI 0.47-0.97), but not observed in patients who
received surgery or no treatment.
Conclusion: In this population-based study, a 10% increase in RT utilization
in elderly patients was associated with improved OS in the SBRT era.
However, improvements in OS were not observed in patients aged 75 who
either underwent surgery or were untreated.
Disclosure: D. Palma: Dr. Palma’s research is supported by the Canadian Assoc.
of Radiation Oncologists-Elekta Fellowship, the Ontario Institute for Cancer
Research, and the Detweiler Fellowship. The VUMC has a research collabora-
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EXTENDING THE BENEFIT OF STEREOTACTIC BODY
RT (SBRT) TO STAGE II/III NSCLC: A TREATMENT
PLANNING STUDY
E. Damen1, A. Holt1, A. Lakeman1, J. Belderbos2, J. Sonke1 1Radiation
Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek
Hospital, Amsterdam/NETHERLANDS, 2Radiotherapy, The Netherlands
Cancer Institute, Amsterdam/NETHERLANDS
Purpose: SBRT for stage I NSCLC results in local control rates of 
90%.
Conventional (chemo-)radiation for stage II/III NSCLC results in high local
recurrence rates, mainly at the site of the primary tumor. In this planning
study we assessed the feasibility of extending the advantage of SBRT to
stage II/III NSCLC by combining SBRT to the peripheral tumor with
conventional fractionated RT to the pathologic lymph nodes.
Material: Nine patients were selected with stage II/III disease and primary
tumors 5 cm in diameter located 2 cm from the main bronchial tree. The
clinical plan consisted of an IMRT treatment plan delivering 24 	 2.75 Gy
to the primary tumor and pathologic lymph nodes. A hybrid stereotactic/
conventional plan was created delivering 3 	 18 Gy to the primary tumor
and 24 	 2.75 Gy to pathologic lymph nodes. Dose to organs at risk (OAR)
was converted to equivalent dose in fractions of 2 Gy (EQD2) using the LQ
model with /  3 Gy (lung, esophagus, heart, and mediastinal structures
(MS)) and 2 Gy (spinal cord), respectively. Planning constraints for OAR
were: mean lung dose (MLD) 20 Gy, maximum dose (Dmax) to the spinal
cord  50 Gy, volume of esophagus receiving 35 Gy or more (V35)  65%,
mean heart dose (MHD)  46 Gy, and Dmax of the MS  94 Gy. In
addition, V20 and V5 for lung were recorded.
Results: Clinically acceptable hybrid plans could be created for eight out of
nine patients. Average changes in dose values for the OAR are listed in the
table. There was no significant change in dose values for spinal cord,
esophagus, heart, and MS when comparing the hybrid plan with the clinical
plan. For lung, a significant decrease in V20 and V5 was seen for the hybrid
plans, but the MLD showed a significant increase.
Conclusion: The novel hybrid stereotactic/conventional technique for stage
II/III NSCLC is feasible with no increased risk to the OAR. We will
introduce this hybrid technique in a phase II clinical trial in which the dose
delivered to the primary tumor will be escalated gradually.
Disclosure: All authors have declared no conflicts of interest.
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A FOUR-GENE SIGNATURE THAT PREDICTS OUTCOME
IN NON SMALL CELL LUNG CANCER PATIENTS
P. Cejas1, C. Belda-Iniesta2, J.J. Sanchez3, R. Machado-Pinilla4, V. Rodrı´-
guez-Fanjul4, I. Iban˜ez de Ca´ceres5, J. Feliu1, M. Nistal6, R. Perona5, J. De
Castro7 1Department of Medical Oncology, IdiPAZ, La Paz University
Hospital. Madrid, Spain. IdiPAZ, Madrid/SPAIN, 2Medical Oncology, Idi-
PAZ, La Paz University Hospital, Madrid/SPAIN, 3Statistics, Autonomous
University of Madrid, Madrid/SPAIN, 4Traslational Oncology Unit, Instituto
de Investigaciones Biome´dicas “Alberto Sols”, Madrid/SPAIN, 5Transla-
tional Oncology Unit, IdiPAZ, La Paz University Hospital. Madrid, Spain.
IdiPAZ, Madrid/SPAIN, 6Department of Pathology, IdiPAZ, La Paz Univer-
sity Hospital. Madrid, Spain. IdiPAZ, Madrid/SPAIN, 7Servicio de Oncolo-
gı´a Me´dica, Hospital Universitario La Paz, Madrid/SPAIN
Background: Cisplatin based adjuvant chemotherapy improves survival among
patients with completely resected non small-cell lung cancer. However, objec-
tive response rates are in the range of 30% to 50% Thus, prediction of treatment
response and outcome before CRT is a major challenge for clinicians.
Methods: In a first stage we perfomed a SAGE analysis on snap-frozen surgical
specimens from three good responder and three bad responder patients. Re-
sponse sensibility to cisplatin was evaluated using cytotoxicity assays in primary
cultures of tumor cells from the surgical specimens. In a second stage we
analyzed the expression of 22 genes and 2 controls using TaqMan low density
arrays in snap-frozen surgical specimens from 51 operable stages non small cell
lung cancer patients. Disease free survival was used as the endpoint of the study.
All patients received Cisplatin based adjuvant chemotherapy. Multivariate Cox
methods were applied to build an optimized predictor of outcome.
Findings: The combination of mTOR, TWIST1, AKCR1C2 and HSPB1
gene expression was able to predict clinical outcome in pretreated tissues. In
addition, DFS analysis revealed that the gene signature-based score was the
only statistically significant prognostic factor remaining in the multivariate
analysis. Interpretation A basal 4-gene signature, obtained from surgical
specimens of non small cell lung cancer, efficiently predicted clinical
outcome in the patients. These preliminary results are very encouraging and,
if they are validated in larger series, could have clinical implications.
Disclosure: All authors have declared no conflicts of interest.
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IMPACT OF ADJUVANT CHEMOTHERAPY IN STAGE IB
NON-SMALL CELL LUNG CANCER. AN ANALYSIS OF 112
CONSECUTIVELY TREATED PATIENTS
M. Dediu, O. Ion, R. Ion, A. Alexandru, D. Median, C. Gal, M. Gongu
Medical Oncology, Institute of Oncology, Bucharest/ROMANIA
The impact of adjuvant chemotherapy (CT) in the management of radically
resected stage IB non-small cell lung cancer (NSCLC) is highly debated. The
aim of the study was to evaluate the outcome of this category of patients treated
at our institution. We retrospectively analyzed the survival data of patients with
pathologically staged IB NSCLC, who received at least 1 adjuvant CT cycle. CT
was planned to be platinum-based and to be delivered for 6 cycles. During
1997–2007 a number of 135 consecutively resected patients were classified as
stage IB. Twenty three patients were excluded from the analysis: 3 patients were
deemed ineligible for adjuvant CT, 11 underwent tumor resection less than
lobectomy/pneumectomy, and 9 patients had no mediastinal lymph nodes
evaluated by the pathologist. The characteristics of the remaining 112 patients
were as following: 83% male , 27% female , median age 60, lobectomy was
performed in 87% of patients and pneumectomy in 13%. Median tumor dimen-
Average Difference 
SD (Hybrid – Clinical)
p-Value
(Paired t-Test)
Lung
MLD (Gy) 2.0  3 0.04
V20 (%) 2.6  3 0.02
V5 (%) 5.8  5 0.01
Spinal cord
Dmax (Gy) 4.3  12 n.s.
Esophagus
V35 (%) 0.9  3 n.s.
Heart
MHD (Gy) 1.3  4 n.s.
MS
Dmax (Gy) 1.7  6 n.s.
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sion was 4 cm, and visceral pleural involvement was present in 58% of cases.
Disease free (DSF) and overall survival (OS) rates after a median follow up
period of 46 months are presented in table.
The median number of CT cycles was 6 ( range 3-6), with 79% of patients
receiving  4 cycles. The median cisplatin (CDDP) dose intensity (DI) was
22 mg/m2/week and the actually delivered vs. the predicted DI ratio was
0.85%. Median total CDDP dose/patient was 412 mg. A number of 28 (25%)
relapses were recorded, of which 14% were local and 86% distant. In a
multivariate analysis we found no significant interaction between OS and the
following variables: gender, type of surgery, histology, tumor volume,
visceral pleural involvement, number of lymph nodes evaluated. Our results
compare favorable with the historical data evaluating the outcome of stage IB
patients treated by surgery alone in a customary medical setting. Overall, our
data support the use of adjuvant CT in stage IB NSCLC patients.
Disclosure: All authors have declared no conflicts of interest.
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OVER-EXPRESSION OF THE MAMMALIAN TARGET OF
RAPAMYCIN (MTOR): A NOVEL BIOMARKER FOR
POOR SURVIVAL IN RESECTED EARLY STAGE
NON-SMALL CELL LUNG CANCER
T. Dhillon1, M. Seckl1, F. Mauri2, G. Belleza3, B. North4, L. Cagini5, M.
Barbareschi6 1Oncology, Imperial College London, London/UNITED
KINGDOM, 2Pathology, Imperial College London, London/UNITED
KINGDOM, 3Pathology, University of Perugia, Perugia/ITALY, 4Statistics,
Imperial College London, London/UNITED KINGDOM, 5Thoracic Surgery,
University of Perugia, Perugia/ITALY, 6Molecular Pathology, S Chiara
Hospital, Trento/ITALY
Introduction: The best hope of cure for patients with non-small cell lung
cancer (NSCLC) is surgical resection. However, even in stage IA patients
30% die within 5 years. Further improvements in survival require a biomar-
ker(s) which defines the subset of these patients destined to do badly so that
they could be targeted for additional therapies. Here, we investigate whether
the immunohistochemical expression of a key kinase implicated in lung
cancer biology, the mammalian target of rapamycin (mTOR) can predict
survival outcome in early stage resected NSCLC patients.
Materials and methods: 134 patients with resected early stage (IA-IIB)
NSCLC were pathologically reviewed centrally prior to staining for mTOR.
Multiple variables including age, sex, stage, angio-invasion, lymph node
status and mTOR staining were assessed by univariate and multivariate
analyses.
Results: Stage (p  0.044), lymph node status (p  0.049), angio-invasion
(p 0.017) and mTOR staining (p  0.007) were significant univariate
predictors of poor survival. However, only angio-invasion (p 0.016) and
mTOR staining (p  0.046) remained significant following multivariate
analysis. Moreover, mTOR staining was the only variable to predict poor
outcome in patients who had either negative lymph-nodes (p 0.016) or
were stage IA (p  0.0016).
Conclusions: mTOR staining provides a new biomarker for poor outcome in
early stage NSCLC and could enable resected stage IA patients to be selected
for novel therapies possibly with an mTOR inhibitor.
Disclosure: All authors have declared no conflicts of interest.
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SINGLE NUCLEOTIDE POLYMORPHISMS OF ATM AND
P53 AND ITS ASSOCIATION WITH RADIATION-INDUCED
PNEUMONITIS
K. Iqbal Oncology, Nuclear Medicine, Oncologyand Radiotherapy Institute,
Islamabad/PAKISTAN
Introduction: To explore the possible relationship between single nucleotide
polymorphisms (SNPs) in candidate genes encoding DNA repair, apoptosis,
and inflammatory cytokines with radiation-induced pneumonitis (RP) in
patients with lung cancer.
Patients and methods: One hundred and twenty-seven non-small cell lung
cancer patients and forty-three small cell lung cancer patients who were
inoperable and underwent thoracic radiotherapy at Cancer Hospital of Peking
Union Medical College (PUMC) and Chinese Academy of Medical Sciences
between January 2004 and August 2006, were evaluated. All of them
consented for blood sampling, SNP analysis and follow up. The primary
endpoint was  grade 2 radiation pneumonitis. We analyzed 37 SNPs in 20
DNA repair, apoptosis and inflammatory Cytokines genes, including ATM,
TP53, ERCC1, XRCC1, XRCC3, XPD, XPC, XPG, NBS1, STK15,
ZNF350, ADPRT, FAS, FASL, CYP2D6*4, CASP8, COX-2, TGF-1,
CD14 and ACE genes, using PCR-based restricted fragment length poly-
morphism (RFLP).
Results: One hundred and seventy patients with a median follow-up of 22
months were evaluated. Twenty-nine patients (17.1%) experienced  grade
2 pneumonitis and the median occurrence time was 59 days from the first day
of irradiation. ATM –111GA and –111AA genotypes were independently
associated with the risk of RP (Hazards ratio (HR)  3.27, 95% confidence
interval (CI)  1.09-9.78, P  .034) and TP53 72Arg/Pro and 72Pro/Pro
genotypes had a trend to decrease the risk of RP (HR  0.43, 95% CI 
0.17-1.12, P  .084). The presence of two risk genotypes (ATM –111A
allele combined with TP53 72Arg/Arg genotype) showed an independent
role for high risk for RP with HR of 4.75 (95% CI  1.33-17.04, P  .017).
Conclusion: Genetic polymorphisms in ATM gene and TP53 gene contrib-
ute to the risk of radiation-induced pneumonitis. These could be used as
putative predictive biomarkers for radiotherapy in the future.
Disclosure: The author has declared no conflicts of interest.
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RADIOLOGICAL PATTERNS IN PATIENTS WITH
OPERABLE NON-SMALL CELL LUNG CANCER (NSCLC)
IN MID-WESTERN IRELAND
K.I. Quintyne1, N. O’Leary2, F. Wallis3, P. Hession3, R.K. Gupta1 1Medical
Oncology, Mid-Western Regional Hospital, Limerick/IRELAND, 2Mid-west-
ern Cancer Centre, Mid-Western Regional Hospital, Limerick/IRELAND,
3Radiology, Mid-Western Regional Hospital, Limerick/IRELAND
Introduction: Non-small cell lung cancer (NSCLC) accounts for approxi-
mately 80% of all lung cancers. Within this group of patients with lung
cancer, almost 20% are suitable to undergo a definitive surgical procedure.
The ultimate outcome for these patients is usually associated to size of the
primary tumour, degree of nodal involvement and clear resection margins.
As such, we herein report our findings for patients with operable NSCLC
with respect to their related radiological patterns and outcomes.
Methods: Study period: 01/01/03 – 31/12/05. Data was derived from (1)
Mid-Western Cancer Centre (MWCC) Oncology Database (2) MWRH
pathology and radiology records (3) individual case records.
Results: 35 patients were found, M: F (23:12). Mean age was 66.2 years (SD
– 10.3 years). The mode for ECOG performance status (PS) at presentation
to was 1. The majority of patients presented at Stage IIIA, with 15/35 (43%).
Months 12 24 36 48 60
DFS (%) 94 84 71 69 68
OS (%) 97 90 88 80 77
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The mean survival based on pre-op stage revealed that IA, IB, IIA, IIB, and
IIIA was 52.5, 30.5, 65, 8.5, and 20 months respectively. The mean survival
by T-status is below.
Conclusions: Male preponderance was noted, with most patients having a
good ECOG PS to tolerate therapy.The higher the stage at onset, the poorer
the overall survival.The smaller the T-status and the lower the N-status, the
better the mean overall survival, these were both significant statistically.
These results underscore the need to review patients as early in the course of
their disease as possible, to ensure the best overall survival, and hence are
potentially highlighting the potential need for screening programs.
Disclosure: All authors have declared no conflicts of interest.
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SURVIVAL OF CONSERVATIVELY TREATED PATIENTS
WITH SECOND STAGE NON-SMALL CELL LUNG
CANCER IN COMPARISON WITH THE SURGICALLY
TREATED
G. Popovic1, D. Bursac1, N. Secen2, A. Tepavac1, D. Sazdanic Velikic1, B.
Zaric2, B. Perin2 1Department for Lung Cancer Treatment, Institute for
Pulmonary Diseases of Vojvodina, Sremska Kamenica/SERBIA AND MON-
TENEGRO, 2Department for Interventional Pulmonology, Institute for Pul-
monary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad,
Sremska Kamenica/SERBIA AND MONTENEGRO
Background: Surgery is the treatment of first choice for patients with stage
II of non-small lung cancer (NSCLC), however some patients with comor-
bidities are subject to conservative therapy. The aim was to determine effects
of conservative treatment in patients with NSCLC.
Methods: Seventy patients with NSCLC who have been treated in the
Institute for pulmonary diseases of Vojvodina from January 2004 to Decem-
ber 2006 were enrolled into the study. All of the patients have pathohisto-
logical or cytological confirmation and had TNM stage II of NSCLC. There
were 30 surgically treated patients in first group and 40 patients in second
group who were treated conservatively with chemotherapy or radiation
therapy due to comorbidities. Patients were scheduled to receive 4 cycles of
standard regimen with cisplatin (60mg/ m2, day 1) and etoposide (100mg/m2,
days 1–3) and thoracic radiation therapy in dose of 40Gy.
Results: Sixty-four (91,4%) patients were male and 6 (8,6%) female. Median
age was 60,1 years. Squamous cell carcinoma was pathohistologically or
cytologically confirmed in 44 (62,8%) patients, adenocarcinoma in 25
(35,7%) and macrocellular carcinoma in 1 (1,5%). Our results have shown
median survival of 17 months in conservatively treated patients compared
with 21,5 months in surgically treated patients (p0,0665). One-year sur-
vival in conservatively treated patients was 72,5% in comparison with 76,6%
in surgically treated. Two-years survival in first group was 10% and in
second group 43,3%. The median time to progression in conservative treated
patients were 12,7 months and in surgically treated 15,4 months.
Conclusions: Patients with TNM stage II NSCLC who cannot be surgically
treated should undergone conservative treatment with the modest results in
comparison with surgical treatment.
Disclosure: All authors have declared no conflicts of interest.
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PREDICTED POSTOPERATIVE PRODUCT AND
DIFFUSION INDEX IN PREOPERATIVE EVALUATION
J. Wang Medicine Department, Taipei Medical University, Taipei City/
TAIWAN
Objectives: The purpose of this retrospective study is to evaluate whether
abnormal predicted postoperative (ppo) variables and predicted postoperative
product (PPP) are useful in predicting postoperative complications and
whether an abnormal diffusion index (DI) is associated with increased
postoperative complications.
Methods: Calculations of the ppo variables were performed using preoper-
ative testing data and the extent of the resected bronchopulmonary segments.
PPP was obtained by multiplying ppo FEV1 % predicted by ppo DLCO %
predicted and measured product (MP) was obtained by multiplying FEV1 by
DLCO. DI, was derived from measurements of the single-breath DLCO
using the 3-equation method as a measure of the heterogeneity of the
distribution of gas exchange in the lung.
Results: Patients with complications had lower ppo FEV1, lower ppo DLCO,
lower ppo maximal oxygen uptake (VO2max/kg), and lower ppo mean increase
in DLCO% predicted at 70% workload from resting DLCO% predicted ((70%-
R)DLCO%). Patients with complications also had lower PPP, and lower MP.
Interestingly, DI deteriorated with exercise in patients with complications but DI
improved with exercise in patients without complications.
Conclusions: All variables including ppo variables, PPP, MP, and DI were
potentially useful predictors for preoperative evaluation in lung resection
pending further confirmation in larger studies.
Disclosure: The authot has declared no conflicts of interest.
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CORRELATION OF IMAGING AND HISTOPATHOLOGY
IN COLD SPOTS ON FDG PET SCANS OF NON
SMALL-CELL LUNG CANCER (NSCLC) PATIENTS
C. Siedschlag1, J. Belderbos2, J. Sonke3, J. Stroom1, K. Gilhuijs1, L.N.
Boersma4, J. van Loon4, A. van Baardwijk5, R. van Suylen6, M. Rossi3
1Radiotherapy, Dutch Cancer Institute, Amsterdam/NETHERLANDS, 2Ra-
diotherapy, The Netherlands Cancer Institute, Amsterdam/NETHERLANDS,
3Radiation Oncology, The Netherlands Cancer Institute / Antoni van Leeu-
wenhoek Hospital, Amsterdam/NETHERLANDS, 4Radiotherapy, Maastro
Clinic, Maastricht/NETHERLANDS, 5Radiotherapy, MAASTRO Clinic,
Maastricht/NETHERLANDS, 6Pathology, Maastricht University Clinic,
Maastricht/NETHERLANDS
Introduction: Recent technical advances like intensity modulated radiother-
apy (IMRT) enables us to adapt the radiation dose to anatomical and
functional image information in lung tumors. The possibility to use FDG-
PET uptake information raises the question how to deal with tumor inho-
mogeneities pre-irradiation. This question is particularly relevant in the light
of ongoing efforts to optimize local control while limiting normal-tissue
toxicity. The aim of this preliminary study was to correlate cold spots visible
on FDG-PET imaging of NSCLC with histopathology.
T Status T1 T2 T3 T4
Mean Survival (Months) 65.1 44.3 48.8 69.2
(Significant at p value  0.05) The mean survival by N-status is below.
N Status N0 N1 N2
Mean Survival (Months) 55.1 40.6 37.1
(Significant at p value  0.05)
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Materials and methods: Sixty-one patients with operable non-small cell
lung cancer scheduled for a lobectomy underwent FDG-PET within six
weeks before surgery. The PET voxel size was 4x4x4 mm3. The scans
were visually inspected for cold spots within the tumor. After surgery, the
excised lung lobes were cut into slices of 0.5 cm thickness. The tumor-
bearing slices were microscopically analyzed; vital and necrotic tumor
tissue was delineated, as well as inflammatory tissue. The annotated
pathology slices were registered to the pre-operative PET/CT data.
Results: In seven out of 61 patients (11.5%) cold spots within the tumor on
the FDG-PET scans were present. In five of these patients, necrosis was
present at microscopic examinationin corresponding locations. The surgical
specimens of the two patients with cold spots on FDG-PET but no necrosis
at microscopy showed extensive inflammatory tissue around the tumor-
bearing tissue.
Conclusions: The results of this preliminary study indicate that necrosis may
be the most common cause for cold spots on FDG-PET scan in NSCLC
patients. Another cause might be relatively high FDG uptake in nearby
inflammatory tissue. When validated in larger cohorts of patients, these
findings may justify reduced radiation dose in tumor regions with relatively
low FDG uptake in order to optimize local control while limiting normal-
tissue toxicity.
Disclosure: All authors have declared no conflicts of interest.
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PREDICTIVE VALUE OF PATIENT CHARACTERISTICS
AND PULMONARY SYMPTOMS FOR RADIATION
INDUCED LUNG TOXICITY
G. Borst1, M. Rossi1, E. Damen1, W. Heemsbergen1, S. Burgers2, J. Belder-
bos3 1Radiation Oncology, Antoni van Leeuwenhoek Hospital - Netherlands
Cancer Institute, Amsterdam/NETHERLANDS, 2Pulmonology, Netherlands
Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam/
NETHERLANDS, 3Antoni van Leeuwenhoekhuis - Netherlands Cancer In-
stitute, Amsterdam/NETHERLANDS
Purpose: Prediction of radiation induced lung toxicity (RILT) after radical
radiotherapy or chemo-radiation for lung cancer remains challenging. The
mean lung dose (MLD) is an important independent predictive factor for
RILT albeit a limited specificity. This limitation may be related to the
complexity and a limited patient specific sensitivity of diagnosing and
scoring RILT. We prospectively evaluated the predictive role of patient
characteristics and pulmonary symptoms before, during and after high dose
irradiation on the incidence of RILT. The scoring differences of pulmonary
symptoms between physicians and patients were also analyzed.
Patients and methods: 83 patients from a phase I/II dose escalation trial
were included. At baseline the patient’s medical history of COPD and heart
disease was recorded. Complaints of dyspnea and cough were scored by the
patients at baseline and at each visit during the follow-up using a validated
questionnaire and by the physician according to NCI-CTC criteria. RILT was
scored as radiation pneumonitis (RP) grade 2 according to NCI-CTC
criteria.
Results: According to the questionnaire, 95% of the patients with more than
one year follow-up (n41) experienced an increase of dyspnea and/or
coughing one year after irradiation. Of these patients 15% were scored by the
physician as having grade  2 RP. Neither the medical history (COPD
and/or heart disease), nor the scoring of dyspnea or coughing at baseline
were significantly (p0.05) predictive for the incidence of RILT whereas the
MLD (p0.05) was predictive. These results were independent of baseline
symptoms scored by the physician and by the patients. The correlations
between the scoring of the physician and the patients at baseline and
during follow up were not significant for coughing (p0.05) or dyspnea
(p0.05), respectively. At one year follow up, changes in dyspnea or
coughing scored by the physician and patient were not significantly
correlated.
Conclusion: Baseline clinical pulmonary symptoms and pulmonary/cardiac
morbidity are not predictive for the incidence of RILT. Scoring of RILT
remains challenging. The subjective symptoms of the patients need to be
objectified by the physician in diagnosing RILT.
Disclosure: All authors have declared no conflicts of interest.
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INDUCTION CHEMOTHERAPY (I-CT) WITH
VINORELBINE AND CISPLATIN FOLLOWED BY
CONCURRENT CHEMOTHERAPY (CT-RT) AND
DYNAMIC ACCELERATED HYPERFRACTIONATED
RADIOTHERAPY (DAHR) (ZAMORA-MITSOURA
REGIMEN) IN LOCALLY ADVANCED NON-SMALL CELL
LUNG CANCER (NSCLC)
J. Zamora-Moreno-Varaona1, D. Gallardo-Rincon1, E. Mitsoura2, M. Blake1,
G. Calderillo3, M. Schlienger4, F. Baillet5, O. Arrieta3 1Radiation Oncology,
Instituto Nacional de Cancerologia, Mexico City/MEXICO, 2Universidad
Autonoma Del Estado De Mexico, Instituto Nacional de Cancerologia,
Toluca, Mexico/MEXICO, 3Medical Oncology, Instituto Nacional de Can-
cerologia, Mexico City/MEXICO, 4Department of Radiotherapy Anf Physics,
Tenon Hospital APHP, Paris, France/FRANCE, 5Radiation Oncology, Ho-
pital Pitie´-Salpeˆtrie`re, Paris, France/FRANCE
Background: Combined CT-RT is the standard treatment for locally ad-
vanced (LA) NSCLC. Hyperfractionated schedules have been implemented
with success in early stage lung cancer, and reports of its use have been
increasing in the last decade. In developing countries, radiotherapy schedules
are saturated because of lack of linear accelerators, therefore it is necessary
to design alternative treatment schedules, based on radiobiological knowl-
edge, to reduce radiotherapy (RT) administration time without increasing
toxicity or compromising tumor control.
Methods: Twenty seven patients were treated with 2 cycles of I-CT with
vinorelbine 30 mg/m2 on days 1 and 8 and cisplatin at 80 mg/m2 on day 1,
every four weeks; followed by 2 additional cycles concurrently with DAHR
(Total Dose 35.5 Gy) during 2 weeks with same drug and dosage consoli-
dation chemotherapy (CT) in patients with LA NSCLC.
Results: Stages IIIA-N2 and IIIB were 33.3% (9/27) and 66.7% (18/27).
Median follow-up was 15.9 months (mo). One patient progressed during
I-CT. Overall response was observed in 37% (10/27) and 53.8% (14/26) of
patients following I-CT and after concurrent CT-RT, respectively. Local and
distant progressions were present in 33.3% and 44.4%, correspondingly.
Median progression-free survival (PFS) was 14 mo (95% Confidence Inter-
val [95% CI], 8.4-19.6) and overall survival (OS) was 19.4 mo (95% CI,
13.8-25). Patients who responded to I-CT had a longer OS, 15.2 (95% CI,
12.2-18.3) vs. 36.3 mo (95% CI, 16.5-56) (p 0.02). Grade III/IV global
toxicity was 44.4% and 25.9% after I-CT and CT-RT, respectively. Grade I
and II radiation pneumonitis was developed in 15.3% (4/26) and 7.6% (2/26),
no grade III/IV was encountered. Grade I, II and III Esophagitis was reported
in 15.3%, 7.6% and 11.5% (N26) of patients, respectively.
Conclusions: This multimodal treatment using CT-RT with DAHR in LA
NSCLC provides a short course of RT and confers satisfactory PFS and OS
with an acceptable toxicity profile. Prospective trials with this fractionation
are necessary to confirm these findings.
Disclosure: All authors have declared no conflicts of interest.
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PEMETREXED (PEM) AND CISPLATIN (CIS) IN
CONCURRENT COMBINATION WITH HIGH DOSE OF
THORACIC RADIATION (RT), AFTER INDUCTION
CHEMOTHERAPY (CT), IN PATIENTS (PTS) WITH
LOCALLY ADVANCED NON-SMALL CELL LUNG
CANCER (NSCLC): A PHASE I STUDY
F. Mornex1, J.M. Tourani2, V. Wautot1, N. Chouaki3, A. Thareau Vaury3, N.
Bourayou4, B. Coudert5 1Radiotherapy, Centre Hospitalier Lyon-Sud,
Pierre Be´nite, Lyon/FRANCE, 2Medical Oncology, CHRU La Miletrie,
Poitiers, Poitiers/FRANCE, 3Medical Oncology, Eli-Lilly Laboratories,
Suresnes/FRANCE, 4Medical Oncology, Eli Lilly Laboratories. France,
Suresnes/FRANCE, 5Medical Oncology, Centre Georges Franc¸ois Leclerc,
Dijon/France
Background: Concurrent RT-CT is the current standard of care of pts with
unresected stage III NSCLC. However, optimal CT regimen and schedule
remain undefined. Pem has an established role in treatment of metastatic
NSCLC and showed interesting data with variable RT doses and carboplatin
in multitumors phase I trial (Seiwert et al. 2007). This work reports on the
first Pem phase I trial targeting exclusively NSCLC pts and using Cis and
fixed-high dose of RT after induction CT. Primary objective was to deter-
mine the Maximum Tolerated Dose of Pem.
Patients and methods: Pts with unresected stage III NSCLC, planned
V2035% and FEV1.3 L, were treated every 21 days for 2 induction
cycles: Pem 500 mg/m2 plus Cis 75 mg/m2, followed by 2 cycles of
concurrent RT-CT: Pem at starting dose of 400 mg/m2 and then escalated to
800 mg/m2 per 100 mg/m2 dose level (DL), Cis at fixed dose of 75 mg/m2
and RT at 66 Gy/33 fractions over 7 weeks.
Results: Nine of 10 enrolled pts were entered on 3 DLs. Age range
[46-68], 6 males, ECOG PS 0: 6; PS 1: 4, stage IIIA: 1; IIIB: 9, 6
adenocarcinoma, 3 squamous cell carcinoma, 1 large cell carcinoma. One
pt received only induction CT due to disease progression. Dose escalation
of Pem was conducted up to 600 mg/m2 based on the independent safety
monitoring board recommendation and available clinical data showing no
dose-effect correlation beyond 500 mg/m2 (Cullen et al. 2008). One Dose
Limiting Toxicity (DLT) occurred at DL3: a grade (G) 4 septic shock. No
G3⁄4 radiation related toxicities. No toxic death.
Conclusion: This is the 1st phase I report of Pem dedicated exclusively to
NSCLC, with high dose RT. Pem at 500 mg/m2, concurrently given with Cis and
RT was well tolerated and appears to be the only 3rd generation agent that can
likely be recommended safely at full dose, in future trials with concurrent RT.
Disclosure: F. Mornex: Study Coordinator; N. Chouaki: Clinical Research
Physician, Eli-Lilly employee A. Thareau Vaury: Study Statistician, Eli-Lilly
employee; N. Bourayou: Clinical Research Physician, employee Eli-Lilly;
All other authors have declared no conflicts of interest.
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ACCELERATED OR HYPERFRACTIONATED
RADIOTHERAPY (RT) VERSUS CONVENTIONAL RT IN NON
METASTATIC LUNG CANCER (LC): INDIVIDUAL PATIENT
DATA (IPD) META-ANALYSIS FROM 2279 PATIENTS (PTS)
C. Le Pechoux1, A. Mauguen2, S.E. Schild3, M.I. Saunders4, A. Turrisi5, W.
Sause6, D. Ball7, C.P. Belani8, A. Zajusz9, J.P. Pignon10 1Department of
Radiotherapy, Institut Gustave Roussy, Villejuif/FRANCE, 2Service de Bio-
statistique et D’epide´miologie, Institut Gustave-Roussy, Villejuif/FRANCE,
3Department of Radiation Oncology, Mayo Clinic Arizona & NCCTG,
Phoenix/USA, 4Mount Vernon Hospital, Marie Curie Research Wing, North-
wood/UNITED KINGDOM, 5Radiation Oncology, Wayne State University,
Detroit/USA, 6Department of Radiation Oncology, Intermountain Medical
group, Salt Lake City/USA, 7Radiation Oncology, Peter MacCallum Cancer
Centre, East Melbourne/AUSTRALIA, 8Penn State Milton S. Hershey Med-
ical Center, Penn State Cancer Institute, Hershey/USA, 9Department of
Radiotherapy, Center of Oncology Maria Sklodowska-Curie Memorial In-
stitute Branch Gliwice, Gliwice/POLAND, 10Biostatistics and Epidemiology,
Institut Gustave-Roussy, Villejuif/FRANCE
Background: The role of and utility of modified RT fractionation for lung
cancer continues to evolve. Randomized trials assessing hyperfractionated or
accelerated RT offer conflicting results regarding its effect on progression-free
survival (PFS) or overall survival (OS). The MAR-LC (Meta-Analysis of Radio-
therapy in Lung Cancer) Collaborative Group was established to address this issue.
Methods: We performed an IPD meta-analysis in pts with non metastatic
LC, that included trials comparing modified RT (accelerated, hyperfraction-
ated or both) to a conventional RT (one 1.8- to 2-Gy fraction per day, 5 days
a week and a minimum total dose of 40 Gy for small cell LC (SCLC) and 60
Gy for non-small cell LC (NSCLC).
Results: Eleven trials were identified; two were excluded due to lost data and
one with factorial design was split into two trials (with and without chemo-
therapy). Ten trials were analyzed including 2279 pts. In NSCLC (8 trials,
1594 pts), modified fractionation improved OS as compared to conventional
RT (hazards ratio HR0.87, 95% confidence interval [0.79-0.97], p0.009),
resulting in an absolute benefit of 3% (8% to 11%) at 5 years. No hetero-
geneity between trials was found and no subgroup of pts benefited more or
less from modified RT. This benefit is not seen on PFS (HR0.94 [0.85-
1.04], p0.23). Even if not significant, modified RT may reduce non-lung
cancer deaths (HR0.79 [0.57-1.11], p0.18) as well as lung cancer deaths
(HR0.89 [0.80-0.99], p0.03). In SCLC (2 trials, 685 pts), similar survival
results were found although not significant (OS: HR0.87 [0.74-1.02],
p0.08; PFS: HR0.88 [0.75-1.03], p0.11). In both histological types, the
use of modified RT increased the risk of acute esophageal toxicity (HR2.11
in NSCLC and HR2.46 in SCLC; p0.001) but did not impact on the risk
of acute hematological, pulmonary or cardiac toxicity.
Conclusion: Patients with non metastatic lung cancer benefit from acceler-
ated or hyperfractionated RT, to a similar degree in NSCLC and SCLC. As
expected, there was an increased acute esophageal toxicity. Supported by
PHRC , LNCC, Sanofi-Aventis.
Disclosure: All authors have declared no conflicts of interest.
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A 4D SOFTWARE FOR BREATHING ADAPTED
RADIOTHERAPY (BART) OF LUNG CANCER
N. Peguret1, J. Vock2, P. Fenoglietto3, D. Azria4, V. Vinh-Hung1, R.
Miralbell1 1Service de Radio-Oncologie, Hoˆpitaux Universitaires de Gen-
e`ve, Gene`ve/SWITZERLAND, 2Service de Radio-oncologie, Hoˆpitaux uni-
versitaires de Gene`ve, Gene`ve/SWITZERLAND, 3Service de Radiothe´rapie,
CRLCC Val d’Aurelle Paul Lamarque, Montpellier/FRANCE, 4CRLC Val
D’aurelle, Montpellier/France
DL
Pem
mg/m2
Pts
Entered
in RT-
CT
Pts
Completed
RT Dose
Pts
Completed
4 Cycles
of CT
Related G3
Toxicities
(Nb of pts)
Related
G4
Toxicities
(Nb of pts)
400 3 2 2 1 Neutropenia
2 Lmphopenia
500 3 3 3 2 Lymphopenia
1 Nausea
1 Vomiting
600 3 3 2 2 Neutropenia
2 Leukopenia
1 Gastric pain
2 lymphopenia
1 Septic
shock
(DLT)
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Background: Pulmonary lesions are subject to respiratory motion. These
movements can be taken into account by respiratory gating, which enables
delivering radiotherapy (RT) in a particular breathing phase. However, the
moment to deliver RT with the best chance of cure without excess toxicity
is not known.
Aim: To develop a 4D image processing software in order to determine this
optimal phase in the respiratory cycle.
Patients and methods: Seven patients with lung cancer were studied. Each
patient underwent a 4DCT which provides ten datasets related to ten phases
of the respiratory cycle (0-100% of the cycle). We defined three morpho-
logical criteria for comparison of 4DCT images in different respiratory
phases: ratio (tumour volume/lung volume), distance between tumour and
spinal cord, distance between tumour and metastatic lymph nodes. Our 4D
image processing software automatizes the calculations (around 300 calcu-
lations per patient) of these criteria for each respiratory phase and presents
their visual comparison. This permits to determine the optimal moment for
RT based on the defined criteria.
Results: Lower lobe tumours not attached to the diaphragm (patient 1, 6, 7)
present an important respiratory motion. In these cases, our software iden-
tified a phase where the volume ratio is 17 to 33% smaller than in the
reference phase (maximal inspiration). For a mediastinal tumour localized
close to the spinal cord (patient 4), the analysis by comparing the distance
spinal cord-tumour detected a phase where the distance to the cord is
increased by 28%. Tumours adherent to the diaphragm or located centrally in
the mediastinum are less mobile and the differences in the comparison
criteria between the respiratory phases are less pronounced (patient 2, 3, 5).
Conclusion: Our software facilitates determination of an optimal moment
for respiratory gated RT based on morphological criteria. It is easy to apply
in daily routine. If these preliminary results are confirmed, our software
might transform the theoretical benefit of 4DCT and respiratory gating into
a real therapeutic gain for future patients.
Disclosure: All authors have declared no conflicts of interest.
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ACUTE ESOPHAGUS TOXICITY IN LUNG CANCER
PATIENTS TREATED WITH INTENSITY MODULATED
RADIOTHERAPY (IMRT)
M.H. Kwint1, W. Heemsbergen1, M. Wentink1, W. Uyterlinde2, J.
Knegjens1, B. Reichelt1, E. Damen1, S. Burgers2, M.M. van den Heuvel2, J.
Belderbos3 1Radiation Oncology, Netherlands Cancer Institute-Antoni van
Leeuwenhoek Hospital, Amsterdam/NETHERLANDS, 2Pulmonology, Neth-
erlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam/
NETHERLANDS, Amsterdam/NETHERLANDS, 3Radiotherapy, The Nether-
lands Cancer Institute, Amsterdam/NETHERLANDS
Background and purpose: The V35 (volume of the esophagus which
receives 35 Gy) is a dosimetric predictor of acute esophageal toxicity (AET)
in lung cancer patients treated with 3D-conformal-radiotherapy (3DCRT)
[1]. Purpose of this study was to investigate the dose-effect relation between
AET and dose-volume parameters in lung cancer patients treated with IMRT.
The incidence of AET with 3DCRT was compared with the incidence of
AET with IMRT.
Patients and methods: 36 patients were prospectively followed and ana-
lyzed. Radiotherapy with or without sequential chemotherapy (RTgroup)
was given to 21 patients and 15 patients received concurrent chemo radio-
therapy (CTRTgroup). Fractionation schemes were: 24x2.75Gy, 17x3Gy, or
25x2Gy. The esophagus constraint was V35 65% [1]. Maximum AET was
scored (CTC 4.0). Dose-volume histograms and dose-volume parameters V5
to V70, Dmean and Dmax of the esophagus were calculated. A logistic
regression analysis was used to analyze the dose-effect relation between the
different dose-volume parameters of the esophagus and AET  grade 2 en 
grade 3. This was done separately for the RTgroup and CTRTgroup.
Results In the RTgroup, 5 out of 21 patients developed AET  grade 2 of
which 1 patient had grade 3 AET. In the CTRTgroup 14 out of 15 patients
developed AET  grade 2 of which 9 patients had grade 3. The analysis
showed no significant dosimetric predictor for AET in the RTgroup. At
univariate analysis in CTRTgroup, most significant dosimetric predictor of
AET was the V60 (p0.032). The Dmean was borderline significant
(p0.055). The incidence of AET in the RTgroup didn’t change compared
to previous reported data with 3D-CRT. Within the CTRTgroup the inci-
dence of AET  grade 3 toxicity was 60%, compared to 27% in previously
published 3DCRT data [1].
Conclusion: The incidence of acute esophagus toxicity was increased in the
CTRTgroup treated with IMRT compared to previous 3DCRT data. The V60
was a significant dosimetric predictor of AET and the Dmean was borderline
significant. A larger group of patients will be analyzed in the near future.
1. J Belderbos et al. Acute esophageal toxicity in non-small cell lung cancer
patients after high dose conformal radiotherapy. Radiother Oncol 2005;
75:157–164.
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PNEUMONECTOMY FOR LUNG CANCER IN NON-
ACADEMIC COMMUNITY PRACTICE: QUALITY
RECOMMENDATIONS FROM A LARGE U.S.
METROPOLITAN AREA
M. Ninan Thoracic Surgery, University of Tennessee Health Science Center,
Memphis/USA
Introduction: Pneumonectomy (PN) for non small cell lung cancer
(NSCLC) has a mortality ranging from three to ten times that of lesser
anatomic resections and requires careful selection. Many central tumors
necessitate mediastinoscopy for accurate staging. Bronchoscopy by surgeon
is mandatory to assess airway tumor extension. Documentation of extent of
parenchymal, vascular , airway, mediastinal or nodal (PVAMN) tumor
invasion is important to establish clinical and medico-legal necessity for PN.
We studied these practices in a defined geographic area.
Methods: Retrospective review of all curative resections for NSCLC per-
formed from 2004 to 2007 in all non-academic hospitals in the Greater
Memphis Metropolitan Area (population 1 million), all were performed by
ten board certified cardiothoracic surgeons.
Results: Of 806 resections for cure, 84 (10.4%) were PN procedures, and 3
(0.4%) were sleeve resections. Of the PNs, 29 were in pathologic Stage I
NSCLC. A bronchoscopy performed by the surgeon was documented in 49
(58%) and a mediastinoscopy was performed in 25 (30%). The non-feasi-
bility of sleeve resections was documented in 3 (3.5%) of PN. The extent of
PVAMN invasion was documented in 33 patients (39%). Mediastinal nodal
samples were submitted in 52 (62%) of PN. The 30 day mortality for PN was
15.5% and the 3 Year Survival Estimate (Kaplan Meier) was 0.38
(SE0.06).
Conclusions: 1. Many patients undergoing PN for NSCLC have no bron-
choscopy documented by the operating surgeon in community practice in our
region. 2. Non-feasibility of rarely performed sleeve resections are often
undocumented. 3. Exact anatomic reasons for PN are documented only in a
minority of cases. 4. We have developed a checklist for community surgeons
to adhere while performing a PN Table 1 Documentation check-list for PN
1. Discussed in multi-disciplinary conference 2. Pulmonary function tests 3.
Bronchoscopy by surgeon 4. Mediastinoscopy 5. PVAMN extension 6. Why
sleeve resection not possible. 7. Mediastinal nodal stations dissected.
Disclosure: The author has declared no conflicts of interest.
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PET-CT DOES NOT IMPROVE THE OUTCOME OF LUNG
CANCER SURGERY
K.K.W. Lau1, J.E. Jacques1, M. Javed1, A. Nakas1, D. Waller2 1Department
of Thoracic Surgery, Glenfield Hospital, Leicester/UNITED KINGDOM,
2General Thoracic Surgery, Glenfield Hospital, Leicester/UNITED KINGDOM
Objective: To evaluate the impact of routine pre-op PET-CT staging on
incidence of resected N2 disease and subsequent outcome.
Methods: We compared patients in the 2 years prior to the introduction of
staging PET-CT (2003-4, ‘pre-PET’) with patients following the introduction
of routine PET-CT (2005-6, ‘PET’). We explored the impact of PET-CT on
resected N2 disease in a tertiary surgical referral unit.
Results: During the study period, 266 patients (156M : 110F, mean age 66
years) underwent anatomical lung cancer resection with systematic nodal
dissection in a single 3-surgeon institution (110 pre-PET vs. 156 PET with no
difference in patient demographic or pathological characteristics). The inci-
dence of resected N2 disease reduced significantly by 54% with the intro-
duction of routine PET-CT (20 (18%) vs 13 (8%), p0.015). The overall
median post-operative survival was similar between the two periods (38
months vs 34 months, p0.71). Median survival of the subgroup of patients
with resected N2 disease was also similar (34 months vs 20 months,
p0.90), even when adjusted for clinicopathological factors and adjuvant
treatment (HR 0.839, 95% CI 0.23 – 3.04, p0.79). The proportion of
resected N2 which was single-station disease was similar in both groups (17
(90%) vs 10 (77%), p0.37).
Conclusion: The introduction of routine PET-CT staging in potential surgi-
cal patients has significantly reduced the incidence of resected N2 disease.
However, this was not accompanied by an improvement in overall post-
operative survival, or in those with resected N2 disease. This may be
explained by the relatively low incidence of resected N2 disease and a similar
proportion of single-station N2 disease in both groups.
Disclosure: All authors have declared no conflicts of interest.
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CONCURRENT CHEMORADIATION TREATMENT FOR
INOPERABLE, NONMETASTASIC, UNFIT NON-SMALL
CELL LUNG CANCER (NSCLC) PATIENTS
F. Pons1, E.S. Nadal1, M. Plana1, R. Palmero1, J.M. Sole´2, I. Brao1, R.
Castany1, S. Padrones3, M.M. Arnaiz4, F. Cardenal1 1Medical Oncology
Department, Institut Catala` d’Oncologia, L’Hospitalet (Barcelona)/SPAIN,
2Radiotherapic Oncology Department, Institut Oncolo`gic del Valle`s, Sa-
badell (Barcelona)/SPAIN, 3Pneumology Department, Hospital de Bellvitge,
L’Hospitalet (Barcelona)/SPAIN, 4Radiotherapic Oncology Department, In-
stitut Catala` d’Oncologia, L’Hospitalet (Barcelona)/SPAIN
Background: There is no consensus treatment for inoperable, nonmetastatic
NSCLC patients (pts) too vulnerable for standard concurrent chemoradiation.
Concurrent carboplatin plus vinorelbine with thoracic radiotherapy (TRT)
has proved to be safer than the sequential treatment with the same drug
combination in a poor-risk patient population (Cardenal F; 2006, 31th ESMO
Congress). We present the results in the routine clinical setting of a simple
chemoradiation platform applied without the strict selection constraints of a
clinical trial.
Patients and methods: From August 2006 to November 2009, 64 pts were
treated with carboplatin AUC 2.5 plus vinorelbine 15mg/m2 days 1, 8, 22
and 28, concurrent with TRT: 70 Gy in 7 weeks with no elective lymph node
irradiation. All pts were staged with FDG-18 PET/TC scan and were
considered inoperable by a chest cancer board meeting. Pts were deemed
suitable for high dose standard radiation, but unfit for investigational or
routine chemoradiation protocols (based on SWOG 9019).
Results: Male/Female: 95%/5%, Median age 74 years (y) (range: 51-82).
Older than 75 y: 34%. ECOG PS 0-1/2 70%/30%; current/former/never
smokers 37.5%/60%/1.6%; squamous/undifferenciated/adenocarcinoma
69%/28%/3.1%; stage I-II/IIIA/IIIB: 14%/37%/48%. Median FEV1 1690 ml
(range: 920-3660). Forty-eight percent of pts had a simplified comorbidity
score (SCS), reported by Colinet 9. Seventy-three percent of pts received
the four doses of both drugs. The median radiation dose was 70 Gy (range:
0-78). One patient developed grade 3 pneumonitis. Three pts (4.7%) died
from respiratory failure (grade 5 pneumonitis the most likely diagnosis). Two
pts (3%) developed grade 3 esophagitis. With a median follow-up for living
pts of 10.6 months (mo), 36 pts have progressed and 23 pts have died.
Median progression-free survival was 10.2 mo (95% CI: 7.7–12.6) and
median survival was 20.2 mo (95% CI: 15.2–25.3).
Conclusions: This simple chemoradiation platform was safe and feasible in
routine clinical practice. Survival outcomes were rather longer than those
currently reported for poor-risk patient populations.
Disclosure: All authors have declared no conflicts of interest.
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RADIOPROTECTION OF LOCALLY ADVANCED
NON-SMALL CELL LUNG CANCER BY AMIFOSTINE –
HISTOPATHOLOGICAL FEATURES
J. Stejskal1, M. Kubecova´2, D. Dvor˘a´kova´1, V. Ulrych1, I. Kola´r˘ova´1, M.
Kheck3, J. Va´asek1 1Radiation Oncology, Regional Hospital Pardubice,
Pardubice/CZECH REPUBLIC, 2Radiation Oncology, University Hospital
Prague, Praha/CZECH REPUBLIC, 3Pathology, Regional Hospital Jihlava,
Jihlava/CZECH REPUBLIC
Purpose: Locally advanced non-small cell lung cancer (LA NSCLC) repre-
sents a disease with poor prognosis. Radiochemotherapy with dose escalation
is an effective treatment for LA NSCLC. This management can be limited by
acute and late toxicities, especially radiation pneumonitis (RP). Amifostine
could reduce the incidence of induced acute and late toxicities.
Methods: Between 2000 and 2007, a total of 36 patients with LA NSCLC
(IIIA, IIIB) were treated. All patients were treated with neoadjuvant chemo-
therapy (4 cycles) followed by concomitant RT-CT (2 cycles) plus amifos-
tine – group A (n18) and without amifostine – group B (n18). Chemo-
therapy consisted of paclitaxel and cisplatin, both day 1, every 3 weeks. All
patients were irradiated using 3D CRT. Lung tissue had been sampled from
two different sites. The first sample came from the area of PTV 2 (Amax,
Bmax) while the second sample was taken from the intact lung outside the
PTV 1 (Aref, Bref).
Results: Median 3D CRT dose was 67.4 Gy (63.8 - 72.8 Gy). Symptoms of
RP grade 3/4 (CTC v 2.0) occurred in 4 pts in group A vs. 9 pts in group B.
Histopatological examination of lung tissue showed major differences be-
tween groups A and B in terms of the thickening of the alveolocapilary
space. Characteristic histopathological features were: proliferation and thick-
ening of alveolocapillary septa, interstitial septal edema, intensive expressing
of collagen (short, loop, fragmentation of fibrillated collagen) and nuclei of
fibroblasts. Fibroproliferative changes (interstitial fibrosis, perivascular fi-
brosis, pulmonary emphysema) are late changes, as impact of acute toxicity.
Median thickness of the alveolocapillary space was 8.6 m (range 2.1-11.2)
and 3.2 m (range 0.9-4.2) for the Amax and Aref samples compared to 49.5
m (range 10.2-71.4) and 2.8 m (range 1.1-3.8) for the Bmax and B ref
samples, respectively. The difference between Amax and Bmax samples was
statistically significant (p0.0001).
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Conclusions: The incidence of radiation pneumonitis was lower for patients
receiving amifostine than for patients receiving radiochemotherapy alone.
Significant differences of the thickness of alveolocapillary space may rep-
resent the effect of amifostine as a radioprotector.
Disclosure: All authors have declared no conflicts of interest.
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THE EFFECT OF P-AKT AT THE PROGNOSIS OF
NON SMALL CELL LUNG CANCER
S. Karabulut Gul1, A. Fatih Oruc2, A. Mayadaglı2, A. Ozkan2, M. Kocak2
1Radiation Oncology, Selcuk University, Konya/TURKEY, 2Radiation On-
cology, Kartal Education and Research Hospital, Istanbul/TURKEY
Akt, known as protein kinase B (PKB) is an intracellular signal transduction
protein which was activated by growth hormones. Akt arranges some cellular
functions such as cellular life continuation, cellular growth and differantia-
tion. PKB/Akt became activated in some cancer types but its role in lung
cancer evolution and progression has not been determined yet. The purpose
of this study is to determine the prognostic value of Akt in lung cancer.
Immunohistochemical expression of p-akt was observed at light microscope.
Cases were evaluated by the strength and diffusiveness of the tumour cell’s
nuclear and cytoplasmic staining. For the diffusiveness degree, nuclear and
cytoplasmic staining ratio of the staining tumour cells were considered.
According to the intension degree, nuclear and cytoplasmic staining were
considered as light, median and potent and cases without staining were
considered as no staining. Between January 2003 and July 2008, 32 cases of
non-small cell lung cancer patient samples were observed before therapy in
our hospital. Samples staining characteristics were evaluated according age,
sex, stage (T and N), response to therapy, histologyical type, and tumour
size. In our study, no correlation was observed between staining and stage,
nodal condition, and T stage. The relation between staining and histopatho-
logical condition, tumour size, and response to therapy was evaluable
statistically. Squamous cell lung cancer histology (p0.03), and tumours
over 5cm (p0.03) showed more staining and such patients expressed less
complete response (p0.049) and survival (p0.3). Correlation shows direct
proportion between the activation of Akt and squamous cell carcinoma
histology, tumour size and therapy response in lung cancer patients. Acti-
vation of Akt in lung cancer patients affects prognosis negatively. We need
further studies to show the relation between Akt activation and therapy
response, and survival in lung cancer patients.
Disclosure: All authors have declared no conflicts of interest.
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TECHNICAL ASPECTS OF THE SURGERY OF T4 LUNG
CARCINOMAS
J. Klein1, C. Neoral1, M. Szkorupa1, T. Bohanes1, T. Janaskova2, D. Petras3
1The 1st Department of Surgery, University Hospital Olomouc, Czech
Republic, Olomouc/CZECH REPUBLIC, 2Department of Pneumology, Hos-
pital Ostrava-V¡tkovice, Ostrava/CZECH REPUBLIC, 3Department of Sur-
gery, KNTB Zlin, Zlin/CZECH REPUBLIC
Objectives: Therapeutic strategy in advanced stages of lung carcinomas
remains controversial. T4 lung carcinomas are a heterogeneous group of
locally advanced tumours. In the past, resections of T4 tumours were not
indicated due to high perioperative mortality, morbidity and poor 5-year
survival rates. Recently however, a few long-term survivors after extended
lung resections without any evidence of recurrence of the cancer have been
reported. Carinal resection, superior cava vein resection, pericardium and
left-atrial resection have become standard operations in lung cancer surgery
with 5-year survival rates of about 10–25%, depending on the nodal status
and completeness of the resection. Invasion of adjacent structures, however,
often makes complete resection of T4 tumours impossible, but induction
treatment can increase the number of successfully operated patients.
Methods: From 1997 to 2007, 37 patients underwent resection of primary
non-small cell non- satellite T4 cancer. Resection was complete in 29
patients (78%). Lymph node involvement was stated as negative in 9 cases,
whereas lymph node involvement was found in 28 cases. Actual survival
time was calculated in both groups, and own technique of the resection of the
superior cava vein or aorta is described.
Results: The 5-year survival was 27,0 % for patients with complete resec-
tion, and 2,7% for incomplete resections (P  0,05). Overall 30-day
mortality was 10,8%. (P  0,05).
Conclusion: Extended resections of T4 carcinomas can be undertaken in
highly selected patients with low morbidity and mortality. Despite described
results of the procedure, the long-term results of such extensive surgery still
remain unclear. Nevertheless, the final success of any oncology therapy has
not as yet been achievable without precise local (surgical) control. This study
was supported by grant IGA MZCR NS 10285.
Disclosure: All authors have declared no conflicts of interest.
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EARLY-ONSET CHEMOTHERAPY-INDUCED
NEUTROPENIA DURING PERIOPERATIVE
CHEMOTHERAPY IS ASSOCIATED WITH A LONG
DISEASE FREE SURVIVAL IN PATIENTS WITH
COMPLETELY RESECTED NON-SMALL-CELL
LUNG CANCER
S.H. Jang1, Y.I. Hwang1, J.C. Lee2, Y.Y. Lee2, C. Choi3, J. Chung4, H.S.
Chung5 1Division of Pulmonary, Allergy and Critical Care Medicine,
Hallym University Sacred Heart Hospital, Anyang/KOREA, 2Department of
Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radio-
logical & Medical Science, Seoul/KOREA, 3Department of Pulmonary and
Critical Care Medicine, Asan Medical Center, Seoul/KOREA, 4Pathology,
Seoul National University Bundang Hospital, Sungnam/KOREA, 5Internal
Medicine, Boramae Hospital, Seoul/KOREA
Background: Neutropenia during adjuvant chemotherapy was a significant
predictor of disease free survival (DFS) in breast cancer. The purpose of this
study was to examine the association between neutropenia during perioper-
ative chemotherapy and prognosis in patients with completely resected
non-small-cell lung cancer (NSCLC).
Methods: This is a retrospective analysis. Assessment of early onset neu-
tropenia was based on the lowest recorded absolute neutrophil count (ANC)
in cycle 1 or 2, and neutropenia was divided into two groups, grade 0-1
(ANC  1,500/mm3) vs. grade 2-4 (ANC  1,500/mm3).
Results: Seventy patients were treated with platinum based doublet chemo-
therapy (vinorebine, gemcitabine, paclitaxel, docetaxel or etoposide) in the
neoadjuvant or adjuvant setting (median 4 cycles, range 2-9). A long DFS
was associated with grade 2-4 neutropenia and early pathologic stage
(stage  IIB) (P0.085 and P0.037, respectively). The median DFS were
20.0 vs. 48.7 months in grade 0-1 vs. grade 2-4 neutropenia group. Overall
survival (OS) was associated with neutropenia, performance and disease
progression. Vinorelbine or gemcitabine containing regimens included drug
infusion schedule on day 8, so they potentially had a lot of chance to detect
lower ANC than the other regimens. Really, a total of 45.8% of the patients
receiving vinorelbine or gemcitabine containing regimen fall into grade 2-4
neutropenia group compared with only 9.1% in the other regimens. If the
analysis was confined to the patients receiving these regimens, grade 2-4
neutropenia was more clearly associated with better DFS (17.5 months vs.
48.7 months, P0.022) and OS (30.6 months vs. 67.8 months, p0.017).
The adjusted HR for disease progression in grade 2-4 neutropenia group
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compared with grade 0-1 neutropenia group was 0.415 (95% CI 0.191-0.903;
P0.027) in multivariate Cox-regression analysis. However, the adjusted
HR for death was not significant (P0.168).
Conclusion: Early onset neutropenia during perioperative chemotherapy was
associated with a long disease free survival in patients with completely
resected non-small cell lung cancer.
Disclosure: All authors have declared no conflicts of interest.
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IMRT VERSUS STANDARD CONFORMAL 3D
RADIOTHERAPY FOR CENTRALLY LOCATED
ADVANCED NON-SMALL CELL LUNG CANCER
A. Kowalczyk1, R. Dziadziuszko1, P. Szewczyk2, E. Szutowicz-Zielinska1,
K. Konopa1, J. Jassem3 1Oncology and Radiotherapy, Medical University of
Gdansk, Gdansk/POLAND, 2Oncology and Radiotherapy Department, Med-
ical University of Gdansk, Gdansk/POLAND, 3Oncology and Radiotherapy,
Medical University, Gdansk/POLAND
Objective: The experience with intensity-modulated radiotherapy (IMRT) in
lung cancer is very limited. We compared lung doses using IMRT and
standard conformal treatment plans for 3D radiotherapy (3D CRT) for
centrally located advanced non-small cell lung cancer (NSCLC).
Methods: Study group included four consecutive patients with locally
advanced NSCLC referred for radical radiotherapy. Gross tumor volume
(GTV), clinical treatment volume (CTV), planning target volume (PTV) and
organs at risk (lungs, spinal cord, heart) were contoured on axial CT slices.
GTV included lung tumor and involved mediastinal lymph nodes. The PTV
dose was 66-72 Gy in 30-36 daily fractions. 3D CRT included 3 oblique
fields technique using 6-12 MV photons and multileaf collimator (MLC) to
minimize the dose to the critical organs. Six or seven-field techniques using
6 MV photons were used for IMRT. The dose-volume histograms (DVHs)
for 3D CRT and IMRT treatment plans were compared.
Results: The mean lung dose (MLD), volume of lungs receiving 20 Gy
(V20 Gy) and 5 Gy (V5 Gy) were compared. With IMRT MLD and V20
Gy for lungs were reduced by an average of 4% and 3.5% compared to 3D,
respectively, whereas V5 Gy was higher by an average of 10%.
Conclusions: IMRT allowed for significant reduction in MLD and the V20
Gy at the expense of larger lung volume receiving smaller doses. The
reduction in high dose volume of normal tissues may potentially translate into
reduction in acute and late treatment-related toxicity, particularly in patients with
borderline planning DVH parameters for definitive radiotherapy.
Disclosure: All authors have declared no conflicts of interest.
196P
EXPERIENCE IN THE TREATMENT OF UNRESECTABLE
STAGE IIIA AND IIIB NON SMALL CELL LUNG CANCER
(NSCLC) WITH COMBINED CHEMOTHERAPY AND
RADIOTHERAPY IN A SINGLE INSTITUTION
M. Majem1, C. Pallare´s2, N. Farre1, N. Sala1, G. Gomez de Segura1, I. Gich1,
A. Barnadas1 1Medical Oncology, Hospital de la Santa Creu i Sant Pau,
Barcelona/SPAIN, 2Oncology Service, Hospital Sant Pau, Barcelona/SPAIN
Background: The best combination of chemotherapy (CT) and radiotherapy
(RT) for the treatment of unresectable stage III NSCLC remains unclear.
There are no definitive data on the best schedule, drugs and dosage. We have
prospectively recorded patients with unresectable NSCLC treated in our
institution. In this study we describe our clinical experience in the treatment
of unresectable stage III NSCLC.
Methods: We have prospectively collected data from 165 patients: demo-
graphic data, clinical characteristics, as well as the treatment received, the
toxicity presented and the best response. Additionally, we have analyzed the
prognostic value of different clinical characteristics according to the Cox
regression model. A survival analysis using the Kaplan-Meier method has
also been performed.
Results: Median age 65 (35-84); Sex: male 90%, female 10%. Smoking
status: 49% active smokers or former smokers. Karnofsky Index: 90-100
42%, 80 30%, 70 21%. Stage: IIIA 13%, IIIB 87% Histology: Squamous cell
carcinoma 50%, large cell carcinoma 36%, adenocarcinoma 14%. Combi-
nation of CT-RT: sequential 74%, concurrent 7%; 19% of patients did not
receive RT. Type of CT in combined treatment: platinum doublet 85% (with
gemcitabine 75%), non-platinum schedule 15%. The concurrent treatment
was always with a platinum compound and a taxane. Total dose of RT:
was 60 Gy in 46%. Response to induction CT: Complete 1%, Partial 42%,
Stable 39%, Progression: 18%. Final Response: Complete 25%, partial 36%,
Stable 31%, Progression 8%. Most frequent toxicity to CT: G2 asthenia 32%,
G1 haematological toxicity 32%. Late toxicity to RT at 6 m: G3-4 pneumo-
nitis 10%-3%; late toxicity to RT at 12 m: G3-4 pulmonary fibrosis 8%-1%.
The median overall survival and progression-free survival were 16.2m and
13.2m, respectively. The overall survival at 5 years was 12.5%.
Conclusions: the response rate and survival rate of unselected population
with unresectable stage III NSCLC in our institution are comparable to the
results obtained in clinical trials. The observed toxicity is acceptable and
manageable.
Disclosure: All authors have declared no conflicts of interest.
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THE ROLE OF CHEMOTHERAPY IN DOWNSTAGING
OF NON-RESECTABLE NSCLC (IIIA AND IIIB) INTO
RESECTABLE NSCLC
V. Radosavljevic, M. Obradovic, V. Milovanovic Pulmology, KBC
“Bezanijska Kosa”, Belgrade/SERBIA AND MONTENEGRO
Chemotherapy is one of the most important therapy modality in the treatment
of NSCLC. The purpose of the study was to examine the influence of
chemotherapy on downstaging of non-resectable NSCLC (stages IIIa and
IIIb) into resectable.
Material and method: The group consisted of 40 patients, (31 male 
77,5%, 9 female  22,5%), aged between 44–64, ECOG rate: 0–22 patients
(55%); 1–18 patients (45%); histology type: carcinoma planocellulare  21
patients (52,5%), adenocarcinoma  17 patients (42,5 %), large cell carci-
noma  2 patients (5,0%); clinical stage: IIIA  18 patients (45%), IIIB 
22 (55%); side: left  12 patients (30%), right 28 (70%); localization:
periferial 26 patients (65%), central 14 (35%). There were two chemotherapy
protocols applied: first group of 20 patients, MIC (Holoxan, Mitomycin,
Cisplatin); the second group also with 20 patients, PE – cisplatin-etoposide
in standard dosages. Standard statistical methods such as Hi2 test and
Student’s T test were used.
Results: The therapy response was the following: partial response  17
patients (42,5%), stable disease  16 patients (40%), complete response 
1 patients (2,5%), progressive disease  6 patients (15,0%) Twelve of the
patients (30%) were successfully operated, and 28 patients (70%) were not.
Conclusion: Chemotherapy as the only therapy modality has a significant
effect on downstaging of non-resectable NSCLC (IIIA, IIIB) to resectable
stages.
Disclosure: All authors have declared no conflicts of interest.
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PRELIMINARY REPORT OF A PILOT STUDY OF
CONTINUOUS ACCELERATED IRRADIATION IN
PATIENTS WITH STAGE III A OR III B NON-SMALL CELL
LUNG CANCER AFTER INDUCTION CHEMOTHERAPY
K. Galwas-Kliber1, S. Blamek1, W. Bal2, A. Zajusz3, R. Suwinski4 1De-
partment of Radiation Oncology, Maria Skłodowska-Curie Memorial Cancer
Center and Institute of Oncology, Gliwice/POLAND, 2Department of Clini-
cal Oncology, Maria Skłodowska-Curie Memorial Cancer Center and Insti-
tute of Oncology, Gliwice/POLAND, 3Department of Radiotherapy, Center
of Oncology Maria Sklodowska-Curie Memorial Institute Branch Gliwice,
Gliwice/POLAND, 4Radiotherapy Department, M. Sklodowska-Curie Memo-
rial Cancer Center and Institute of Oncology, Gliwice Branch, Poland,
Gliwice/POLAND
Aim: The aim of this report is to evaluate the acute normal tissue reactions
in patients with stage III A or III B non-small cell lung cancer treated with
continuous accelerated irradiation (CAIR) after induction chemotherapy.
Material: 26 patients (21 men), age 43-72 (mean 58.5) were enrolled into the
study. Nineteen patients had squamous cell carcionoma, 2 – adenocarcinoma
and 5 non-small cell cancer of unspecified subtype.
Methods: The patients received 2-4 cycles of induction chemotherapy. After
chemotherapy they were irradiated with 1.8 Gy per fraction to dose of 43.2
Gy from Monday to Friday and with 2 Gy per fraction during weekends to
total dose of 67.2-71.2 Gy. Acute radiation reactions in esophagus, skin,
lungs and heart were assessed weekly during treatment, and monthly during
the follow-up. Blood cell count was analysed during and after treatment.
Results: 19 patients were irradiated according to study protocol. Four
patients refused participation in the study, two had distant metastases on PET
and were irradiated with palliative intent, one was assigned to surgery after
an internal audit. No grade 3 or 4 acute radiation effects occurred, in one
patient esophageal grade 2 toxicity since 3rd week of irradiation was
recorded, in the remainder mild (grade 1) skin, lung and esophageal toxicities
were noted. Statistical analysis did not reveal significant alterations in blood
cell count during treatment.
Conclusions: The proposed protocol of continuous accelerated irradiation in
patients with advanced non-small cell lung cancer after induction chemo-
therapy is well tolerated, suggesting its feasibility for phase III study with
respect to acute tolerance.
Disclosure: All authors have declared no conflicts of interest.
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CARDIAC TOXICITY AFTER DEFINITIVE
RADIOTHERAPY OF LOCALLY ADVANCED NSCLC
T. Schytte1, O. Hansen1, T. Stolberg-Rohr2, C. Brink2 1Oncology, Odense
Universityhospital, Odense C/DENMARK, 2Laboratory of Radiation Phys-
ics, Odense Universityhospital, Odense C/DENMARK
Background: Lung and oesophageal toxicity have been regarded as main
toxicity in definitive radiotherapy (RT) of non-small cell lung cancer
(NSCLC), whereas cardiac toxicity has not been offered much concern. This
is probably due to the poor prognosis for patients with unresectable NSCLC.
In this study we report the heart toxicities in locally-regionally advanced
NSCLC (LA-NSCLC) patients (pts) treated with RT in our centre.
Methods and material: From 01.01.1995-30.11.2007, 287 pts with LA-
NSCLC (stage IIB-IIIB) were treated with RT at our centre with planned
dose 60-66 Gy. All RT was applied as 3D RT in 2 Gy/F without elective
nodal irradiation. Cardiac toxicity is defined as myocardial infarction (MI),
exudative pericarditis (ED), cardiac insufficiency (CI), pulmonary embolism
(PE), found dead with unknown cause, non specific cardiac disease (CD),
supra- or ventricular arrhythmia (SA, VA). The cardiac events (CE) were
collected from patient files. All patients were followed to death. Median
follow-up was 86 month, with 24 month as minimum.
Results: 38 pts had a CE: 7 MI, 3 EP, 5 CI, 4 PE, 2 found dead, 3 CD, 13
SA and 1 VA. Median survival was 17.2 month and overall survival for 1, 2
and 5 year was 64%, 35% and 14%, respectively. In a Cox regression
analyses of time to CE, age  65 year,  induction chemotherapy, smoking,
high mean dose to left right ventricles or whole heart was not a statistically
significant factor, whereas low FEV-1, large GTV, low Hb, poor PS, high
V20 to lunge, and gender did.
Discussion: We did not find a correlation between high mean dose to left 
right ventricles or whole heart and having a CE. Having a CE was not related
to worsen survival.
Disclosure: All authors have declared no conflicts of interest.
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AMIFOSTINE AS A RADIOPROTECTOR IN THE
MANAGEMENT OF ADVANCED NON-SMALL CELL
LUNG CANCER - HISTOPATHOLOGICAL FEATURES
J. Stejskal1, M. Kubecova´2, D. Dvor˘a´kova´3, V. Ulrych1, I. Kola´r˘ova´1, M.
Kheck3, J. Van˘a´sek1 1Radiation Oncology, Regional Hospital Pardubice,
Pardubice/CZECH REPUBLIC, 2Radiation Oncology, University Hospital
Prague, Praha/CZECH REPUBLIC, 3Pathology, Regional Hospital Jihlava,
Jihlava/CZECH REPUBLIC
Purpose: Locally advanced non-small cell lung cancer (LA-NSCLC) represents
a disease with poor prognosis. Radiochemotherapy (RT-CT) is an effective
treatment for LA-NSCLC. This management can be limited by acute and late
toxicities, especially acute esophagitis (AE) and radiation pneumonitis (RP).
Amifostine could reduce the incidence of induced acute and late toxicities.
Methods: Between 2000 and 2007, a total of 36 patients with locally advanced
NSCLC stage IIIA and IIIB were treated. All patients were randomized to
treatment with neoadjuvant chemotherapy (4 cycles) followed by concomitant
RT-CT (2 cycles) plus amifostine i.v. infusion 500 mg daily – group A (n18)
and without amifostine – group B (n18). Chemotherapy consisted of paclitaxel
175 mg/m2 and cisplatin 75 mg/m2, i.v. infusion, both day 1, every 3 weeks. All
patients were treated using 3D conformal radiotherapy (3D-CRT). All patients
were assessed at each follow-up visit for signs and symptoms of AE and RP
according to the CTC-version 2.0. Lung tissue had been sampled from two
different sites. In both patient groups, the first sample came from the area of PTV
2 (Amax, Bmax) while the second sample was taken from the intact lung outside
the PTV 1 (Aref, Bref). Hematoxylin and eosin-stained slides were reviewed
with light microscopy.
Results: Median 3D-CRT dose was 67.4 Gy (63.8 - 72.8 Gy). Symptoms of
AE grade 3/4 and RP grade 3/4 occurred in 3 and 4 patients in group A vs.
8 and 9 patients in group B. Differences were statistically significant
(p0.001). Median thickness of the alveolocapillary space was 8.6 m
Factors in Model
Relative
Hazard Ratio
(95% CI) p-Value
FEV-1 ( 1.30 (1.00–1.68) 0.046
GTV (150 ml) 2.02 (1.51–2.71) 0.0001
Hb ( 1.44 (1.12–1.86) 0.0046
Mean dose to ventricles
(20 Gy)
1.23 (0.92–1.67) 0.17
PS (1) 1.64 (1.11–2.42) 0.014
Gender (male) 1.37 (1.06–1.77) 0.016
V20 (35%) 1.85 (1.43–2.40) 0.0001
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(range 2.1-11.2) and 3.2 m (range 0.9-4.2) for the Amax and Aref samples
compared to 49.5 m (range 10.2-71.4) and 2.8 m (range 1.1-3.8) for the
Bmax and B ref samples, respectively. The difference between Amax and
Bmax samples was statistically significant (p0.0001).
Conclusions: The incidence of esophagitis and pneumonitis was lower for
patients receiving amifostine than for patients receiving radiochemotherapy
alone. Significant differences of the thickness of alveolocapillary space may
represent the effect of amifostine as a radioprotector. Amifostine reduces the
incidence of pneumonitis, lung fibrosis, and esophagitis.
Disclosure: All authors have declared no conflicts of interest.
ADVANCED NSCLC
201O
EGFR MUTATION TESTING IN NON-SMALL-CELL LUNG
CANCER (NSCLC): CLINICAL RECOMMENDATIONS
FROM THE EUROPEAN EGFR WORKSHOP GROUP
R. Pirker1, F.J.F. Herth2, K. Kerr3, M. Filipits4, D. Grunenwald5, H. Popper6,
R. Rosell7, E. Smit8, F. Cappuzzo9, R.A. Stahel10 1Department of Internal
Medicine I, Medical University of Vienna, Wien/AUSTRIA, 2Department of
Internal Medicine, Pneumology and Critical Care Medicine, University of
Heidelberg, Heidelberg/GERMANY, 3Department of Pathology, Aberdeen
Royal Infirmary, Aberdeen/UNITED KINGDOM, 4Department of Medicine
I, Medical University Vienna, Vienna/AUSTRIA, 5Thoracic Surgery, Univer-
sity of Paris Hoˆpital Tenon, Paris/FRANCE, 6Laboratories for Molecular
Cytogenetics, Environmental and Pulmonary Pathology, Institute of Pathol-
ogy, Medical University of Graz, Graz/AUSTRIA, 7Medical Oncology Ser-
vice, Catalan Institute of Oncology, Badalona/SPAIN, 8Department of Pul-
monary Diseases, Vrije Universiteit Medical Center, Amsterdam/
NETHERLANDS, 9Oncology, Livorno Hospital, Livorno/ITALY, 10Klinik
Und Poliklinik fu¨r Onkologie, Universita¨tsspital, Zu¨rich/SWITZERLAND
Purpose: The epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-
TKI) gefitinib has received European approval for the treatment of adult patients with
locally advanced or metastatic NSCLC with activating mutations of the EGFR-TKI.
ASCO guidelines recommend EGFR mutation testing in NSCLC patients, whereas
this procedure is less well established in European clinical practice.
Methods: Recommendations to facilitate the implementation of standardized
EGFR mutation testing in clinical practice were developed at an IASLC-ETOP
European multidisciplinary workshop of biologists, pathologists, surgeons, chest
physicians, and medical oncologists. All aspects of the EGFR mutation testing
process were discussed, such as biopsy and sampling, pathology and mutation
testing.
Results: The decision to request EGFR mutation testing should be made by the
treating physician. Results should be available within 7 working days. All patients
with NSCLC may eventually be tested, but exceptions may be made when likelihood
of mutation is low. No consensus agreement on pre-screening algorithms was
achieved. Standardization of tumor sample handling is required. Numerous methods
can be used to detect EGFR mutations including direct sequencing, Amplification
Refractory Mutation System (ARMS), length analysis, and denaturing high perfor-
mance liquid chromatography (dHPLC). Some tests only seek the most common
activating mutations, others can detect all mutations. Ideally pathologists should
report tumor histology and mutation status concurrently. Sample size/quality, tumor
nuclei percentage, methodology used, exons tested, and mutation present/absent
should be included in the final report. Close collaboration and co-ordination between
the different specialists involved is considered to be essential for the success of
EGFR mutation testing. Reference laboratories may also be helpful.
Conclusions: These recommendations from a multidisciplinary European
workshop will help to optimize routine EGFR mutation testing in Europe.
Disclosure: R. Pirker: R Pirker has acted as a consultant or in an advisory role
for, and has received honoraria from, AstraZeneca, Merck Serono, Roche, and
Lilly. K. Kerr: KM Kerr has acted as a consultant or in an advisory role for
AstraZeneca, Roche-Genentech-OSI, Lilly, and BI, and has received honoraria
from AstraZeneca. M. Filipits: M Filipits has received honoraria from Astra-
Zeneca, Merck and Co., and Lilly. H. Popper: HH Popper has acted as a
consultant or in an advisory role for AstraZeneca and Lilly, and has received
honoraria from AstraZeneca, Lilly, and Menarini. F. Cappuzzo: F Cappuzzo has
acted as a consultant or in an advisory role for AstraZeneca, Boehringer
Ingelheim, and Roche, and has received honoraria from AstraZeneca, Boehr-
inger Ingelheim, Roche, and Lilly. R.A. Stahel: RA Stahel has acted as a
consultant or in an advisory role for, and has received honoraria from, Astra-
Zeneca and Roche. All other authors have declared no conflicts of interest.
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DIFFERENT KRAS MUTATIONS MAY PREDICT A
DIFFERENT IMPACT ON DRUGS ACTIVITY IN
LUNG (NSCLC) CANCER
M.C. Garassino1, O. Martelli2, M. Broggini3, F. Bianchi4, S. Veronese5, I.
Floriani6, S. Marsoni7, M. Marabese8, G. Farina9, A. Scanni1 1Oncology,
Fatebenefratelli and Ophtalmic Hospital, Milano/ITALY, 2Oncology, San
Giovanni e Addolorata, Rome/ITALY, 3Oncology, Istituto ”Mario Negri“,
Milano/ITALY, 4Oncology, Fatebenefratelli and Ophtalmic Hospital, Milan/
ITALY, 5Pathology, Ospedale Ca’granda Niguarda, Milan/ITALY, 6Istituto
Di Ricerche Farmacologiche ”Mario Negri“, Laboratorio di Clinical Trials,
Milano/ITALY, 7Oncology, SENDO Tech Srl, Milan/ITALY, 8Oncology,
Istituto” Mario Negri“, Milan/ITALY, 9Oncology, Ospedale Fatebenefratelli
e Oftalmico, Milan/ITALY
Background: The RAS/RAF/MEK/ERK pathway is a therapeutic target in
both colorectal (CRC) and NSCLC cancer, but while mutated KRAS is a
negative prognostic marker and a negative predictor for anti EGFR therapy
in CRC, its role in lung cancer is quite ambiguous. KRAS is a pool of
mutations mostly occurring in codons 12 and 13 but differing for the replaced
basis and for the aminoacid substitution. In CRC the most expressed KRAS
mutation is G12D. We hypothesized a different KRAS mutational status in
NSCLC patients, bearing a potential different profile in the tumour response
to treatment which we tested in vitro.
Methods: TAILOR (NCT00637910) is a multicenter Italian phase III trial
powered to evaluate a differential effect of all biological markers in selecting
patients for erlotinib and docetaxel as 2nd line. Consecutive patients are regis-
tered and molecularly profiled centrally. KRAS and EGFR mutations were
detected by direct sequencing. Therefore, we identified all KRAS mutations
types. The EGFR-wt NCI-H1299 lung cell line was transfected with expression
plasmids encoding all different identified KRAS mutations and tested in vitro for
the activity of cisplatin, taxanes, erlotinib and pemetrexed.
Results: To date, KRAS and EGFR mutational status is available on 161 of
256 patients registered into the trial. We found six types of KRAS mutation
in 35 patients (20%): G12C (45.7%) G12D (20%) G12V (20%) G12A
(5.7%) G13C (5.7%) G13D (2.8%). Preliminary data, in the NCI-H1299
transfected cell lines, indicate that specific KRAS mutations are associated to
different sensitivity or resistance drug profiles.
Conclusions: Final results will be presented at the congress and clearly
suggest that the specific mutational status of KRAS gene in NSCLC seems
to differ from that reported for CRC. This clinical observation, with in vitro
results suggesting different patterns of sensitivity/resistance to EGFR inhi-
bition in transfected cell lines, might explain the ambiguous role of KRAS as
a predictor to anti EGFR therapy in NSCLC. Final results of the randomized
TAILOR study will definetely allow to verify this suggestive hypothesis.
Disclosure: All authors have declared no conflicts of interest.
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SERUM PROTEOMIC PREDICTION OF OUTCOMES IN
ADVANCED NSCLC PATIENTS TREATED WITH
ERLOTINIB/PLACEBO IN THE NCIC CLINICAL
TRIALS GROUP BR.21 TRIAL
D.P. Carbone1, L. Seymour2, K. Ding3, H. Roder4, M. Tsao5, F.A. Shepherd6
1Medicine and Cancer Biology, Vanderbilt-Ingram Comprehensive Cancer
Center, Nashville/USA, 2Ncic Ctg, Queens University, Toronto/CANADA,
3Community Health & Epidemiology, Queen’s University, Ontario/CAN-
ADA, 4Chief Scientific Officer, Biodesix, Inc., Broomfield/USA, 5Oncology,
Princess Margaret Hospital, Toronto/CANADA, 6Medical Oncology, Prin-
cess Margaret Hospital, Toronto/CANADA
Background: BR21 demonstrated a survival benefit from erlotinib in pre-
viously treated patients with NSCLC. Serum proteomic profiling by MALDI
MS has demonstrated the ability to predict PFS and OS outcomes in patients
treated with EGFR-TKIs. These profiles, proteomic good and proteomic
poor, have been found to be specific for EGFR-TKIs and not for chemother-
apy treatments. The purpose of this study is to validate the ability of
proteomic profiling to predict outcomes to EGFR-TKI treatment in samples
derived from BR.21, a phase III randomized trial of erlotinib vs. placebo in
second- or third-line advanced NSCLC.
Methods: Blinded baseline plasma samples were available from 441 patients from
the BR.21 study of erlotinib 150 mg/day vs. placebo. Sample MALDI MS analysis
was run in triplicate and analyzed by Biodesix, Inc. Colorado in their CLIA-
approved facility. A clinical label (good, poor, undefined) together with spectral
characteristics of the eight peaks in the proteomic classifier were recorded.
Results: Proteomic results were available from 441 patients 266 (60.3%) good
proteomic profile, 170 (38.5%) poor profile and only 5 (1.1%) indeterminate.
Analyses of response rates, overall and progression-free survival will be per-
formed and correlated with other known prognostic factors, treatment arm
(erlotinib or placebo) and signature. In addition, for the subset of patients with EGFR
and KRAS biomarker data available, correlations will be made with proteomic
profile and outcome. Final analysis will be available by the time of the meeting.
Disclosure: D.P. Carbone: Genentech advisory board, research support,
Biodesix advisory board; H. Roder: Employed by Biodesix as Chief Scien-
tific Officer; F.A. Shepherd: Consulting, Genentech. All other authors have
declared no conflicts of interest.
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SURVIVAL BENEFIT WITH ERLOTINIB MAINTENANCE
THERAPY RELATIVE TO PRIOR CHEMOTHERAPEUTIC
RESPONSE: A SUBANALYSIS OF THE PHASE III SATURN
STUDY IN NSCLC
B. Coudert1, T. Ciuleanu2, K. Park3, Y. Wu4, G. Giaccone5, F. Cappuzzo6
1Medical Oncology, Centre Georges Franc¸ois Leclerc, Dijon/FRANCE,
2Oncology, Institutul Oncologic Prof Dr I. Chiricuta, Cluj-Napoca/
ROMANIA, 3Division of Hematology/Oncology, Department of Medicine,
Samsung Medical Center, Sungkyunkwan University School of Medicine,
Seoul/KOREA, 4Department of Lung Cancer, Cancer Center & Lung Cancer
Research Institute, Guangzhou/CHINA, 5Chief Medical Oncology Branch,
CCR, National Cancer Institute, NIH, Bethesda/USA, 6Oncology, Livorno
Hospital, Livorno/ITALY
Background: The phase III SATURN trial investigating erlotinib maintenance
therapy vs placebo met its endpoints of improved progression-free survival (PFS)
and overall survival (OS) with clinical and statistical significance. Numerous sub-
group analyses were conducted to identify patients with particularly large clinical
benefit. We present the trial outcomes according to response to initial chemotherapy:
complete or partial response (CR/PR) vs stable disease (SD).
Methods: Patients with neither progression nor unacceptable toxicity fol-
lowing 4 cycles of platinum-based chemotherapy (CT) were randomised to
receive either erlotinib 150mg/day or placebo until progression or unaccept-
able toxicity. Co-primary endpoints were PFS in all patients and PFS in
EGFR immunohistochemistry-positive (IHC) disease. Secondary end-
points included OS, response, safety and quality of life.
Results: 889 patients with CR, PR or SD after first-line CT received erlotinib
(n438) or placebo (n451). PFS was significantly prolonged in patients with SD
after first-line CT (HR0.68 [0.56–0.83]; p0.0001) and in those with CR/PR after
first-line CT (HR0.74 [0.60–0.92]; log-rank p0.0059). However, OS was sig-
nificantly prolonged only in those patients who had SD (HR0.72 [0.59–0.89];
p0.0019 vs HR0.94 [0.74–1.20]; p0.6181 in those with CR/PR). OS results for
the EGFR wild-type population were similar to the overall population: HR0.65
[0.48–0.87]; p0.0041 for SD vs HR0.97 [0.68–1.38]; p0.8544 for CR/PR.
Similar outcomes were seen in non-squamous (HR 0.76 [0.59–1.00]; p0.0457
for SD vs HR0.85 [0.62–1.16]; p0.3031 for CR/PR) and squamous-cell carci-
noma (HR0.67 [0.48–0.92]; p0.0116 for SD vs HR1.07 [0.73–1.56];
p0.7309 for CR/PR).
Conclusions: Erlotinib maintenance therapy can increase PFS in all patients
with SD or CR/PR after first-line platinum-based CT. Patients with SD
gained a particularly large survival benefit. We hypothesise that differences
in the proliferative capacities of the tumours may explain this difference.
These results may help physicians to identify patients most likely to benefit
from erlotinib maintenance therapy.
Disclosure: B. Coudert: I have financial interests to declare. Advisory boards for:
Laboratoire Astra Zeneca Laboratoire LILLY Laboratoire ROCHE Laboratoire
sanofi aventis Laboratoire Shering Plough K. Park: I have financial intersts to
declare. I have been involved in Advisory Boards for: Pfizer, Roche, AstraZeneca,
Eli Lilly, Merck Sereno; F. Cappuzzo: I have financial interests to declare. I have
taken part in Advisory Boards for: Roche, Lilly, Boeringer, AstraZeneca, Glaxo,
BMS. All other authors have declared no conflicts of interest.
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QUALITY OF LIFE (QOL) IN A RANDOMIZED PHASE III
FIRST-LINE STUDY OF GEFITINIB (G) VS
CARBOPLATIN/PACLITAXEL (CP) IN CLINICALLY
SELECTED ASIAN PATIENTS (PTS) WITH ADVANCED
NSCLC (IPASS)
S. Thongprasert1, E. Duffield2, Y. Wu3, C. Yang4, N. Saijo5, D.T. Chu6, V.
Chan7, T. Mok8, P. Magill9, M. Fukuoka10 1Medical Oncology Unit,
Department of Medicine, Maharaj Nakorn Chiang Mai Hospital, Chiang
Mai/THAILAND, 2Research, AstraZeneca, Macclesfield/UNITED
KINGDOM, 3Guangdong General Hospital & Guangdong Academy of
Medical Sciences, Guangzhou/CHINA, 4Department of Oncology, National
Taiwan University Hospital, Taipei/TAIWAN, 5Department of Medical On-
cology, National Cancer Center Hospital East, Chiba/JAPAN, 6Department
of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sci-
ences, Beijing/CHINA, 7Medical Oncology Section, Veteran’s Memorial
Medical Centre, Quezon City/PHILIPPINES, 8Department of Clinical On-
cology, The Chinese University of Hong Kong, Shatin, Hong Kong/CHINA,
9AstraZeneca, Macclesfield/UNITED KINGDOM, 10Department of Medical
Oncology, Kinki Universty School of Medicine, Osaka/JAPAN
Purpose: QoL is important for cancer pts. Evaluation of symptom improve-
ment and QoL were pre-planned secondary objectives for the overall popu-
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lation and post-hoc analyses for EGFR mutation positive/negative (M/-)
populations in the IPASS study.
Methods: QoL was measured by the FACT-L questionnaire (total score,
trial outcome index [TOI]) and, symptom improvement (SI) by the lung
cancer subscale (LCS) of the FACT-L. Improvements were defined as
increases from baseline of 6 (total FACT-L and TOI) or 2 (LCS)
points maintained for 21 days. Treatments were compared by logistic
regression, and improvement rates calculated as the percentage of pts
with an overall improved response. Time to worsening (FACT-L, TOI,
LCS; supplementary evaluation) was the interval from randomization to
worsening.
Results: QoL was evaluable in 1151 (n 590 [G]; n561 [CP]) pts;
compliance rates were 93.6% (G) and 85.3% (CP) for FACT-L (with
similar compliance in M/M-/M unknown subgroups). Significantly
more pts receiving G than CP experienced total score and TOI improve-
ments; LCS improvement was similar for both treatments. Significantly
more EGFR M pts experienced improvements in total score, TOI and
LCS with G vs CP; results significantly favoured CP for EGFR M- pts. In
pts with tumours of unknown M status, QoL improvements were similar
to the overall population. Time to worsening for FACT-L was longer with
G vs CP (median 8.3 vs 2.5 months) overall and for EGFR M pts (15.6
vs 3.0 months). Results for G were similar to CP in EGFR M- patients
(median 1.4 months for both arms).
Conclusions: Clinically important improvements in QoL were observed
more frequently in pts treated with G than CP with marked differences in the
M (favouring G) and M- (favouring CP) subgroups. SI was similar for G
and CP overall, with results significantly favouring G and CP in the M and
M- subgroups, respectively.
Disclosure: S. Thongprasert: Honoraria from AstraZeneca. Research
Funding: AstraZeneca, Sanofi-Aventis; E. Duffield: Equity/stock holder:
AstraZeneca. Employee of AstraZeneca; Y. Wu: Consultancy fees and
paid advisory boards: AstraZeneca, Roche, Pfizer, Eli Lilly. Lecture fees
from commercial sponsors: AstraZeneca, Roche, Eli Lilly; C. Yang:
Consultancy fees and paid advisory boards: AstraZeneca. Lecture fees
from commercial sponsors: AstraZeneca; N. Saijo: Equity/stock holder:
Takeda. Research Funding: AstraZeneca, Taiho, Takeda, Chugai; D.T.
Chu: Honoraria from AstraZeneca; V. Chan: Clinical trials: Roche
Philippines, Glaxo and AMGEN. Advisory Board: Glaxo; T. Mok:
Consultancy fees and paid advisory boards: AstraZeneca, Roche, Pfizer,
Eli Lilly. Lecture fees from commercial sponsors: AstraZeneca, Roche,
Eli Lilly. Research funding: AstraZeneca; P. Magill: Equity/stock holder:
AstraZeneca. Employee of AstraZeneca. M. Fukuoka: Honoraria from
AstraZeneca, Chugai and Boehringer Ingelheim.
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RANDOMIZED TRIAL OF CONCURRENT VERSUS
SEQUENTIAL DOCETAXEL PLUS BORTEZOMIB (PS-341)
IN PLATINUM-TREATED NON-SMALL CELL LUNG
CANCER (NSCLC) PATIENTS (PTS): A CALIFORNIA
CANCER CONSORTIUM STUDY
P.N. Lara1, J. Longmate2, A. Argiris3, B. Gitlitz4, P.C. Mack5, D. Lau1, M.
Koczywas6, N.B. Leighl7, D.R. Gandara8 1Medical Oncology, University of
California, Davis Campus, Sacramento/USA, 2Biostatistics, City of Hope,
Duarte/USA, 3Cancer Center, University of Pittsburgh, Pittsburgh/USA,
4Medical Oncology, University of Southern California, Los Angeles/USA,
5Department of Internal Medicine Hematology/oncology, University of Cal-
ifornia, Davis Campus, Sacramento/USA, 6Medical Oncology and Thera-
peutics Research, City of Hope, Duarte/USA, 7Medical Oncology, Princess
Margaret Hospital, Toronto/CANADA, 8Department of Internal Medicine
Hematology/oncology, University of California Davis Cancer Center, Sac-
ramento/USA
Background: The proteasome inhibitor PS-341 sensitizes tumor cells to
chemotherapy-induced apoptosis. In A549 & Calu1 NSCLC lines, the
sequence of docetaxel (Doce) followed by PS-341 appears to optimally
induce cell death by reducing levels of anti-apoptotic Bcl-2 & increasing
levels of the tumor suppressor p27, as compared to the reverse sequence or
simultaneous administration. To further explore these observations, we
conducted a randomized phase II trial of concurrent vs. sequential Doce-PS-
341 in NSCLC pts.
Methods: Platinum pre-treated metastatic NSCLC pts were randomized to
either concurrent (Arm 1) or sequential (Arm 2) Doce 75 mg/m2 IV followed by
PS-341. Arm 1 pts received PS-341 (1.6 mg/m2 IV) on days 1 and 8; Arm 2 pts
received PS-341 starting on day 2. Prophylactic GCSF support was recom-
mended. Cycle length was 3 weeks. Pts must have path-confirmed NSCLC,
Zubrod performance status 0-1, and adequate end-organ function. Prior erlotinib
was allowed (n13) as were pts with treated/controlled brain metastasis.
Primary endpoint was RECIST response rate (RR), while progression-free (PFS)
and overall survival (OS) were secondary endpoints. With 40 pts per arm, there
was 90% probability to correctly “pick the winner” if the RR on the 2 arms were
0.05 vs. 0.13, or 0.10 vs. 0.20, or 0.15 vs. 0.27.
Results: Eighty-one pts were randomized: 40 in Arm 1, 41 in Arm 2. Grade (Gr)
3 toxicities were mostly due to myelosuppression (arm 1 vs. 2), leukopenia (6
vs. 11), lymphopenia (10 vs. 2), neutropenia (8 vs. 15), & thrombocytopenia (0
vs. 3). One pt each had gr4 sodium and syncope. One pt (Arm 2) died after gr4
heme toxicities, gr3 neuropathy and gr3 anorexia.
Conclusion Docetaxel plus PS-341 concurrently given on day 1 has similar
RR as sequential therapy, but results in OS that exceeds prior published OS
estimates for either agent alone or in combination. (NO1 CM-62209).
Disclosure: All authors have declared no conflicts of interest.
Population
QoL
Measure
G C/P
Odds
ratio
G:CP 95% CI p-ValueN
%
Improved N
%
Improved
Overall FACT-L 590 48.0 561 40.8 1.34 1.06–1.69 0.0148
TOI 590 46.4 561 32.8 1.78 1.40–2.26 0.0001
LCS 590 51.5 561 48.5 1.13 0.90–1.42 0.3037
EGFR M FACT-L 131 70.2 128 44.5 3.01 1.79–5.07 0.0001
TOI 131 70.2 128 38.3 3.96 2.33–6.71 0.0001
LCS 131 75.6 128 53.9 2.70 1.58–4.62 0.0003
EGFR M- FACT-L 89 14.6 80 36.3 0.31 0.15–0.65 0.0021
TOI 89 12.4 80 28.8 0.35 0.16–0.79 0.0111
LCS 89 20.2 80 47.5 0.28 0.14–0.55 0.0002
Arm 1
(Concurrent)
Arm 2
(Sequential) Overall
Male Sex 23 (57%) 20 (49%) 43 (53%)
Zubrod PS0 17 (42%) 21 (51%) 38 (47%)
Median age, years 61 62 61
Partial response (PR) 4 (10%) 4 (10%) 8 (10%)
Disease control rate
(PRSD)
20 (50%) 20 (49%) 40 (49%)
6-month PFS 30% 17% 25%
OS, median in months 13.3 (7,17) 7.8 (6,18) 10.5 (7, 14)
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EFFICACY AND SAFETY OF DOUBLET COMPARED TO
SINGLE AGENT IN ADVANCED NON SMALL CELL LUNG
CANCER. A SYSTEMATIC REVIEW AND META-ANALYSIS
G. Des Guetz1, B. Uzzan1, P. Nicolas1, J. Morere2 1Oncology, Hoˆpital
Avicenne, Bobigny/FRANCE, 2Medical Oncology, Hoˆpital Avicenne, Paris/
France
Background: In the elderly (age  70) with advanced Non Small Cell Lung
Cancer (NSCLC), the relative risk-to-benefit ratio of chemotherapy (CT)
administered as single-agent or doublets (including the same single agent) is
not established. We performed a meta-analysis (MA) of all published studies
to clarify this issue.
Methods: PubMed query using the following keywords simultaneously Ran-
domized Controlled Trial, Aged, Antineoplastic Combined Chemotherapy Pro-
tocols/therapeutic use, Carcinoma, NSCL.drug therapy. Articles were also ob-
tained by cross-checking references; abstracts from ASCO and WCLC
proceedings. The efficacy outcome was based on 1-year Overall Survival (OS).
Hazard Ratios (HRs) were calculated from the recorded events. We used
EasyMA software and fixed-effect model, due to absence of statistical hetero-
geneity between studies. By convention, HRs  1 corresponded to a decreased
survival among the single-agent compared with the doublet.
Results: Eight eligible studies included 1804 patients (mean age 73; 1362 men
and 368 women; 461 stage IIIB and 1114 stage IV; 600 epidermoid cancers, 565
adenocarcinomas, 410 other pathological types). One-year OS was similar for
single-agent and doublets (HR 0.98; 95% Confidence Interval or CI: 0.92–1.05),
HRs for nausea/vomiting, neutropenia, thrombopenia and anaemia were signif-
icantly higher for doublets than for single agent (1.29, CI 1.13–1.46; 1.28, CI
1.17–1.41; 1.60, CI 1.26–2.02; 1.36, CI 1.19–1.55 respectively). HRs for
diarrhea and stomatitis were close to 1. Concerning grade 3⁄4 toxicity, only the
HRs for the biological side effects were significantly higher for doublets:
neutropenia (1.40; 1.15–1.71), thrombopenia (2.46; 1.60–3.78) and anaemia
(1.61; 1.04–2.48). Alopecia, peripheral neuropathy, febrile neutropenia could
not be analyzed precisely due to their low frequency.
Conclusion: Compared with single-agent CT, doublets not improved OS.
Neutropenia, thrombopenia and anaemia were more frequent with doublets. Thus,
the benefit-to-risk ratio of doublets in advanced NSCLC is not proved. Future
elderly-specific studies should be needed to determine the best CT regimen.
Disclosure: All authors have declared no conflicts of interest.
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RISK FACTORS FOR EARLY COMPLICATIONS OF HIGH
DOSE RATE ENDOBRONCHIAL BRACHYTHERAPY (HDR
EBBT) IN THE PALLIATIVE TREATMENT OF LUNG
CANCER
B. Zaric1, B. Perin1, A.N. Jovelic2, N. Lalic1, N. Secen1, M.N. Antonic3
1Department for Interventional Pulmonology, Institute for Pulmonary Dis-
eases of Vojvodina, Faculty of Medicine, University of Novi Sad, Sremska
Kamenica/SERBIA AND MONTENEGRO, 2Clinic for Cardiology, Institute
for Cardiovascular Diseases of Vojvodina, Faculty of Medicine, University
of Novi Sad, Sremska Kamenica/SERBIA AND MONTENEGRO, 3Clinic for
Pulmonary Oncology, Institute for Pulmonary Diseases of Vojvodina, Fac-
ulty of Medicine, University of Novi Sad, Sremska Kamenica/SERBIA AND
MONTENEGRO
Introduction: The major aims of this study were to identify the complication
rate and clinical risk factors for early complications of HDR-EBBT. Identi-
fication of these risk factors can result in a decrease or avoidance of
complications.
Patients and methods: In this study we analyzed risk factors for compli-
cations in 761 patients with advanced stage lung cancer who were treated
with HDR-EBBT as a part of the multi-modality therapy. We reviewed
patient, radiology and bronchology charts for complications of HDR-EBBT.
Complications were defined as severe hypoxemia, global respiratory failure,
cardiac arrhythmia requiring additional treatment, haemoptysis, pneumotho-
rax, pneumomediastinum, pulmonary oedema, TE fistulae and death. Risk
factors were defined as: acute myocardial infarction6 months ago, hyper-
tension, arrhythmia, chronic obstructive pulmonary disease (COPD), cardio-
myopathy, previous external beam radiotherapy, chemotherapy and interven-
tional pulmonology treatment. Age, gender, tumor histology and tumor
localization were also analyzed for multivariate analysis.
Results: The rate of complications was 5.4%. Statistically significant
(p0.001) risk factors for complications of HDR-EBBT were hypertension,
controlled chronic cardiac arrhythmias, COPD and cardiomyopathy. We
found a significant correlation between the age and the number of risk
factors, and occurrence of complications (p0.001).
Conclusion: The results of this study suggest a closer monitoring of patients
with identified risk factors is advisable. The closer monitoring of the patients
should be performed prior to, and after the treatment in order to avoid
complications.
Disclosure: All authors have declared no conflicts of interest.
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PEMETREXED-RELATED RENAL TOXICITY IN
PATIENTS (PTS) WITH THORACIC MALIGNANCIES
P. Trenta1, R. Iacovelli2, A. Palazzo2, D. Conte2, F. Morano3, G. Campennı`2,
E. Risi2, K. Truscelli1, S. Mezi2, E. Cortesi2 1Medical Oncology, Policlinico
Umberto I, Rome/ITALY, 2Experimental Medicine, Medical Oncology B,
Sapienza University of Rome, Rome/ITALY, 3Experimental Medicine, Med-
ical Oncology, Sapienza University of Rome, Rome/ITALY
Background: Pemetrexed is a multitargeted antifolate drug approved in
treatment of pleural mesothelioma (PM) and lung adenocarcinoma (ADK).
This agent is almost exclusively cleared by renal excretion. Pemetrexed-
related renal toxicity is reported in clinical trials. We report our experience
about variations of renal function in pts treated with pemetrexed.
Patients and methods: Since January 2006 to December 2009, a total of 39
pts (36 ADK and 3 PM), with glomerular filtration rate (GFR)  45 ml/m,
received pemetrexed (500 mg/m2, d 1, every 3 wks) in combination with
platinum compounds in first line setting or as single agent until tolerance or
tumor progression in second line setting. Renal function was evaluated with
GFR, calculated with Cockcrof-Gault formula. Laboratory data were col-
lected at the start and at the end of therapy. Pts’ baseline renal functions were
divided according to chronic renal failure criteria.
Results: A median of 6.0 cycles (1 to 13) of pemetrexed was administered.
28 pts (71.7%) showed a GFR decrease. 19 pts (48.7%) showed grade (G) 1
to 3 of renal toxicity, with 12.8% of G3. In first line setting (16 ADK and 3
PM), 16 pts (84,2%) had a decrease of GFR. 4 pts with baseline GFR
(b-GFR)  100 ml/m showed a 8.5% reduction of GFR, without renal
toxicity. 12 pts with GFR  100 ml/m showed a 36% median reduction of
GFR, with 3 cases (25%) of GFR  25 ml/m (G3 toxicity): one occurred in
1 pt with a b-GFR of 90 ml/m and 2 in pts with a b-GFR  70 ml/m. In
second line setting (20 ADK pts), 12 pts (60%) had a decrease of GFR. 3 pts
with b-GFR  100 ml/m showed a 17% reduction of GFR, without renal
toxicity. 9 pts with b-GFR  100ml/m experienced a GFR median reduction
of 28% with 2 cases (22%) of G3 toxicity. No relationship between
percentage of GFR reduction and cycles number was observed. In both
settings G3 toxicities occurred in women aged 65 yrs (median 62 yrs).
Conclusions: We observed that acute, high grade, no-dose cumulative renal
toxicity is a common adverse event in pts treated with pemetrexed alone or
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in association with platinum compounds. Moreover, toxicity is strictly
related to baseline pts’ renal function (b-GFR  100 ml/m), female sex and
age ( 65 yrs). These data seem to be relevant especially in planning
maintenance strategy with pemetrexed.
Disclosure: All authors have declared no conflicts of interest.
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MO19390 (SAIL): FINAL SAFETY AND EFFICACY DATA
FOR FIRST-LINE BEVACIZUMAB (BV)-BASED THERAPY
IN ADVANCED NON-SMALL CELL LUNG CANCER
(NSCLC)
P. Garrido Lopez1, C. Chouaid2, R. Passalacqua3, J. De Castro4, J. Laskin5
1Medical Oncology, Hospital Ramon Y Cajal, Madrid/SPAIN, 2Service De
Pneumologie, Hoˆpital Saint Antoine, APHP, Paris/FRANCE, 3Medicina 1 E
Oncologia Medica, Azienda Istituti Ospitalieri di Cremona, Cremona/
ITALY, 4Servicio De Oncologı´a Me´dica, Hospital Universitario La Paz,
Madrid/SPAIN, 5Medical Oncology, BC Cancer Agency, Vancouver/
CANADA
Background: SAiL is a large, international, multicentre, single-arm study that
assessed the safety and efficacy of first-line Bv plus chemotherapy in advanced
non-squamous NSCLC in a real-life clinical setting. Final data analysis reported
an overall survival (OS) benefit of 14.6 months, further confirming the findings
of the pivotal phase III clinical trials (E4599 and AVAiL).
Methods: The primary endpoint was safety, and secondary endpoints in-
cluded time to disease progression (TTP) and OS. Pts with untreated locally
advanced, metastatic or recurrent non-squamous NSCLC (ECOG PS 0–2)
received Bv (7.5 or 15mg/kg) plus standard chemotherapy for up to 6 cycles,
followed by Bv until disease progression.
Results: Final analysis was based on 2,172 pts (mean age 59 years). Pts were
(%): male 60.1; stage IIIB/IV 19.6/80.4; adenocarcinoma/large cell/other
85.9/7.0/4.1; ECOG PS 0/1/2 37.4/56.3/6.3. Pts received a median of 7 Bv
cycles and 5 chemotherapy cycles. 37.9% of pts experienced an SAE (any
grade [G]), of which 26.2% were considered to be Bv-related. The results of
SAiL confirm on a large scale that adverse events (AEs) of special interest
for Bv are essentially G 1–2, with a low incidence of clinically significant
events; bleeding events of any G (42.7% of pts) consisted mainly of G1–2
epistaxis (26.6% of pts). Other AEs of special interest with G 3 also had
low incidence (% of pts): pulmonary haemorrhage (0.7%), proteinuria
(3.1%) and thromboembolic events (7.9%). Bv was infrequently interrupted
or discontinued due to bleeding (2.0% and 8.1% respectively) or hyperten-
sion events (6.8% and 3.9% respectively). No new safety signals were
reported. Final efficacy outcomes are remarkable; for the overall population
median TTP was 7.8 months, median OS was 14.6 months, overall response
rate was 51.5% and 88.7% of pts had a best response of stable disease
(37.2%) or better.
Conclusions: This final analysis of SAiL confirms the well-established and
manageable safety profile of first-line Bv in combination with chemotherapy for
advanced NSCLC. The efficacy outcomes in this real-life population are con-
sistent with those seen in the pivotal trials of Bv in NSCLC (E4599 and AVAiL).
Disclosure: P. Garrido Lopez: Advisory Role for Roche, Lilly, Boehringer-
Ingelheim and Astra-Zeneca. Honoraria for Roche and Lilly C. Chouaid:
Christos Chouaid has received fees for speaking and consulting from Astra-
Zeneca, Boehringer-Ingelheim, Roche, Amgen and Lilly; travel to the ASCO
and/or IASLC congress was funded by Merck Serono and Roche. J. Laskin:
I have received small honoraria for academic talks sponsored by: Roche
Canada, Eli Lilly, and Astra Zeneca. My instituition receives research
funding from Roche that is directed to my investigator initiated research
projects. All other authors have declared no conflicts of interest.
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SAFETY OF BEVACIZUMAB (BV)-BASED THERAPY AS
FIRST-LINE TREATMENT OF ELDERLY PATIENTS (PTS)
WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL
LUNG CANCER (NSCLC): MO19390 (SAIL)
M. Reck1, J. Mazie`res2, Z. Mark3, W. Schuette4, E. Dansin5 1Thoracic
Oncology, Hospital Grosshansdorf, Grosshansdorf/GERMANY, 2Depart-
ment of Pneumology, Larrey Hospital, CHU Toulouse, Toulouse/FRANCE,
33th Pulmonology, Pest Megyei Tudogyogyintezet, Torokbalint/HUNGARY,
4Klinik Fuer Innere Medizin Ii, Krankenhaus Martha-Maria Halle-Doelau
GmbH, Halle/GERMANY, 5Oncology, Centre Oscar Lambret, Lille/FRANCE
Background: SAiL (MO19390) is an international, open-label, single-arm
study of first-line Bv plus chemotherapy in pts (n2,172) with advanced
NSCLC. SAiL showed an overall survival (OS) benefit of 14.6 months for
the overall population. Here, we present a final safety subanalysis of Bv plus
chemotherapy in pts aged 65 years (yrs).
Methods: Eligible pts received up to 6 cycles of Bv (7.5 or 15mg/kg) plus
chemotherapy. Non-progressors continued Bv as single-agent therapy until
progression or unacceptable toxicity. Primary endpoint was safety; second-
ary endpoints included time to disease progression (TTP) and OS.
Results: 610 pts 65 yrs (median 70 yrs) and 1,562 pts 65 yrs (median 56
yrs) were evaluable for this final analysis. Pts 65 yrs were (%): male 62.8;
ECOG PS 0/1/2 32/61/7; adenocarcinoma/large cell/other 83/9/4. Median
cycles of Bv and chemotherapy were 6 and 4 for pts 65 yrs and 8 and 5 for
pts 65 yrs. The incidence of grade (G) 3 SAEs considered to be related
to Bv was overall in similar ranges (13.1% and 9.4% for pts 65 yrs and pts
65 yrs, respectively). Most Bv-related SAEs in pts 65 yrs (73%) and pts
65 yrs (75%) resolved or improved. Incidence of AEs of special interest
(SI) was relatively low and comparable between groups (21.5% and 19.1%,
for 65 yrs and 65 yrs respectively), which is interesting considering the
higher baseline rate of comorbidities in the elderly pts subgroup. Rate of
pulmonary haemorrhage was nearly the same for both groups (0.7% and
0.6%, for 65 yrs and 65 yrs respectively). Rate of G 3 congestive heart
failure events was low at 0.8% for 65 yrs and 0.4% for 65 yrs. There
were no G 5 hypertension events. Of all AEs of SI, 1.6% and 1.4% were G
5 for pts65 yrs and 65 yrs respectively. The efficacy outcomes were also
similar for both groups: median TTP for pts 65 yrs vs 65 yrs was 8.3 vs
7.6 months, respectively, and median OS was 14.6 months for both groups.
Conclusions: Pts 65 yrs are not at increased risk of experiencing AEs of
SI when treated with first-line Bv-based therapy compared with pts 65 yrs.
TTP and OS data from this final analysis of SAiL indicate that Bv-based
therapy offers a similar level of clinical benefit, irrespective of age.
Disclosure: M. Reck: Honoraria: Hoffmann-La Roche, Lilly, Merck, Astra-
Zeneca; Advisory Board: Hoffmann-La Roche, Lilly, Merck, Astra-Zeneca
All other authors have declared no conflicts of interest.
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FINAL SAFETY DATA FOR CHINESE PATIENTS (PTS)
WITH NON-SQUAMOUS NON-SMALL CELL LUNG
CANCER (NSCLC) WHO RECEIVED FIRST-LINE
BEVACIZUMAB (BV) PLUS CHEMOTHERAPY IN
SAIL (MO10390)
Y. Wu1, A.C. Cheng2, J.S. Au3, Y. Zhu4, C. Tsai5 1Guangdong General
Hospital & Guangdong Academy of Medical Sciences, Guangzhou/CHINA,
2Oncology, Princess Margaret Hospital, Hong Kong/HONG KONG, 3Clin-
ical Oncology, Queen Elizabeth Hospital, Hong Kong/HONG KONG, 4On-
cology, Beijing Chest Hospital, Beijing/CHINA, 5Department of Chest,
Taipei Veterans General Hospital, Taipei/TAIWAN
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Background: The large international SAiL study aimed to assess the safety
profile of first-line Bv-based therapy in advanced NSCLC in a real-life
clinical population. In the overall population there was an overall survival
(OS) of 14.6 months. Here, we present the final results of a pre-planned
analysis of Chinese pts enrolled in the trial.
Methods: To ensure comparability of the data from this pre-planned analysis
and those from the E4599 trial, a specific protocol amendment was submitted
to allow only Chinese pts with ECOG PS 0–1 and Bv at a dose of 15mg/kg
plus carboplatin/paclitaxel for up to 6 cycles, followed by single-agent Bv
until progression. Primary endpoint was safety; secondary endpoints in-
cluded time to disease progression (TTP) and OS.
Results: The intent-to-treat population (n198) was from 9 centres in
mainland China: male 55%; mean age 55 years; past or active smokers 46%,
stage IV disease 70%. Median number of Bv cycles was 10, with 71.2% of
pts receiving 7 Bv cycles. Incidence of clinically significant adverse events
(AEs) was low. The most common AEs of special interest were grade [g] 1–2
proteinuria (36.9%) and epistaxis (38.9%). Only 13.1% of pts had any [g] 3
AE of special interest; proteinuria (8.6%), hypertension (3.0%), epistaxis
(1.5%), haemoptysis (0.5%) and thromboembolism (0.5%). No CNS bleed-
ing was reported, including in the 26 pts who developed CNS metastases
during therapy. No [g] 3 wound-healing complications or congestive heart
failures were reported and only 8 serious AEs were deemed to be Bv-related.
Bv was interrupted for only 3.1% of AEs and discontinued for 1.3% of AEs.
Only 2 [g] 5 events were reported. Efficacy outcomes were remarkable:
overall response rate 68.7%; disease control rate 96.4%; median TTP 8.8
months; median OS 18.5 months.
Conclusions: The SAiL study confirms the safety and remarkable efficacy of
first-line Bv in combination with carboplatin/paclitaxel in Chinese pts with
advanced non-squamous NSCLC. These findings are consistent with those
for the global SAiL population and the overall population in E4599, the
pivotal phase III trial. No new safety signals were identified in this analysis.
Disclosure: Y. Wu: I have honoraria from Roche, AstraZeneca, Eli Lilly,
Pfizer to disclose. All other authors have declared no conflicts of interest.
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RISK OF SEVERE PULMONARY HEMORRHAGE (SPH)
ASSOCIATED WITH DEVELOPMENT OF CAVITATION
WHILE ON BEVACIZUMAB (BV) THERAPY IN PATIENTS
(PTS) WITH NON SMALL CELL LUNG CANCER (NSCLC):
RESULTS FROM ARIES, A BV TREATMENT
OBSERVATIONAL COHORT STUDY (OCS)
D.R. Spigel1, J.R. Brahmer2, N.A. Fischbach3, P. Kumar4, M. Kosty5, A.J.
Wozniak6, S.L. Teng7, E.D. Flick8, A.P. Sing9, T.J. Lynch10 1Oncology,
Sarah Cannon Research Institute, Nashville/USA, 2Sidney Kimmel Compre-
hensive Cancer Center, Johns Hopkins University School of Medicine,
Baltimore/USA, 3Oncology, Oncology Associates of Bridgeport PC, Fair-
field/USA, 4Hematology, Oncology, & Transplantation, University of Min-
nesota, Minneapolis/USA, 5Hematology/Oncology, Scripps Clinic, La Jolla/
USA, 6Karmanos Cancer Institute, Wayne State University, Detroit/USA,
7Biostatistics, Genentech, Inc, South San Francisco/USA, 8Epidemiology,
Genentech, Inc, South San Francisco/USA, 9Biooncology, Genentech, Inc,
South San Francisco/USA, 10Oncology, Yale Cancer Center, New Haven/
USA
Background: BV (Avastin®) prolongs progression free and overall survival
(OS) in advanced NSCLC pts. sPH (grade 3) is a rare but often fatal event
that has been associated with BV-based therapy in phase 3 trials (rate,
2–4%). Potential risk factors include squamous histology, history of hemop-
tysis, and tumor cavitation. Rates of baseline (BL) cavitation in NSCLC pts
and development of cavitation on BV therapy are unknown. ARIES is an
OCS of 1970 pts with NSCLC that has assessed BL scans for presence of
tumor cavitation. A substudy collected follow-up (F/U) scans to examine the
potential association of developing cavitation on BV therapy and risk of sPH.
In addition, any pt that develops sPH is assessed for tumor cavitation.
Methods: Pts at specified ARIES sites submitted BL and on-study CT scans
to an independent review facility. Substudy evaluable pts had at least 1
measurable (meas) tumor at BL and at least 1 post-BL scan. Correlations
between cavitation (pre-existing or developing), clinical, tumor and treat-
ment characteristics were evaluated by chi-square test or t-test. Incidence of
sPH based on cavitation status was assessed by Fisher’s exact test. OS is
estimated by Kaplan Meier.
Results: As of 12/14/09, 1494 pts had meas tumors at BL. Of these, 199 have
a post-BL scan. For the 1494 pt cohort: median F/U is 9.6 mo. BL
characteristics for the substudy (n199) and overall cohort with meas tumor
at BL (n1494), respectively, include: 30% vs 33% 70 yrs; 68% vs 70%
adenocarcinoma; 4.5% vs 4.4% therapeutic anticoagulation; 43% vs 49%
central tumor; 13% vs 15% cavitation. 60 (30.2%) substudy evaluable pts
developed cavities while on BV, none of whom had sPH. There was 1 sPH
event (0.5%) reported from the 218 pts with BL cavitation in their meas
tumor. Preliminary median OS (95% CI) for substudy pts developing
cavitation and the entire ARIES cohort are similar at 13.9 mo (10.0, 20.5)
and 13.7 mo (12.6, 14.9), respectively.
Conclusions: sPH is a rare, potentially fatal event in pts with NSCLC
receiving BV. The findings of this substudy suggest that cavitation alone is
not a risk factor for sPH.
Disclosure: D.R. Spigel: Advisor to Genentech (not financially compen-
sated); J.R. Brahmer: Advisor to Genentech (financially compensated); P.
Kumar: Advisor to Genentech (financially compensated) and have received
honoraria from Genentech; M. Kosty: Have received honoraria and research
funding from Genentech; A.J. Wozniak: Genentech advisory board (finan-
cially compensated) and research funding from Genentech; S.L. Teng:
Employee of Genentech, Inc and stockholder in Roche; E.D. Flick: Em-
ployee of Genentech and stockholder of Roche; A.P. Sing: Employee of
Genentech and stockholder of Roche T.J. Lynch: Board of Directors member
and stockholder: Infinity Pharma Consultant: Genentech, Merck, Boehringer-
Ingelheim (BIPI), Astra-Zeneca. All other authors have declared no conflicts
of interest.
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SYNCHRONOUS BRAIN METASTASES FROM
NON-SMALL CELL LUNG CANCER: TIME FOR
REAPPRAISAL OF EXTRACRANIAL TREATMENT
OPTIONS?
J.S.W. Lind1, F.J. Lagerwaard2, E.F. Smit3, P.E. Postmus4, B.J. Slotman5, S.
Senan2 1Pulmonary Diseases, VUMC, Amsterdam/NETHERLANDS, 2Radiation
Oncology, VU University Medical Center, Amsterdam/NETHERLANDS, 3Pulmo-
nary Diseases, VU University Medical Center, Amsterdam/NETHERLANDS,
4Pulmonary Diseases 4a50, VU University Medical Center, Amsterdam/
NETHERLANDS
Purpose: The optimal treatment of the primary tumour in patients with brain
metastases (BM) from newly diagnosed non-small cell lung cancer (NSCLC)
remains unclear. Our aim was to identify patient groups with synchronous
BM for whom radical treatment of the primary site may be appropriate.
Methods: The medical records of 167 patients treated at our centre between
November 2000-June 2009 for newly diagnosed NSCLC and synchronous
BM were reviewed. All patients underwent surgery/radio-surgery (n86) or
whole-brain radiotherapy (WBRT; n81) of their BM. Univariate and
multivariate analysis were performed to assess prognostic factors significant
for overall survival (OS).
Results: The median OS of patients undergoing surgery/radio-surgery for
BM was 12.1 months. Those undergoing ‘radical’ thoracic treatment (n24)
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had a longer median OS (28.4 months) than those undergoing chemotherapy
(n74; 12.1 months) or supportive therapy (n69; 5.6 months), p0.01.
Patients with stage I thoracic disease (n23) had a longer median OS (18.5
months) than those with stage III (n43; 9.4 months) or with intra/extra-
thoracic metastases other than BM (stage IV; n20; 2.7 months), p0.01.
The median OS of the WBRT patients was 3.7 months. One patient
underwent radical thoracic treatment. Patients undergoing chemotherapy
(n42) had a longer median OS (5.7 months) than patients undergoing
supportive therapy only (n38; 1.6 months), p0.01. Patients with perfor-
mance status (PS) 0-1 (n53) had a median OS of 5.0 months; OS was 1.8
months for PS 2-3 (n27), p0.01.
Conclusions: Radical thoracic treatments may be justified in patients eligible
to undergo surgery/radio-surgery for synchronous BM from NSCLC, even
when stage III thoracic disease is present. The role of chemotherapy in
selected patients with a good PS undergoing WBRT warrants further eval-
uation.
Disclosure: All authors have declared no conflicts of interest.
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AN ANALYSIS OF PATIENTS WITH BRAIN METASTASES
FROM NON SMALL CELL LUNG CANCER TREATED
WITH SHORT COURSE ACCELERATED RADIOTHERAPY
(SCAR)
A. Munshi1, J.P. Agarwal1, T. Wadasadawala1, R. Apsani1, M. Upasani1,
S.G. Laskar1, C.S. Pramesh1, N. Jambhekar1, H. Menon1, K. Prabhash2
1Radiation Oncology, Tata Memorial Hospital, Mumbai/INDIA, 2Medical
Oncology, Tata Memorial Hospital, Mumbai/INDIA
Aims: Study various prognostic factors affecting outcome and validate
Radiation Therapy Oncology Group-Recursive Partitioning Analysis
(RTOG-RPA) class in non small cell lung cancer (NSCLC) with brain
metastases treated with short course accelerated radiotherapy (SCAR).
Material and methods: Case records of 100 patients of NSCLC consecu-
tively treated at Tata Memorial Hospital from August 2006 to August 2009
were studied for various patient, tumor and treatment related prognostic
factors. Patients received whole brain radiotherapy to a dose of 20Gy/5# over
one week (n90) or 30Gy/10# over two weeks (n10). Univariate and
multivariate analysis was conducted using SPSS v15.
Results: Overall survival (OS) for the entire cohort was 7 months (1-61
months) whereas median post metastases survival (PMS) was 4.0 months
(0.5-30.0 months). Of the various prognostic factors, RPA class (II vs. III, p
value0.003), Karnofsky Performance Score (KPS 70 vs. 70, p val-
ue0.005), primary disease status (controlled vs. uncontrolled, p val-
ue0.031), time of detection of brain metastases (synchronous vs. meta-
chronous, p value0.000), use of systemic therapy (yes vs. no, p
value0.00) and metastases free interval (MFI 6 months vs.  6 months,
p value0.000) emerged significant on univariate analysis. On multivariate
analysis, use of systemic therapy (p value0.000) and length of MFI of at
least 6 months strongly predicted OS. There was a strong correlation between
median OS and MFI (p value0.000), it was stronger for RPA class II as
compared to RPA class III (r0.665 vs. 0.557).
Conclusion: SCAR regime is an effective and resource sparing palliative
strategy for brain metastases in NSCLC. Patients with long MFI have
significant survival advantage especially if they belong to RPA class II. Thus,
short MFI and synchronous presentation indicate aggressive tumor biology.
Use of systemic therapy significantly improves survival. However, validation
of these findings in future prospective trials is required.
Disclosure: All authors have declared no conflicts of interest.
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PULMONARY NEUROENDOCRINE TUMOURS:
PREVALENCE IN 1,000 RESECTED PATIENTS AND
ANALYSES OF PATIENT CHARACTERISTICS, SMOKING
HABITS AND TUMOUR STAGE
W. Engel-Riedel, J. Zimmermann, C. Ludwig, E. Stoelben Lung Departure,
Kliniken der Stadt Ko¨ln gGmbH, Cologne/GERMANY
Objective: Neuroendocrine tumours of the lung can be divided in typical
carcinoid (TC), atypical carcinoid (AT), large cell neuroendocrine carcinoma
(LCNEC) and small cell lung carcinoma (SCLC). Apart from SCLC which
accounts for 20-25% of pulmonary tumors, carcinoids and LCNEC are rare
tumors with a reported prevalence of approximately 3% among surgically
resected lung cancers. Generally speaking there is only little information on
the prevalence of neuroendocrine tumors in resected patients so that we
would like to present the data collected our institution.
Patients and method: Retrospective analysis of 1,000 surgically resected
lung cancer patients in our institution between January 2007 and March
2009. For patients with a diagnosis of TC, AT and LCNEC we compared the
data in terms of age, sex, smoking habits and tumor stage.
Results: Among the resected patients 17 (1.7%) were diagnosed with TC, 6
with AT (0.6%) and 25 patients with LCNEC (2.5%). A mixed histology of
LCNEC and SCLC was found in 8 out the 25 patients with a LCNEC.
LCNEC highly correlated with smoking (all were smokers) and the patients
were diagnosed at a later stage compared to those with carcinoids. Patients
with TC and AT happened more likely to be women, never-smokers and
were mainly diagnosed in Stage I. There was no significant difference in age
between these groups.
Conclusions: Neuroendocrine tumours of the lung are rare. Retrospective
analysis of this data allows us to differentiate between these patients in terms
of prognosis. The importance of clinical trials is underlined especially for
patients with LCNEC as they have a poor prognosis.
Disclosure: All authors have declared no conflicts of interest.
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PHASE I STUDY OF THE IGF-IR INHIBITOR FIGITU-
MUMAB (CP-751,871) IN COMBINATION WITH CISPLA-
TIN (C) AND GEMCITABINE (G) OR C AND PEMETREXED
(P) IN TREATMENT-NAı¨VE PATIENTS (PTS) WITH AD-
VANCED NON-SMALL CELL LUNG CANCER (NSCLC)
J. Corral1, J.M. Sanchez-Torres2, K. O’Byrne3, L. Iglesias2, D. Li4, M.
Atienza5, J. Canon6, M. Carpentieri7, A. Gualberto4, L. Paz-Ares1 1Oncol-
ogy, Hospital Universitario Virgen del Rocio, Seville/SPAIN, 2Oncology,
Hospital Universitario 12 De Octubre, Madrid/SPAIN, 3Oncology, St James
Hospital, Dublin/IRELAND, 4Oncology Business Unit, Pfizer Inc, New Lon-
don/USA, 5Oncology, Hosptial Universitario Virgen del Rocio, Seville/
SPAIN, 6Oncology, Grand Hopital de Charleroi, Charleroi/BELGIUM, 7On-
cology Business Unit, Pfizer Inc, Milan/ITALY
Background: Figitumumab (F) is a potent and selective fully human IgG2
monoclonal antibody against IGF-IR. Preclinical data indicate that F in-
creases the antitumor activity of chemotherapy in cancer xenograft models.
We evaluated the safety, tolerability, pharmacokinetics (PK) and pharmaco-
dynamics (PD) of F in combination with C and G or C and P in pts with
treatment-naı¨ve advanced NSCLC.
Methods: This open-label, dose-escalation study investigated F 6–20 mg/kg
given in 2.5-hr infusions on day 1 of 3-wk cycles in combination with C (80
mg/m2, day 1) and G (1,250 mg/m2, days 1 & 8) for 6 cycles. The
tolerability of 1-hr F infusion was also investigated in expansion cohorts (C
80 mg/m2  G 1,250 mg/m2, or C 75 mg/m2  P 500 mg/m2). Pts could
receive additional cycles of single-agent F upon chemotherapy discontinua-
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tion. The primary objective was the identification of the maximum tolerated
dose (MTD) and the recommended phase II dose (RP2D) of F in combination
with chemotherapy.
Results: 45 pts were enrolled (median age 59 yrs, range 44–74); 44% had
adenocarcinoma and 16% had squamous cell carcinoma. The only dose-
limiting toxicity (DLT) was grade 4 neutropenia that lasted 8 days in 1/6 pts
treated with CG  F at 20 mg/kg. No dose escalation above 20 mg/kg was
planned. No pts required dose reduction. Safety and preliminary efficacy
results are shown in the table. Two responding pts underwent surgery; no
residual tumor was found (pathologic CRs). Median TTP was 5.7 mos (3 pts
still on follow up). Analyses of PK and PD endpoints are ongoing.
Conclusions: F was well tolerated in combination with CG for the first-line
treatment of pts with NSCLC. In addition, no safety concerns were observed
with CP  F at 20 mg/kg. Based on the favorable safety profile, the 1-hr
infusion of F (20 mg/kg every 3 wks) was selected as the RP2D. Preliminary
efficacy results are encouraging.
Disclosure: K. O’Byrne: I have received grants to support a PhD studentship
for 4 years (supplied by Pfizer Ireland), honoraria for participation in
advisory boards, and participated on asteering committee for ADVIGO
program (Pfizer Inc). D. Li: I hereby declare that I have no conflict of interest
in stock ownership, membership of any advisory board and other substantive
relationships. I am Pfizer employee. J. Canon: I have received funding for
data management from Pfizer Inc. M. Carpentieri: I am employed by Pfizer
Inc. and hold Stock in Pfizer Inc. A. Gualberto: I am employed by Pfizer Inc.
and hold Stock in Pfizer Inc. L. Paz-Ares: I have acted as an advisory
consultant for Pfizer Inc. All other authors have declared no conflicts of
interest.
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CLINICAL OUTCOMES IN PATIENTS WITH NON-SMALL-
CELL LUNG CANCER TREATED IN PHASE I CLINICAL
TRIALS
F. Janku, J. Gong, I. Garrido-Laguna, H.A. Parsons, C. Vaklavas, R.
Kurzrock Investigational Cancer Therapeutics, UT MD Anderson Cancer
Center, Houston/USA
Background: Lung cancer is the most frequent cause of cancer-related death
in the US. The outcomes of patients with advanced non-small-cell lung
cancer (NSCLC) treated on phase I clinical trials have not been systemati-
cally analyzed.
Methods: We reviewed the records of consecutive patients with advanced/
metastatic NSCLC who were referred to the Phase I Clinical Trials Program
from August 2004 to May 2009. Best response was assessed by Response
Evaluation Criteria in Solid Tumors 1.0.
Results: Eighty-five patients (54 men and 31 women) were identified. The
median age was 62 years (range: 30–85). Of 72 patients evaluable for
response, 10 (14%) had a partial response (PR), and 30 (49%) had stable
disease (SD) for 12 weeks. The median progression-free survival (PFS)
was 2.8 months (95% CI; 2.2-3.4), similar to the 3.4 months (95% CI;
2.5-4.3) PFS observed in the 2nd line treatment within the same population
(Table). The median overall survival (OS) was 10.6 months. The 1-year
survival rate was 25%. In univariate analysis, factors predicting shorter
survival were hemoglobin  12 g/dL (p0.0035),  2 organ systems
involved (p0.021), ECOG  1 (p0.0001), smoking history (p0.005),
and male gender (p0.038). PS  1, smoking history and male gender were
associated with worse survival in the multivariate analysis.
Conclusion: Patients with advanced NSCLC treated on phase I clinical trials
had a PFS comparable to 2nd line treatment, and OS of 10.6 months. Poor PS,
smoking history, and male gender were significant factors associated with
shorter OS in the multivariate analysis. Table: PFS and OS on 1st line, 2nd
line, and Phase I treament.
Disclosure: All authors have declared no conflicts of interest.
219PD
RANDOMISED PHASE II TRIAL OF 4 DOSE LEVELS OF
SINGLE AGENT DOCETAXEL IN PERFORMANCE
STATUS (PS) 2 PATIENTS WITH ADVANCED
NON–SMALL CELL LUNG CANCER (NSCLC):
DOC PS2 TRIAL
R. Califano1, R. Griffiths2, P. Lorigan3, L.F. Ashcroft4, P. Burt5, M.
Harris5, P. Taylor6, C. Faivre-Finn7, N. Thatcher8, F. Blackhall9 1De-
partment of Medical Oncology, The Christie NHS Foundation Trust,
Manchester/UNITED KINGDOM, 2Medical Oncology, The Christie NHS
Foundation Trust, Manchester/UNITED KINGDOM, 3Department of Medi-
cal Oncology, Christie Hospital, Manchester/UNITED KINGDOM, 4Depart-
ment of Biostatistics, Christie Hospital, Manchester/UNITED KINGDOM,
5Department of Clinical Oncology, The Christie NHS Foundation Trust,
Manchester/UNITED KINGDOM, 6Northwest Lung Centre, South Manches-
ter University Hospital, Manchester/UNITED KINGDOM, 7Department of
Clinical Oncology, Christie Hospital NHS Trust, Withington, Manchester/
UNITED KINGDOM, 8Department of Medical Oncology, Christie Hospital
NHS Foundation Trust, Manchester/UNITED KINGDOM, 9Department of
Medical Oncology, Christie Hospital NHS Trust, Manchester/UNITED
KINGDOM
Background: The role of chemotherapy for advanced NSCLC patients and
poor PS (Karnofsky score 50-60) remains controversial. We evaluated 4
doses of docetaxel with the aim of identifying a less toxic, clinically effective
dose.
Methods: Seventy-two patients with stage III (22%) (unsuitable for
radiotherapy) and IV (78%) NSCLC were randomized to receive 4 doses
of 3-weekly docetaxel, for 4 cycles: Arm A) 40 mg/m2 (n17), Arm B)
50 mg/m2 (n17), Arm C) 60 mg/m2 (n19), Arm D) 50 mg/m2
escalated by 10 mg/m2 to a maximum of 70 mg/m2 if no dose-limiting
toxicities occurred (n19). Primary endpoints: Maximum tolerated dose,
CGF
(6mg/kg)
CGF
(10mg/kg)
CGF
(20mg/kg)
CPF
(20mg/kg)
Patients, n 6 3 23 13
Cycles, median (range) 3 (1–5) 4 (2–6)
Objective Response Rate, n (%) 13 (40.6) 3 (23.1)
CR 2 (6.3) 0
PR 11 (34.4) 3 (23.1)
SD 7 (21.9) 3 (23.1)
Grade 3/4 toxicity (treatment
related, 8%), n (%)
Hyperglycemia 6 (18.8) 1 (7.7)
Asthenia 4 (12.5) 1 (7.7)
Neutropenia 12 (37.5) 5 (38.5)
Anemia 3 (9.4) 1 (7.7)
Thrombocytopenia 9 (28.1) 3 (23.1)
1st Line
Treatment
2nd Line
Treatment
Phase I
Treatment
PFS months 6.1 3.4 2.8
OS years 3.5 2.9 0.9 (10.6 months)
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RR, duration of response, symptom improvement, toxicity and QoL.
Secondary endpoint: overall survival (OS). Patients and disease charac-
teristics were well balanced. Median age was 67 (range 45-81), M/F31/
41, Histology subtype: Squamous/Adenocarcinoma/Mixed/NOS 42%/
49%/4%/5%.
Results: Seven patients did not receive any treatment because of deteri-
oration in PS or death. 50% of patients in arm D, who received more than
one cycle, received dose escalation. There was no statistical difference in
the number of cycles administered: arms A, B and D median two cycles
and arm C three cycles and no difference in RR: Arm A 6%, Arm
B6%, Arm C10%, and Arm D0%. Incidence of G3-G4 leucopenia
was higher in arm C (p0.01) and G3-G4 neutropenia was higher in Arm
D (p0.03). Most common G3 non-haematological toxicity was infec-
tion, with no difference between the groups; there were no G4 toxicities.
We found no difference in administration of intravenous (iv) antibiotics
or hospitalization between the arms. QoL: no difference in total scores
between baseline and cycles 1, 2, 3 and 4. Amalgamating scores for
specific symptoms, looking at baseline to pre-cycle 2, there was a
significant decrease in pain scores (p0.025). We found no difference in
OS (p0.992). Median survival was 86, 86, 88 and 82 days and 6-month
survival was 32%, 29%, 21% and 21% for arms A, B C, and D,
respectively.
Conclusions: In this poor prognosis group of patients responses to docetaxel
were seen at all dose levels including 40mg/m2. Higher dose levels are not
associated with increased toxicities, use of iv antibiotics or hospitalization
rates. However, these data do not support further evaluation of single agent
docetaxel in the chemonaive PS2 population.
Disclosure: All authors have declared no conflicts of interest.
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DOCETAXEL (D) VERSUS DOCETAXEL/GEMCITABINE
(D&G) IN THE TREATMENT OF OLDER PATIENTS WITH
ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC):
AN ALPE ADRIA THORACIC ONCOLOGY
MULTIDISCIPLINARY GROUP RANDOMIZED
PHASE II TRIAL (ATOM 017)
E. Rijavec1, O. Belvedere2, M. Aita3, C. Rossetto3, A. Follador3, C. Sacco4,
T. Ceschia5, C. Genova1, G. Fasola3, F. Grossi1 1Medical Oncology, Na-
tional Institute for Cancer Research, Genoa/ITALY, 2Leeds Institute of
Molecular Medicine, University of Leeds, Leeds/UNITED KINGDOM, 3Di-
partimento di Oncologia, Azienda Ospedaliera Universitaria, Udine/ITALY,
4U.O. Oncologia, Azienda Ospedaliera S. Maria della Misericordia, Udine/
ITALY, 5Radiotherapy, Azienda Ospedaliera S. Maria della Misericordia,
Udine/ITALY
Optimal chemotherapy for older patients with advanced NSCLC is still unde-
termined. Both single agent D and the combination of D&G are active and
well-tolerated. The aim of this study was to compare the efficacy of single-agent
weekly D with weekly D&G in elderly patients with advanced NSCLC. This
multicenter, one-stage, randomized phase II trial aimed to identify the most
promising of the two regimens; 49 patients per arm were planned, with  8
objective responses required for the “winner” to warrant further study. Chemo-
therapy-naive patients with stage wet-IIIB/IV NSCLC aged  70 years, with
ECOG performance status  2 were randomized to receive D (35 mg/m2) on
days 1, 8, and 15 (arm A) or D (35 mg/m2) plus G (800 mg/m2) on days 1, 8,
and 15 (arm B). In both arms, treatment was repeated every 4 weeks for a
maximum of 4 cycles. The primary end point was response rate (RECIST);
secondary endpoints were: toxicity, time-to-progression (TTP), survival. Be-
tween July 2002 and November 2009, 75 patients were randomized; 69 were
evaluable (intention to treat). Enrollment was closed early due to slow accrual.
Median age was 75 years (range 70-82). There was 1 (3%) CR in arm B, with
5 (14%) and 10 (28%) PRs in arms A and B, respectively. Disease control
(CRPRSD) was achieved in 56% and 73% of patients in arms A and B,
respectively. Median survival was 7.2 months in arm A and 7.9 months in arm
B (p.58; HR1.15, 95% CI 0.69-1.9). Median TTP was longer in arm B (7.4
months and 3.9 months; p.099, HR1.57, 95% CI 0.91-2.7). Grade 3-4
neutropenia was more common with D&G than D (3% and 25%, respectively;
p.013), as was anemia (3% and 9%, respectively). No case of neutropenic
fever was observed. Non-hematological toxicity was mild with all grades fatigue
occurring in 58% and 78% of patients receiving D and D&G, respectively.
Treatment with D&G resulted in higher response rate and modest improvement
in TTP but not survival when compared with single-agent D. The combination
of D&G has met the statistical endpoint of  8 responses and is worthy of
further investigation.
Disclosure: M. Aita: Honoraria: Sanofi-Aventis; G. Fasola: Honoraria:
sanofi-Aventis and Eli-Lilly; F. Grossi: Honoraria: Sanofi-Aventis and Eli-
Lilly Research funding: Eli-Lilly; All other authors have declared no con-
flicts of interest.
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CLINICAL OUTCOMES OF 2ND LINE ADVANCED
NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
RECEIVING MONOTHERAPY IN THE OUTPATIENT
COMMUNITY SETTING
S.K. Gruschkus1, C. Reyes2, M.T. Forsyth1, E.S. Nadler3 1Healthcare Infor-
matics, US Oncology, The Woodlands/USA, 2Health Outcomes & Payer
Support, Genentech, Inc, South San Francisco/USA, 3Texas Oncology, US
Oncology, Dallas/USA
Background: 2nd line monotherapy options for advanced NSCLC include
erlotinib (E), docetaxel (D), or pemetrexed (P). The purpose of this retro-
spective study was to describe clinical outcomes among patients (pts)
receiving 2nd line monotherapy in a large network of outpatient community
clinics in the United States.
Methods: This retrospective study used data from US Oncology’s
iKnowMed EMR system. Advanced NSCLC patients who received 2nd line
monotherapy from 7/1/2006 – 6/30/2008 were identified. Patients were
followed through 7/1/2009 to estimate treatment duration, progression-free
(PFS), and overall survival (OS). Disease progression was defined as esca-
lation in line of therapy. The Kaplan Meier method and Cox proportional
hazards regression analysis were used to estimate and compare PFS and OS
across treatment cohorts.
Results: We identified 610 pts – 73 (12%) received E, 87 (14%) received D,
and 450 (74%) received P. Overall median age of pts was 67 years (range 31
– 91) and 55% were male. No significant differences in stage at diagnosis,
baseline performance status, hemoglobin level, or body mass index were
observed by treatment. Mean therapy duration was 88 days (95% CI:72-103)
for patients treated with D; 103 days for P (95% CI93-113); and 116 days
for E (95% CI78-154). Overall median OS was 197 days (192 days for D;
211 days for P; and 229 days for E; log-rank p0.13). Overall median PFS
was 133 days (132 days for D; 132 days for P; and 155 days for E; log-rank
p0.39). In Cox regression analyses using a backwards elimination ap-
proach, we found no significant association between treatment and OS
(p0.36) or PFS (p0.26) after considering age, gender, stage at diagnosis,
performance status, and hemoglobin level as potential covariates.
Conclusions: In this observational study within the outpatient community
setting, we observed no significant differences in OS/PFS among patients
receiving 2nd line P vs. E vs. D. Given this observed parity in objective
clinical outcomes, other factors such as costs, convenience, and tolerability
may become increasingly important factors in determining the most appro-
priate 2nd line therapy for NSCLC.
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USEFULNESS OF MONITORING SERUM
CARCINOEMBRYONIC ANTIGEN (CEA) TO DEFINE
RESPONSE TO CHEMOTHERAPY AND ITS
CORRELATION WITH SURVIVAL IN PATIENTS WITH
NON SMALL-CELL LUNG CANCER WITH ABNORMAL
BASELINE CEA LEVELS
M. Morales1, O. Pen˜a1, A. Astorga1, J. De la Garza2, L. Martinez-Barrera3,
O. Arrieta1 1Department of Medical Oncology, Instituto Nacional de Can-
cerologı´a, Mexico City/MEXICO, 2Medical Oncology, Instituto Nacional de
Cancerologia, Mexico City/MEXICO, 3Department of Medical Oncology,
Instituto Nacional de Enfermedades Respiratoria, Mexico City/MEXICO
Background: Carcinoembryonic antigen (CEA, CEACAM5) is an oncofetal
protein that functions as a cell-adhesion molecule. It is usually over-
expressed in a variety of neoplasms; moreover, high serum CEA levels are
an independent prognostic factor for recurrence and survival in patients with
non small-cell lung cancer (NSCLC). To date, there are no markers that
satisfactorily predict objective response to chemotherapy in NSCLC.
Purpose: The aim of the study was to evaluate the relationship between
serum CEA with response rate to chemotherapy, progression free-survival
(PFS) and overall survival (OS) in patients with NSCLC.
Methods: NSCLC patients were evaluated for the serum CEA levels at
baseline and after 2 cycles of chemotherapy. Serum CEA levels were
correlated with objective response rate, PFS and OS.
Results: 182 (67.4%) of 270 patients had a baseline CEA serum level
5ng/ml (range 5-7,440). 169 patients (92.9%) received a platinum-based
chemotherapy and 13 patients (7.1%) a tyrosine kinase inhibitor-based
chemotherapy. The median follow-up was 12.6 months. Objective global
response was found in 29.7% and 25% CEA reduction was found in 32.4%
of the patients. 100% of patients with complete response had a 25% CEA
reduction value, 60% for partial response, 24.7% for stable disease and 9.3%
for progressive disease (Pearson’s 	2 value 38.49, p0.0001). Sensitivity,
specificity, positive predictive value and negative predictive value were 80%,
62%, 57% and 83% respectively. PFS was longer in patients with a 25%
reduction in CEA (11.3 months [CI 95% 9.5-13.1] vs 8.7 months [CI 95%
7.5-9.8], p0.04) and OS showed a tendency for longer survival 19.9 months
[CI 95%12.3-27.5] vs 14.7 months [CI 95% 13.2-16.1]; p0.09).
Conclusions: A 25% reduction from baseline CEA is associated with
objective response and PFS. CEA is a noninvasive, accurate and specific
predictor of objective response to treatment in locally advanced and ad-
vanced NSCLC.
Disclosure: All authors have declared no conflicts of interest.
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SERUM CARCINOEMBRYONIC ANTIGEN (CEA) LEVELS
ARE ASSOCIATED WITH WORSE PROGNOSIS IN
ADVANCED NON- SMALL CELL LUNG CANCER (NSCLC)
S. Cedre´s, I. Nun˜ez, M. Longo, P.N. Martı´nez, E. Rodriguez Checa, M.
Cazorla, E. Felip Medical Oncology, Vall d’Hebron University Hospital,
Barcelona/SPAIN
Background: The usefulness of tumor markers in NSCLC is not well
defined. High levels of CEA are considered a negative prognostic factor in
early-stages NSCLC but its role in advanced disease is yet to be defined. The
aim of our study is to analyze the prognostic value of basal level of CEA in
advanced NSCLC patients.
Methods and patients: Two hundred and seventy five patients diagnosed in
our institution between April 2004 and March 2009 were retrospectively
reviewed. Baseline prognostic factors analyzed were gender, histology and
brain metastases. Overall survival (OS) and progression free survival (DPFS)
were calculated by the Kaplan-Meier method. The cutoff value of serum
CEA level was 5 ng/ml.
Results: Baseline patients characteristics: median age 63 (30–81 years),
males 84.4%,stage III: 38.3% and IV: 61.7%; squamous carcinoma 22.4%,
adenocarcinoma 38.6%, large cell carcinoma 21.7% and undifferentiated
carcinoma 17.3%. High levels of CEA were detected in 163 (58.8%) patients.
Significant higher levels of CEA at baseline were present in adenocarcinoma
(p0.03) but not difference according sex or brain metastases were detected.
After a median follow-up of 9.1 months, 229 patients relapsed and 185
patients had died. The PFS was 5.3 months in patients with CEA5 ng/ml
and 7.4 months in patients with normal CEA (p0.011). The OS was 10.0
months vs 14.0 months in patients with normal CEA (p0.085). In the
multivariate analysis only high levels of CEA and histology were significant
correlated with worse prognostic.
Conclusion: In our analysis, high levels of CEA at baseline are correlated
with worse survival in stage III-IV NSCLC patients.
Disclosure: All authors have declared no conflicts of interest.
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ERLOTINIB IN PATIENTS WITH ADVANCED
NON-SMALL-CELL LUNG CANCER (NSCLC): RESULTS
ON 973 PATIENTS FROM TARCEVA REGISTER
OF CZECH REPUBLIC
J. Skr˘ic˘kova´1, M. Pes˘ek2, P. Zatloukal3, V. Kolek4, L. Koubkova´5, F.
Salajka6, M. Tomı´s˘kova´7, J. Krejc˘ı´8, M. S˘tı´cha9, B. Kadlec10 1Department
of TB and Respiratory Disease, University Hospital Brno, Brno/CZECH
REPUBLIC, 2Department of Tuberculosis and Respiratory Diseases, Uni-
versity Hospital Plzen˘, Plzen˘-Bory/CZECH REPUBLIC, 3Department of TB
and Respiratory Disease, University Hospital Bulovka, Praha/CZECH
REPUBLIC, 4Department of Pneumology, University Hospital Olomouc,
Czech Republic, Olomouc/CZECH REPUBLIC, 5Department of Pulmonol-
ogy, University Hospital Motol, Prague/CZECH REPUBLIC, 6Department
of Pulmonology, University Hospital Hradec Kra´love´, Hradec Kra´love´/
CZECH REPUBLIC, 7Department of Respiratory Diseases and TB, Univer-
sity Hospital Brno, Brno/CZECH REPUBLIC, 8Department of TB and
Respiratory Disease, University Hospital Plzen, Plzen/CZECH REPUBLIC,
9Institut of Biostatistics and Analyses, Masaryk University Brno, Brno/
CZECH REPUBLIC, 10Department of Respiratory Diseases and TB, Uni-
versity Hospital Brno, Brno/CZECH REPUBLIC
Background: Our study evaluates the data from Czech Tarceva Register,
which is the common project of the Czech Pneumological Society, Czech
Society for Oncology and Institute of Biostatistics and Analyses of Masaryk
University Brno. We evaluated the efficacy and toxicity of the 973 patients
with advanced NSCLC treated with erlotinib between 12/2005 and 10/2009
in 10 institutions in the Czech Republic.
Patients and methods: In 973 patients was erlotinib administered orally
150mg/day until disease progression or unacceptable toxicity. Female were
329 (33,8 %) and male 644 (66,2%), non-smokers were 220 (22,6%),
stop-smokers 393 (40,4%) and current smokers 360 (37,0%) patients. Me-
dian age was 65 years.
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Results: Erlotinib was used as 1st line therapy in 12,8%, as 2nd line in
44,2% and as 3rd line in 43,0% patients. At the time of indication for
erlotinib was ECOG PS 0 in 68 patients, PS 1 in 538, PS 2 in 341 and PS 3
in 26 patients. Adenocarcinoma was confirmed in 449 (46,2%), squamous-
cell carcinoma in 380 (39,7%), large–cell carcinoma in 25 (2,6%) and non
specified carcinoma in 109 (12,6%) patients. Complete response (CR) was
confirmed in 8 (0,8%), PR (partial response) in 77 (7,9%) patients, SD (stable
disease) in 425 (43,7%), 269 (43,7%) patients progressed and 194 patients
was not evaluated. Major toxicities were skin toxicity in 413 (42,4,3%) and
diarrhoea in 189 (19,4 %). but the therapy was finished due to toxicity grade
3-4 only in 38 (5,3%) patients. Median survival (95% CI) was 6,8 month
(6,0; 7,5). Probability of 3-month survival was 72,3% (69,3;75,3), probabil-
ity of 6-month survival was 52,9% (49,3; 56,5) and probability of one-year
survival was 30,9 (26,9; 34,9). Progression free survival (PFS) (95% CI) was
2,9 months. Statistically significant (p 0,001) were the differences between
groups of patients according to PS (01 vs. 23) and according skin
toxicity. The best median survival (13,3 month) was in patients with PS 0.
We don’t find the differences between groups of patients according smoking
(p0,006), according morphology (p0,046) and according sex (p0,377).
Conclusions: Erlotinib was well tolerated with evidence of antitumour
efficacy in 1st, 2nd and 3rd line of treatment.
Disclosure: All authors have declared no conflicts of interest.
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TEN-YEAR RETROSPECTIVE ANALYSIS OF 494 CONSEC-
UTIVE METASTATIC NSCLC PATIENTS TREATED WITH
FIRST LINE CHEMOTHERAPY: A SINGLE INSTITUTION
EXPERIENCE
F. Oniga, O. Nascimben, R. Biason, C. Mastromauro, M. Medici, P.
D’Amanzo, M.G. Ghi, R. Carnuccio, G. Crivellari, A. Paccagnella Oncol-
ogy, Ospedale dell’ Angelo di Mestre (VE), Zelarino (VE)/ITALY
Purpose: Clinical outcome is a major question in oncology. The aim of the
study was to assess an instrument to measure the real clinical outcome of non
selected patients (pts).
Methods: From Jan 1998 to Jan 2009 essential clinical data from all
consecutive pts of our center were recorded and constantly updated in an
electronic database. We considered 9 items in non selected NSCLC: histol-
ogy, stage (IV), sex, age, PS (ECOG 0 or 1), 1st line chemotherapy schedule
with date of start, date of last follow up and status (dead or alive). We
analysed the clinical outcome of 3rd generation chemotherapy employed at
our center: mono chemotherapy (vinorelbine (V), gemcitabine (G)), doublets
(carboplatin (C)-G, C-paclitaxel (P), CV) and triplet (CPG). Pts treated with
target therapy were excluded. We tested univariate and multivariate statisti-
cal analysis to understand if different outcome of pts was related to the
different chemotherapy combinations or to pts’ prognostic factor.
Results: A total of 494 metastatic NSCLC pts were analysed and 424
underwent 3rd generation chemotherapy. Pts characteristics were: median age
68 y (33-85), sex M/F 78%/22%, ECOG PS 0/1 48%/52%, Histology
Adeno/Squamo/LC/Other 45%/32%/1%/22%, chemotherapy schedule
mono/doublets/triplet 19%/60%/21%. Median survival for all pts was 8.3
months. Median survival was respectively 6 months for monochemotherapy,
8.1 for doublets and 11.1 for triplet group. At univariate analysis, only PS
and chemotherapy were statistically significant for overall survival. At
multivariate analysis, after correcting for prognostic factor , the only signif-
icant independent variable of better outcome were PS (0 vs. 1, p0.0000)
and triplet chemotherapy treatment (triplet vs. doublet vs. mono, p0.0022).
Conclusion: With the limits of a retrospective analysis, this methodical
seems a simple powerful instrument to evaluate clinical outcome of onco-
logic treatments. The results suggest a survival advantage for the triplet
(CPG), independent from prognostic factors. This analysis seems to confirm,
in single center clinical practice, the data from multicenter randomised trial
comparing CPG to CP (J Clin Oncol 24:681-7, 2006).
Disclosure: All authors have declared no conflicts of interest.
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TO ANALYSE THE ROLE OF QUALITY OF LIFE IN GUID-
ING MANAGEMENT DECISIONS IN ADVANCED NSCLC
U. Batra1, D.C. Doval2, S. Goyal2 1Department of Medical Oncology,
Kidwai Memorial Institute of Oncology, Bangalore/INDIA, 2Department of
Medical Oncology, Rajiv Gandhi Cancer Institute & Research Center,
Delhi/INDIA
Background: The therapeutic options for patients with advanced non-small-
cell lung cancer (NSCLC) are essentially palliative. Survival and Quality of
Life improvements are two major goals in treating advanced NSCLC. Lung
cancer is not just associated with a high mortality but a high morbidity as
well, with a significant proportion of patients severely incapacitated by
disease-related symptoms such as chest pain, cough, hemoptysis, and dyspnea.
In such scenario, the evaluation and improvement of quality of life (QOL)
assumes great importance in the overall management of these patients.
Aim: This study was designed to evaluate the impact of chemotherapy on
Quality of Life and symptoms for all patients and to evaluate correlation
between Quality of Life and Response rates.
Materials and methods: 50 patients with stage IIIB or IV NSCLC under-
going palliative chemotherapy were evaluated. Patients received Gemcitab-
ine/ Pemetrexed based Platinum based doublet chemotherapy. Quality of life
was measured using EORTC QLQ-C30 questionnaire. Patients were evalu-
ated after every 3 cycles.
Results: 42 men and 8 women were evaluated. The most common histology
was squamous cell carcinoma (55%) followed by adenocarcinoma
(38%).The overall response rate was as follows: Partial response: 38%
Complete response: 5% Stable disease: 30% Progressive disease: 27%
Quality of life score was better in patients who achieved any response rates
to chemotherapy. Even in patients who achieved stable disease, QOL was
better than in patients with Progressive disease.In the SD category, patients
who had higher QOL fared better than patients with low QOL index.
Conclusion: An improvement in Quality of life is associated with higher
response rates and better prognosis for patients. Quality of life indices are an
important tool in guiding management decisions in lung cancer and should be
used more frequently in making treatment decisions.
Disclosure: All authors have declared no conflicts of interest.
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EGFR GENOTYPE DOES NOT AFFECT CLINICAL
OUTCOMES OF THE KOREAN PATIENTS WITH
ADVANCED PULMONARY ADENOCARCINOMA IN
THE FIRST-LINE CYTOTOXIC CHEMOTHERAPY
K.Y. Lee1, H.J. Kim1, W. Kim2, K. Lee3 1Internal Medicine, Konkuk
University Hospital, Seoul/KOREA, 2Pathology, Konkuk University Hospi-
tal, Seoul/KOREA, 3Internal Medicine, Yeungnam University Hospital,
Daegu/KOREA
Introduction: EGFR mutation is the most important predictive marker for
EGFR-TKI, and tailored therapy based on EGFR genotyping in the front-line
treatment of advanced NSCLC patients becomes increasingly important.
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EGFR mutations are more frequent in female, non-smokers, adenocarcinoma
and Asian people. However, few clinical studies have addressed whether
EGFR genotyping before the initiation of treatment affect clinical outcomes
of the first-line cytotoxic chemotherapy and the subsequent EGFR-TKI
treatment. This study was undertaken to investigate the effects of EGFR
mutations on treatment response to the first-line chemotherapy in the Korean
patients with advanced pulmonary adenocarcinoma.
Methods: One hundred and forty-four stage III or IV pulmonary adenocar-
cinoma patients were included at two centers in Korea. DNA from biopsy or
cytology specimen was determined for EGFR mutation by pyrosequence-
based typing in the initial staging period. All patients received at least two
cycles of the first-line platinum-based doublet chemotherapy. EGFR-TKI
was used as second or third-line treatment in patients after failure to
cytotoxic chemotherapy. We evaluated objective response rate (ORR) and
progression-free survival to the first-line chemotherapy and 1-year survival
rate between the groups with EGFR-mutant and EGFR wild-type.
Results: EGFR mutations were presented in 47 patients (32.6%): exon 19
deletion mutations 66.0 %, exon 21 L858R point mutation 23.4 %, and others
10.6 %. There was no significant statistical difference in objective response rate
(ORR) (40.4%, 95% CI [26.4-54.5] vs. 37.1%, 95% CI [27.5-46.7] , p0.70)
and disease control rate (DCR) (83.0%, 95% CI [76.9-89.1] vs. 78.4%, 95% CI
[71.2-84.8], p0.52) and median progression-free survival (PFS) (6.6 months,
range 2.0-15.3 vs. 4.8 months, range 1.7-15.4) between patients with EGFR-
mutant and wild-type. However, the patients with EGFR mutations showed
better 1-yr survival rate (YSR) (85.7%, 95% CI [74.1-97.3] vs. 54.2%, 95% CI
[41.5-67.0], p0.002) and longer median PFS (7.7 5.6 months vs. 4.1 3.9,
p0.007) to EGFR-TKI than those patients with EGFR wild-type.
Conclusions: First-line platinum-based combination chemotherapy admin-
istered in advanced pulmonary adenocarcinoma showed similar ORR, DCR
and PFS regardless of EGFR mutation status. However, patients with EGFR
mutation who received cytotoxic chemotherapy had superior 1-YSR and
longer PFS to EGFR-TKI than those with wild-type EGFR. These results
suggest that EGFR genotype does not affect clinical outcomes of the first-line
cytotoxic chemotherapy before the subsequent EGFR-TKI treatment.
Disclosure: All authors have declared no conflicts of interest.
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COMPARISON OF EGFR-TKIS AND PEMETREXED FOR
KOREAN PATIENTS WITH ADVANCED NON-SMALL
CELL LUNG CANCER
J.H. Lee, Y.J. Ryu, E.M. Chun, J.H. Chang Internal Medicine, Ewha
Womans University School of Medicine, Seoul/KOREA
Background: Recently the epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKIs) and pemetrexed became standard palliative chemother-
apy for advanced non-small cell lung cancer (NSCLC). We compared the efficacy
of EGFR-TKIs and pemetrexed in Korean patients with advanced NSCLC.
Methods: We collected the clinical information of advanced NSCLC pa-
tients treated with EGFR-TKIs or pemetrexed for more than two weeks at a
University Hospital between July 2003 and December 2009. Median surviv-
als were calculated using the Kaplan-Meier method.
Results: One-hundred thirty-six patients (108 EGFR-TKIs vs. 28 pem-
etrexed) were enrolled. Their median age was 64 years and 86 (63%) were
male. Fifty-five patients (40%) were non-smokers and 94 (69%) had non-
squamous cell carcinoma (NSQ). There were 37% at stage IIIb. Out of 136
patients, 2 achieved a complete remission (CR), 48 achieved a partial
remission (PR), and 15 experienced stable disease (SD) while 59 experienced
progressive disease (PD), resulting in a response rate of 37% and a disease
control rate of 48%. After a median follow-up of 494 days, the median
progression-free and overall survival time was 69 and 210 days, respectively.
There were no differences in median survival time (EGFR-TKIs 301 days vs.
pemetrexed 155 days, p0.058), and time to progression (93 days vs. 64
days, p0.333). Although the overall response rate is higher in EGFR-TKIs-
treated patients (EGFR-TKIs 42% vs. pemetrexed 18%, p0.02), pem-
etrexed was more frequently chosen for more than third line chemotherapy
because of its late introduction (EGFR-TKIs 5% vs. pemetrexed 24%,
p0.002). In patients with NSQ, there was no difference in the response rate
(EGFR-TKIs 47% vs. pemetrexed 24%, p0.08). Multivariate analysis using
Cox regression model identified NSQ as an independent predictor of survival
(p0.001; relative risk [RR], 0.397; 95% confidence interval [CI], 0.233-
0.678). Among patients with NSQ, non-smoker and stage IIIB were associ-
ated with longer survival (p0.038; RR, 0.489; 95% CI, 0.249-0.961)
(p0.046; RR, 0.413; 95% CI, 0.173-0.984).
Conclusions: In advanced NSCLC, both EGFR-TKIs and pemetrexed had
similar efficacy in the overall survival and time to progression.
Disclosure: All authors have declared no conflicts of interest.
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CLINICAL ACTIVITY OF BIBW 2992, AN IRREVERSIBLE
INHIBITOR OF EGFR/HER1 AND HER2 IN ADENOCARCI-
NOMA OF THE LUNG WITH MUTATIONS IN THE KI-
NASE DOMAIN OF HER2NEU
J. De Gre`ve1, L. Decoster1, J. De Mey2, P. In ’t Veld1, C. Geers1, M. Taton3,
M. Shahidi4, D. Galdermans5, E. Teugels6, D. Schallier6 1Medical Oncol-
ogy, Oncologisch Centrum, UZ Brussel, Brussels/BELGIUM, 2Medical On-
cology, Oncologisch Centrum, UZ Brussels, Brussels/BELGIUM, 3Rease-
arch and Development, Boehringer Ingelheim, Brussels/BELGIUM,
4Boehringer Ingelheim, Uk, Bracknell, Berks/UNITED KINGDOM, 5Medi-
cal Oncology, ZNA Middleheim Hospital, Antwerp/BELGIUM, 6Medical
Oncology, UZ Brussel, Brussels/BELGIUM
Background: 2–4% of lung adenocarcinomas harbour HER2neu mutations
and, similarly to EGFR mutations, are more common in females, non-
smokers and patients of Asian background. BIBW 2992 is a potent, irrevers-
ible inhibitor of EGFR/HER1 and HER2 (IC50 0.5 and 14 nM, respectively)
with preclinical and clinical activity in EGFR mutated NSCLC. This explor-
atory Phase II study is investigating the use of BIBW 2992 in demograph-
ically and genetically selected patients with NSCLC.
Methods: The studies primary endpoint is objective response rate. Stage
IIIB/IV lung adenocarcinoma patients who are never or light ex-smokers
with EGFR or HER2 mutation positive tumours (current report) or are EGFR
FISH are eligible. BIBW 2992 is administered at 50 mg qd until disease
progression. Tumour assessments are performed every 8 weeks. Any patients
who progress may continue treatment with BIBW 2992 and weekly pacli-
taxel (80 mg/m2 weekly, 3/4 weeks).
Results: To date, five patients with lung adenocarcinoma and HER2 muta-
tions in exon 20 have been included. All patients are female, non-smokers
with Stage III/IV adenocarcinoma of the lung and had failed prior chemo-
therapy. Preliminary analysis shows significant improvement of patients’
symptoms and performance status as well as reduction in tumor size,
amounting to a partial response in three patients. One patient has remained
on treatment 12 months. Diarrhoea and skin rash were the predominant
adverse events and led to early discontinuation of BIBW 2992 in one patient.
Updated information on all patients will be provided at the meeting.
Conclusions: The presence of HER2 mutations characterizes a subgroup of
NSCLC that is dependent on the HER2 pathway for survival. In pre-treated
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patients with adenocarcinoma and activating HER2 mutations, BIBW 2992
can provide a significant benefit. This clinical observation closely mimics
recent results obtained with BIBW 2992 in a HER2-driven lung cancer in a
transgenic animal model. Further investigation of BIBW 2992, an irrevers-
ible EGFR/HER2 inhibitor, as a potential new treatment option for these
patients is warranted.
Disclosure: J. De Gre`ve: Unrestricted research grant from Boehringer In-
gelheim; M. Taton: Boehringer Ingelheim employee; M. Shahidi: Boehringer
Ingelheim employee. All other authors have declared no conflicts of interest.
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PHASE I OPEN-LABEL TRIAL OF CONTINUOUS DOSE OF
BIBW 2992 IN PATIENTS WITH ADVANCED NON-SMALL
CELL LUNG CANCER FAILING CHEMOTHERAPY
AND/OR ERLOTINIB AND/OR GEFITINIB (LUX-LUNG 4)
N. Yamamoto1, T. Tamura2, T. Takahashi3, H. Murakami1, H. Nokihara4, T.
Naito1, K. Nishio5, Y. Seki6, A. Sarashina7, M. Shahidi8 1Department of
Thoracic Oncology, Shizuoka Cancer Centre, Shizuoka/JAPAN, 2Medical
Oncology, National Cancer Center Hospital, Tokyo/JAPAN, 3Department of
Thoracic Oncology, Shizuoka Cancer Center, Shizuoka/JAPAN, 4Depart-
ment of Thoracic Oncology, National Cancer Center, Tokyo/JAPAN, 5De-
partment of Oncology, Kinki University of Medicine, Osaka/JAPAN, 6Re-
search & Development, Nippon Boehringer Ingelheim, Tokyo/JAPAN,
7Research and Development, Nippon Boehringer Ingelheim, Kobe/JAPAN,
8Boehringer Ingelheim, Uk, Bracknell, Berks/UNITED KINGDOM
Background: BIBW 2992, an irreversible inhibitor of EGFR/HER1 and
HER2, has preclinical activity in lung cancer models harbouring activating
and resistant EGFR mutations. A Phase I study of BIBW 2992 in pts
advanced with NSCLC was conducted to evaluate the safety, tolerability,
PK, tumour response and recommended dose for Phase II.
Methods: In this study, pts with NSCLC (stage IIIB/IV; ECOG 0–1), who
had either failed standard chemotherapy and/or treatment with gefitinib or
erlotinib, or those with no other appropriate therapy available, were eligible.
Oral BIBW 2992 started at 20 mg qd; doses were increased to 50 mg qd until
33.3% or more Grade 2 toxicity occurred. PK sampling was performed on
Days 1–2 and at steady state of the initial treatment course. Tumour response
was assessed by RECIST. EGFR mutation analysis in serum and tumour
specimens was performed where possible.
Results: 12 evaluable pts have been treated (doses of 20–50 mg; 5 male, 7
female; median age 62.5 years [range 39–67]). One DLT was seen in Course
1; 1 pt developed Grade 3 mucositis at 50 mg, which subsided following dose
reduction. Most AEs were mild (Grade 1 or 2) and included diarrhoea, dry
skin, stomatitis, rash, paronychia, and anorexia. Peak plasma concentrations
of BIBW 2992 were reached 3-4 hrs after administration; the half life was
30–40 hrs. 6/12 pts had tumour size reductions, with three achieving
prolonged SD (table). EGFR mutation status was wild-type for 4 pts and
EGFR exon 19 deletion and T790M for 2 pts.
Conclusion: The safety and PK profile of BIBW 2992 in Japanese pts were
similar to non-Japanese pts. Continuous oral BIBW 2992 at a starting dose
of 50 mg once daily was well tolerated with acceptable safety profile. The
recommended starting dose for Phase II has been defined as 50 mg in
Japanese pts.
Disclosure: Y. Seki: Boehringer Ingelheim employee; A. Sarashina: Boehr-
inger Ingelheim employee; M. Shahidi: Boehringer Ingelheim employee. All
other authors have declared no conflicts of interest.
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PLINABULIN (NPI-2358), A NOVEL VASCULAR
DISRUPTING AGENT (VDA), IN NON-SMALL CELL
LUNG CANCER (NSCLC)
O. Aren1, L. Matamala1, M. Reyes1, A. Santini1, K. McArthur2, G.K. Lloyd3,
M.A. Spear4 1Medical Oncology Service, Instituto Nacional Del Cancer,
Santiago/CHILE, 2Clinical, Nereus Pharmacueticals, Inc, San Diego/USA,
3Research and Development, Nereus Pharmaceuticals, San Diego/USA,
4Clinical, Nereus Pharmaceuticals, San Diego/USA
Plinabulin is a vascular disrupting agent (VDA) that destabilizes the endothelial
cytoskeletal structure, leading to selective collapse of established tumor vascu-
lature. VDAs are a new class of oncology agents that have utility in attacking
tumor vasculature through a mechanism different from the VEGF targeted
agents, thus they have different efficacy and toxicity profiles from these agents
as well as cytotoxic agents. Recently, data has indicated significant potential in
the treatment of NSCLC. A large increase in survival was seen by adding
DMXAA (another VDA) to carboplatin / paclitaxel in a randomized Phase 2 trial
in patients with NSCLC, with subset analysis indicating favorable outcomes in
squamous cell carcinoma. The first-in-human study of plinabulin was a dynamic
accelerated dose titration (DADT) with encouraging pharmacokinetic, pharma-
codynamics (decreases in tumor blood flow) and safety results. In murine models
plinabulin was markedly synergistic with cytotoxic chemotherapy agents, par-
ticularly docetaxel in NSCLC models, with improvements in both toxicity and
efficacy seen. This led to a Phase 1/2 clinical trial of the combination with
docetaxel in NSCLC. The Phase 1 portion of the study indicated favorable
safety, pharmacokinetic and efficacy profiles for the combination. This led to the
initiation of the Phase 2 portion in which patients with advanced NSCLC that
received prior chemotherapy were enrolled. 110 patients were randomized to
receive 75 mg/m2 docetaxel / 30 mg/m2 plinabulin, and subsequently an
additional 57 patients are being randomized to receive docetaxel/ 20 mg/m2
plinabulin. Interim response data for the 30 mg/m2 combination arm was
encouraging with 26% (5/19) of then evaluable patients having a 30%
decrease in tumor measurements compared with 3% (1/30) in the docetaxel arm.
Safety and efficacy data will continue to be compared between plinabulin dosing
groups to determine which dose to assess in a Phase 3 study. Given the
differences in safety and efficacy with currently available therapies, and potential
for use in underserved patient subsets, this data continues to suggest VDAs may
translate into new treatment paradigms for NSCLC and other malignancies.
Disclosure: K. McArthur: Katherine McArthur is an employee of Nereus
Pharmaceuticals and has options in company stock. G.K. Lloyd: Dr. Lloyd is an
employee of Nereus Pharmaceuticals and has options in company stock.M.A.
Age Sex Histology
Dose
(daily)
Months
on
Study**
Previous
Treatment
EGFR
Mutation
Status
64* F Adeno 20 mg 11 1. cisplatin  TS-1
2. gefitinib
3. erlotinib
4. gefitinib
Exon 19 del
T790M
57* F Adeno 40 mg 19 1. cisplatin 
gemcitabine
2. nimotuzumab
WT (serum)
65* M Adeno 40 mg 13 1. cisplatin 
docetaxel
2. docetaxel
3. gefitinib
4. gefitinib 
gemcitabine
5. gefitinib
WT (serum)
*never-smoker; **as of the date of 10th Jan 2010.
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Spear: Dr. Spear is an employee of Nereus Pharmaceuticals and has options in
company stock. All other authors have declared no conflicts of interest.
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HIGH RESPONSE OF SECOND-LINE CHEMOTHERAPY
WITH PEMETREXED OR GEMCITABINE COMBINED
WITH CARBOPLATIN IN PATIENTS WITH NON-SMALL-
CELL LUNG CANCER EXPERIENCING PROGRESSION
FOLLOWING 6 -MONTHS AFTER CONCLUDING
PLATINUM-BASED CHEMOTHERAPY
O. Arrieta1, C. Villarreal-Garza1, M. Morales1, D. Pachuca1, R.M. Michel1,
L. Martinez-Barrera2, A. Astorga1 1Department of Medical Oncology, In-
stituto Nacional de Cancerologı´a, Mexico City/MEXICO, 2Department of
Medical Oncology, Instituto Nacional de Enfermedades Respiratoria, Mex-
ico City/MEXICO
Background: Because of improved therapeutic results after first-line plati-
num-based chemotherapy in patients with stage IV non-small-cell lung
cancer (NSCLC), second-line chemotherapy may be considered for a grow-
ing number of patients. Approximately 10% of patients have an interval time
after concluding first-line platinum-based chemotherapy greater than six
months. These patients may achieve high tumor responses when platinum is
again used in second-line treatment.
Patients and methods: Twenty-three patients experiencing progression following
6-months after concluding platinum-based chemotherapy were managed with sec-
ond-line treatment with carboplatin combined with gemcitabine or pemetrexed.
Overall response, progression-free survival (PFS), and overall survival (OS) after
initiation of second-line treatment were calculated for all patients.
Results: Median PFS after first-line treatment was 12.6 months (95% CI,
10.4–14.7 months). Partial response was achieved in 7 of 23 patients, resulting
in an overall response of 30.4% (95% confidence interval [95% CI], 11.6–49.0).
Following initiation of second-line chemotherapy, median PFS was 5.9 months
(95% CI, 1–10.9 months) and median OS was 12.5 months (95% CI, 3.5-21.5
months). The 1-year survival rate for all patients was 61.0% (95% CI,
29.5– 82.0). Adding these results to those of the previously 10 published
trials, 75 of 326 patients, 23%, (95% CI, 18.7-27.3) presented an overall
response with the use of second-line platinum-based chemotherapy.
Conclusion: The use of platinum combinations as second-line chemotherapy
seems to have a place in the management of patients with advanced NSCLC,
especially those with an interval time to progression greater than 6 months.
Disclosure: All authors have declared no conflicts of interest.
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DORSET CANCER CENTRE EXPERIENCE OF FIRST- AND
SUBSEQUENT LINE SYSTEMIC THERAPY IN THE
TREATMENT OF NON-SMALL CELL LUNG CANCER
K.L. Bradley1, M.T. Lwin1, B.K. Eccles2, V.M. Laurence1, T.R. Geldart3
1Clinical Oncology, Dorset Cancer Centre, Poole, Dorset/UNITED
KINGDOM, 2Oncology, Royal Bournemouth Hospital, Bournemouth/
UNITED KINGDOM, 3Clinical Oncology, Dorset Cancer Centre,
Bournemouth/UNITED KINGDOM
Purpose: Systemic therapy has a key role in the treatment of non-small cell
lung cancer, both in the primary setting, and at relapse or progression. We
present our outcomes and compare these with published data.
Methods: We carried out a retrospective review of consecutive patients treated with
systemic therapy at our centre during a two-year period, January 2007 to December
2008. In analysis of outcomes following first-line therapy, we included patients with
stage IIIb or IV disease whose primary treatment was palliative systemic therapy.
Second-, third- and fourth-line data also include patients previously treated radically
with surgery, radiotherapy or chemoradiotherapy. We report response-rates, overall
survival and time-to-progression in each setting.
Results: 176 systemic treatment episodes were identified during the study
period. Following 1st line therapy, 1 year survival was 37% and 2 year
survival, 11%.
From the second-line of systemic therapy, patients were a heterogeneous
group. Outcomes varied with previous treatment received.
Conclusion: Following first line systemic therapy for advanced non-small
cell lung cancer, response rates are reported around 19% with median
survival 7.9 months, 1 year survival of 33% and 2 year survival of 11% [1].
Our audit of our own data shows that even within a district general hospital
setting, outcomes from lung cancer can be as good as or better than trial
outcomes by adopting a tailored approach to treatment.
References
Schiller, JH et al. Comparison of Four Chemotherapy Regimens for Ad-
vanced Non-Small-Cell Lung Cancer. N Engl J Med 2002;346:92–98.
Disclosure: All authors have declared no conflicts of interest.
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SALVAGE CHEMOTHERAPY WITH PEMETREXED (PEM)
FOR NON SMALL CELL LUNG CANCER (NSCLC): AN
IMPLEMENTATION STUDY
T. Berghmans1, C. Jungels2, A.P. Meert3, J.J. Lafitte4, J. Sculier5 1Medicine,
Institut Jules Bordet, Brussels/BELGIUM, 2Intensive Care Unit and Tho-
racic Oncology, Institut Jules Bordet, Brussels/BELGIUM, 3Soins Intensifs
et Cancerologie Pulmonaire, Institut Jules Bordet, Brussels/BELGIUM,
4Pneumology, CHRU Lille, Lille/FRANCE, 5Soins Intensifs et Oncologie
Thoracique, Institut Jules Bordet, Bruxelles/BELGIUM
Purpose: Salvage treatment with PEM in NSCLC has been reported in the
context of phase II-III trials, only dealing with selected patients. The aim of this
retrospective study is to assess the generalizability of these results in an
Previous Treatment
Number
Treated
Overall
Survival
(months)
Radical treatment (stage I-IIIa) 4 19 (15–60)
Palliative treatment (stage IIIb/IV) 44 15 (5–45)
Total number of patients treated with
2nd line chemotherapy
48 16 (5–60)
Line of
Therapy
Number
Treated
Response Rates (%)
Overall
Survival
Median/
(Range)
(months)CR PR SD PD
1 113 0 48 (42%) 17 (15%) 48 (42%) 9 (1–32)
2 48 0 7 (14%) 7 (14%) 34 (71%) 16 (5–60)
3 12 0 4 (33%) 3 (25%) 5 (42%) 31 (14–44)
4 3 0 0 0 3 (100%) 40 (19–60)
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unselected population, in terms of response rate, survival, progression-free
survival and toxicity.
Patients and methods: All consecutive NSCLC patients progressing after at
least 1 previous chemotherapy regimen and receiving PEM (500mg/m2/21
days with folate and vitB12 supplementation) at the Bordet Institute were
eligible. Response was assessed according to WHO criteria and toxicity
using CTC criteria. Overall and progression-free (PFS) survival times were
the periods from the first day of PEM until death (or last date known to be
alive) and first date of progression, respectively.
Results: From 07/07 until 09/09, 33 patients with relapsed stage IV NSCLC
were treated with PEM. Their principal characteristics were: male/female 22/11,
median age 59 years, adenocarcinoma/squamous/other histology 23/6/4. PEM
was administered as 2d, 3rd or 3rd line in 15/10/8 patients. Patients received a
median of 3 cycles of PEM (range 1–11), with the following results:
Conclusions: Salvage PEM for relapsing NSCLC after previous chemother-
apy showed, in unselected heavily pre-treated population, a similar activity
to prospective studies despite significant toxicity. Further inclusion of pa-
tients from another institution is planned.
Disclosure: All authors have declared no conflicts of interest.
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A RETROSPECTIVE STUDY OF PEMETREXED
COMBINED WITH OXALIPLATIN AS THE SECOND LINE
TREATMENT FOR ADVANCED NON-SMALL CELL LUNG
CANCER: COMPARABLE TOXICITY, BETTER
OUTCOME
J. Zhu, X.X. Zhang, M.J. Huang, L. Zhou Department of Thoracic Oncol-
ogy, West China Hospital, Chengdu/CHINA
Background: Outcome of the single agent regimen as the second-line or post
second-line chemotherapy for metastatic NSCLC is poor. Pemetrexed com-
bined with oxaliplatin was reported to be well-tolerated and active for the
chemotherapy-naı¨ve NSCLC. Current retrospective study was designed to
evaluate the feasibility and the therapeutic effect of pemetrexed plus oxali-
platin regimen for pretreated NSCLC.
Patients and methods: Medical records of consecutive patients with meta-
static NSCLC failed to the prior chemotherapy between January 2007 and
January 2009 were reviewed for treatment, toxicity and outcome. A total of
79 patients were administered pemetrexed included regimen whose records
could be exactly traced. 34 of them were treated with the regimen PO
(pemetrexed 500mg/m2 day1 plus oxaliplatin 125mg/m2 day1, repeated
every 21 days). Another 45 patients were administered pemetrexed only.
Chi-Square test was used to compare the response rates between groups.
Kaplan-Meier curve and Log-Rank test was used to analyze the survival.
Results: Treatment of the two groups were well-tolerated, no therapy related
death happened. The most common toxicity was neutropenia. Comparable
response rate (15.2% vs. 11.1%, P0.743) and tumor control rate (63.6% vs.
47.5%, P0.168) were observed in the two groups. Median time to progres-
sion and overall survival in the PO group were 18 weeks (95% CI:
13.72
22.28 weeks) and 31 weeks (95% CI: 15.56
46.44 weeks), respec-
tively. It was significantly longer than pemetrexed group (P0.002 and
0.006, respectively).
Conclusions: Pemetrexed combined with oxaliplatin as the second line
treatment for advanced NSCLC showed comparable safety and response as
single pemetrexed regimen. The survival was impressively improved in the
doublet agents group in current study. A prospective study is supported.
Disclosure: All authors have declared no conflicts of interest.
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PEMETREXED: 3RD LINE PALLIATIVE CHEMOTHER-
APY AND BEYOND IN METASTATIC NON SMALL CELL
LUNG CANCER (NSCLC): SINGLE INSTITUTION CASE
SERIES
H. Charalambous, M.P. Decatris Department of Medical Oncology, Bank of
Cyprus Oncology Centre, Nicosia/CYPRUS
Introduction: Pemetrexed (Pem) is indicated only for first and second line
treatment of non squamous NSCLC. There are currently no data for its use
as third line or beyond third line treatment. Due to funding restrictions in
Cyprus (no reimbursement for Pem), Pem was used in selected patients when
all other therapeutic options had been used (ie post first line gemcitabine
platinum doublet, second line docetaxel and third line erlotinib).
Methods: Six patients are included in this retrospective study. One patient
received Pem as 3rd line, four patients as 4th line (previous treatments as
above) and one as 5th line (previous treatments as above and also vinorel-
bine). Two patients are still on treatment, whilst three patients are still alive.
All patients received Pem 500mg/m2 with folic acid and B12 supplementa-
tion. Patients had regular Chest X-rays and CT scans (every 2–3 cycles) and
formal assessment of their toxicity with CTC criteria every 3 weeks. PFS and
OS were calculated with the Kaplan-Meier Method.
Results: 5 males and 1 female patients, median age 55 years (range 49-68),
2 never and 3 ex smokers, WHO performance status PS1 n4 and WHO PS2
n2, histology adenocarcinoma n3, mixed adenocarcinoma / BAC n2
and pure BAC n1. They received a median 11 cycles of Pem (range 2-16).
Toxicity: grade 1-2 (g1–2) malaise n6, g1 constipation n3, g1 stomatitis
n2, g 1 taste disturbance n1, g1 neurosensory changes n1, g1 diarhoea
n1, g1 nausea n1 and g1 anorexia n1. Five of the six patients had
symptomatic improvement. Radiological response 1 patient had a partial
response, 3 patients minor response, 1 patient stable disease and 1 patient
progressive disease. Median PFS was 196 days (95% Confidence intervals CI
0–426 days). Median survival from the date of starting Pem chemotherapy
was 457 days (95% CI 36-878), whilst median overall survival from the
initiation of first line therapy was 31.3 months (951 days, range 892–1175).
Conclusions: In well selected patients with well preserved performance
status, lack of significant other comorbidity and non squamous NSCLC, Pem
as 3rd line chemotherapy and beyond can result in very meaningful palliation
of symptoms and prolongation in survival.
Disclosure: All authors have declared no conflicts of interest.
Present Study
Literature Data
(phase II-III trials)
Response rate 12.9% (95% CI 1.1%–24.7%)* 6.0–18.5%
Stabilisation rate
(response plus no
change)
42% (95% CI 25%–59%) 36–68%
Median PFS 2.5 months 2–3 months
Median survival time 6.4 months 5.7–16.0 months
*all observed in non-squamous histologies. Grade 3 and 4 neutrophil and platelet
toxicity were observed in 7 (including 1 toxic death) and 2 patients, respectively. PEM
was stopped in two patients for excessive toxicity.
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CIS-PLATINUM, PEMETREXED AND BEVACIZUMAB
(CPBEV) AS FIRST-LINE THERAPY FOR LOCALLY
ADVANCED OR METASTATIC ADENOCARCINOMA OF
THE LUNG: PRELIMINARY DATA OF SAFETY AND
EFFICACY OF A PHASE II STUDY
R. Bordonaro1, H. Soto-Parra1, A. Nacci2, F. Latteri1, P. Rizzo2, S. Cordio1,
P. Salice1, D. Sambataro1, E. Potenza1, S. Cinieri2 1Oncology, ARNAS
Garibaldi, Catania/ITALY, 2Oncology, Perrino Hospital, Brindisi/ITALY
The paradigms of advanced non-small cell lung cancer therapy are rapidly
changing; data from two large randomized trials showed that Pemetrexed and
Bevacizumab, when administered separately with platinum compounds,
prolong survival of patients with non-squamous histologies. On these basis,
we started a phase II trial to test safety and activity of a three-drugs-regimen
containing cis-platinum, pemetrexed and bevacizumab (CPBev). Eligible
criteria are: chemonaive patients with proven histology of non-squamous
non-small cell lung cancer, PS-ECOG-WHO  2, adequate hematological,
liver and renal functions, no previous history of hemoptysis, stage IIIB - IV
without cerebral metastases, at least one measurable lesion, absence of
uncontrolled hypertension or other severe comorbidities, non anamnestic
episodes of venous thromboembolism. In the baseline assessment a CT-scan
of the brain, of the thorax and of the abdomen and a Bone scan were
mandatory. We adopt the two-stage of Simon model as statistical design of
the study. Administered doses were 75 and 500 mg/p.s.m for cis-platinum
and pemetrexed respectively and 7.5 mg./kg for Bevacizumab, for 3 – 6
cycles. G-CSF were administered only after the first cycle of therapy,
whereas vitamin supplementation started from day 1 of the first cycle. Since
now, 13 patients have been enrolled. Patients characteristics are: male/female
11/2, median age (years) 60 (r. 36 – 77), ECOG-WHO/PS 0/1: 8/2. At a
preliminary evaluation of safety data, no grade 3-4 extra-hematological
adverse events were registered. Administration of the CPBev regimen seems
feasible and safe. To date, 11 of the 13 pts. enrolled completed six cycles of
therapy; we registered 5 PR, 4 SD and 2 PD. If another clinical response will
be register among the next 4 pts., enrollment will proceed to the second step
of the study design.
Disclosure: All authors have declared no conflicts of interest.
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PEMETREXED-INDUCED FLUID RETENTION
A. Katz, D.A. Bastos, A. Calabrich, A. Shimada Medical Oncology, Hos-
pital Sirio Libaneˆs, Sao Paulo/BRAZIL
Despite the favorable toxicity and safety profiles of pemetrexed, several
adverse events have been reported, including blood and lymphatic system
disorders, gastrointestinal and general disorders. We describe a case series
consisting of eight patients who developed clinically significant fluid reten-
tion, an uncommon adverse effect associated with the use of pemetrexed. All
patients have received vitamin supplementation and were pretreated with
corticosteroids as indicated in the package insert. Other causes of edema
were excluded and all patients had normal echocardiogram, normal levels of
B-type natriuretic peptide and albumin, normal renal, hepatic and thyroid
function tests and no significant proteinuria. Most patients presented with
mild to moderate edema, mainly in periorbital area, while 4 developed
pleural effusions. One of these patients required a bilateral thoracocentesis
was necessary for symptom relief and the pleural effusion analysis was
consistent with an exsudate with no malignant cells and negative cultures.
There was complete disappearance of generalized edema and bilateral pleural
effusion after discontinuation of pemetrexed treatment. Other patients also
had complete resolution of the fluid retention (including pleural effusion)
after pemetrexed was discontinued due to disease progression. All other
cases were managed with observation only or salt restriction and diuret-
ics, with limited control of this side effect. Pemetrexed-associated pe-
ripheral and eyelid edema has been rarely reported, with an estimated
incidence of 1% in clinical trails. To our knowledge there were no severe
cases reported with need for treatment discontinuation until now. The
mechanism involved in the development of fluid retention and consequent
edema is unknown but may be due to capillary leakage syndrome. Now
that pemetrexed has demonstrated efficacy in the first line setting and is
an option as maintenance or early second line therapy, more patients will
be exposed to this agent and therefore more individuals will potentially
develop this treatment related adverse effect. Therefore, we believe it is
important to report this unusual adverse event and to understand its
pathophysiology in order to attempt to develop strategies to avoid and
manage this side effect.
Disclosure: All authors have declared no conflicts of interest.
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RISK OF FATAL ADVERSE EVENTS WITH
BEVACIZUMAB IN LUNG CANCER PATIENTS TREATED
WITH CHEMOTHERAPY: A META-ANALYSIS
V. Ranpura1, S. Hapani1, S. Wu2 1Department of Medicine, Suny Stony
Brook University Medical Center, Stony Brook/USA, 2Department of Medi-
cal Oncology and Hematology, Suny Stony Brook University Medical Center,
Stony Brook/USA
Background: Bevacizumab is approved for the treatment of metastatic
non-squamous non-small cell lung cancer (NSQ-NSCLC) in combination
with chemotherapy. However, its use has been associated with fatal adverse
events (AE), particularly in squamous NSCLC. In order to assess the risk of
fatal AE with bevacizumab in NSCLC, particularly NSQ-NSCLC, we
performed a systematic review and meta-analysis of published randomized
control trials (RCT).
Methods: We searched the databases of PubMed, Web of Science, and
American Society of Clinical Oncology conferences until August, 2009 to
identify relevant clinical trials. Eligible studies included prospective RCTs in
which bevacizumab was compared to a control concurrently with standard
anti-neoplastic therapy in lung cancer. Summary incidence rates, relative
risks (RRs), and 95% confidence intervals (CIs) were calculated using
random-effects or fixed-effects models based on the heterogeneity of the
included studies.
Results: A total of 2,072 patients with NSCLC from 4 RCTs were included
for analysis. The incidences of fatal AE in NSCLC and NSQ-NSCLC were
4.2% (95% CI: 1.5-10.9%) and 2.7% (95% CI: 1.2-6.0%) respectively. When
compared to controls, bevacizumab significantly increased the risk of fatal
AE in NSCLC and NSQ-NSCLC with RRs of 3.54 (95 % CI: 1.48-8.51,
p0.005) and 3.39 (95% CI: 1.28-8.95) respectively. The risk was increased
significantly for bevacizumab at 5mg/kg/wk (RR, 4.20; 95 % CI 1.72-10.21,
p0.002), but not at 2.5mg/kg/week (RR, 2.19, 95 % CI 0.56-0.84, p0.26).
The most common cause of fatal AE was pulmonary hemorrhage (51.4%),
followed by neutropenia (17.1%).
Conclusion: Bevacizumab significantly increased the risk of fatal AE in
patients with NSQ-NSCLC receiving chemotherapy. Further studies are
strongly recommended to optimize the treatment.
Disclosure: S. Wu: Dr. Wu receives Honararia from Onyx, Novartis and
Wyeth Pharmaceuticals and speaker for Onyx, Novartis and Pfizer pharma-
ceuticals All other authors have declared no conflicts of interest.
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METASTATIC ADENOCARCINOMA OF THE LUNG IN
ELDERLY PATIENTS RESPONSIVE TO ERLOTINIB,
REPORT OF 3 CASES AND LITERATURE REVIEW
G. Shoja e Razavi, A. Goharian Internal Medicine, Golestan University of
Medicine, Gorgan/IRAN
Introduction: Advanced lung cancers generally show aggressive behaviour
and their prognosis are usually unfavorable specially in elderly patients ,be
cause the age and underlying diseases not only delay the diagnosis but also
complicates the outcome and management of the patients.Among different
pathologic subtypes of lung cancer,adenocarcinoma shows different natural
history specially when erlotinib is added to its theraputic regimen.We report
3 cases of elderly patients with metastatic adenocarcinoma of the lung which
responded to Erlotinib in combination with Navelbine and Cisplatin and
followed with Erlotinib as single agent.
Materials and method: 3 cases (one male and two females) were selected
from the patients referred to Medical Oncology Clinic at 5th Azar University
Hospital. All the cases have had Coronary Artery Bypass Graft due to IHD
and the tumor was found during thoracotomy for CABG in one case and 2
to 3 months after surgery in another case. The third case was first presented
with abnormal gait, dizziness and mild abnormal unilateral muscle weakness
and a right cerebellar mass detected on brain MRI with past history of CABG
2 years ego. Further investigation for the latter showed a lung mass without
any other distant metastases and metastatic work up for the first two cases
showed asymptomatic metastases in left frontal area.Cardiologic consult and
echocardiogram showed borderline LVEF and Taxanes were omitted from
chemotherapy schedule for the patients. Single cerebellar metastasis was
removed surgically in patient with symptomatic cerebellar mass lesion perior
to reference to our clinic.
Results: Median age of the patients was 73 ranging from 70 to 76 years.
skeletal metastases were present in patient with cerebellar lesion but not in
other cases and no visceral mets. were found in none of the cases.All of the
patients were planned to receive navelbine 25mg/m2 D1 and8 with Cisplatin
75mg/m2 on D1 every 21 days with Erlotinib 150 mg per Day continous-
ly.The case with metastatic bone disease receives monthly Zometa 4 mg
infusions as well. Whole brain RT was done perior to chemotherapy for the
case with resected cerebellar metastasis and following 4 courses of chemo-
therapy for 2 cases with asymptomatic brain lesions.Re evaluation showed
tumor disappearance in 1 case and 50% reduction in tumor size in 2 other
cases, chemotherapy was held and erlotinib continued at the same dose (150
mg daily).
Conclusions: The patients were followed for median of 9 months. One case
died due to Acute Coronary Syndrome which was unrelated to underlying
malignancy and the 2 cases are alive and symptom free with stable disease
after 9 months of follow up. No side effect was found and no neutropenic
fever episode was reported as well.We found the combination of Navelbin,
Cis platin and Erlotinib feasible without significant side effects but positive
effects on metastatic friable elderly patients with Adenocarcinoma of Lung.
Disclosure: All authors have declared no conflicts of interest.
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TARGETED THERAPY FOR NSCLC: A CASE FOR
CHANGE
B.K. Eccles1, M.T. Lwin2, K.L. Bradley2, V.M. Laurence2, T. Geldart3
1Oncology, Royal Bournemouth Hospital, Bournemouth/UNITED KINGDOM,
2Clinical Oncology, Dorset Cancer Centre, Poole, Dorset/UNITED KINGDOM,
3Department of Oncology and Haematology, Royal Bournemouth Hospital,
Bournemouth/UNITED KINGDOM
Histology directed therapy is a hot topic in treatment of NSCLC. Recent data
suggests that response to first line tyrosine kinase inhibitors is strongly
correlated with EGFR mutational status. Recent data also suggests a differ-
ential response to chemotherapy based on histological subtype. Within the
UK, historically NSCLC has not been routinely sub-classified by all his-
topathologists and at present mutational testing is not routinely available.
NHS funding for TKI therapy is only available for patients receiving 2nd line
therapy for advanced disease.
Methods: We present recent retrospective data on use of erlotinib in 2 UK
district general hospitals for patients with advanced (stageIIIb/IV) NSCLC
over a 3 year period from Jan 2007 - Jan 2010 looking at smoking history,
number of previous therapies, duration of treatment, response-rate, overall
survival, and grade of rash, classification of histological subtype, method of
histological diagnosis and sample quality / size.
Results: 43 patients were identified during the study period. 1 patient
received gefitinib, the rest erlotinib. 2 patients were treated in the 1st line
setting (4.7%), 38 (88%) 2nd line, 2 (4.7%) 3rd line and 1 patient 4th line
(2.3%). Clinical benefit (Partial response, PR and stable disease, SD) was
seen in 35%; with no complete responders, 14% PR (n6), 21% SD (n9).
55 % progressive disease (n23) and unknown response in 11% (n5).
Overall survival from date of diagnosis ranged from 2-44 months with 13
patients still alive, 3 of which are still receiving treatment. Median overall
survival was 14 months, broken down into 20.8 months in those with clinical
benefit and 11.8 months in those who progressed or whose response could
not be evaluated. Histology was squamous subtype in 21%, non-squamous in
49% and not otherwise specified in 28%. Histology was obtained by biopsy
in (49%) or brushings (33%); but only 46% of histology was of a sufficient
sample for mutational testing.
Conclusion: Our data show good overall survival but many patients fail to
benefit from an unselected treatment approach. Close multidisciplinary
working with chest physicians and histopathologists will be required to
maximise histological information and facilitate histology directed therapy.
Disclosure: All authors have declared no conflicts of interest.
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RADIOTHERAPY FOR LOCOREGIONAL RECURRENT
NON-SMALL CELL LUNG CANCER
J. Kim1, M. Kim2, N. Jang1, J. Lee3 1Radiation Oncology, Seoul National
University Bundang Hospital, Seongnam-si/KOREA, 2Radiation Oncology,
Seoul National University Hospital, Seoul/KOREA, 3Medical Oncology,
Seoul National University Bundang Hospital, Seongnam-si/KOREA
Purpose: To evaluate outcome and complication of curative radiotherapy for
locoregionally recurrent non-small cell lung cancer (NSCLC).
Methods and materials: From 2004 to 2008, 21 patients received curative
radiotherapy for locoregionally recurrent NSCLC without systemic metasta-
sis after surgery at Seoul National University Bundang Hospital. At the time
of recurrence, median age was 70 years (range 49-81), and 19 patients were
male. Majority of patients (N 17) was ECOG 0 or 1 performance status.
The interval between the date of initial surgery and the date of recurrence
diagnosis (disease free interval) was median 15 months. Distribution of
recurrence sites were as follows; 10 patients in mediastinal lymph node area,
4 in ipsilateral hilar area, 4 in ipsilateral lung parenchyma, 2 in bronchial
stump and 1 in ipsilateral supraclavicular area. Radiotherapy was adminis-
tered with median 66 Gy (range 59.4-70 Gy) by 3D conformal technique.
Thirteen patients received chemotherapy concurrently during radiotherapy.
Pulmonary function test (PFT) was also analyzed to detect the lung function
change after radiation.
Results: The median survival, 1- and 2-year survival rates were 17 months,
68% and 34%, respectively. In multivariate analysis, good performance
status, longer disease free interval and radiation dose more than 66 Gy
increased in survival significantly (p0.043, 0.019, and 0.028, respectively).
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Concurrent chemotherapy did not affect survival significantly (p 0.1836).
DLCO of lung after radiotherapy decreased significantly compared with
pre-radiotherapy status (p0.033), but not FEV1 (p0.312). Radiation
pneumonitis of any grade was seen in 11 patients. Three patients died of
acute respiratory distress syndrome; 1 patient due to combined bacterial
pneumonia, 1 due to exacerbation of underlying interstitial pulmonary
fibrosis, 1 due to radiation pneumonitis.
Conclusion: Our retrospective study showed that curative radiotherapy for
locoregionally recurrent NSCLC resulted in median survival of 17 months
and 2-year survival rate 34%, comparable to other studies. Patients suitable
for curative radiotherapy for recurrent NSCLC could be treated aggressively,
such as high dose radiation. However, post-radiotherapy lung function
should be carefully evaluated to avoid serious lung damage after treatment,
considering poor lung function of post-resection patients.
Disclosure: All authors have declared no conflicts of interest.
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CEREBRAL METASTASES IN PATIENTS WITH LUNG
CARCINOMA AT THE CLINIC FOR LUNG DISEASES
CLINICAL CENTRE BANJA LUKA FOR THE PERIOD
AUGUST 1, 2008 - AUGUST 1, 2009
S. Mijatovic´1, M. Stanetic´2, L. Novakovic´ Lackovic´2 1Clinic of Oncology,
Clinical Centre Banja Luka, Banja Luka/BOSNIA AND HERZEGOVINA,
2Clinic for Lung Diseases, Clinical Centre Banja Luka, Banja Luka/BOSNIA
AND HERZEGOVINA
Lung carcinoma is the most frequent source of brain metastases. Although
the brain is not the most common metastatic site, brain metastases often
causes greater morbidity and mortality than other metastatic sites. The aim of
this work is to analyse time to development of cerebral metastases, their
number and recommended treatment in lung cancer patients, according to
tumor type and previous therapy. In retrospective analysis medical records of
54 patients with diagnosed cerebral metastases from lung carcinoma treated
at the Clinic for Lung Diseases Clinical Centre Banja Luka in the period
August 1, 2008 - August 1, 2009 were analyzed; 43 males and 11 females,
with age mean of 56.4. 24 patients developed brain metastases following the
lung cancer diagnosis (median time to development of cerebral metastases
was 8.7 months). 10 of those patients had a complete primary tumor
resection; in 3 (30%) of those patients solitary metastasis was diagnosed 1
month after the resection, all of them with verified NSCLC. 15 patients had
cerebral metastases diagnosed at the same time as the primary tumor. In 10
patients cerebral lesions were diagnosed first, all of them with diagnosed
NSCLC. Single metastatic lesions were found in 24 (44.4%) patients (23
with NSCLC, 1 with SCLC), while 30 (55.6%) patients (21 NSCLC, 9
SCLC) had multiple brain metastases. 19 patients were treated only with
first-line chemotherapy; most commonly used protocol was PE. 5 patients
received second-line chemotherapy, while one patient was treated with
third-line chemotherapy. 2 patients with verified SCLC received profilactic
endocranial radiation; one of them developed brain metastases 2 months, the
other one 7 months after radiation. Four patients among 24 cases of solitary
lesions were operated before the primary tumor diagnosis; in 20 other
patients 14 (70%) had an operable solitary lesion. Sugested treatment for one
patient was combined resection of the primary tumor and the solitary lesion.
For 25 (46.3%) patients palliative radiotherapy was recommended. At first
for 29 patients recommended treatment was chemotherapy and for 9 patients
symptomatic therapy.
Disclosure: All authors have declared no conflicts of interest.
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WHOLE-BRAIN RADIOTHERAPY VERSUS
STEREOTACTIC RADIOSURGERY IN CEREBRAL
LUNG CANCER METASTASES
C.M. Sagerup, B.H. Høvik, Å. Helland, O.T. Brustugun Insitute of Clinical
Medicine, Radiumhospitalet, University of Oslo, Oslo/NORWAY
Objective: Lung cancer is the most common cause of brain metastases, and
up to 50% develop CNS manifestations. In our institution, stereotactic
radiosurgery (SRS) is offered to patients with 3 or less brain metastases (
40mm in dm). The purpose of this report is to present our results comparing
overall survival in lung cancer patients treated with SRS and whole brain
radiation therapy (WBRT).
Patients and methods: We performed a retrospective analysis of 33 patients
treated with SRS (/- WBRT) in the period 2007-2009 and 52 patients
treated with WBRT (30 Gy’s in 3 Gy fractions) alone in the period
2004-2006. Cerebral magnetic resonance imaging was performed in all
patients, and number of cerebral metastases did not exceed 3 in either
treatment group. The Kaplan-Meier method was used and univariate com-
parison with log-rank test was performed.
Results: In the SRS group, 23 (70%) patients had a solitary metastasis and
10 patients (30%) extracranial metastases. 26 patients (79%) had deceased
and 7 were alive at time of analysis. Median follow up of survivors was 6
months (mean 10, range 4.5- 20.3). 16 patients (47%) received SRS as their
only radiation treatment. Doses ranged from 14 to 26 Gy (median 18 Gy). 17
patients received WBRT previous to (n6), or in combination with (n11)
SRS. Doses ranged from 10 to 25 Gy (median 18 Gy). In the WBRT group,
17 patients (33%) had a solitary metastasis and 17 patients (33%) had
extracranial metastases. 1 patient was alive at time of analysis. A significant
survival benefit was seen when SRS was used as a boost in addition to
WBRT vs. WBRT alone (10 months vs. 3 months, p0.0489). Compared to
WBRT alone, a survival benefit was present in patients with 1 metastasis
who received SRS for a new or recurrent lesion previously treated with
WBRT (p 0.0398) as well as in patients who received SRS as a boost in
addition to WBRT (p 0.0466). When comparing patients treated with SRS
only to patients who received WBRT, no significant difference in survival
was evident (p  0.413).
Conclusion: No statistically significant difference in survival between the
treatment modalities was found when not used in combination. A survival
benefit in patients that receive SRS in addition to WBRT versus WBRT alone
is suggested.
Disclosure: All authors have declared no conflicts of interest.
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MULTIDISCIPLINARY MANAGEMENT OF BRAIN
METASTASES FROM NON-SMALL CELL LUNG CANCER:
A RETROSPECTIVE STUDY
Y. Xu, S. Ma, X. Yu, Y. Yu, Y. Ji, X. Sun Department of Radiation
Oncology, Zhejiang Cancer Hospital, Hangzhou/CHINA
Objective: The incidence of brain metastases (BM) from non-small cell lung
cancer (NSCLC) is increasing, and the management of this complication at
a single institution is reported.
Methods: The records of all patients with BM from December 2003 to
January 2007 were reviewed, and 251 patients with BM from NSCLC were
identified. Associations between patient and tumor characteristics, treatment
modality, and survival were assessed.
Results: 198 patients (79%) had other systemic disease. Twenty-five patients
(10%) underwent surgery, 183 patients (73%) underwent whole-brain radiother-
apy (WBRT) during their management, and 135 patients (54%) received sys-
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temic chemotherapy. Twenty-five patients (10%) treated with Gefitinib. 133
patients (53%) who were treated radically with chemotherapy, radiation and
possibly surgery developed brain failure. The overall 1-, 2- and 3-year survival
rates were 34.1%, 13.7% and 8.7% with a median survival time of 9.0 months
(95% CI 8.04–9.97 months). On multivariate analysis, recursive partitioning
analysis (RPA) grouping, weight loss, LDH in blood serum and treatment were
independent prognostic factors. The median survival time of chemotherapy
alone, WBRT alone, surgery alone, WBRT with chemotherapy, surgery with
chemoradiation, WBRT with Gefitinib and others was 6.0, 9.0, 12.0, 9.0, 22.0,
13.0 and 4.0 months, respectively, which were significantly different
(X243.104, P0.000). In 95 patients who were treated radically with chemo-
therapy, radiation and possibly surgery developed brain failure, a longer (9
months) interval from diagnosis of NSCLC to diagnosis of BM was associated
significantly with longer survival (X24.606, P0.032). The stratify analysis
indicated the median OS of patients received concurrent WBRT/chemotherapy
(13.0 months) was longer than it of patients received sequential WBRT/
chemotherapy (9.0 months) (X23.89ı¨1⁄4ŒP0.049).
Conclusion: The main prognostic factors are RAP grouping, weight loss,
LDH in blood serum and treatment. The effect of combined treatment of
multidisciplinary is favorable, but the choice of the patient is important.
Disclosure: All authors have declared no conflicts of interest.
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LOW INCIDENCE OF GRADE >3 BLEEDING EVENTS
AND LOW DISCONTINUATION RATES IN SAIL
(MO19390): FIRST-LINE BEVACIZUMAB (BV) IN
PATIENTS (PTS) WITH ADVANCED NON-SQUAMOUS
NON-SMALL CELL LUNG CANCER NSCLC
L. Crino`1, C. Steppert2, S. Cinieri3, N. Thatcher4 1Medical Oncology, S.
Maria della Misericordia Hospital, Perugia/ITALY, 2Thoraxclinic, BK Ober-
main, Ebensfeld/GERMANY, 3Medical Oncology Division, Senatore Antonio
Perrino Hospital, Brindisi/ITALY, 4Department of Medical Oncology,
Christie Hospital NHS Foundation Trust, Manchester/UNITED KINGDOM
Background: SAiL is a large, international, open-label study of first-line Bv
in combination with chemotherapy, and has reported an overall survival (OS)
of 14.6 months. Final safety data focusing on the incidence of serious
bleeding events, including pulmonary haemorrhage, are reported here.
Methods: Eligible pts had no history of grade [G] 2 haemoptysis (up to 3
months prior to enrolment) and received Bv (7.5 or 15mg/kg) in combination
with chemotherapy for up to 6 cycles followed by Bv until disease progres-
sion or unacceptable toxicity. Primary endpoint was safety; secondary
endpoints included time to disease progression (TTP) and OS.
Results: Final data are available for 2,172 pts. Baseline characteristics were
(%): male 60.1; stage IIIB/IV 19.6/80.4; adenocarcinoma 85.9; ECOG PS 0/1/2
37.4/56.3/6.3. Mean age was 59 years. 37.9% of pts experienced a serious
adverse event (SAEs) of any G; approximately 3/4 of these events were
considered to be non-Bv-related (mostly related to chemotherapy). Bleeding
events of any cause and any G were reported in 42.7% of pts, with the most
common event being G 1-2 epistaxis (26.6%) and G 3 bleeding events
occurring in only 3.6% of pts. G3 pulmonary haemorrhage (PH) was reported
in 0.7% of pts, G 3 central nervous system (CNS) bleeding in 0.1% of pts and
G 3 gastrointestinal bleeding in 0.4% of pts. Bv was temporarily interrupted
for 2.0% and permanently discontinued for 8.1% of bleeding events.
Conclusions: Bv-treated pts in SAiL were at low risk of experiencing G 3
bleeding events, with G 3 PH occurring in only 0.7% of pts in this large
study. Furthermore, the rate of discontinuation or interruption of Bv for
bleeding events was low, reflecting the manageability of Bv in NSCLC pts
in normal clinical practice.
Disclosure: N. Thatcher: Nick Thatcher has received honoraria and research
funding rom Roche. He has also been compensated by Roche for acting as an
advisor and providing expert testimony. All other authors have declared no
conflicts of interest.
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EFFECTIVENESS AND TOLERANCE OF MAINTENANCE
THERAPY IN PATIENTS WITH NON-SQUAMOUS NON-
SMALL CELL LUNG CANCER (NSCLC)
E.S. Santos, A. Belalcazar, A. Vazquez, J.E. Gomez, L.E. Raez Oncology,
University of Miami, Miami/USA
Background: Prior studies have established the role of pemetrexed (Pem) or
bevacizumab (B) as maintenance chemotherapy (MCX) after first-line che-
motherapy (FCX) with platinum-base doublet for patients (pts) diagnosed
with advanced non-squamous non-small cell lung cancer (NSCLC). How-
ever, there is not enough data about the combination or the role of single
agent Pem as MCX after FCX with Pem. Moreover, the best MCX (by
efficacy and cost) is not yet defined. Thus, the objectives of this study were
to evaluate the efficacy of Pem single agent or in combination as MCX for
NSCLC pts who have received Pem as FCX.
Methods: A retrospective review from January 2008 to January 2010
focused on stage IIIB/IV NSCLC pts who have received or are planned to
receive MCX with single agent Pem or in combination (as part of FCX or
second-line); those whose MCX is part of FCX must also have Pem as FCX.
Results: Nineteen subjects were identified; median age: 60 years (range,
34-77), 10 males, 11 Hispanic, 6 White, 2 African-American, 17 had
adenocarcinoma, 15 had received at least 1 cycle of MCX (median number
of MCX cycles: 5; range: 1-18). All chemotherapy regimens were frontline
unless otherwise specified: 16 Carboplatin/Pem/B (1 pt received it as second
line), 1 Cisplatin/Pem/B, 1 Carboplatin/Pem, and 1 Pem/B (as second line).
The best response after completion of FCX (n18) was: 2 PR, 14 SD, and
2 PD. Thirteen of 15 pts on MCX also received Pem as FCX; 14 of these pt.
received Pem/B combination and 1 Pem alone as MCX regimen. Two pts on
MCX developed grade 3-4 adverse events: fatigue, anemia and thrombocy-
topenia. One of them died with pneumonia during Pem MCX without disease
progression. After a median follow up of 7 months (range: 4-14), 4 pts have
progressed (2 after completion of FCX and 2 on MCX after 9 and 18 cycles
of MCX, respectively).
Conclusions: Carboplatin/Pem/B is becoming a common regimen used as
FCX followed by MCX Pem/B in eligible patients with non-squamous
NSCLC. As MCX, Pem/B is well tolerated with most AEs being grade 1-2.
A longer follow up will take place and updated data in term of efficacy and
long-term side effects will be presented.
Disclosure: E.S. Santos: Genentech- Speaker Bureau Lilly- Speaker Bureau;
J.E. Gomez: Genentech- Speaker Bureau Lilly- Speaker Bureau; L.E. Raez:
Genentech- Speaker Bureau Lilly- Speaker Bureau All other authors have
declared no conflicts of interest.
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A PHASE II TRIAL OF IRINOTECAN MONOTHERAPY IN
ADVANCED NON-SMALL-CELL LUNG CANCER
PATIENTS WITH ECOG PERFORMANCE STATUS (PS) 2:
RESULTS OF KOREAN CANCER STUDY GROUP LU05-05
B.S. Kim1, Y.M. Ahn1, H.K. Kim2, J.H. Kim3, K.H. Lee4, E.K. Cho5, S.H.
Bae6, S.J. Gong7, H.W. Lee8, J.H. Choi9 1Department of Internal Medicine,
Seoul Veterans Hospital, Seoul/KOREA, 2Department of Internal Medicine,
St Vincent’s Hospital, Seoul/KOREA, 3Department of Internal Medicine,
Yonsei Cancer Center, Seoul/KOREA, 4Hemato-Oncology, Yeungnam uni-
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versity hospital, Daegu/KOREA, 5Hematology-oncology, Medicine, Gachon
University Gil Medical Center, Incheon/KOREA, 6Oncology/Hematology,
Daegu Catholic University Hospital, Daegu/KOREA, 7Department of Inter-
nal Medicine, Seoul Eulji Hospital, Seoul/KOREA, 8Hematology-Oncology,
Ajou University School of Medicine, Suwon/KOREA, 9Hematology-Oncol-
ogy, Ajou University Hospital, Suwon/KOREA
Background: For advanced non-small cell lung cancer (NSCLC) patients
(pts) with ECOG PS 2, single agent chemotherapy with 3rd generation agent
has been recommended as a preferable option. This study evaluated the
efficacy and safety of single agent irinotecan for advanced NSCLC pts with
ECOG PS2.
Methods: This was an open-label, single-arm, multicenter phase II trial, de-
signed to detect a response rate of 16%. Chemonaive NSCLC pts with stage IV
or stage IIIB with malignant effusion received irinotecan 80 mg/m2 on days 1
and 8 every 21 days for 4 cycles. The primary end point was response rate.
Secondary end points included overall survival (OS), progression-free survival
(PFS), and safety.
Results: Forty pts (planned: 56 pts) were enrolled with a median age of 68
(42-74), 30 males, and 35 pts with stage IV. Median cycle of irinotecan
chemotherapy was 2 (1-6). As an intention to treat analysis, 7 pts (18%) had
partial response, and 14 pts (35%) had stable disease. Median PFS was 2.6
months, while 1-year and median OS were 23% and 4.6 months, respec-
tively. NCI CTCAE grade 3 or higher toxic effects were as follows: anemia
(10%), neutropenia (10%), thrombocytopenia (10%), pneumonia (10%),
diarrhea (8%), and general weakness (8%). Eight pts (20%) died during or
just after treatment period (aspiration or infectious pneumonia: 2, pneumonia
with sepsis: 1. pneumonia with myocardial infarction: 1, septic shock: 1,
disease progression:1, unknown: 2).
Conclusions: Irinotecan monotherapy for advanced NSCLC pts with ECOG
PS2 demonstrated modest activity in terms of response rate and comparable
OS with previous trials. However, a relatively high rate of deaths during
treatment suggests careful selection of pts and monitoring throughout che-
motherapy period.
Disclosure: All authors have declared no conflicts of interest.
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THE PRIMARY TREATMENT OF PATIENT WITH
ADVANCED NON-SMALL CELL LUNG CANCER
PRESENTING WITH BRAIN METASTASIS AT DIAGNOSIS
M. Calis1, V. Calis2, O. Incekara1 1Radiation Oncology, Sisli Etfal Reserch
and Training Hospital, Istanbul/TURKEY, 2Neurosurgery, Istinye State Hos-
pital, Istanbul/TURKEY
A lot of trials evaluating platinum-based chemotherapy (CT) have recently
challenged the standart option of radiotherapy (WBRT) in the treatment of
NSCLC patients presenting with brain metastasis. The common approach
including WBRT followed by CT could not represent the tretment of choice
when brain metastases symptoms are absent or controlled by supportive
therapy. A subset of 71 pts fulfilling the following criteria: patholojic proof
of NSCLC, stage IV with BM at first diagnosis, age 70 yrs, ECOG PS2,
median age 56 yrs (33–69), median PS 1. The first treatment was surgery in
43 pts. platinum-based CT included etoposide in 71 pts. All of pts were
performed WBRT. Regardless of treatment the overal BM response was 40%
(36% vs 49% for Ct and local treatment subgroups, respectively). For the
general population the overal response PFS and MST were 37%, 10 and 13
months, respectively. The optimal treatment choice for pts presenting with
brain metastasis should deserve prospective evaluation.
Disclosure: All authors have declared no conflicts of interest.
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SURGICAL RESECTION OF ISOLATED ADRENAL
METASTASES IN PATIENTS WITH NON-SMALL CELL
LUNG CANCER. A SINGLE INSTITUTION EXPERIENCE
S. Bastian, T. Clerici, T. Cerny, M. Fru¨h Oncology/Hematology, Cantonal
Hospital of St. Gallen, St. Gallen/SWITZERLAND
Introduction: The role of surgical resection of solitary adrenal metastases in
patients with non-small cell lung cancer (NSCLC) is controversial. Proper
selection of patients who are likely to benefit from adrenalectomy remains
unclear.
Methods: We retrospectively reviewed clinico-pathological factors and
outcomes in all NSCLC patients treated with adrenalectomy at our centre
between 1997 and 2009.
Results: Pathological staging of the four patients showed pT1pN0, pT2pN0,
pT2pN0 and ypT1ypN0 (after neoadjuvant chemotherapy for cT3cN2).
There were three adeno- and one squamous cell carcinoma. All had a
performance status of 0. Median age was 56 years (range: 53-58), including
one female and three males. All were current or ex-smokers. None received
adjuvant chemotherapy after resection of the primary. One received adjuvant
radiotherapy due to close margins. Adrenal metastases were detected by
Computed Tomography in one and Positron Emission Tomography in three
patients. Three patients had metachronous adrenal metastases. Median time
from lobectomy to occurrence of the adrenal metastases was 12.3 months
(11–14 months). Two received laparoscopic and two open adrenalectomy.
Peri-operative mortality was zero. No additive chemotherapy after adrenal-
ectomy was given. Three patients recurred systemically after adrenalectomy.
Median time to recurrence in these patients was four months (2-5 months).
First- line chemotherapy regimen administered in progressing patients in-
cluded carboplatin and gemcitabine, carboplatin and paclitaxel and gemcit-
abine monotherapy. Two patients died due to systemic progression six and
15 months after adrenalectomy. One patient who had an interval between
resection of the primary and the adrenal metastasis of 14 months and remains
in remission after more than 39 months following adrenalectomy.
Conclusion: Adrenalectomy in NSCLC patients with isolated adrenal me-
tastases is feasible. However, despite careful patient selection, long term
survival is rare due to often rapid systemic progression. Prolonged interval
between resection of the primary tumor and adrenalectomy may indicate a
more favourable outcome with surgery.
Disclosure: All authors have declared no conflicts of interest.
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INTUSSUSCEPTION ILEO-ILEUM AS A SYMPTOM OF
NSCLC METASTASIS TO THE SMALL INTESTINE
A.L. Zygulska1, A. Wojcik2, P. Richter3, R. Tomaszewska4 1Oncological,
University Hospital, Krakow/POLAND, 2Surgical, Narutowicz Hospital,
Krakow/POLAND, 3IIIrd Department of General Surgery, Jagiellonian Uni-
versity School of Medicine, Krakow/POLAND, 4Department of Pathomor-
phology, Jagiellonian University School of Medicine, Krakow/POLAND
Purpose: The case of 55-year old male patient who had intussusception
ileo-ileum because of non-small cell lung cancer metastasis to the small
intestine is presented. Background: Cases of metastases to the intestine from
non-small cell lung cancer are casuistry.
Material and methods: The patient with non-small cell lung cancer and the
initial clinical stage III A after 1 cycle of chemotherapy with cisplatine plus
vinorelbine had resections superior lobe and 6 th segment of inferior lobe of
the left lung on January 30 th , 2009. Diagnosis of squamous cell carcinoma
with low grading was confirmed. Metastasis in 1 out of 5 lymph nodes of
pulmonary hilus was diagnosed. After surgical operation the next 3 cycles of
chemotherapy with cisplatine plus vinorelbine were given. The patient with
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suspicion of occlusion was admitted to Surgical Ward during emergency
service on May 13 th, 2009. He suffered from vomiting after every meal,
coprostasis and malaise lasting 4 days. Radiogram of the alimentary tract
suggested the presence of an obstacle in distal section of jejunum. Intussus-
ception ileo-ileum with retraction of mesentery vessels was diagnosed with
CT scans of the abdomen and the pelvis.
Results: Surgical operation was performed on May 28 th, 2009, during
which intussusception of the small intestine in 1/3 proximal of bowel in
stretch of 20 centimeters was diagnosed. After disinvagination a tumor of
small intestine was revealed. Segmental resection of jejunum in macroscopic
margins of normal tissue was done. Histopathological examination con-
firmed the same malignant lesion as in pulmonary tissue resectioned earlier.
Postoperative course was uneventful.
Conclusions: 1. Resection of metastasis to the intestine from malignant
neoplasms with primary localization apart from alimentary tract is the only
effective treatment. 2. In spite of described single cases of long-term
survival, prognosis is poor.
Disclosure: All authors have declared no conflicts of interest.
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QUALITY OF LIFE (QOL) AND SYMPTOM
MANAGEMENT BARRIERS IN LUNG CANCER
M. Koczywas1, M. Cristea1, T. Borneman2, B. Piper3, G. Uman4, B. Ferrell2
1Medical Oncology and Therapeutics Research, City of Hope, Duarte/USA,
2Nursing Research and Education, City of Hope, Duarte/USA, 3Nursing
Research, Scottsdale Healthcare/University of Arizona, Scottsdale/USA, 4Vi-
tal Research, Vital Research, Los Angeles/USA
QOL and symptom concerns are of great importance to patients with lung
cancer. However, the quality of symptom management continues to be
suboptimal. This project is a prospective, longitudinal study that assessed
barriers to pain and fatigue management in cancer patients. This abstract
reports baseline descriptive data for the lung cancer patients (n72) in the
study. Patients with moderate to severe pain and/or fatigue were accrued.
Outcomes were obtained using the COH QOL tool, Barriers to Pain and
Fatigue tools, Piper Fatigue Scale (PFS), and Patient Knowledge tools for
pain and fatigue. Subjects’ mean age was 60, and included 28% ethnic
minorities. The majority (58%) had Stage IV disease, and 73% were
receiving treatment. QOL concerns were identified for the following: fatigue,
appetite changes, pain, sleep changes (physical well-being); loss of control,
feeling useful, changes to appearance, high levels of distress from initial
diagnosis and treatments, fear of recurrence (psychological well-being);
family distress, interference with employment and daily activities (social
well-being); and high levels of uncertainty (spiritual well-being). Subjects
reported high levels of distress from fatigue that interfered with daily
functions. Pain-related misconceptions included the inevitability of addiction
with pain medications, difficulties in controlling medication-related side
effects, and tolerance to pain medications. Fatigue-related misconceptions
included the belief that there are no effective treatments for fatigue, and that
fatigue is not as important as treating cancer. Overall, patient knowledge of
pain and fatigue was high (0.82-0.91), but lack of knowledge persisted with
items related to the cause of pain and fatigue, common side effects of pain
medications, the proper use of pain medications, and avoiding exercise in
order to conserve energy. The study results suggest that lung cancer patients
have high QOL and symptom concerns, and barriers to pain and fatigue
management are common. Findings will aid in the development of effective
palliative care interventions to improve and maintain QOL and symptom
management for this cancer population.
Disclosure: M. Koczywas: Speaker bureau for Genentech and Eli Lilly All
other authors have declared no conflicts of interest.
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USE OF ZOLEDRONIC ACID IN LUNG CANCER
R.G. Calderone1, K. Nimako2, A.N. Leary3, S. Popat4, E. Kipps2, M.N.
O’Brien5 1Head and Neck, Istituto Nazionale dei Tumori, Milano/ITALY,
2Lung, Royal Marsden Hospital, London/UNITED KINGDOM, 3Breast Unit,
Royal Marsden Hospital, London/UNITED KINGDOM, 4Department of Medi-
cine, Royal Marsden Hospital, London/UNITED KINGDOM, 5Lung Unit, The
Royal Marsden NHS Foundation Trust, London/UNITED KINGDOM
Background: The skeleton is the preferred site of metastasis for many solid
tumours. Patient with lung cancer have a prevalence of metastatic bone
disease (MBD) of around 40%. Zometa, a 3rd generation bisphosphonates
(BPs), is used to treat MBD in many cancers. There have been reports of
increased survival in patients receiving BPs particularly in breast cancer.
There has been a recent observation of an increased response rate when used
with chemotherapy e.g. Doxorubicin and Zometa in a mouse model. We
examined the rates of Zometa administration in lung cancer patients with
MBD, and compared overall survival (OS) between patients who had Zometa
from diagnosis to those who did not. In general Zometa was given for
symptomatic MBD but there was no formal policy.
Material and method: This was a retrospective audit approved by the local
audit committee with a plan to obtain at least 50 patients with MBD treated
with Zometa and 50 without to have an 80% chance of seeing a HR of 2
corresponding to a survival difference of 25-30%. We identified 398 stage IV
NSCLC patients, diagnosed between July 2004 and July 2009. Among them 168
presented with MBD (42%). We collected the data of 114 random patients to get
49 pts who received Zometa and this gave 75 who did not. Treatment consisted
of platinum-based chemotherapy with or without Zometa.
Results: There were 29% (49/168) of patients diagnosed with MBD who
received Zometa. Patients on Zometa had better (OS), with a median of 34
weeks, compared to those did not, who had a median of 19 weeks (p0.01).
After adjusting for prognostic factors, Zometa patients maintained better OS
(p0.06) 34 versus 21 weeks.
Conclusions: Patients with MBD are common in advanced NSCLC, but the
percentage of patients treated with BPS is still low. The addition of Zometa
Zometa (%) No Zometa (%)
Patients 43 71
Gender
Male : female 18/25 (42/58) 40/31(56/44)
Age
Median (range) 61 (28–82) 63 (39–86)
Ethnicity
Caucasian Black Other & not
known
37 (32) 0 6 62 (53) 3 7
Histology
Adenocarcinoma  BAC
Squamous Other/not
specified
28 (65) 5 10 36 (51) 15 20
PS
0/1/2/3 3/28 (65) /8/4 8/46 (65) / 15/2
Chemotherapy
Platinum  Navelbine
Platinum  Gemcitabine
Platinum  Taxane Other
platinum comb. Single
agent
18 4 5 0 16 (42) 32 19 3 3 14 (45)
Metastases
Liver CNS 12 (28) 7 16 (23) 12
No sites (other than bone)
None 1 site 2 sites
10 11 22 (51) 16 20 35 (49)
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increase OS in NSCLC patients with MBD in this audit. This may be a treatment
worthy of further consideration even in asymptomatic patients and more formal
policies on the treatment of MBD in NSCLC patients need to be put in place.
Disclosure: All authors have declared no conflicts of interest.
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OUR EXPERIENCE WITH ENDOBROCNCHIAL
BRACHYTHERAPY AS PALLIATIVE TREATMENT IN
ADVANCED NSCLC
R. Anghel1, L.N. Minea1, X. Bacinschi1, I. Isacu1, A. Tarlea1, D. Ples2
1Radiochemotherapy, Institute of Oncology Bucharest, Bucharest/ROMANIA,
2Oncology, Clinical hospital Constanta, Constanta/ROMANIA
Background: Patients with inoperable non-small cell lung cancer previously
treated by external beam radiation therapy have a poor prognosis if endo-
bronchial obstruction persists or relapses. The therapeutic options are limited
to controlling symptoms (dyspnea, cough, hemoptysia) and maintaining their
quality of life. We intended to evaluate if HDR endobronchial brachytherapy
is tolerable and efficient as palliative treatment for these patients.
Methods: The study group was 48 patients with stage IIIB NSCLC treated
in the Radiation Therapy Department of the Oncological Institute of Bucha-
rest, Romania, between June 2005 and December 2008. All the patients
previously underwent external beam radiation therapy. 37 patients had no or
partial tumor response and 11 patients relapsed after initial complete re-
sponse to external irradiation. These patients, which experienced obstructive
symptoms and hemoptysia, were referred to brachytherapy. Endobronchial
irradiation consisted in 2 fractions of 7.5 Gy Day 1 and 8 and was delivered
using remote HDR afterloading brachytherapy with Iridium-192. The pa-
tients were evaluated prior to therapy, at the end of radiation, and every 2
months thereafter. The evaluation consisted in complete clinical examina-
tion, bronchoscopy and quality of life QLQ-C30 questionare, adverse events
and survival follow-up.
Results: Bronchial obstruction and consequently dyspnea was significantly
improved in 32 patients (66.67%) hemoptysis diminished in 43 cases
(89.58%). Quality of life was improved in 39 cases (81.25%). Symptoms
improvement lasted for at least 3 months in 21 cases and at least 6 months
in 8 cases. The median actuarial survival for the entire group was 5 months
from the beginning of therapy. Acute toxicities were mucositis, and mild
hemoptisia. Grade 3-4 complications occurred in 5 patients (10.42%); one of
them experienced fatal hemoptysia.
Conclusions: Endobronchial brachytherapy effectively palliates most symp-
toms caused by endobronchial obstruction with few complications but no
overall survival benefit.
Disclosure: All authors have declared no conflicts of interest.
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CLINICAL OUTCOMES (CO) FOR SPECIAL
POPULATIONS OF PATIENTS (PTS) WITH ADVANCED
NON-SMALL CELL LUNG CANCER (NSCLC): RESULTS
FROM ARIES, A BEVACIZUMAB (BV) OBSERVATIONAL
COHORT STUDY (OCS)
A.J. Wozniak1, J. Garst2, M. Jahanzeb3, M. Kosty4, R. Vidaver5, S. Beatty6,
S.L. Teng6, E.D. Flick7, A.P. Sing8, T.J. Lynch9 1Karmanos Cancer Insti-
tute, Wayne State University, Detroit/USA, 2Oncology, Regional Cancer
Care, Durham/USA, 3Hematology and Oncology, University of Tennessee
Cancer Institute, Memphis/USA, 4Hematology/Oncology, Scripps Clinic, La
Jolla/USA, 5Oncology, National Lung Cancer Partnership, Madison/USA,
6Biostatistics, Genentech, Inc, South San Francisco/USA, 7Epidemiology,
Genentech, Inc, South San Francisco/USA, 8Biooncology, Genentech, Inc,
South San Francisco/USA, 9Oncology, Yale Cancer Center, New Haven/USA
Background: BV (Avastin®) prolongs progression-free (PFS) and overall
survival (OS) in advanced NSCLC. ARIES, a prospective OCS evaluating
BV in a real world setting, includes pts underrepresented in randomized
controlled trials (RCTs), i.e. pts 70y, with poor performance status (PS), or
with CNS metastases (mets). Preliminary COs (effectiveness and safety) in
ARIES subpopulations are presented.
Methods: Pts with locally advanced non-squamous NSCLC on 1st line
chemotherapy (CT) and BV enrolled. No prespecified treatments, doses or
assessments. Data are collected electronically at baseline (BL) and quarterly
(QU), including BV-targeted adverse events (AEs) and serious AEs (SAEs).
Descriptive safety analyses were conducted for all pts and for subgroups.
Median (med) PFS and OS are Kaplan-Meier estimates.
Results: ARIES enrolled 1970 NSCLC pts. Med follow-up at the 09/2009
data cut was 9.6 mo; 98% have 1 QU follow-up. Med PFS is 6.7 mo and
OS is 13.6 mo for the entire cohort and were similar across subgroups except
pts with PS2. The most common 1st line CT is carboplatin/paclitaxel (CP).
Pts 70y and pts with PS2 or CNS mets at BL generally used more
nonplatin-containing CT and pemetrexed. AE rates across subgroups were
similar to the overall cohort except for increased arterial thromboembolic
events (ATE) in pts 70y and with PS2. No CNS bleeding events occurred
in pts with CNS mets at BL.
Conclusion: The COs (safety/effectiveness) of BV in pts 70y, or with
PS2 or CNS mets are consistent with the known BV efficacy and safety
profile. Pts with PS2 received less CP and had worse COs but not more
AEs/SAEs. Pts 70y had COs similar to the overall cohort despite less
doublet CT, suggesting that advanced age, poor PS or CNS mets should not
necessarily exclude pts from receiving BV therapy.
Disclosure: A.J. Wozniak: Consultant on advisory board at Genentech
(financially compensated), and have received research funding from Genen-
tech; J. Garst: Consultant on advisory board for Genentech (financially
compensated) and has received Speaker’s Bureau honoraria and research
funding from Genentech M. Jahanzeb: Has received honoraria from and is a
consultant (financially compensated) for Genentech, Aventis, Glaxo-Smith-
Kline, and Eli Lilly; M. Kosty: Have received honoraria and research funding
from Genentech; R. Vidaver: Genentech pays consulting fees and honoraria
directly to National Lung Cancer Partnership (not to Dr. Vidaver personally);
S. Beatty: Contract employee at Genentech; S.L. Teng: Employee at Genen-
tech and stockholder of Roche; E.D. Flick: Employee at Genentech and
stockholder of Roche; A.P. Sing: Employee at Genentech and stockholder of
Roche; T.J. Lynch: On Board of Directors of and stockholder of Infinity
All
NSCLC
Pts
(n  1970)
Age
>70
(n650)
PS >2
(n182)
CNS
Mets
(n150)
Med PFS (mo) 6.7 6.8 5.8 6.0
Med OS (mo) 13.6 12.6 8.1 11.7
CP 1st-line CT, n (%) 1215 (62) 382 (59) 107 (59) 82 (55)
Severe pulmonary
hemorrhage (PH), n
(%)
15 (0.8) 2 (0.3) 2 (1) —
Gr 3-5 bleeding
excluding PH, n
(%)
52 (3) 20 (3) 7 (4) —
ATEs, n (%) 35 (2) 20 (3) 6 (3) —
Gr 3-5 CNS bleed, n
(%)
2 (0.1) 0 1 (0.5) 0
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Pharma. Consultant (financially compensated) for Genentech, Merck, BIPI,
Astra Zeneca
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OUTCOME OF METASTATIC NON-SMALL CELL LUNG
CARCINOMA PATIENTS RECEIVING SYSTEMIC
TREATMENT: A SINGLE LATINAMERICAN
INSTITUTION EXPERIENCE
O. Aren1, L. Matamala1, M. Fica2, A. Santini1, H. Harbst3, M. Carcamo4, H.
Cerda1 1Medical Oncology Service, Instituto Nacional del Cancer, Santiago/
CHILE, 2Servicio de Cirugia, Instituto Nacional del Torax, Santiago/CHILE,
3Radiation Oncology Service, Instituto Nacional del Cancer, Santiago/
CHILE, 4Biostatistics Service, Instituto Nacional del Cancer, Santiago/
CHILE
Introduction: Non-Small Cell Lung Cancer (NSCLC) is one of the leading
causes of cancer death in Chile. Palliative chemotherapy has shown clear
benefit over best supportive care. We analized all patients that received
systemic treatment for Stage IV NSCLC at our institution (Instituto Nacional
del Cancer, Santiago, Chile), from January 2004 to April 2009.
Patients and methods: We analyzed 68 consecutive patients with metastatic
NSCLC at presentation, who met the following inclusion criteria: no previ-
ous chemotherapy, performance status (PS) 0-2, adequate bone marrow
reserve, normal hepatic and renal function, and no exclusion criteria: history
of treatment for other cancers, treatment at other institutions, or lack of data
on file. The database was obtained from the chemotherapy database at our
institution, from January 2004 to April 2009. All patients met inclusion
criteria, no patients met exclusion criteria. Survival was calculated (using
Kaplan-Meier) from the date of histolgical diagnosis until death (obtained
from death certificates) or last available control on file (for living patients).
Results: Median age was 60 years (range 20–87). 48 (59%) patients were male.
The most frequent histology was adenocarcinoma (67%). Median number of
cycles was 3 (range 1–6). First line chemotherapy was Platin (cisplatin or
carboplatin) plus Etoposide in 56% of patients, paclitaxel-carboplatin in 29%,
other combinations 15%. Only 29% of our patients received second line therapy,
most frequently docetaxel, followed by TKI. Median overall survival (OS) time
was 11.3 months (range 1.1–61.8; 95% CI: 11.19–15.68 ). One-year OS was
63.6%, two-year OS was 31.7%. OS at 36 months was 10,6%.
Conclusion: Despite methodological limitations, this patient sample had a
remarkable good outcome in comparison previously reported results. The favor-
able results could be explained by the fact than treatments are conducted by a
multidisciplinary experienced team dedicated exclusively to thoracic oncology.
Disclosure: All authors have declared no conflicts of interest.
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PRIMARY MUCINOUS ADENOCARCINOMA
(SIGNET-RING TYPE) OF THE LUNG
N. Valizadeh Hematology/Medical Oncology, Internal Medicine, Urmia
University of Medical Sciences, Urmia/IRAN
Background: Primary mucinous adenocarcinoma of the lung (Signet-ring
type) is a very rare type of lung adenocarcinoma. It accounts for approxi-
mately 0.25% of all lung tumors.
Case report: A 50 year old man with a non-smoking history was presented
with chronic productive cough. He did not report anorexia and weight loss,
and physical examination revealed coarse rales in both lungs. A chest CT-
scan showed a defined consolidation in the left lung with multiple hetrog-
enous density in both lungs. Bronchoscopy was performed and the biopsy
result confirmed lung mucinous adenocarcinoma (signet-ring type). Upper
GI-endoscopy was normal. Abdomino-pelvic CT was reported with normal
findings, except for a small calcification in the prostate. Total and free PSA
were in a normal range and further performed IHC was negative for PSA. We
started treatment by Taxotere and cisplatin in 21 days interval.
Result: In this man with a non-smoking history, a diagnosis of primary lung
mucinous adenocarcinoma with multiple metastasis in both lungs was
established.
Conclusion: Primary lung mucinous adenocarcinoma is a rare pathologic
subtype of lung cancer. It may be seen in non-smokers and may be metastatic
at initial presentation. Primary mucinous adenocarcima of the lung has
similar pathologic findings as extrapulmonary mucinous adenocarcinoma of
other sites (gastrointestinal, stomach, ovary, breast, pancreas). When diag-
nosis of the extrapulmonary mucinous adenocarcinoma with lung metastasis
is suspected, further evaluation by IHC is mandatory.
Disclosure: The author has declared no conflicts of interest.
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ADVANCED NON SMALL CELL LUNG CANCER
S.V.N. Krishnamurthy Surgical Oncology, Kidwai Memorial Institute of
Oncology, Bangalore/INDIA
Introduction: Chemotherapy prolongs survival in advanced non-small cell
cancer and shows an improved survival in patients receiving chemotherapy
compared with those receiving best supportive care at acceptable treatment
costs (JCO vol 6:1998 & Vol 8:1990). In our Institute, 90% of patients with
lung cancer present in an advanced or a metastatic stage requiring immediate
attention. The clinician is left with the option of providing the best palliation
at the least available time for investigation. We are analyzing the time of
presentation of these patients to the cancer centre as critical and that
prompted us to analyse the mode of presentation, the age at presentation, the
performance status of patients, the time to diagnosis, survival of patients and
quality of life of patient with the available treatment over a 2 year period
(2006–2007).
Method: 95 patients with suspected lung cancer were registered between
January 2006 to December 2007; 15 of these patients died even before the
establishment of diagnosis. Of the remaining 80 patients in whom diagnosis
was confirmed, 4 patients were found to have stage II and were offered
surgery and 40 patients refused treatment for various reasons. We analyzed
36 patients who received treatment during this period. The presentation of
patients was quite variable. It ranged from cough with expectoration (5),
hemoptysis (2), dyspnea (20), chest pain (6), hoarseness (2), swelling neck
(6), and subcutaneous swelling (2). The youngest patient in this series was 46
years old and the oldest was 82. A total of 29 patients (80%) in this study
were in the age group of 60 years. The Karnofsky performance status in
majority (23 patients) were 50% which made time as an important factor
in deciding about the treatment. We obtained a cytological confirmation of
diagnosis by ultrasound (18) or CAT guidance (6), nodal/subcutaneous
nodules (8), pleural fluid cytology (4). Six patients who presented with
pleural effusion underwent immediate intercostal drainage. Chemotherapy
was initiated within 7 days of attending the outpatient department. The
standard therapy offered was a combination of gemcitabine and cisplatin.
Gemcitabine was given in a dose of 1000mg/m2 on day 1, 8 and 15 and
cisplatin 75mg/m2 in divided doses on day 1 and day 2. The cycles were
repeated every 28th days. Only haemogram was repeated on the day of
giving gemcitabine. We recorded that 10 patients had a fall in platelet counts
to 1 lakh but only 3 patients who were symptomatic were given platelet
transfusion and the delay in continuing chemotherapy in these patients
ranged between 3-5 days. All the 36 patients completed a minimum of 3
cycles and 8 of these patients continued chemotherapy for a period of 6
months. Five patients received palliative radiotherapy to ipsilateral lung and
6 patients received radiation to brain successfully. Radiation was also offered
to 3 patients who had symptomatic bone metastasis. In 6 patients who
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underwent intercostal drainage before initiation of chemotherapy, we noticed
disappearance of the pleural fluid and the intercostal tube was removed after
the 1st cycle of chemotherapy.
Results: Of the 36 patients who successfully completed 3 cycles of chemo-
therapy, 24 patients (66.6%) had a survival of 5 months and 12 patients
(33.3%) continued chemotherapy for 6 months with an interception of 15
days for those patient who received radiotherapy of lung, brain or bone. The
symptom control in all 36 patients was excellent. As far as age is concerned,
we did not see any major difference in the tolerability to chemotherapy.
Disclosure: All authors have declared no conflicts of interest.
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PLEOMORPHIC CARCINOMA OF THE LUNG – PATIENT
CHARACTERICTICS, THERAPY AND OUTCOME:
A MONOCENTRIC RETROSPECTIVE ANALYSIS
C. Grohe1, O. Zaba1, H. Lu¨ders1, D. Holbe1, G. Leschber2 1Pulmonary
Division, ELK, Berlin/GERMANY, 2Thoracic Surgery Division, ELK, Berlin/
GERMANY
Background: Pleomorphic carcinoma of the lung (PC) is an uncommon
pulmonary tumour entity, which is not well characterized due to low patient
numbers. In general these patients tend to show poorer prognosis than other
histological subgroups of pulmonary malignancies. This is a retrospective
study that included the data of 47 patients with PC at every stage (collected
2004-2009) particularly with regard to epidemiology, morbidity, therapy and
outcome with a 5-year follow up.
Results: Characteristics of 47 pts: 33 male, 14 female; median age 66,7
years. 38,3% current smokers, 12,8 % former smokers, no documented never
smokers but 48,9% with no documented smoking status. Stage IA: 12,7%;
IB: 10,6%; IIA: 2,1%; IIB: 10,6%; IIIA: 6,4%; IIIB: 12,7%; IV: 44,7%.
Surgical treatment was conducted in 42,6%, mainly simple lobectomy (70%)
furthermore advanced lobectomy (25%) and pneumonectomy (5%). Chemo-
therapy was documented in 19 cases; Regimens: cisplatin/vinorelbine
(n12) , carboplatin/vinorelbine (n2) , cisplatin/etoposide (n2), cispla-
tin/gemcitabine (n1) and gemcitabine mono (n1). Metastasis were
mainly located in the lung (n10), brain (n9), liver and suprarenal gland
(each n8). Median OS (all stages): 1,29 years. Only 35,2% reached 5-year
survival and all of them had stages I or II. OS dependent on stage, I: 4,5 y,
II: 3,4 y, III: 0,76 y , IV: 0,31 y. In patients with advanced disease (IIIB–IV)
palliative chemotherapy showed different median OS, cisplatin/vinorelbine:
15,6 months , carboplatin/vinorelbine : 4,08 months, cisplatin/etoposide :
21,84 months, cisplatin/gemcitabine 6,96 months and gemcitabine mono 4,2
months. Median PFS at stage IV was 2,04 months only.
Discussion: Our analysis shows that male sex, ages 60-70 years and an
active or former smoking history seem to be the main epidemiological
characteristics in patients with PC. Concerning palliative chemotherapeutic
treatment it appears to be hard to recommend a specific regimen due to low
patient numbers although cisplatin based doublets with either vinorelbin or
etoposide showed the best results in our collective. More multicenter studies
with greater patient numbers are definitively necessary.
Disclosure: All authors have declared no conflicts of interest.
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CLINICAL SIGNIFICANCE OF CAVITATED LUNG MASS
AMONG LUNG CANCER PATIENTS RECEIVING FIRST
LINE CHEMOTHERAPY AT A TERTIARY CARE
INSTITUTE IN NORTH INDIA
V.K. Mootha1, N.N. Singh2, A.N. Aggarwal2, D. Behara1 1Pulmonary and
Critical Care Medicine, PGIMER, chandigarh/INDIA, 2Pulmonary Medi-
cine, Postgraduate Institute of Medical Education & Research (PGIMER),
Chandigarh/INDIA
Background: the clinical significance of the cavitated lung mass (CLM) on
chest radiographs (CXR) prior to and during first line chemotherapy (CTx)
of lung cancer (LC) is unclear. An evaluation of the incidence and prognostic
value of CLM among LC patients (pts) receiving first line CTx was
undertaken.
Methods: In a retrospective analysis, data about demographic and baseline
characteristics, CTx administration and findings of serial CXRs was col-
lected for consecutive newly diagnosed LC pts who received CTx/targeted
therapy over a 18 month period. Outcome variables assessed were objective
response rate (ORR) and overall survival (OS). Patients who received 3
cycles of CTx were included in analysis of ORR and new onset CLM.
Numerical and categorical data were compared among pts with and without
CLM using students t-test and chi-square test respectively.
Results: Out of 295 patients enrolled during study period, 30 pts who
received gefitinib as first line therapy and 5 patients who had non broncho-
genic tumors were excluded. Base line characteristics of 260 pts who
received CTx are shown in Table. Twenty pts (7.7%) had CLM at baseline.
The most commonly used CTx regimens were irinotecan-cisplatin in 92.5%
of small cell LC pts and taxane-platinum in 90% of non-small cell LC pts
respectively. Of the 260 pts, 187 received 3 cycles of CTx and were
included for ORR analysis. Squamous cell histology was the only charac-
teristic that is significantly associated with presence of baseline or new onset
CLM.Distribution of ORR was as follows: CRPR - 56.7%, SD-23.5% and
PD- 19.8% and did not differ significantly between pts with and without
CLM. New onset CLM was seen in 22 pts. Pateints with or without CLM at
baseline or during CTx had same OS.
Conclusions: Squamous cell histology is the only characteristic that is
associated with presence of CLM at diagnosis or after first line CTx.
Presence of CLM has no effect on ORR or OS.
Disclosure: All authors have declared no conflicts of interest.
Table
Characteristic All Patients (n260)
Patients with Cavitated
Lung Mass (n20)
Patients Without Cavitated
Lung Mass (n240)
p
Value
Age in years
(mean[SD])
57.76 [10.9] 57.63 [10.94] 59.3 [10.75] 0.498
Gender (male) 217 (83.5%) 16 (80%) 197 (82.3%) 0.69
Tobacco smokers 197 (75.5%) 13 (65%) 184 (76.6%) 0.14
Histology Squamous-98(37.7%)
Adenocarcinoma- 61(23.5%)
Undifferentiated-47 (18.1%)
Small cell-54 (20.8%)
Squamous-16 (80%)
Adenocarcinoma- 3(15%)
Undifferentiated-0%
Small cell-1 (5%)
Squamous-82(34.1%)
Adenocarcinoma- 58(24.1%)
Undifferentiated-47 (19.6%)
Small cell-53 (22%)
0.002
Stage of NSCLC Stage I- 2(1%)
Stage II- 9(4.4%)
Stage IIIA- 26(12.7%)
Stage IIIB- 93(45.1%)
Stage IV- 76(37.1%)
Stage I- 0%
Stage II- 1(5%)
Stage IIIA- 1(5%)
Stage IIIB- 10 (50%)
Stage IV- 7(35%)
Stage I- 2(1%)
Stage II- 8(4.2%)
Stage IIIA- 25 (13.6%)
Stage IIIB-83 (44.6%)
Stage IV- 69(36.5%)
0.903
Stage of SCLC Limited- 25(46.3%)
Extensive-29 (53.3%)
Limited-0(0%)
Extensive-1(100%)
Limited-25 (46.2%)
Extensive-28 (53.8%)
0.547
Bronchoscopic
abnormality
Normal-60(23%)
Abnormal-121 (46.5%)
Not done-79 (30.3%)
Normal- 4(20%)
Abnormal-12 (60%)
Not done-4(20%)
Normal-56(23.3%)
Abnormal- 109(45.4%)
Not done- 75 (31.2%)
0.474
Extra thoracic disease 57 (22%) 3 (15%) 54 (22.5%) 0.579
Karnofsky
performance status
100-166 (63.8%) 100-10 (50%) 100-156 (23.3%) 0.146
90-75 (28.8%) 90-10 (50%) 90-65 (27.3%)
80-18 (6.9%) 80-0% 80-18 (7.5%)
70-1 (0.4%) 70-0% 70-1 (0.4%)
Number of cycles
received
(mean[SD])
3.9 [1.75] 3.4 [1.5] 3.94 [1.77] 0.148
Survival in days
(median)
178.5 194 148 0.145
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IS THERE A ROLE FOR HIGH DOSE HEMITHORACIC
RADIOTHERAPY IN UNPNEUMONECTOMISED
MESOTHELIOMA PATIENTS?
M. Feigen Radiation Oncology Centre, Austin Health, Heidelberg/AUSTRALIA
Background: Malignant pleural mesothelioma is a disease with few cures
where the majority of patients die of overwhelming tumor masses that spread
over the involved hemithorax to adjacent organs. Even in cases selected for
radical surgery, local recurrence rates are high and cannot be controlled
long-term by intrapleural or systemic therapies. Radiotherapy has long been
regarded as ineffective and hazardous.
Methods: We have since 2003 been offering high dose radiotherapy to
selected patients who have residual local disease following incomplete
surgical resection for mesothelioma, using technologically advanced
methods including intensity-modulated radiotherapy, and utilising PET
scans to precisely target active disease and assess locoregional control
rates.
Results: We have found no major acute or late toxicities after radiation
doses of 45 to 60 Gy to large volumes of the hemithorax in thirty patients,
and total glycolytic volume analysis has found long-term reductions of
60% following radiotherapy. Benefits include tumor reduction, durable
palliation and improved survival. There were no radiation-related deaths
after a median followup of eighteen months. A phase II trial is being
planned.
Conclusions: Our results demonstrate that high dose modern radiotherapy is
an effective modality to control the locoregional progression of pleural
mesothelioma. It should be considered in all patients who have had ex-
trapleural pneumonectomies as well as in those undergoing less radical
resections.
Disclosure: The author has declared no conflicts of interest.
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INTENSITY MODULATED RADIOTHERAPY AS PART OF
THE TRIMODALITY CONCEPT IN PATIENTS WITH MA-
LIGNANT PLEURAL MESOTHELIOMA
P. Dimmerling, D.R. Zwahlen, J. Krayenbu¨hl, C. Glanzmann, G. Studer, I.F.
Ciernik, O. Riesterer Radiation Oncology, University Hospital Zurich,
Zurich/SWITZERLAND
Objectives: The impact of radiation therapy (RT) and the optimal techniques
in the trimodal treatment concepts of malignant pleural mesothelioma
(MPM) are subject of current investigations. We review the clinical outcome
with IMRT after extrapleural pneumonectomy (EPP) at the University
Hospital Zurich.
Materials and methods: From 2005 to 2009 12 patients with stage 1 or 2
MPM received IMRT after induction chemotherapy and EPP. 10 patients
received postoperative, adjuvant IMRT and 2 patients were irradiated with
curative intent for local recurrence. The target volume encompassed the
hemi-thorax and a boost was given to the high risk area either as simulta-
neously integrated boost (SIB, 10 patients) or in a second phase (2 patients).
IMRT was applied using 5 coplanar beams to a total median dose of 56 Gy
(54-60). For plan comparison 9 IMRT plans were replanned for 3D confor-
mal RT.
Results: The median age at diagnosis was 61 years (46-72) and median
follow-up was 21 months (9-56). Two out of 10 adjuvantly treated patients
experienced in-field local relapse and the local thoracic control rate was 80%.
Median time to local progression and distant metastasis after radiotherapy
were 6.5 (4-9) and 12 months (3.5-39.5), respectively. Median overall
survival for all patients was 23.4 months (9-56). The 2 patients who were
irradiated for local recurrence died 3 and 16 weeks after RT, respectively.
IMRT was superior to 3-D conformal RT in respect of dose coverage and
homogeneity (p0.01), except for the remaining lung (mean lung dose with
IMRT: 7.8 Gy, p0.01). One patient experienced grade 4 pneumonitis.
Replanning of the respective IMRT plan showed room for plan optimization
if novel lung constraints were considered. This and recently published data
led us to adapt our lung constraints for subsequent patients (mean lung dose
below 7.0 to 7.5 Gy, V20 below 5 to 10% and V5 below 40 to 50%).
Conclusions: IMRT following EPP resulted in a high local control rate. RT
of locoregionally recurrent MPM was not associated with sustainable disease
control. Optimized IMRT planning using stringent constraints with low
probability for subsequent toxicity are recommended.
Disclosure: All authors have declared no conflicts of interest.
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A RETROSPECTIVE ANALYSIS OF SECOND-LINE
CHEMOTHERAPY FOR MALIGNANT PLEURAL
MESOTHELIOMA (MPM)
A. Bramati1, A. Moretti1, M.C. Garassino2, R. Califano3, G. Farina4, M. Lo
Dico5, M. Cinquini6, G.N. Michetti7, M. Tiseo8, P.A. Zucali9 1Medical
Oncology, A. O. Ospedale Fatebenefratelli e Oftalmico, Milan/ITALY, 2On-
cology, Fatebenefratelli and Ophtalmic Hospital, Milano/ITALY, 3Depart-
ment of Medical Oncology, The Christie NHS Foundation Trust, Manchester/
UNITED KINGDOM, 4Oncology, Ospedale Fatebenefratelli e Oftalmico,
Milan/ITALY, 5Division of Medical Oncology, Civil Hospital Livorno,
Livorno/ITALY, 6Oncology, Mario Negri Institute, Milano/ITALY, 7Oncolo-
gy/pneumology, Ospedali Riuniti, Bergamo/ITALY, 8Medical Oncology,
Parma Hospital, Parma/ITALY, 9Department of Oncology, Istituto Clinico
Humanitas IRCCS, Istituto Clinico Humanitas, Rozzano/ITALY
Background: Chemotherapy is the only option for MPM. Cisplatin 
pemetrexed became the standard in the first-line (FL), while the role of a
second-line (SL) remains controversial.
Materials and methods: We retrospectively collected data of all consecu-
tive MPM patients (pts), from 8 institutions, receiving SL chemotherapy after
a platinum based FL treatment from 1996 to 2008. The primary endpoint was
overall survival (OS). Secondary endpoints were progression-free survival
(PFS), best overall response rate (ORR) and prognostic factors. Kaplan
Meier curves and Log Rank were used for statistical analysis.
Results: Of 414 MPM pts treated in FL setting, 161 underwent a SL chemotherapy
(63% male; median age 62,5 years). Main regimens were: platinum rechallenge (21
pts, 13,1%), pemetrexed rechallenge: (23 pts - 14,4%), pemetrexed  platinum
rechallenge (32 pts - 20%), biological agents (23 pts - 14,3%) and others (62
pts-38,2%). 89 pts achieved disease control (partial remission stable disease) with
a SL regimen (55,6%) (median OS 10,23 months (mths), median PFS 5,72 mths).
OS was statistically significantly higher in pts rechallenged with platinum 
pemetrexed (20.56 vs 8.49 mths – HR 0.39 95%IC 0.21-0.71; p0.0015), while PFS
wasn’t (9.77 vs 5.39 mths – HR 0.71 95%IC 0.47-1.08; p0.111). PFS (p0,0001)
and OS (p0,0001) were statistically significant in pts responding to FL and with an
epithelial histology (p0,0008). Univariate and multivariate logistic analysis showed
that the only factors for the choice of SL regimen were response after FL and
smokers.
Conclusions: The benefit of SL is strictly dependent on histology and response to
FL. According to our data, rechallenge with platinum-based regimens seems the best
option. No benefit has been proven in favour of polichemotherapy regimens in
respect to single agents. The superiority of cisplatin  pemetrexed rechallenge has
been demonstrated also at the multivariate analysis adjusted for time to SL and
histology. The role of platinum-based rechallenge in SL should be further investi-
gated, considering also that a SL has palliative intent on the basis of histology and of
the extent of response to FL treatment.
Disclosure: All authors have declared no conflicts of interest.
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INDUCTION OF SENESCENCE MARKERS BY
NEO-ADJUVANT CHEMOTHERAPY OF MALIGNANT
PLEURAL MESOTHELIOMA AND ASSOCIATION WITH
CLINICAL OUTCOME: AN EXPLORATORY ANALYSIS
E. Felley-Bosco1, R. Sidi1, G. Pasello1, I. Opitz2, A. Soltermann3, M.N. Tutic4, W.
Weder2, R.A. Stahel5 1Oncology, University Hospital Zurich, Zurich/SWIT-
ZERLAND, 2Division of Thoracic Surgery, University Hospital Zurich,
Zurich/SWITZERLAND, 3Institute of Pathology, University Hospital Zurich,
Zurich/SWITZERLAND, 4Thoracic Surgery, Thoracic Surgery, Zurich/
SWITZERLAND, 5Klinik und Poliklinik fu¨r Onkologie, Universita¨tsspital,
Zu¨rich/SWITZERLAND
Purpose: The aim of this study was to assess the induction of senescence
markers versus apoptosis pathways in malignant pleural mesothelioma (MPM)
tumor samples before and after neo-adjuvant platinum-based chemotherapy and
to investigate their relationship with clinical outcome.
Experimental Design: Specific senescence pathways were assessed by quan-
tifying the expression of p21 and plasminogen activator inhibitor-1 (PAI-1) for
the p21-p53 pathway, IGBP7 for the IGF pathway and ALDH3A for the IFN
pathway. p21 and PAI-1 expression was also assessed by immunohistochemis-
try. In addition, beta-galactosidase activity staining at pH 6.0 was performed.
Apoptosis was determined by TUNEL assay. Clinical outcome was assessed by
modified RECIST criteria and progression-free and overall survival.
Results: In a training set (n9 patients) paired comparison demonstrated a
significant increase in p21 and PAI-1 expression and apoptosis after chemo-
therapy. The patients with the highest increase in senescence markers
expression had stable disease, while patients with little change accompanied
by a high increase in apoptosis had an objective response after chemother-
apy. The hypothesis that stable disease might be associated with an increased
senescence markers was confirmed in a tissue microarray (n26 patients)
using p21 and PAI-1 immunohistochemistry as readout. In the 21 patients
where survival data was available, a decrease in senescence markers was
significantly associated with a better outcome.
Conclusions: Our results demonstrated induction of senescence markers by
neo-adjuvant chemotherapy to be associated with outcome.
Disclosure: All authors have declared no conflicts of interest.
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VALIDATION AND COMPARISON OF PUBLISHED
PROGNOSTIC CLASSIFICATIONS FOR SURVIVAL IN
PATIENTS (PTS) WITH SMALL CELL LUNG
CANCER (SCLC)
M.N. Paesmans1, J.J. Lafitte2, J.N. Lecomte3, T. Berghmans4, A.N. Efremi-
dis5, A.P. Meert6, N.N. Leclercq7, J. Sculier8 1Data Centre, Institut Jules
Bordet, Brussels/BELGIUM, 2Pneumology, CHRU Lille, Lille/FRANCE,
3Pneumology, CHU de Charleroi, Charleroi/BELGIUM, 4Medicine, Institut
Jules Bordet, Brussels/BELGIUM, 5Medicine, St-Savas Hospital, Athens/
GREECE, 6Soins Intensifs et Cancerologie Pulmonaire, Institut Jules Bor-
det, Brussels/BELGIUM, 7Institut Jules Bordet, Brussels/BELGIUM, 8De-
partment of Intensive Care and Thoracic Oncology, Jules Bordet Institute,
Brussels/BELGIUM
Background: Several prognostic classifications are available for predicting survival
in pts with SCLC : Albain et al (1), Sagman et al (2), Paesmans et al (3), Sculier et
al (4), Foster et al (5), (5) focusing on pts with extensive disease (ED). We had as
objective to validate them and to compare their discriminant ability.
Methods: We pooled the data collected in phase III clinical trials: 2 in pts with
ED treated by chemotherapy and 1 in pts with limited disease treated by
chemoradiotherapy. We selected pts registered before 31/10/2007. We used Cox
regression models and calculated concordance probability estimates (CPE).
Results: We included 693 pts: 82% male pts, 81% performance status 80 or
more, 54% older than 60 years and 66% with ED. Depending on the models,
rates of pts with the best predicted prognosis ranged from 9% to 28% and
with the poorest predicted prognosis from 11% to 26%. All the classifications
had a highly significant impact on survival with hazard ratios (HR) (95%
confidence intervals) being respectively: (1) 1.57 (1.44-1.71), (2) 1.85
(1.64-2.10), (3) 1.67 (1.52-1.83) and (4) 1.57 (1.45-1.71) (all p0.001).
Median survival times were for the best group: 17, 22, 19 and 16 and for the
poorest group 7, 6, 6 and 7 months. Most of the paired comparisons were also
statistically significant. Restricting the analysis to ED pts, HR were: (1) : 1.84
(1.48-2.29), (2) 1.67 (1.32-2.08), (3) 1.43 (1.26-1.64), (4) 1.79 (1.46-2.21) and (5)
1.25 (1.14-1.38). In 3 studies, Cox models were also published. The HR ratios for a
single covariate derived from them are in all pts : (3) 2.86 (2.41-3.40), (4) 3.74
(3.04-4.61) and in pts with ED : (3) 2.35 (1.76-3.14), (4) 4.39 (2.73-3.05) and (5) 4.08
(2.70-6.17). CPEs ranged from 0.58 to 0.63 for prognostic classifications and from
0.63 to 0.65 for Cox models (all pts) and from 0.52 to 0.57 and 0.58 to 0.60 (pts with
ED) with overlapping confidence intervals.
Conclusion: All the classifications are validated and suitable for use, for instance,
in clinical trials for stratification purposes. Expectedly, prediction at an individual
level remains poor. A specific model for pts with ED does not seem more useful.
Disclosure: All authors have declared no conflicts of interest.
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OUTCOME OF PROPHYLACTIC CRANIAL
RADIOTHERAPY IN EXTENSIVE-STAGE SMALL CELL
LUNG CANCER: THE CHRISTIE EXPERIENCE OVER
TWO YEARS
N. Ghosal1, K. Gupta2, C.E. Lee3, P. Lorigan4, F. Blackhall5, R. Swindell1,
N. Bayman1, N. Thatcher6, C. Faivre-Finn3 1Clinical Oncology, The
Christie Hospital, Manchester/UNITED KINGDOM, 2Clinical Oncology,
The Christie Hospital, manchester/UNITED KINGDOM, 3Clinical Oncol-
ogy, christie, manchester/UNITED KINGDOM, 4Department of Medical
Oncology, Christie Hospital, Manchester/UNITED KINGDOM, 5Depart-
ment of Medical Oncology, Christie Hospital NHS Trust, Manchester/
UNITED KINGDOM, 6Department of Medical Oncology, Christie Hospital
NHS Foundation Trust, Manchester/UNITED KINGDOM
Objective: Prophylactic cranial irradiation (PCI) in extensive-stage small
cell lung cancer does not only reduce the risk of developing brain metastases
(BM) but also prolongs disease-free and overall survival [1]. We adopted this
treatment as standard in patients who responded to chemotherapy, PS 0-2 and
age 75 years. We present the outcome data of patients treated in our
institution over a period of 2 years.
Methods: We reviewed the casenotes of all patients treated with PCI
between January 2007 and December 2008. Patients did not routinely
undergo imaging of the brain prior to receiving PCI or chemotherapy if there
was no clinical suspicion of BM. The median follow up was 14 months.
Results: There were 51 patients in total (25 males and 26 females). The median age
was 63 yrs (43-75). Prior to radiotherapy 29 patients had documented WHO
performance (PS) status 0-1, 14 patients had PS 2, 1 had PS 3 and in 6 cases the PS
was not documented. Patients received either 4 (15), 5 (n5) or 6 (n31) cycles
of cisplatin or carboplatin and etoposide chemotherapy. All patients responded to
chemotherapy (at least stable disease). All patients received 20 Gy in 5 daily fractions
of whole brain prophylactic cranial radiotherapy. 13 patients (25%) developed BM.
The survival figures are shown in table 1.
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Conclusion: Using the same inclusion criteria as described in the Slotman
study the rates of BM (and survival) after PCI were in keeping with the
published data in our institution. It is encouraging that the results of the
randomised controlled trial are applicable to a standard population.
1. Slotman, B., et al., Prophylactic cranial irradiation in extensive small-cell
lung cancer. N Engl J Med, 2007;357(7): p. 664–72.
Disclosure: All authors have declared no conflicts of interest.
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STANDARDIZED UPTAKE VALUES OF POSITRON
EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY
(PET/CT) AS MALIGNANT PREDICTOR IN THYMOMA
L. Bertolaccini1, G. Rizzardi1, P. Scanagatta1, A. Bianchi2, A. Biggi2, A.
Campione3, A. Comino3, A. Terzi1 1Thoracic Surgery, S. Croce e Carle
Hospital, Cuneo/ITALY, 2Nuclear Medicine, S. Croce e Carle Hospital,
Cuneo/ITALY, 3Pathology, S. Croce e Carle Hospital, Cuneo/ITALY
To evaluate the role of PET/CT as predictor of pathological type and stage of
thymomas, 22 patients (13 M, 9 F; mean age 58 14 ys) were assessed by PET.
Maximum standardized uptake value (SUVmax) and tumour SUVmax/back-
ground mediastinal SUVmax (T/M) ratio were recorded. Thymomas were clas-
sified according to World Health Organization (WHO) classification, and di-
vided in two groups based on histological finding: low-risk thymoma (LRT),
including types A, AB and B thymoma; high-risk thymoma (HRT), including
types B2, B3 and thymic carcinoma. Thymic epithelial tumours were staged
according to Masaoka staging system. Two-tailed t-tests (normally distributed
data) or Wilcoxon–Mann–Whitney U-test (not-normally distributed data) were
used for evaluating significance of differences between group means. Signifi-
cance of any proportional differences in attributes were evaluated using Fisher’s
Exact Test. Correlation between variables was evaluated using Bravais-Pearson
linear correlation coefficient and using Spearman rank correlation coefficient.
Results are showed in Table 1 In Masaoka staging system, differences between
mean of SUVmax are significant (p0.0231), but differences between mean of
SUVT/M are not statistically significant. Considering Masaoka staging system,
differences between mean of SUVmax are significant (p0.0098) but differences
between mean of SUVT/M are not statistically significant. Highly statistical
correlation is shown between SUVmax and Masaoka staging system (0.7869),
and SUVT/M and Masaoka system (0.9455). In groups of risk classification,
differences between mean of SUVmax and SUVT/M are highly significant
(p0.0073), despite small statistical sample. We found highly significant cor-
relation with comparison of SUVmax (0.8759) and SUVT/M (0.9844) with
group of risk subdivision. In conclusion, SUVT/M is directly correlated to
advanced stage of disease and to higher degree of malignity.
Disclosure: All authors have declared no conflicts of interest.
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MULTIPLE MICRORNA ARE DYSREGULATED IN
MESOTHELIOMA
C.D. Hoang1, Y. Xu1, M. Zheng1, G. Peltz1, J. Shrager1, R. Kratzke2
1Cardiothoracic Surgery, Stanford University, Stanford/USA, 2Medicine,
University of Minnesota, Minneapolis/USA
Objective: microRNA (miRNA) expression profiles of mesothelioma (MM)
tumors were investigated to better understand the molecular mechanisms
involved in disease development.
Methods: Total RNA was extracted from 25 fresh frozen specimens of
biopsy proven human MM (18 epithelial, 4 sarcomatoid, and 3 biphasic) and
6 specimens of normal pleura. miRNA microarray profiling was performed
on the Illumina miRNA expression profiling panel containing 858 miRNA.
To assess for significant miRNA in our data, we used a stringent adjusted
p-value of  0.01. Various computational tools were used for analysis:
principle component analysis, hierarchical clustering, TargetScan mRNA
gene prediction software, and DAVID network analysis software. We also
used the NIH gene expression omnibus database of MM for additional
analyses. Validation techniques included TaqMan real-time RT-PCR and
western blotting.
Results: We detected 119 miRNA with significant differential expression
between the tumor and normal pleural groups; 55 miRNA were over-
expressed and 64 miRNA were under-expressed. Gene mapping identified

17,000 different mRNA target sites corresponding to the 119 miRNA. In
order to assess biologically important miRNA:mRNA pairings, we queried a
MM mRNA public database to find the subset of mRNA targets common to
our in-silico predictions. This resulted in a set of 572 genes. Network
analysis of this reduced subset of target genes revealed groups of genes
related to: cell signaling, cell differentiation, regulation of RNA polymerase,
metal and ion-binding processes, nucleic acid metabolism, RNA biosynthe-
sis, and cell cycle regulation. Notably, hsa-miR-133b was down-regulated by
16.7-fold in MM specimens. This miRNA negatively regulates members of
the BCL-2 gene family which is known to participate in cell survival; and
thus loss of expression of miR-133b correlates with escape from apoptosis/
uncontrolled cell growth.
Conclusion: We identified many novel miRNA that are significantly altered
in MM. Our results suggest that various miRNA are extensively involved in
Table 1. Survival Figures
Median
Survival
1 yr
Survival
Calculated from date of diagnosis 331 days 42%
Calculated from 4 weeks prior to
start of PCI
199 days 20%
Slotman study (calculated from
randomisation)
201 days 27%
Table 1. Results
Masaoka
Staging System No (%)
SUVmax
(mean  SD)
SUVM
(mean  SD)
SUVT/M
(mean  SD)
Stage I 5 (22.7) 3.8  0.90 1.7  0.29 2.4  1.31
Stage II 8 (36.4) 4.7  1.20 1.8  0.35 2.4  1.46
Stage III 5(22.7) 12.1  6.87 2.5  0.38 3.6  0.19
Stage IV 4 (18.2) 17.6  6.24 2.0  1.40 11.5  0.19
WHO
Classification
Type A 2 (9.1) 3.5  0.80 1.7  0.05 0.9  0.74
Type AB 5 (22.7) 4.0  1.68 1.9  0.34 2.0  0.45
Type B1 4 (18.2) 4.9  0.85 2.2  0.13 2.1  0.28
Type B2 2 (9.1) 6.6  1.00 1.4  0.15 4.9  0.15
Type B3 2 (9.1) 9.4  3.60 2.8  1.20 3.4  0.18
Type C 5 (22.7) 14.3  4.25 2.0  0.70 7.2  6.36
Carcinoid 2 (9.1) 18.7  12.63 1.7  0.10 11.1  7.60
Groups of risk
classification
Low risk 11 (55.0) 4.2  1.70 2.0  0.46 1.9  0.70
High risk 9 (45.0) 13.3  7.62 2.0  0.92 7.1  5.94
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the pathogenesis of MM and represent potential therapeutic targets. These
results also serve as a database for functional characterization of miRNA
in MM.
Disclosure: All authors have declared no conflicts of interest.
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FOLLOW-UP OF ASBESTOS-EXPOSED INDIVIDUALS
USING MESOTHELIOMA SERUM BIOMARKERS
K. Hollevoet1, J. Van Cleemput2, J. Thimpont3, P. De Vuyst4, L. Bosque´e5,
K.N. Nackaerts6, Y. Kishi7, C. Legrand8, J.R. Delanghe9, J.P. van Meer-
beeck10 1Respiratory Medicine, 7K12, Ghent University Hospital, Ghent/
BELGIUM, 2Occupational Diseases, Eternit NV, Kapelle-op-den-Bos/
BELGIUM, 3Occupational Diseases, Occupational Diseases Fund, Brussels/
BELGIUM, 4Respiratory Medicine, Erasme Hospital ULB, Brussels/
BELGIUM, 5Pulmonology, CHU Sart Tilman, Liege/BELGIUM, 6Pulmonol-
ogy, UZ Leuven, Leuven/BELGIUM, 7Medical & Biological Laboratories,
Co. Ltd., Ina Institute, Nagano/JAPAN, 8Institut De Statistique, Universite´
Catholique de Louvain, Louvain-la-Neuve/BELGIUM, 9Clinical Chemistry,
Ghent University Hospital, Ghent/BELGIUM, 10Department of Respiratory
Medicine, University Hospital, Ghent/BELGIUM
Introduction: Prediction of malignant mesothelioma (MM) risk in asbestos-
exposed individuals is hampered by the limited accuracy of current screening
techniques and the low prevalence of MM. Serum biomarkers might increase
the former by enriching the population at risk. This abstract reports the
follow-up of asbestos-exposed individuals with soluble mesothelin (SM) and
megakaryocyte potentiating factor (MPF).
Methods: Individuals with professional asbestos exposure were recruited at
the Belgian Occupational Diseases Fund, 2 companies, and the participating
departments of Respiratory Medicine. After 1 year, participants were con-
tacted for a 2nd blood sample. Serum SM (nM) and MPF levels (ng/mL) were
assayed with the Mesomark® and Human MPF ELISA kit, respectively, and
cut-offs were set at 2.00 nM and 12.38 ng/mL [Hollevoet, 2010]. Glomerular
filtration rate (GFR), a confounder of these biomarkers [Hollevoet, 2009],
was determined with the CKD-EPI equation (mL/min/1.73 m2).
Results: From the 214 individuals included at baseline, 9 had both SM and
MPF levels above cut-off, while respectively 4 and 5 were either MPF or
SM-positive. The GFR of these 18 individuals (median-IQR: 65-44 mL/min/
1.73 m2) was significantly lower (Mann Whitney U, p0.001) than those
with a negative test (median-IQR: 80-23 mL/min/1.73 m2). In the 133
individuals who already gave a 2nd sample, biomarker levels correlated
highly significantly between the 2 time points (Spearman rank, p0.001),
and Bland-Altman analysis revealed a mean difference of 0.29 ng/mL and
0.26 nM, respectively, with acceptable limits of agreement. Currently, no
participants presented a malignancy. Updated results will be presented at the
meeting.
Conclusion: In asbestos-exposed individuals, SM and MPF levels reveal a
long-term stability and a manageable percentage of positive test results. At
present, it is not possible to conclude whether an elevated biomarker level
reflects an insidiously developing malignancy or merely a false positive, e.g.
due to renal failure. As such, only further long-term follow-up can establish
whether triaging asbestos-exposed populations based on biomarker levels
indeed results in a population with increased MM prevalence.
Disclosure: J.P. van Meerbeeck: I received a research grant from Cis bio
International (25 000 €). All other authors have declared no conflicts of
interest.
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COMPLETE RESPONSE TO CHEMOTHERAPY FOR
MALIGNANT PLEURAL MESOTHELIOMA - WHAT
NEXT?
M. Feigen1, N. Alam2, S. White3 1Radiation Oncology Centre, Austin
Health, Heidelberg/AUSTRALIA, 2Thoracic Surgery, East Melbourne Heart
and Lung Foundation, Fitzroy/AUSTRALIA, 3Oncology, Warringal Medical
Centre, Heidelberg/AUSTRALIA
Background: This is a case report of a 56 year old man diagnosed in
November 2007 with stage IV malignant pleural mesothelioma. He was
treated with palliative chemotherapy and had a complete response on CT and
PET scan followup.
Methods: A CT scan performed to investigate right chest pain showed
pleural thickening at the right lung base and an effusion. Pleural biopsy
found epithelioid mesothelioma and a PET/CT scan showed intense FDG
activity involving thickened pleura over the entire right hemithorax, includ-
ing the fissures, paraoesophageal, retrocardiac and retrocrural spaces and
costophrenic recess, IMIG stage T4NxM0. Six cycles of cisplatin and
pemetrexed were given from January to June 2008. A progress CT scan
showed a marked reduction in all the previous disease with pleural thicken-
ing under 1 cm and a PET/CT scan showed minimal nonspecific residual
FDG uptake. The mesothelin level fell from 29.0 to 0.7 nmol/L.
Results: A pleurectomy/decortication was performed in September 2008
finding residual low volume disease on the right hemidiaphragm and parts of
the visceral pleura. Followup scans showed a recurrence in the right 8th rib
in March 2009 and at other sites in the right hemithorax and retrocrural nodes
in October. These did not respond to four cycles of the same chemotherapy
he had two years earlier.
Conclusion: Less than 1% of mesothelioma patients have a complete
radiological response to chemotherapy. A careful observation policy with
close followup is recommended as future relapse is likely and the expectation
that this may be responsive to the initial chemotherapy may be unsustained.
Disclosure: All authors have declared no conflicts of interest.
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MMP-9, TIMP-1 AND VEGF IN SMALL CELL LUNG
CANCER PATIENTS
E.L. Wojcik1, B.N. Sas-Korczynska2, J.N. Jakubowicz2, Z.N. Stasik1, P.P.
Skotnicki3, J.K. Kulpa1 1Clinical Biochemistry, Center of Oncology, Kra-
kow/POLAND, 2Radiotherapy, Center of Oncology, Krakow/POLAND, 3Sur-
gery, Center of Oncology, Krakow/POLAND
Introduction: Small cell lung cancer (SCLC) is an aggressive and rapidly
growing neoplasms that represents a strong tendency to dissemination.
Matrix metalloproteinases are thought to play an important role in stromal
invasion and degradation of the extracellular matrix components. Elevated
expression of some of them, especially MMP-2 and MMP-9, has been
reported in several types of human cancer, including small cell lung cancer.
Currently, special attention is given to serum level of these metalloprotein-
ases and their inhibitor in respect to the patients prognosis. The aim of
presented study was the evaluation of relationship between MMP-9, TIMP-1,
VEGF, IL-6 versus NSE and ProGRP in respect to SCLC patients survival.
Material and methods: MMP-9, TIMP-1, VEGF, IL-6, NSE, and ProGRP
determinations were performed in 55 SCLC patients and in the reference
group consisting of 44 healthy persons. Whereas NSE was determined using
ECL method (cobas e411 analyzer), ProGRP – CMIA method (Architect
i2000), for the remaining parameters ELISA method and Bender MedSystem
reagents were applied.
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Results: In SCLC patients there were found significantly higher levels of all
assessed parameters than in the reference group. Frequency of elevated
results were, respectively: for MMP-9 – 41.8%, TIMP-1 – 34.5%, VEGF –
47.3, IL-6 – 50.9, NSE and ProGRP – 72.7%. In the studied group of patients
were observed relationships between MMP-9 and TIMP-1 (r  0.381), as
well as MMP-9 and VEGF (r 0.364) and lack of them between metallo-
proteinase as well as its inhibitor, with tumor markers. Moreover, there was
shown influence of IL-6 on the levels of the ”cascade metastasis” markers.
Spearman’s correlations with IL-6 were: for MMP9 rs  0.560, for TIMP-1
rs  0.400, for VEGF rs  0.289 and for NSE rs 0.257. The analysis of
relationships between pretreatment levels of studied parameters and patients
survival revealed that apart from the extent of disease, TIMP-1, NSE and
ProGRP also have significant impact on prognosis.
Conclusions: Relationships between IL-6 and MMP-9, TIMP-1 as well as
VEGF may indicate complex mechanisms leading to development of inva-
sive phenotype in SCLC patients. Elevated pretreatment TIMP-1, NSE, and
ProGRP levels are associated with worse prognosis of SCLC patients.
Disclosure: All authors have declared no conflicts of interest.
272P
PROTEIN EXPRESSION AND GENE COPY NUMBER OF
INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF1R)
IN SMALL CELL LUNG CANCER (SCLC)
A. Badzio1, M.W. Wynes2, R. Dziadziuszko3, M. Pardo4, D. Merrick4, J.
Ranger-Moore5, A. Kowalczyk1, W. Rzyman6, J. Jassem7, F.R. Hirsch8
1Oncology and Radiotherapy, Medical University of Gdansk, Gdansk/PO-
LAND, 2Medicine-division of Medical Oncology, University of Colorado
Denver, Aurora/USA, 3Department of Oncology and Radiotherapy, Medical
University of Gdansk, Gdansk/POLAND, 4Division of Medical Oncology,
University of Colorado Denver, Aurora/USA, 5Biostatistics and Data Man-
agement, Ventana Medical Systems Inc., Tucson/USA, 6Toracic Surgery,
Medical University of Gdansk, Gdansk/POLAND, 7Oncology and Radiother-
apy, Medical University, Gdansk/POLAND, 8Medicine-oncology, University
of Colorado Cancer Center, Aurora/USA
Background: IGF1R is a tyrosine kinase receptor implicated in the patho-
genesis of several malignancies. In addition to mediating cell proliferation
and apoptosis, IGF signalling also influences tumor cell motility and adhe-
sion, affecting the propensity for invasion and metastasis. Consequently,
IGF1R is now an attractive target for anti-cancer treatment. There is a
paucity of data on the protein expression and IGF1R gene copy number, and
their clinical relevance in SCLC.
Methods: We analyzed IGF1R protein expression and gene copy number in
primary tumors from 90 SCLC patients who underwent pulmonary resection
in a period from 1982 to 2001. This series included 67 males and 32 females
67 (74%); stage IA 6, IB 26, IIA 5, IIB 13, IIIA 24, IIIB 11, IIIB/IV 1,
unknown 1. IGF1R expression was evaluated by immunohistochemistry
using Ventana CONFIRM antibody and scored by three observers, taking
into account percentage of positive cells (0-100%) and staining intensity
(0-4). H-score was calculated as a percentage of positive cells times staining
intensity. IGF1R gene copy number was evaluated using silver in-situ
hybridization (SISH) technique and scored by two pathologists.
Results: Median H-scores for IGF1R protein expression was 81 (range
0-352). The positive immunostaining rates (cut-off H-score of 10) in the
entire group were 77%. IGF1R expression did not correlate with any
clinicopathological parameters such as age, tumor size, lymph node involve-
ment and stage of the disease. Survival was not influenced by protein
expression of IGF1R (p0.34). Increased IGF1R gene copy number (aver-
age of four copies per cell or more) was found in 15 cases, gene amplification
was rare in this subset and was detected in 5 patients. No correlation with
clinicopathologic parameters or survival (p0.4) was found. Gene copy
number did not correlate with IGF1R expression (p0.54).
Conclusions: Increased IGF1R gene copy number and IGF1R protein
overexpression was found in numerous SCLC patients, but did not affect
prognosis. These findings support potential role of targeting IGF1 signalling
pathway in SCLC and warrant further investigations in this field.
Disclosure: J. Ranger-Moore: Employment: Ventana Medical Systems,
Roche Tissue Diagnostics F.R. Hirsch: Advisory Boards: AstraZeneca,
Merck Serono, BMS/Imclone, Syndax, Pfizer, Boehringer-Ingelheim, Lilly
Oncology, GSK, OSI/Genenetech/Roche Research Funding: AstraZeneca,
OSI, Genentech, Syndax, Biogen-Idec, Ventana-Roche, Merck, Genmab. All
other authors have declared no conflicts of interest.
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OUTCOME PREDICTION IN LIMITED DISEASE SMALL
CELL LUNG CANCER ON THE BASIS OF EARLY TREAT-
MENT RESPONSE ASSESSMENT WITH 18FDG-PET
J. van Loon1, C. Offermann1, M. Ollers1, W. van Elmpt1, P.N. Lambin1, D.
De Ruysscher2 1Radiotherapy, Maastro Clinic, Maastricht/NETHERLANDS,
2Department of Radiation Oncology (Maastro Clinic), Maastricht University
Medical Center  GROW Research Institute, Maastricht/NETHERLANDS
Background: The majority of patients with limited disease (LD) SCLC still
show disease progression short after the completion of concurrent chemora-
diotherapy (CRT). Therefore, it is of great value to select patients early
during treatment with the highest probability of benefit, avoiding ineffective
treatment in the group with poor prognosis. Early metabolic response would
be a logical choice. In contrast to NSCLC, data on the predictive value of an
early metabolic response in SCLC are scarce. Thus, the purpose of the
current study was to evaluate whether metabolic response early after the start
of chemotherapy has predictive value in LD-SCLC.
Methods Patients: with LD-SCLC treated with CRT who had both an
FDG-PET scan available before the start of chemotherapy and after the first
cycle of chemotherapy, before the start of radiotherapy, were evaluated.
Minimum follow-up was 18 months. The volume of FDG-uptake areas was
quantified both within the primary tumour as in the involved nodal stations
using the 40% (MV40) and 50% (MV50) threshold of the SUVmax.
Metabolic response was assessed by the % change in the metabolic volume
(MV) between both time points, and analyzed for its association with overall
survival (OS) by univariate cox regression analysis.
Results: 15 patients, with an age of 48-85 years, were included. The
median OS was 20 months. The time interval between the two PET-scans
was 20  8.4 days. The metabolic response as assessed by the % change
in MV40 and MV50, was 32  38% (131.6 cm3 to 89.8 cm3) and
41  38 % (86,0 cm3 to 48,5 cm3), respectively. Both the metabolic
response based on MV40 and MV50 showed a significant association
with survival (HR 1.02, p0.042; HR  1.02 and p0.048 respec-
tively), indicating a 2% reduction in survival hazard for 1% reduction in
metabolic volume. The mean tumour volume delineated on CT before the
start of RT was 103.5 cm3. Neither this parameter, nor the MV at any time
point was associated with survival.
Conclusions: This study shows that the metabolic response assessed with
PET early after the start of chemotherapy has the potential to predict outcome
in SCLC. On basis of these data, a prospective study is planned in a larger
patient population to allow multivariate analysis.
Disclosure: All authors have declared no conflicts of interest.
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PHASE II STUDY COMPARING ACCELERATED TWICE
DAILY AND ONCE DAILY THORACIC RADIOTHERAPY
IN PATIENTS WITH LIMITED-STAGE SMALL CELL
LUNG CANCER (LS-SCLC) TREATED CONCURRENTLY
WITH CHEMOTHERAPY
C.E. Lee1, P. Lorigan2, F. Blackhall3, P. Taylor4, L.F. Ashcroft5, N. Thatch-
er6, C. Faivre-Finn1 1Clinical Oncology, Christie, Manchester/UNITED
KINGDOM, 2Department of Medical Oncology, Christie Hospital, Manches-
ter/UNITED KINGDOM, 3Department of Medical Oncology, Christie Hos-
pital NHS Trust, Manchester/UNITED KINGDOM, 4Northwest Lung Centre,
South Manchester University Hospital, Manchester/UNITED KINGDOM,
5Department of Biostatistics, Christie Hospital, Manchester/UNITED
KINGDOM, 6Department of Medical Oncology, Christie Hospital NHS
Foundation Trust, Manchester/UNITED KINGDOM
Introduction: Over the past few decades the role of radiotherapy in SCLC
has expanded and one particular study (Turrisi et al, 1999) reported
improved survival rates with accelerated hyperfractionated (BDRT) ver-
sus once daily (ODRT) treatment concurrently with chemotherapy. Some
however suggest that the total dose in the comparative arm (45Gy OD)
was inadequate as the local relapse rate was high (52%). We conducted
a phase II study to compare the BD schedule with a higher dose in the OD
arm.
Methods: 38 patients were randomised from July 2004 to March 2008. They
had histological and radiological confirmation of LS-SCLC, with a perfor-
mance status of 0-1. In the OD arm, 66Gy in 33 fractions were delivered over
45 days and in the BD arm, 45Gy in 30 fractions over 15 days. Patients
received cisplatin, 60 mg/m2 IV d1 with etoposide 120 mg/m2 IV d1-3, q3
wks 	 4 cycles with concurrent RT (3D conformal without elective nodal
irradiation) from cycle 2. The primary endpoint was acute grade 3 and 4
oesophagitis. Secondary endpoints were response rates, acute and late treat-
ment toxicity and overall survival.
Results: 38 patients were randomised on a 2:1 basis (ODRT n12; BDRT
n26) and 32 evaluated for response. The median age was 61 yrs (range
39–78). 66% were male and 82% were PS1. 15% had grade 3 acute
oesophagitis in the OD arm and 25% in the BD arm. There was no grade 4
acute oesophagitis. No patients developed grade 3 or 4 late oesophagitis.
Only 1 patient (4%) in the OD arm had grade 3 acute pneumonitis. 4% in the
OD arm and 11% in the BD arm had grade 3 late pneumonitis at 6-9 months.
There was no statistically significant difference in overall survival between
the 2 arms (p0.910). To date 26 patients have died and 12 are still alive. At
a median follow up of 33.6 mths (range 15-53), the median survival for the
OD arm was 16.9 months and 15.5 months in the BD arm.
Conclusions: This study shows that treatment in both arms is feasible and
tolerable. The multinational randomised phase III CONVERT trial is cur-
rently recruiting with the end point of overall survival. We would encourage
interested PIs to join the trial in order to establish a standard of care in
LS-SCLC.
Disclosure: All authors have declared no conflicts of interest.
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DOSE-INTENSITY OF RADIOTHERAPY BEST PREDICTS
LONG-TERM SURVIVAL IN PATIENTS WITH LIMITED
DISEASE SMALL-CELL LUNG CANCER
I. Wzietek, M. Bialas, E. Nowara, R. Suwinski Radiotherapy Department,
M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,
Gliwice Branch, Poland, Gliwice/POLAND
Purpose: It has been recently proposed (De Ruysscher et al. J Clin Oncol.
2006, 24: 3815-6) that time between Start of any cytotoxic treatment until the
End of Radiotherapy (SER) is an important predictor of survival in limited-
disease small-cell lung cancer (LD-SCLC). The purpose of this study is to
verify this concept based on analysis of large database of patients treated in
a single institution.
Material and methods: The analysis included 364 patients with LD-SCLC
treated between 1994 and 2007. Only the patients who received radiation
doses of more than 40 Gy were included. All 364 patients received Cis-Pt
based chemotherapy. Timing of chest radiotherapy (RT) relative to the start
of chemotherapy varied over the years resulting in heterogeneity in SER.
Also, radiation prescription practice varied (split course, conventional and
hyperfractionated RT) resulting in heterogeneity of treatment times, while
total radiation doses were relatively uniform (45-50 Gy in most of the
patients). The average dose-intensity of radiotherapy (DI) was calculated as
a quotient of RT dose and RT time.
Results: SER (120 days vs. 3120 days) did not significantly influence
overall survival (RR0.88, p0.32). By contrast, DI (8 Gy/week vs. 38
Gy/week) significantly influenced overall survival (RR0.73, p0.02), with
2-year survival rate of 10% and 25% in the respective groups. The param-
eters related to chemotherapy (number of courses, time of chemotherapy) did
not appear significant.
Conclusion: The results of present analysis suggest that dose-intensity of
radiotherapy better predicts long-term survival in LD-SCLC than the param-
eter SER proposed in the literature.
Disclosure: All authors have declared no conflicts of interest.
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FIVE-YEAR RESULTS OF RADIOTHERAPY FOR SMALL
CELL LUNG CANCER
Y.A. Ragulin1, A.G. Zolotkov2, Y.S. Mardynsky2, V.N. Medvedev1, I.N.
Ivanova2 1Thoracic Department, Medical Radiological Research Center
RAMS, Obninsk/RUSSIAN FEDERATION, 2Radiology Department, Medical
Radiological Research Center RAMS, Obninsk/RUSSIAN FEDERATION
Background: Results of the treatment of small cell lung cancer are unsat-
isfactory. The aim of the study is to compare efficiency of nonconventional
(hyperfractionated, accelerated radiotherapy with doze escalation) with tra-
ditional (conventional) radiotherapy.
Materials and methods: Between 1995 and 2003, 157 patients with locally
advanced small-cell lung cancer received chemo-radiotherapy. All patients
received 2 induction and 4 adjuvant cycles of platinum-based chemotherapy
(cisplatin/carboplatin plus etoposide). Patient demographics, tumor charac-
teristics, treatment details, and survival were recorded retrospectively. All
patients earlier did not receive any special anticancer treatment. Group A
(hyperfractionated, accelerated radiotherapy with doze escalation) - 75 pa-
tients received two daily fractions of 1.4 Gy with an interval 5–6 hours
during 3 weeks, further two daily fractions of 1.6 Gy to a total dose of 60–64
Gy. Group B (conventional radiotherapy) - 82 patients: 2 Gy daily to a total
dose of 60-64 Gy. Radiotherapy was carried on the linear accelerator Clinac
2100C.
Results: Five-year overall survival rate in patients Group A was 26% (20
pts) and in patients Group B 11% (9 pts), p  0,022. Local recurrence was
observed in 15 pts (20%) and in 32 pts (39%), respectively. Post-radiation
esophagitis grade III developed in 18 pts Group A (24%) and in 12 pts Group
B (15%). Post-radiation pneumonitis and pulmonary fibrosis developed in 15
pts (20%) and in 10 pts (12%), respectively. Complete response of a tumor
to hyperfractionated, accelerated radiotherapy with doze escalation are sta-
tistically significant prognostic factors, influencing on five-year overall
survival rate.
Conclusions: Hyperfractionated accelerated radiotherapy with doze escala-
tion is more effective than traditional radiotherapy with higher levels of
toxicity in small cell lung cancer. Low ability to reparation of sublethal
damages increases small cell lung cancer radiosensitivity because it has
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considerable part of proliferating clone, short time of tumor duplication, high
ability to repopulation, heterogeneity of a new growth with prevalence of any
subpopulation.
Disclosure: All authors have declared no conflicts of interest.
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EFFICACY AND SAFETY OF COMBINED RADIO-
CHEMOTHERAPY IN LIMITED-STAGE SMALL CELL
LUNG CANCER TREATMENT: A SINGLE-INSTITUTION
EXPERIENCE
I. Meattini, V. Scotti, A. Rampini, P. Bastiani, C. De Luca Cardillo, C.
Santomaggio, V. Di Cataldo, B. Agresti, M. Mangoni, G. Biti Radiation-
Oncology, University of Florence, Florence/ITALY
Purpose: To evaluate the efficacy and safety of the combined modality
treatment in patients with limited-stage small cell lung cancer (SCLC).
Patients and methods: Fifty-eight patients affected by limited-stage SCLC
were treated between July 1987 and January 2006 at University of Florence.
All patients were treated with combined early chemotherapy and thoracic
radiotherapy. Median age was 62 years (range 41–77), 44 were female and
14 male. No patient underwent surgery. A total of 238 cycles of chemother-
apy (range 3–8, median 5 cycles) were administered; composed of platin-
etoposide (CE, 34 patients) or alternated CE and epirubicin-ifosfamide
(CE/EI, 24 patients) were used. A median total dose of 6000 cGy (range
5000–6400 cGy) with 200 cGy daily fractions was given to the primary
tumour and mediastinum in 45 patients (77.6%) and only to the primary
tumour in 13 patients (22.4%). Prophylactic cranial irradiation (PCI) was
performed in all patients with complete response after combined treatment.
Results: Median follow-up time was 20 months (range 3-159). Five-years
PFS and OS rates were 27 % and 18 %, respectively. No difference in terms
of PFS and OS emerged between EC and CE/EI regimens (p0.41). After
combined treatment we registered 55% of complete response, 39% of partial
response and 6% of progressive disease. Univariate analysis showed that a
total radiation dose 6000 cGy significantly improved PFS (p0.05).
According to the Common Terminology Criteria for Adverse Events (CT-
CAE, Version 3.0) we registered 14 cases of G1-2 dysphagia and 11 cases of
G1-2 esophagitis. Concerning haematological toxicity our results showed 16
cases of G1-2 neutropenia, 8 cases of G1-2 anaemia and 3 cases of G1-2
piastrinopenia. No significant differences emerged between different chemo-
therapy regimens (p0.30).
Conclusions: Our treatment results are in accordance with the most relevant
literature studies. In our experience the combined approach with radio-
chemotherapy in limited-stage SCLC was effective and well-tolerated. Our
results suggest that limited radiotherapy volumes and higher doses obtained
with dose-escalation may improve SCLC outcome.
Disclosure: All authors have declared no conflicts of interest.
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CISPLATIN, ETOPOSIDE AND IFOSFAMIDE (PEI) IN THE
TREATMENT OF SMALL CELL LUNG CANCER:
MONOINSTITUTIONAL EXPERIENCE OF 59
CONSECUTIVE CASES
C. Boni1, E. Radighieri1, V. Bertolini2, D. Formisano3, F. Zanelli1 1Medical
Oncology, Arcispedale Santa Maria Nuova, Reggio Emilia/ITALY, 2Infor-
mation Department, Arcispedale Santa Maria Nuova, Reggio Emilia/ITALY,
3Statistics Department, Arcispedale Santa Maria Nuova, Reggio Emilia/
ITALY
Combination chemotherapy is very active in SCLC, although no improve-
ment has been done in the last 20 years, with Cisplatin-Etoposide (PE) still
considered the world-wide standard, with an average median survival of
about 7 months in pts with extended disease (ED). In 1995, a randomized
trial of the Hoosier Group, in 171 ED pts, showed a significant advantage in
overall survival in the arm treated with PEI, compared to PE. Despite that,
PEI is not a commonly used regimen in SCLC. Here we present a serie of 59
consecutive pts with SCLC that were treated at our Institution, in first and/or
subsequent line with PEI: Cisplatin 20mg/m2, Etoposide 75mg/m2 and
Ifosfamide 1200mg/m2, day 1 to 4, every 3 weeks. From Dec 1998 to Dec
2008, 59 pts, 40 males and 19 females, were considered; 21 with LD and 38
with ED. Median age was 59, with PS 0 in 59%, PS 1 in 32% and PS 2 in
9%. Overall, 364 cycles of PEI were given, with an average of 6 cycles and
2 lines per patient. 48 pts received PEI in first line, 24 in second, 16 in third
and 4 in subsequent lines (range 4-6 ). In the serie of 59 pts, the PR rates were
75%, 42% and 13% and CR were 13%, 17% and 13% in 1st, 2d and 3d line,
respectively, with a ORR of 87%, 58% and 25%. In 21 LD pts, Time To
Progression was 12.7, 7.9 and 5.8 mts in 1st, 2d and 3d line, respectively; in
38 ED pts, TTP was 6.8, 5,0 and 3.0 mts. OS was 26.3 mts in LD pts, and
13.2 mts in ED pts, with 2 year Survival of 62% in LD and 24% in ED.
Median Dose Intensity for all 3 drugs was about 89% when PEI was given
in first line, 80% in second line and 87% in third line. Haematologic toxicity was
the most frequent adverse event, with G3-4 Neutropenia in 56%, Anemia in 27%
and thrombocytopenia in 21% of the pts, in first line. Three toxic deaths were
observed, all in PS  1 pts: two for febrile neutropenia in pts receiving the first
cycle of a third line, and one in the first cycle of a first line, for heart failure in
a cardiopatic patient. In our study the regimen PEI confirmed a high activity and
efficacy, both in LD and ED pts. Toxicity was manageable, with a high dose
intensity also in pts heavily pretreated, that received PEI as rechallenge, after two
previous lines of PEI or other Platinum based chemotherapy.
Disclosure: All authors have declared no conflicts of interest.
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FIRST AND SECOND LINE SYSTEMIC CHEMOTHERAPY
RESPONSES IN SMALL CELL LUNG CARCINOMA
A. Besen, F. Kose, A. Sezer, A.T. Sumbul, T. Canbolat, U. Disel, O.
Ozyilkan Medical Oncology, Baskent University, Adana/TURKEY
Introduction: Small cell lung cancer (SCLC) accounts for approximately %15
of all lung neoplasm. Treatment of limited-stage SCLC consists of combination
chemotherapy and concurrent radiotherapy while chemotherapy is cornerstone
of treatment in extensive-stage. Although SCLC is both chemotherapy and
radiotherapy sensitive, recurrences are common during the course of the disease.
Here we discuss survival rates, treatment patterns and characteristics of patients
that were followed up between 2005 to 2009 in our centre.
Material-methods-results: Thirty eight patients were studied during this
period and the patients characteristics were as follows: 35 patients were men
and 3 patients were women. Mean age and mean cigarette smoking were 57
years old (range 38–85 years old) and 45, 9 pack-years (range 0–110
pack-years) respectively. 20 patients had limited-stage and 18 patients had
extensive-stage disease at diagnosis. All patients except two of them received
chemotherapy with or without radiotherapy. Cisplatin plus etoposide was
initiated as a first-line chemotherapy regimen to all patients. Median overall
survival time, determined by the Kaplan-Meier method, was 11 months
(range 6.8–15.1 months). There was no relationship between overall survival
and patients LDH and hemoglobin levels. Median progression free survival
after first line chemotherapy was 7 months (range 6.1–7.8 months). Of 18
patients who were given second-line chemotherapy seven of them received
cyclophosphamide, doxorubicin, vincristine (CAV) combination chemother-
apy and remainder received irinotecan based therapy. Progression free
survival after second line chemotherapy was 2 months (1.1–2.8 months) and
there was no statistically significant difference between these two regimens.
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In conclusion, SCLC is a highly aggressive tumor with a rapid doubling
time. Cisplatin plus etoposide is the established regimen in the first line
setting. Despite good responses to chemotherapy observed during the course
of the disease, early relapses are common and further investigations are
needed to determine optimal chemotherapy regimens.
Disclosure: All authors have declared no conflicts of interest.
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PATTERNS OF CARE AND INFLUENCE ON SURVIVAL IN
SMALL CELL LUNG CANCER: A SINGLE AUSTRALIAN
ONCOLOGY UNIT EXPERIENCE
K.B. Pittman1, M. Colbeck1, T.J. Price1, S. Sukumaran1, B. Hooper1, M.
Tuck1, D. Roder2, L. Milliken3, J. Hardingham1 1Medical Oncology, The
Queen Elizabeth Hospital, Adelaide/AUSTRALIA, 2Epidemiology, Cancer
Council South Australia, Adelaide/AUSTRALIA, 3Epidemiology, Department
of Health, Adelaide/AUSTRALIA
Background and Aims: The Queen Elizabeth Hospital (TQEH) Clinical
Cancer Registry has collected clinical data on small cell lung cancer (SCLC)
for over 25 years. SCLC outcomes have changed little over the past couple
of decades. The aims of this study were to identify patterns of care (POC)
and survival over two 10 year time periods (1/1/1987 to 31/12/1996- Cohort
A and 1/1/1997 to 31/12/2006-Cohort B).
Methods: Demographic, management and outcome data was determined from
clinical records. Stage wise survival analysis was undertaken using the Kaplan-
Meier product-limit method and the log-rank test. Factors influencing survival
outcome were assessed using Cox proportional hazards regression.
Results: Study population comprised of 392 patients (224 in A, 168 in B).
The percentage of males were 70% in A compared with 55% in B. At
diagnosis 38% of patients in cohort A and 24% in cohort B had limited stage
disease (LD), while the remainder had extensive stage disease(ED). The
majority of patients were smokers or former smokers in both groups.
Combined chemotherapy and radiotherapy for LD was used in 6% in A and
58% in B. Chemotherapy drugs in cohort A included variable combinations
involving Vincristine, Etoposide Cyclophosphamide and Adriamycin,
whereas in B it was predominantly Carboplatin/Etoposide. The median
survival for LD in cohort B was significantly higher (19.5 months), compared
to A (11.8) months (P0.03). In ED the median survival was 6.2 months in
A and 4.3 months in B (p0.7). Variables for poorer outcome were STA,
male gender, ECOG 2, ED and diagnosis in cohort A.
Conclusions: This data provides information regarding changing POC and
outcomes for patients with SCLC. Trends in outcomes may be indicative of
more accurate staging as well as standardisation of treatment (particularly the
use of chemo/radiotherapy) in the later cohort.
Disclosure: All authors have declared no conflicts of interest.
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THE EXACTRAC SNAP VERIFICATION (SV), A NEW
TOOL FOR ENSURING THE QUALITY CONTROL FOR
STEREOTACTIC BODY RADIATION THERAPY (SBRT).
THE FRENCH EXPERIENCE
F. Mornex1, C. Udrescu1, B. De Bari1, G. Michel-Amadry2, O. Chapet1
1De´partement de Radiotherapie Oncologie, Centre Hospitalier Lyon Sud,
Pierre Benite/FRANCE, 2De´partement de Physique Me´dicale, Centre Hos-
pitalier Lyon Sud, Pierre Benite/FRANCE
Purpose: The new system: intra-fraction patient (pt) imaging and verifica-
tion provided by ExacTrac® SV allows tracking possible isocenter displace-
ment within the pt throughout SBRT treatment and intratreatment realign-
ment, improving radiotherapy quality. The purpose of this study was (1) to
measure, for the first time, the intra-fraction variations of isocenter position,
(2) to study the amplitude of variation function of the fraction duration and
(3) to evaluate the impact of the table movement on pt positioning, using SV.
Methods: ExacTrac® SV uses X-ray real-time images acquired at any
moment during treatment delivery or between fields to instantly detect and
visualize isocenter displacement (beam on or off). The displacement can be
measured using the fusion of the bony structures or the implanted markers
with the DRRs. A tolerance margin indicates if a patient setup correction is
needed or not. We already evaluated 18 pts irradiated for lung/liver tumors,
using SBRT. The pts had a SV at each fraction, before each treatment beam.
Finally, 1751 beams were verified with a measure of the isocenter displace-
ment. The time from the pt installation on the table to each SV was
systematically noted.
Results: The mean isocenter deviation for all the beams and all the fractions
was 1.95 mm. The total mean time of one fraction was 21 minutes [9- 64
minutes]. The mean deviations were 1.98mm. The percentages of devia-
tion  3 mm were 12.5% and the percentage of deviation  5 mm were
4.58%. In 12 pts, a table rotation was necessary. Pain, caugh or talk may
explain the observed deviations in a few situations.
Conclusions: For the first time, it is shown that SV allows detecting
isocenter deviations, which increase in amplitude and frequency with the
fraction duration. It makes possible and highly suitable the intra-fraction
verification during SBRT. With high-quality images at low X-ray doses, SV
gives an accurate targeting from the beginning to the end of each fraction,
inducing confidence to escalate the dose. SV appears to be an important tool
for ensuring the quality control for SBRT. More results will be available at
the time of the meeting.
Disclosure: All authors have declared no conflicts of interest.
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POSTOPERATIVE COMPLICATIONS AFTER LUNG
CANCER SURGERY IN ELDERLY PATIENTS: SURGICAL
PROCEDURES AND RISKS
S. Shiono1, M. Abiko1, N. Kanauchi2, T. Sato1 1Thoracic Surgery, Yama-
gata Prefectural Central Hospital, Yamagata/JAPAN, 2Thoracic Surgery,
Nihonkai General Hospital, Sakata/JAPAN
Background: Postoperative complications for elderly patients after lung cancer
surgery remain higher than for young patients. Decreasing these postoperative
complications in elderly patients is a major issue. Objective: To identify the risk
factors of postoperative complications for elderly patients who underwent lung
cancer surgery. In particular, we investigated surgical factors, including surgical
time, blood loss and thoracotomy size.
Methods: From January 2000 to September 2009, 567 patients underwent lung
cancer surgery at our institution. We retrospectively reviewed 157 patients aged 75
years or older for possible risk factors of postoperative complications.
Results: Patients’ mean age was 78 years (range, 75-89 years). There were
105 men and 52 women. There were no perioperative or postoperative
deaths. Postoperative complications developed in 47 (30%) patients, includ-
ing 21 (13%) with arrhythmia, 11 (7%) with prolonged air leak, 10 (6%) with
delirium, 10 (6%) with hypoxia, 8 (5%) with pneumonia, 2 (1%) with
cerebrovascular disease and 2 (1%) with postoperative hemorrhage. Univar-
iate analyses showed that males (P0.04), smoking history (P0.03),
preoperative PaCO2 (P0.03), surgical time (P0.01), blood loss (P0.01),
blood transfusion (P0.03), thoracotomy size (P0.01), lobectomy
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(P0.02) and the period when surgery was done (before April, 2004 vs. after
May 2004) (P0.01) were risk factors for postoperative complications.
Multivariate analysis showed that surgical time (P0.04), thoracotomy size
(P0.04) and the period for surgery (P0.03) were independent risk factors
for postoperative complications.
Conclusions: This study demonstrated that the quality of surgery was an
important factor for postoperative complications. Although severe adhesion
and inflammation of the lung are difficult conditions during lung cancer
surgery, in the case of elderly patients, skillful and meticulous surgical
technique are required.
Disclosure: All authors have declared no conflicts of interest.
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CONE BEAM CT AND LUNG STEREOTACTIC BODY
RADIOTHERAPY: TUMOR LOCALIZATION AND SETUP
CONTROL
F. De Rose1, G. Mantini1, B. Meduri1, M. Balducci1, G.R. D’Agostino1, G.C.
Mattiucci2, S. Margaritora3, A.R. Larici3, F. Varone4, V. Valentini1 1Radio-
therapy, Polyclinic, Rome/ITALY, 2Radiology, Polyclinic, Rome/ITALY,
3Thoracic Surgery, Polyclinic, Rome/ITALY, 6Pneumology, Polyclinic,
Rome/ITALY
Purpose: Lung stereotactic body radiotherapy (SBRT) requires high preci-
sion in daily patients’ repositioning. Given the availability of onboard
cone-beam CT (CBCT) imaging at our institution, we used daily volumetric
image-guidance to evaluate the reliability of simulation and planning proce-
dure and setup accuracy.
Materials and methods: The patients’ selection criteria were: (1) primary
unresectable tumour or (2) oligometastatic patients (less then three metastatic
lesions with maximum diameter smaller than 5 cm). Every patient formerly
trained to have normal breath during simulation had 3 CT scan on three
subsequent days. CT were repeated in the same technical conditions. Patients
were immobilized using a fixing device built by a vacuum bag modelled on
the body of the patient and a thermoplastic mask to reduce respiratory
movement (3D-LINE - Body Frame). 3D localization of the target was
obtained by a stereotactic body frame external to the patient. Gross Tumor
Volume (GTV) was identified by every CT scan; individual GTV was
defined as an extent to wrap the whole volume of the three subsequent GTV.
Planning target volume (PTV) was defined by increasing GTV of 3 mm in
any direction. Prior to every fraction a CBCT was acquired in treatment
position, errors between planned and actual tumour position were measured
and corrected.
Results: Since May 2008, 16 patients were candidate for hypofractionated
sterotactic body radiotherapy. 19 treatments were performed by 6-15 MV
LINAC. Diameter of the lesions was comprised between 1.5 cm and 5 cm
with a median value of 3 cm. Median delivered total dose was 4200 cGy
(range 4200-5000 cGy, EQD2100 Gy). The mean tumour motion in the 3
referencing directions were the following: lateral 2.6 mm (median 2mm,
range 0 – 17 mm); longitudinal 3.8 mm (median 2.5 mm, range 0 – 23 mm);
vertical 2.6 mm (median 2 mm, range 0 – 12 mm). In 168/255 (66%) cases
the error detection was lesser than 3 mm.
Conclusion: The our simulation and planning procedure is reliable, but these
data support the use of a daily, pre-treatment cone beam CT in stereotactic
treatments in order to account for setup errors larger than 3 mm, which in our
sample was present in 34% of patients.
Disclosure: All authors have declared no conflicts of interest.
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SURGICAL TREATMENT OF NEUROGENIC TUMORS OF
THE CHEST
F. Gradica1, A.Y. Pere2, A. Menzelxhiu1, S. Mulosmani3, D. Argjiri3, I.
Skenduli1 1Thorax Surgery Department, University Hospital of Lung Dis-
ease, Tirana/ALBANIA, 2Onkologie Department, University Hospital Center,
Tirana/ALBANIA, 3Pneumologie, University Hospital of Lung Disease, Ti-
rana/ALBANIA
Background: Neurogenic tumors are commonly found in the mediastinum,
especially in the posterior mediastinum or in the chest wall, and have a
variety of clinical and histological features. We reviewed our experience
with these types of tumors and assessed diagnostic and therapeutic ap-
proaches.
Patients and methods: A series of 23 consecutive patients with a neurogenic
tumor of the chest, all seen for 5 years period, was retrospectively reviewed.
Results: The mean age of the 23 patients was 40 years, including 12 males
and 11 females. Preoperative symptoms were present in seven patients
(30.4%). Median tumor size was 6.4 cm, ranging from 3.6 to 28 cm. The
major location of the tumor was the posterior mediastinum in 19 cases
(82.6%) and the chest wall in 4 cases (17.4%). The operative procedure
performed was tumor extirpation in 21 cases (91.3%), in posterior thoracot-
omy approach was performed in twenty one patients and chest wall resection
in two cases. The histological type of the tumors was neurilemmoma in 15
cases (65.2%) neuroganglioma in 2 cases (8.7%), neurofibroma in 4 cases
(17.4%), and malignant schwannoma in two cases (8.7%).Tumor related
death occurred in only one case with malignant schwannoma. Five patients
with neurilemmoma were diagnosed by magnetic resonance imaging (MRI).
Conclusion: Almost all cases of intrathoracic neurogenic tumours were
benign in nature. Therefore, surgical indications may be carefully determined
in cases with no symptom and with imaging that indicate benign neurilem-
moma. Dumbbell tumours require a combined thoracic and neurosurgical
approach.
Disclosure: All authors have declared no conflicts of interest.
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COMORBIDITY RISK ASSESSMENT FOR LUNG
CANCER SURGERY IN ELDERLY PATIENTS
N. Lukavetskyy1, T. Fetsych1, V. Myronovych2 1Oncology, Lviv Medical
University, Lviv/UKRAINE, 2Surgery, Lviv Cancer Center, Lviv/UKRAINE
In patients with resectable non-small cell lung cancer, surgical resection is
the treatment of choice. The purpose of the present study was to identify
preoperative risk factors related to age of the patients focusing on comor-
bidities.
Materials and methods: Retrospective review of the clinical records of all
patients operated on thoracic department in 2000-2003. A comparison was
carried out between patients with lung cancer 70 years and older (38
patients), and younger lung cancer patients (44patients) who underwent
curative open operation. The influence of comorbidity (cardiac, pulmonary,
second primary cancer, anemia, diabetes mellitus etc) in postoperative
complication were also analyzed. None of the patient received preoperative
chemo and/or-radiotherapy. Type of surgery, histology type of tumors was
compared in both groups.
Results: No significant difference was observed in the comorbidities be-
tween elderly and young patients (p0.05). The 30-day operative mortality
rates were 6.25% in elderly population, postoperative morbidity was – 40.0%
- significantly higer in elderly lung cancer population (p0.05). But type of
comorbidities is not independently related to postoperative morbidity and
mortalities in both group of patients (p0.05)
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Conclusions: Elderly patients undergoing curative surgery for lung cancer
have a higher risk of developing postoperative complications, but mortality
rates is equal to younger population. Age or the presence of comorbidity
should not be considered contraindications for lung resection. Additional
functional evaluation is indicated in specific subgroup of elderly lung cancer
patients.
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TREATMENT DELAYS IN NON-SMALL CELL LUNG
CANCER (NSCLC) AND THEIR PROGNOSTIC
IMPLICATIONS
R. Diaconescu1, C. Lafond2, L. Choiniere3, C. Sirois3, B. Laliberte4, M.
Doyon1, R. Whittom1 1Hematology Oncology, Hopital Sacre Coeur Mon-
treal, Montreal/CANADA, 2Pulmonology, Hopital Sacre Coeur Montreal, Mon-
treal/CANADA, 3Thoracic Surgery, Hopital Sacre Coeur Montreal, Montreal/
CANADA, 4Radiation Oncology, Hopital Maisonneuve Rosemont, Montreal/
CANADA
Background: The impact of treatment delays on NSCLC patients’ survival
is uncertain. While later treatment could negatively affect their psychological
wellbeing, the maximum acceptable waiting time has not been determined.
Methods: We analyzed consecutive patients diagnosed with NSCLC be-
tween January 2005 and May 2007 who received standard treatment at
Hoˆpital du Sacre´-Coeur de Montre´al. Treatment delay was calculated from
the first abnormal radiographic study. Patients were classified into three
groups, based on TNM staging and the treatment received: localized (stages
I and II), regional (most of stage III) and advanced (stages IIIB and IV). Cox
proportional hazards analysis was used to identify predictive factors for
survival among the following parameters: age, gender, histology, smoking
status, type of treatment, tumor board discussion and treatment delay.
Kaplan-Meier curves were used to estimate survival.
Results: Three hundred twenty eight patients were identified. Their median
treatment delay was 72 days (25-75% interquartile range  37-110 days),
and distributed as follows: 85 (56-130) days for localized, 91 (37-120) days
for regional and 50 (30-76) days for advanced stages (p0.01 for the latter).
Treatment delay did not have a significant prognostic meaning for localized
or regional stages. The opposite was true for advanced disease, both in
univariate (p0.006) as well as multivariate (p0.009) analysis; for each
week that the treatment could be delayed, the hazard ratio for mortality was
improved at 0.93 (95% confidence interval 0.89-0.98). Survival of advanced
patients who began treatment earlier versus later than 50 days was 6.8
months compared to 11.6 months (p0.027). None of the other factors were
significant in uni or multivariate analyses.
Conclusions: Treatment delays did not impact outcome in patients having
localized or regional stage NSCLC in our cohort. For advanced stages,
shorter treatment delays were associated with shorter survival. Rather than
having a direct negative impact, this likely reflects that urgent treatment
carried a negative prognostic meaning, as it was preferentially offered to
patients having more aggressive disease.
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RADIATION PNEUMONITIS AND PULMONARY FIBROSIS
IN LUNG CANCER
Y.A. Ragulin1, L.V. Kursova2, I.N. Ivanova2 1Thoracic Department, Medical
Radiological Research Center RAMS, Obninsk/RUSSIAN FEDERATION,
2Radiology Department, Medical Radiological Research Center RAMS,
Obninsk/RUSSIAN FEDERATION
Background: Radiotherapy is the main method of treatment of inoperable
lung cancer. The doses necessary for tumour eradication considerably exceed
tolerance of a pulmonary tissue and radiation pneumonitis often develops
after anticancer treatment and it is most frequently complication of
radiotherapy.
Materials and methods: We observed patients with radiation pneumonitis
from 2005 to 2008 in MRRC. Adjuvant course of radiotherapy of 50 Gy have
received 4 patients (prs) (16%), simultaneous chemo-radiotherapy (60–70
Gy)  9 pts (36%), photodynamic therapy with following radiotherapy
(65–70 Gy) 6 pts (24%), and radiotherapy only (65–70 Gy) 6 pts (24%).
Radiotherapy was administered as accelerated hyperfractionated with non-
uniform (1  1,5 Gy) dose crushing. Most of patients (21) had tumour stage
III. In most cases radiation pneumonitis was developed during the course of
radiotherapy or within three months after irradiation. Radiation pneumonitis
grade II (scale LENT SOMA) was observed in 10 patients, grade III in 12
pts, and grade IV in 3 pts. The performance status was about 50% (Karnofsky
scale).
Results: Treatment of radiation pneumonitis in patients with lung cancer is
long and complex, hospitalizations alternated with the outpatient therapy.
Patients with expressed symptoms of radiation pneumonitis require hospi-
talization of 4–5 times in a year. Treatment of radiation pneumonitis (II–IV
grade) is difficult and expensive, but it is necessary as a part of treatment and
rehabilitation actions in lung cancer therapy. Within a year lung cancer
progression was revealed in 5 patients, fatal pulmonary bleeding was devel-
oped in 4 pts, and fatal pulmonary embolism in 1 patient. Pulmonary fibrosis
stage II as the outcome of radiation pneumonitis was developed in 7 patients,
grade III - in 4 pts, grade IV - in 4 pts. Anti-inflammatory agents, infusions,
antiaggregants, inhalation therapy, cardiac drugs and therapy of concomitant
diseases improve patients’ status, functional and biochemistry indicators.
Conclusions: Radiation pneumonitis and pulmonary fibrosis are serious
medical and social problem. It is necessary to introduce new therapy
techniques for improvement of results of lung cancer treatment.
Disclosure: All authors have declared no conflicts of interest.
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PRIMARY PULMONARY HEMANGIOENDOTHELIOMA:
CT, HRCT AND PET/CT MANIFESTATIONS
U. Yilmaz Turay, A. Yilmaz, C . Biber, Y. Erdog˘an, N.Y. Demirci, H. Yu¨cel
Chest Disease, Ataturk Chest Disease and Surgery Education Hospital,
Ankara/TURKEY
A 26 year old man was admitted to our hospital with right sided chest pain
complaint. His physical examination was revealed normal. Chest X-Ray
showed bilaterally, linear and micronodular opacities predominantly lung
bases. His pulmonary function tests showed restriction and diminished
diffusion capacity (49% of predicted). HRCT and CT of the thorax showed
aproximatelly 8 mm in diameter, perivascular, subpleural, multiple nodules
predominantly in lung bases, mosaic areas of ground –glass opacity and
multipl mediastinal lymphadenopathy . The working diagnosis was intersti-
tial lung disease and transbronchial biopsy was performed. Because of this
procedure nondiagnostic surgical biopsy was performed. The histological
findings and immunohistochemistry tests were consistent with pulmonary
epitheloid hemangioendothelioma (PEH). The patient underwent 18F-fluoro-
deoxyglucose positron emission tomography/CT (18F-FDG-PET/CT), ab-
dominal CT, ultrasonography to evaluate the multiple nodules and to search
for a metastasis. There was no evidence of multiorgan disease, metastasis,
FDG up take. PEH is rare vascular tumor of low grade malignancy.
Significant factors of poor prognosis are loss of weight, anemia, pulmonary
symptomps and hemorrhagic pleural effusion. Our patient didn’t have any of
these features. Because of rarity of PEH there is no standard for treatment.
After six months of diagnosis lesions were stable and there were no
progression without therapy. This case was discussed for its rarity and HRCT
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findings that mimicking interstitial lung disease and in contrast to the
literature there were no up take of the FDG any of the nodules and
lymphadenopathy.
Disclosure: All authors have declared no conflicts of interest.
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A CASE REPORT: ASKIN’S TUMOR OF CHEST WALL
WITH PLEURAL EFFUSION
S. Kashyap, M. Sarkar, R.S. Negi, K. Sidhu Pulmonary Medicine, Indira
Gandhi Medical College, Shimla, Shimla/INDIA
Introduction: Askin’s tumor is a very rare primitive neuroectodermal tumor
of the thoraco-pulmonary region. It is generally associated with dismal
prognosis. Here, we report a patient who presented with chest wall mass
which on further investigations turned out to be Askin tumor.
Material and methods: A 23 year old female was admitted in the depart-
ment of pulmonary medicine of our institution with pain and swelling right
anterior chest wall for last 6 months, cough with mucoid expectoration and
progressive dyspnea for last 3 months and low grade fever of 10 days
duration. On physical examination a chest wall mass with local tenderness
and right sided pleural effusion was revealed. Computed tomography scan
noted a 16 	 17 cm heterogeneously enhancing mass occupying right hemi
thorax with chest wall invasion, erosion of ribs and right sided pleural
effusion. Fine needle aspiration cytology (FNAC) of the chest wall mass and
subsequent immunohistochemistry of the aspirated material was done.
Results: FNAC of chest wall swelling was suggestive of malignant small
round cell tumor which on immunohistochemical staining showed positivity
to Neuron Specific Enolase (NSE), CD-99(MIC-2) but negative on Desmin
staining. The final diagnosis of Askin tumor with pleural effusion was made
THERAPY: Patient was given induction chemotherapy followed by surgery
and post-operative radiotherapy. Pre-operative chemotherapy was given in a
total of 6 cycles with alternatingVACA/IE regime (Vincristine, Actinomy-
cinD, Cyclophosphamide, Adriamycin/Ifosfamide Etoposide).
Discussions: Askin tumor is a rare, malignant, small round cell tumour of the
thoraco-pulmonary region, typically presents as a solitary mass or multiple
masses in the thoracic region. Seventy-five percent of Askin’s tumors have been
reported in patients younger than 20 years. Conventional histological features
show compact nests of small, round cells and Homer-Wright pseudorosettes.
Neuron-specific enolase stain is considered as a good marker for this tumor and
supports its neurogenic origin.. The treatment for Askin’s tumor should consist
of radical resection supplemented with radiotherapy (3500 to 5500 rads) and
aggressive chemotherapy. Overall prognosis is usually dismal.
Disclosure: All authors have declared no conflicts of interest.
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VASCULAR EVENTS IN LUNG CANCER
N. Yilmaz Demirci1, U. Yilmaz Turay2, A. Yilmaz2, Y. Erdog˘an2, C . Biber2,
H. Yu¨cel2 1Chest Disease, Ataturk Chest Diseases and Chest Surgery
Education and Research Hospital, Ankara/TURKEY, 2Chest Disease,
Ataturk Chest Disease and Surgery Education Hospital, Ankara/TURKEY
Introduction: Many factors have prognostic significance in lung cancer.
Thrombocytosis is observed frequently in these patients. The association
between vascular events, which are the outcomes of paraneoplastic symptom,
and mortality and morbidity have evaluated in numerous studies. The aim of
this study is to evaluate thrombocytosis which is observed frequently in
patients with lung cancer and vascular events.
Material and method: 281 patients who were histopathologically diagnosed
as lung cancer between March 2007 and August 2009 were evaluated
retrospectively.
Results: In 281 patient 234 (%83.27) were male, 47(%16.72) were female
with median age 60.35( 31-83 year). Histopathologically 40(%14.23) were
small cell lung cancer, 241 (% 85.76 ) were non small cell lung cancer.
Totally 17(%6.04) vascular event were determined. 11(%64.70) were deep
vein thrombosis, 3(%17.64) were pulmonary thromboembolism, 1(%5.88)
were cerebral arterial thrombosis, 1(%5.88) were vena cava superior throm-
bosis. In the course of thrombosis thrombocytosis have not determined but
following visits thrombocytosis presented.
Conclusion: Thrombocytosis is observed frequently in patients with lung
cancer. Further prospective researches are required to evaluate the necessity of
profilactic anticoagulants in these patients. The association between coagulation
parameters and survival, other step of the study, continues prospectively.
Disclosure: All authors have declared no conflicts of interest.
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DIABETES INCIPIDUS, A RARE FIRST CLINICAL
MANIFESTATION OF LUNG ADENOCARCINOMA
F. Gharemanfard, F. Malek, A. Sadeghi Internal Medicine, Seman Univer-
sity of Medical Sciences, Fatemie Hospital, Semnan/IRAN
Lung cancer is the most common cause of cancer mortality worldwide,
causing approximately 1.2 million deaths per year. Adenocarcinoma account
for 38 percent of lung cancer. The syndrome of inappropriate antidiuretic
hormone secretion (SIADH) is frequently caused by SCLC but it is rare in
NSCLC. DI as the initial manifestation of malignancy is rare. Our case was
a 52 years man who visited with polyuria and polydipsia and blurred vision.
Pituitary stimulation test revealed central diabetes insipidus. Retinal angiog-
raphy demonstrated multiple choroid lesions suspicious to metastastic le-
sions. Chest X Ray and CT scan showed right sided pleural effusion and
lower lobe opacity. Open lung biopsy showed adenocarcinoma.
Disclosure: All authors have declared no conflicts of interest.
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EFFECTIVENESS AND PROGNOSIS OF INITIAL
PERICARDIOCENTESIS IN THE PRIMARY
MANAGEMENT OF MALIGNANT PERICARDIAL
EFFUSION
O. Arrieta1, A´. Apodaca-Cruz2, B. Torres-Avila1, C. Villarreal-Garza1, J.
Torres2, A. Meneses1, D. Flores-Estrada1, F. Lara-Medina1 1Medical On-
cology, Instituto Nacional de Cancerologia, Mexico City/MEXICO, 2Depart-
ment of Internal Medicine, Instituto Nacional de Cancerologia, Mexico
City/MEXICO,
Introduction: The management of pericardial effusion in patients with cancer
denotes a complex condition, one which is frequently encountered. In terms of
determining a better selection of treatment strategies, the purpose of this study was
to determine the effectiveness of initial pericardiocentesis and examine prognostic
factors influencing survival in patients with solid malignant tumors and symptomatic
pericardial effusion treated initially with pericardiocentesis.
Patients and methods: We retrospectively reviewed the records of 100
patients with malignant disease and symptomatic pericardial effusion ini-
tially treated with pericardiocentesis at the National Cancer Institute of
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Mexico between 1985 and 2009. We analyzed predictive factors for recur-
rence of pericardial effusion by bi- and multivariate analyses.
Results: The group comprised 74 females and 26 males. Twenty patients had
developed malignant pericardial effusion at the time of primary cancer diagnosis.
Recurrence rate (RR) after pericardiocentesis was 33%. Progression-free sur-
vival for pericardial effusion at 1 year was 59% (range, 47–71%). Median
overall survival after pericardiocentesis was 40.3 7.9 weeks (95% Confidence
interval [95% CI], 24.9–55.7). The sole factor that correlated with increased
progression-free survival for pericardial effusion was the presence of bloody
pericardial effusion. For overall survival, multivariate analysis yielded that
female gender and presence of pericardial effusion at time of primary malig-
nancy diagnosis were associated with higher life expectancy.
Conclusion: Initial pericardiocentesis can provide successful management of
patients with a control rate of 67%. In spite of the high effectiveness of the
primary management of pericardial effusion with pericardiocentesis, it might be
considered for initial treatment in this type of patients, especially those with poor
prognosis, leaving pericardial window as a secondary strategy for recurrence.
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CYTOREDUCTIVE OPERATIONS IN COMPLEX
TREATMENT FOR LUNG METASTASES OF
COLORECTAL CANCER
A.V. Reshetov1, R.V. Orlova2, S.M. Lasarev1, F.M. Markin3, P.K. Yablon-
sky3, A.V. Nohrin4, G.N. Volgin1, S.M. Simkin5 1Thoracic Surgery, St.
Petersburg Medical Academy named after I.I. Mechnikov, St. Petersburg/
RUSSIAN FEDERATION, 2Chemotherapy Department, State City Oncology
Dispancer, St. Petersburg/RUSSIAN FEDERATION, 3Thoracic Surgery,
Multifield City Hospital No. 2, St. Petersburg/RUSSIAN FEDERATION,
4Thoracic Surgery, State City Oncology Dispancer, St. Petersburg/RUSSIAN
FEDERATION, 5Thoracic Surgery, Leningrad Regional Hospital, St. Peters-
burg/RUSSIAN FEDERATION
Comparative studies of different treatment methods for intrapulmonary
metastases in patients with colorectal cancer have always been a hot topic.
Methods: Retrospective analysis of 121 patients with intrapulmonary me-
tastases of colorectal cancer since 1996 till 2008 was carried out. Forty three
patients received system chemotherapy, 78 were operated. Median follow-up
was 34.5 months (from 13 to 74 month). On the basis of age, sex of a patient
the size and the number of metastases, FDI, secondary lymphnodal involve-
ment we formed two groups: A and B using u-criterion Mann-Whitney.
Group A included 21 patients who underwent surgery, group B - 21 patients
who received systemic chemotherapy only. Similarly two groups were
formed from operated patients: C and D. Group C included 34 patients who
underwent surgery only. In group D (29 patients) we used system chemo-
therapy in addition to operation. Survival was calculated by the Kaplan-
Meier formula using the moment method.
Results: One-year, three-year and five-year survival were estimated to be
95%, 42%, 15% and 92%, 12%, 7% in surgical group and in chemotherapy
only group respectively. Survival in group A was significantly better than in
group B. Median survival was (M) was 24.5 months and 11.7 respectively
p0.003. We did not find significant difference in survival between group D
(M - 18.9 months) and C (M - 20.1 months) p0.29.
Conclusion: Cytoreductive surgical resection of lung metastasis in patients
with colorectal cancer in some patients may be the treatment of choice.
Disclosure: All authors have declared no conflicts of interest.
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INHIBITION OF CELL SURVIVAL, TUMOR GROWTH
AND HISTONE DEACETYLASE (HDAC) ACTIVITY BY
THE DIETARY FLAVONOID LUTEOLIN IN HUMAN
EPITHELIOID CANCER CELLS
R. Iratni1, S. Attoub2, A.H. Hassan3, B. Vanhoecke4, A.M. Gaben5, M.
Bracke6, M. Al-Sultan7, K. Arafat7, C. Gespach5, G. Petroianu8 1Biology,
UAE University, Al Ain/UNITED ARAB EMIRATES, 2Pharmacology, Fac-
ulty of Medicine and Health Sciences UAE University, Al Ain/UNITED
ARAB EMIRATES, 3Biochemistry, Faculty of Medicine and Health Sciences,
UAE University, Al Ain/UNITED ARAB EMIRATES, 4Laboratory of Exper-
imental Cancer Research, University Hospital, De Pintelaan, Gent/
BELGIUM, 5INSERM U673 and U938, University Pierre et Marie Curie
Paris VI, Paris/FRANCE, 63Laboratory of Experimental Cancer Research,
University Hospital, De Pintelaan, Gent/BELGIUM, 7Pharmacology, UAE
University, Al Ain/UNITED ARAB EMIRATES, 8Pharmacology and Thera-
peutics, Faculty of Medicine and Health Sciences, UAE University, Al
Ain/UNITED ARAB EMIRATES
Phytochemical compounds and histone deacetylase inhibitors (HDIs) are
emerging as a new generation of anticancer agents with limited toxicity to
cancer patients. The present study investigates the impact of luteolin, a
dietary flavonoid, on survival, motility, invasion of cancer cells, and tumor
growth in vivo. We found that luteolin (25-200 mM) decreased the viability
of human cancer cell lines originating from the lung (LNM35). Luteolin
effectively increased the sub-G1 fraction of apoptotic cells through caspases
3 and 7-dependent pathways. The effect of luteolin on cell-cell adhesion,
motility and invasion was investigated. We also demonstrate that luteolin is
a potent HDI and that it potentiates the cytotoxicity of cisplatin in cultured
LNM35 cells and decreased the growth of LNM35 tumor xenografts after
intra-peritoneal injection (20 mg/kg) in athymic mice. Our results indicate
that luteolin is a promising HDI for the treatment of lung cancer in
combination with standard anticancer drugs such as cisplatin.
Disclosure: All authors have declared no conflicts of interest.
295P
PYOTHORAX-ASSOCIATED LYMPHOMA: AN UNUSUAL
CASE WITH BOTH T- AND B-CELL GENOTYPES
D. Kim1, E. Ko2, Y. Lee1, J.J. Shim3 1Internal Medicine, Soonchunhyang
University Bucheon Hospital, Gyeonggi-Do/KOREA, 2Pathology, Soonchun-
hyang University Bucheon Hospital, Gyeonggi-Do/KOREA, 3Department of
Internal Medicine, Korea University Guro Hospital, Seoul/KOREA
Pleural lymphoma is a non-Hodgkin’s lymphoma that occurs exclusively in
patients with long standing pyothorax. Histologically, most of these tumors
are classified as diffuse large B-cell lymphoma(DLBCL) with immunoblastic
morphology being the most common, but unusual types of those have also
been reported. Aozasa proposed the term pyothorax-associated lymphoma
(PAL) for this type of lymphoma. PAL is now accepted as a distinctive entity
and has a strong association with Epstein-Barr virus (EBV) infection. In the
recent WHO classification, however, PAL is not listed as a variant of
DLBCL, probably due to its rarity in Western countries. We report a patient
with pyothorax-associated lymphoma who exhibited a unique surface phe-
notype. An 73-year-old man was admitted to Soonchunhyang university
hospital with pain on the left side of the chest. He has a history of having
undergone surgery for artificial pneumothorax for pulmonary tuberculosis 30
years ago. Computed tomographic (CT) scan revealed the mass to be
confined to the left pleural cavity affected by pyothorax. Pleural surgical
biopsies performed under computed tomography and was diagnosed with
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diffuse large cell lymphoma. Immuohistochemically, the tumor cells were
positive for CD79a, CD3 and TIA-1 but negative for CD20, CD30, CD56. In
situ hybridization for EBER mRNA revealed positive signals in the nucleus
of the neoplastic cells.
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DIFFICULTIES IN DIFFERENTIAL DIAGNOSIS OF
PRIMARY PULMONARY LYMPHOMA
I.N. Subortseva1, I. Poddubnaya2, A.M. Kovrigina1, N.V. Kokosadze1, D.S.
Osmanov1 1Chemotherapy of Haemoblastosis, Blokhin’s Cancer Research
Center of RAMS, Moscow/RUSSIAN FEDERATION, 2Oncology, Russian
Academy of Postgraduate Education, Moscow/RUSSIAN FEDERATION
Background: Among malignant lymphomas the specific interest refers to
primary extranodal non-Hodgkin’s lymphoma (PENHL). According to the
data of existing literature, extranodal lymphomas cover 24%-48% of all
non-Hodgkin’s lymphomas. PENHL of pulmonary tissue is the uncommon
and poorly studied pathology. According to the data of existing literature,
PENHL of lungs involves 2%–3,6% of all extranodal lymphomas, 0,4% of
NHL, 0,5–1% of all primary lung tumours. Lack of specific clinical and
radiology signs and symptoms causes objective difficulties in diagnosis of
PENHL.
Methods: In the Blokhin’s Cancer Research Center of RAMS, between
1983–2007, we observed 704 patients with PENHL; lesions in lungs were
found in 13 patients (1,8%): 7 female and 6 male, age 26–79 years (median
- 59 years). In all cases tumors were of B-cell immunophenotype. The most
common histology variant of PENHL of lungs was MALT lymphoma - 7
patients (54%), 5 patients (38,5%) - diffuse large B-cell lymphoma (DL-
BCL), 1 patient (7,5%) - follicular lymphoma. Diagnosis was verified by
histology and immunohistochemical analysis of biopsy of tumour tissue of
the lung, and thoracotomy in 7 patients (54%), thoracoscopy in 3 patients
(23%), operative surgery (lobectomy, atypical resections of a part of the
lung) - 3 patients (23%). In 8 patients (61,5%) the clinical signs and
symptoms of the disease were absent. Within scheduled fluorography pro-
cedure of these patients, the solitary tumour was found in 5 patients (62,5%),
and multiple tumour focuses in 3 patients (37,5%). All these patients had
indolent lymphomas (MALT, follicular lymphoma of type I). In 5 patients
(38,5%) the diagnosis of DLBCL was established during generalization of
the primary lesion developed since 6 months after detection of lung pathol-
ogy: 2 patients developed the lesion of lung tissue from the opposite side, in
2 patients the lung tissue and bone marrow were involved in the pathology
process, 1 patient developed the lesion of lung tissue and shoulder bone
which corresponded to stage IV. Difficulties to define the character of
pathology process are explained by the fact that from the moment of
diagnosis of the tumour in the lung up to verification of the diagnosis, the
period of 3–36 months passed (median 15 months). All patients were
monitored in the district anti-tuberculosis or oncology follow up. In 3
patients (23%) the pathological focuses were evaluated as small cell lung
cancer, and they received symptomatic therapy. One patient received con-
tinuous anti-tuberculosis therapy which was not successful, and the patient
was subsequently directed to Blokhin’s Cancer Research Center of RAMS.
Conclusions: Verification of primary pulmonary lymphomas is difficult. To
clarify the true character of pathology process in such patients, it is required
to conduct the careful analysis of clinical and radiographical data, subse-
quently using X-ray, and computer tomography. Application of such meth-
ods allows us to evaluate the character of changes in the lung parenchyma
more precisely. The final diagnosis in complicated cases is established as per
data of morphology analysis of biopsies received after thoracoscopy.
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